SERFF Tracking #:	BCVT-130935776	State Tracking #:	Co	ompany Tracking #:
State:	VermontGMCB		Filing Company:	TVHP
TOI/Sub-TOI:	ML02 Multi-Line	- Other/ML02.000 Multi-Lin	e - Other	
Product Name:	Q3 2017 TVHP	Large Group Rating Program	m Filing	
Project Name/Numb	per: /			

Filing at a Glance

Company:	TVHP
Product Name:	Q3 2017 TVHP Large Group Rating Program Filing
State:	VermontGMCB
TOI:	ML02 Multi-Line - Other
Sub-TOI:	ML02.000 Multi-Line - Other
Filing Type:	GMCB Trend / Admin Charge
Date Submitted:	02/24/2017
SERFF Tr Num:	BCVT-130935776
SERFF Status:	Closed-Approved
State Tr Num:	
State Status:	
Co Tr Num:	
Implementation	On Approval
Date Requested:	
Author(s):	Pam Young, Jude Daye, Martine Brisson-Lemieux, Andrew Proulx
Reviewer(s):	Noel Hudson (primary), Thomas Crompton, David Dillon, Judith Henkin, Jacqueline Lee,
	Marisa Melamed
Disposition Date:	05/24/2017
Disposition Status:	Approved
Implementation Date:	05/24/2017

State Filing Description:

SERFF Tracking #:	BCVT-130935776	State Tracking #:	С	ompany Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line	- Other/ML02.000 Multi-Line	e - Other		
Product Name:		Large Group Rating Program	m Filing		
Project Name/Numb	per: /				

General Information

Project Name: Project Number: Requested Filing Mode: Explanation for Combination/Other: Submission Type: New Submission Group Market Type: Employer Filing Status Changed: 06/30/2017 State Status Changed: Created By: Martine Brisson-Lemieux Corresponding Filing Tracking Number: Status of Filing in Domicile: Date Approved in Domicile: Domicile Status Comments: Market Type: Group Group Market Size: Large Overall Rate Impact:

Deemer Date: Submitted By: Martine Brisson-Lemieux

Filing Description: February 23, 2017

Noel Hudson Director of Health Policy Green Mountain Care Board 89 Main Street, Third Floor, City Center Montpelier, Vermont 05620

Subject:The Vermont Health Plan - NAIC # 95696 Q3 2017 Large Group Rating Program Filing

Dear Mr. Hudson:

Attached for the Green Mountain Care Board's review and approval is The Vermont Health Plan's Q3 2017 Large Group Rating Program Filing. As directed by the Board, this filing combines the various factor filings for large group rating components (trend, large claims, benefit relativity, administrative fees and contribution to reserve, and the formula itself) into a single filing.

Please let me know if we can answer any questions or provide further information during your review.

Sincerely,

Ruth Greene

cc:Tom Crompton/GMCB Paul Schultz/BCBSVT Martine Lemieux/BCBSVT

SERFF Tracking #: BC	VT-130935776 State	e Tracking #:	Company Tracking #:
State:	VermontGMCB	Filing Company:	TVHP
TOI/Sub-TOI:	ML02 Multi-Line - Othe	r/ML02.000 Multi-Line - Other	
Product Name:	Q3 2017 TVHP Large	Group Rating Program Filing	
Project Name/Number:	/		
Company and	Contact		
Filing Contact Info	ormation		
Jude Daye, Executiv	e Assistant	dayej@bcbsvt.com	
445 Industrial Lane		802-371-3244 [Phone]	
Montpelier, VT 0560	1		
Filing Company In	formation		
TVHP		CoCode: 95696	State of Domicile: Vermont
PO BOX 186		Group Code:	Company Type: HMO
Montpelier, VT 0560)1	Group Name:	State ID Number:
(802) 371-3450 ext.	[Phone]	FEIN Number: 03-0354356	

Filing Fees

Fee Required?	Yes
Fee Amount:	\$150.00
Retaliatory?	No
Fee Explanation:	

SERFF Tracking #:	BCVT-130935776	State Tracking #:		Company Tracking #:
_				
State:	VermontGMCB		Filing Company:	TVHP
TOI/Sub-TOI:	ML02 Multi-Line -	Other/ML02.000 Multi-Line - Other		
Product Name:	Q3 2017 TVHP La	rge Group Rating Program Filing		
Project Name/Number:	/			

Correspondence Summary

Dispositions

Status	Created By	Created On	Date Submitted
Approved	Noel Hudson	06/30/2017	06/30/2017

Objection Letters and Response Letters

Objection Letters

Response Letters

Status	Created By	Created On	Date Submitted	Responded By	Created On	Date Submitted
Pending Response	Jacqueline Lee	04/19/2017	04/19/2017	Martine Brisson-Lemieux	04/26/2017	04/26/2017
Pending Response	Jacqueline Lee	04/11/2017	04/11/2017	Martine Brisson-Lemieux	04/12/2017	04/12/2017
Pending Response	Jacqueline Lee	04/03/2017	04/03/2017	Martine Brisson-Lemieux	04/05/2017	04/05/2017
Pending Response	Jacqueline Lee	03/23/2017	03/23/2017	Martine Brisson-Lemieux	03/31/2017	03/31/2017
Pending Response	Jacqueline Lee	03/07/2017	03/07/2017	Martine Brisson-Lemieux	03/14/2017	03/14/2017

Amendments

Schedule	Schedule Item Name	Created By	Created On	Date Submitted
Supporting Document	Amended Exhibits per GMCB Order - 06.20.2017	Martine Brisson-Lemieux	06/26/2017	06/26/2017

SERFF Tracking #:	BCVT-130935776	State Tracking #:	C	Company Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line - 0	Other/ML02.000 Multi-Line - Other			
Product Name:	Q3 2017 TVHP La	rge Group Rating Program Filing			
Project Name/Number:	/				

Disposition

Disposition Date: 05/24/2017 Implementation Date: 05/24/2017

Status: Approved

Comment:

Rate data does NOT apply to filing.

Schedule	Schedule Item	Schedule Item Status	Public Access
Supporting Document	Actuarial Memorandum		No
Supporting Document	Civil Union Rating Requirements		No
Supporting Document	Filing Compliance Certification		No
Supporting Document	Third Party Filing Authorization		No
Supporting Document	Plain Language Summary		No
Supporting Document	Exhibits		No
Supporting Document	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 1		No
Supporting Document	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 2		No
Supporting Document	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 3		No
Supporting Document	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 4		No
Supporting Document	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 5		No
Supporting Document	Amended Exhibits per GMCB Order - 06.20.2017		No

SERFF Tracking #:	BCVT-130935776	State Tracking #:	Co	ompany Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line	- Other/ML02.000 Multi-Line	- Other		
Product Name:	Q3 2017 TVHP	Large Group Rating Program	n Filing		
Project Name/Num	ber: /				

Objection Letter Status	Pending Response	
Objection Letter Date	04/19/2017	
Submitted Date	04/19/2017	
Respond By Date	04/26/2017	

Dear Jude Daye,

Introduction:

Please see the attached inquiry letter and respond no later than the end of day on April 26th.

Conclusion:

Sincerely, Jacqueline Lee Dallas Cabe W. Chadick, F.S.A. S. Scott Gibson, F.S.A. Glenn A. Tobleman, F.S.A., F.C.A.S. Michael A. Mayberry, F.S.A. David M. Dillon, F.S.A. Gregory S. Wilson, F.C.A.S. Steven D. Bryson, F.S.A. Brian D. Rankin, F.S.A. Bonnie S. Albritton, F.S.A. Jacqueline B. Lee, F.S.A. Xiaoxiao (Lisa) Jiang, F.S.A. Brian C. Stentz, A.S.A. Jennifer M. Allen, A.S.A Josh A. Hammerquist, A.S.A. Johnathan L. O'Dell, A.S.A. Clint Prater, A.S.A. Larry Choi, A.S.A. Kevin Ruggeberg, A.S.A. Traci Hughes, A.S.A.



Kansas City Gary L. Rose, F.S.A. Terry M. Long, F.S.A. Leon L. Langitz, F.S.A. D. Patrick Glenn, A.S.A., A.C.A.S. Christopher J. Merkel, F.S.A. Christopher H. Davis, F.S.A. Karen E. Elsom, F.S.A. Jill J. Humes, F.S.A. Kimberly S. Shores, F.S.A. Michael A. Brown, F.S.A. Naomi J. Kloeppersmith, F.S.A. Stephanie T. Crownhart, F.S.A. Mark W. Birdsall, F.S.A. Andrea J. Huckaba, F.S.A., C.E.R.A.

London/Kansas City Timothy A. DeMars, F.S.A., F.I.A. Scott E. Morrow, F.S.A., F.I.A.

Denver Mark P. Stukowski, F.S.A. William J. Gorski, F.S.A.

Indianapolis Kathryn R. Koch, A.C.A.S.

Baltimore David A. Palmer, C.F.E.

April 19, 2017

Jude Daye, Executive Assistant The Vermont Health Plan 445 Industrial Lane Montpelier, VT 05601

Re: The Vermont Health Plan 3Q 2017 LG Rating Program Filing SERFF Tracking #: BCVT-130935776

Dear Jude Daye:

We have been retained by the Green Mountain Care Board ("GMCB") to review the above referenced group products filing submitted on 2/24/2017. The following additional information is required for this filing.

Notice regarding proper responses:

- A minimum-acceptable response to quantitative questions from us must include a spreadsheet calculation with retained formulas such that we can replicate the calculations therein.
- Explanatory responses are merely a supplement to the spreadsheet material and in of themselves will constitute a lack of response.

Questions:

General Methodology Questions

- 1. Page 3*: Do your 2 months run out factors remove explicit conservatism and reflect any claims retractions that may take place in future time periods?
- 2. Page 3: Your administrative increases for this filing seem unreasonable. Can you demonstrate a drop in administrative expense to other lines of business? If yes, please specify what lines of businesses and how much of a decrease you are planning to apply to each.





- 3. We did not see references to the impact of the change in definition of the Large Group size. What changes if any have you made to the filing to reflect this change in Large Group size?
- 4. Page 6: Underwriting judgement: what is your process of reviewing the Underwriter's rationale to ensure it is in line with factor filings and other regulation?

Trend

- 5. On page 2 you identify changes to the rating formula (pertaining to the credibility formula, calculation of ISL factors, and development of ASL and Refund-Eligible charges) and on page 3 you outline how you checked the average change in all accounts from the changes in factors. Please supply the distribution of changes to individual accounts by each of the formula changes and all of them in total. Please show a count of accounts impacted grouped by 2% intervals (that is 7+% increase, 5 to 7% increase, 3 to 5% increase, 1 to 3% increase,+-1% change, 1 to 3% decrease...,more than 7% decrease.)
- 6. Page 10: Where in the utilization trend development do you reflect your attempts to mitigate unnecessary utilization?
 - a. Are you planning to drive utilization to more optimal (high quality / low cost) levels?
 - b. Please describe any activities intended to place providers at risk for unnecessary utilization or to review patterns of unnecessary utilization.
 - c. Are either action plans included as offsets to the utilization trend increase?
- 7. Page 12: Please demonstrate how you adjust for scripts transitioning from brand to generic and itemize the resulting drop in trend.

Benefit Relativities

- 8. Page 18: In your Induced Utilization approach, please explain how you controlled for the presence of multiple benefit offerings and its potential of adverse selection.
- 9. Page 18: Please describe any new or innovative benefit designs or aspects which you introduced and which could lead to a cost reduction in the rating period and specify the amount of the cost reduction.

Administrative Cost

- 10. Please provide your total administrative costs for all groups for each year over the past five years, the total population number served each year, and the per member per month administrative charge for Individual, Small group, and Large group for each year.
- 11. Pages 23- 25: Besides economies of scale could you describe any administrative cost savings programs? Such programs would include but are not limited to:
 - a. Activities to remove waste or address inefficiency
 - b. Insourcing or outsourcing functions at lower costs
 - c. Reduction in broker compensation or other reductions to distribution channel costs
 - d. Re-evaluation of and/or limits on senior management or board compensation packages
- 12. Pages 23-25: If any administrative cost reduction programs are described in your answer to question 14, how are the cost savings built into rate projections?
- 13. Pages 23-25: You mentioned an account's moving to ASO. Why wouldn't this account still pay its fair share of overhead cost as ASO? Did it receive a reduction in services offered?
- 14. Pages 23-25: We did not see information about the cost impact of Wellness programs. Please provide a demonstration of the administrative cost of Wellness programs and any support showing that the programs reduce medical costs.





15. Pages 23-25: Will the Individual and Small Group line of business receive an administrative cost reduction or is this an overall corporate increase?

Large Group Financial Performance

- 16. Page 31: The Large Group line of business has seen high loss ratios. Is this a corporate wide issue or historically have other lines been subsidizing the Large Group line of business?
- 17. Page 31: Is there any implicit subsidization of Large Group by other lines of business built into future period projections?

Other

18. Exhibit 5B: SIC (Industry) factors: When was the last time you reviewed and to what extent are the industry factors supported by data? How do you ensure these do not implicitly or unintentionally adversely lead to discrimination in rates?

*Page numbers refer to the Actuarial Memorandum for the BCBSVT filing

Please be aware that we expect to have further questions regarding the filing as the review continues.

To ensure that the review of your filing has been completed before statutory deadlines, we expect you to respond as expeditiously as possible to every objection in our letter, but no later than April 26, 2017. Note that the responses can be submitted separately and do not have to be submitted all at the same time.

We trust that you understand these forms may not be used in Vermont until they are formally approved by the GMCB.

Sincerely,

Jonn Hammerquiset

Josh Hammerquist A.S.A., M.A.A.A. Assistant Vice President & Consulting Actuary Lewis & Ellis, Inc. jhammerquist@lewisellis.com (972)850-0850





SERFF Tracking #:	BCVT-130935776	State Tracking #:	Co	ompany Tracking #:
State:	VermontGMCB		Filing Company:	TVHP
TOI/Sub-TOI:	ML02 Multi-Line	- Other/ML02.000 Multi-Line	e - Other	
Product Name:	Q3 2017 TVHP	Large Group Rating Program	n Filing	
Project Name/Num	ber: /			

Objection Letter Status	Pending Response	
Objection Letter Date	04/11/2017	
Submitted Date	04/11/2017	
Respond By Date	04/12/2017	

Dear Jude Daye,

Introduction:

Please see the attached inquiry letter and respond no later than the end of day on April 12th.

Conclusion:

Sincerely, Jacqueline Lee Dallas Cabe W. Chadick, F.S.A. S. Scott Gibson, F.S.A. Glenn A. Tobleman, F.S.A., F.C.A.S. Michael A. Mayberry, F.S.A. David M. Dillon, F.S.A. Gregory S. Wilson, F.C.A.S. Steven D. Bryson, F.S.A. Brian D. Rankin, F.S.A. Bonnie S. Albritton, F.S.A. Jacqueline B. Lee, F.S.A. Xiaoxiao (Lisa) Jiang, F.S.A. Brian C. Stentz, A.S.A. Jennifer M. Allen, A.S.A Josh A. Hammerquist, A.S.A. Johnathan L. O'Dell, A.S.A. Clint Prater, A.S.A. Larry Choi, A.S.A. Kevin Ruggeberg, A.S.A. Traci Hughes, A.S.A.



Kansas City Gary L. Rose, F.S.A. Terry M. Long, F.S.A. Leon L. Langlitz, F.S.A. D. Patrick Glenn, A.S.A., A.C.A.S. Christopher J. Merkel, F.S.A. Christopher H. Davis, F.S.A. Karen E. Elsom, F.S.A. Jill J. Humes, F.S.A. Kimberly S. Shores, F.S.A. Michael A. Brown, F.S.A. Naomi J. Kloeppersmith, F.S.A. Stephanie T. Crownhart, F.S.A. Mark W. Birdsall, F.S.A.

London/Kansas City Timothy A. DeMars, F.S.A., F.I.A. Scott E. Morrow, F.S.A., F.I.A.

Denver Mark P. Stukowski, F.S.A. William J. Gorski, F.S.A.

Indianapolis Kathryn R. Koch, A.C.A.S.

Baltimore David A. Palmer, C.F.E.

April 11, 2017

Jude Daye, Executive Assistant The Vermont Health Plan 445 Industrial Lane Montpelier, VT 05601

Re: The Vermont Health Plan 3Q 2017 LG Rating Program Filing SERFF Tracking #: BCVT-130935776

Dear Jude Daye:

We have been retained by the Green Mountain Care Board ("GMCB") to review the above referenced group products filing submitted on 2/24/2017. The following additional information is required for this filing.

Notice regarding proper responses:

- A minimum-acceptable response to quantitative questions from us must include a spreadsheet calculation with retained formulas such that we can replicate the calculations therein.
- Explanatory responses are merely a supplement to the spreadsheet material and in of themselves will constitute a lack of response.

Questions:

1. Please provide a revised Exhibit 3C with 46 months of historical data ending August 2016.

Please be aware that we expect to have further questions regarding the filing as the review continues.

To ensure that the review of your filing has been completed before statutory deadlines, we expect you to respond as expeditiously as possible to every objection in our letter, but no later than April





12, 2017. Note that the responses can be submitted separately and do not have to be submitted all at the same time.

We trust that you understand these forms may not be used in Vermont until they are formally approved by the GMCB.

Sincerely,

Jonn Hammerquiet

Josh Hammerquist A.S.A., M.A.A.A. Assistant Vice President & Consulting Actuary Lewis & Ellis, Inc. jhammerquist@lewisellis.com (972)850-0850





SERFF Tracking #:	BCVT-130935776	State Tracking #:	Co	ompany Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line	- Other/ML02.000 Multi-Line	- Other		
Product Name:	Q3 2017 TVHP	Large Group Rating Program	n Filing		
Project Name/Num	ber: /				

Objection Letter Status	Pending Response	
Objection Letter Date	04/03/2017	
Submitted Date	04/03/2017	
Respond By Date	04/05/2017	

Dear Jude Daye,

Introduction:

Please see the attached inquiry letter and respond no later than the end of day on April 5th.

Conclusion:

Sincerely, Jacqueline Lee Dallas Cabe W. Chadick, F.S.A. S. Scott Gibson, F.S.A. Glenn A. Tobleman, F.S.A., F.C.A.S. Michael A. Mayberry, F.S.A. David M. Dillon, F.S.A. Gregory S. Wilson, F.C.A.S. Steven D. Bryson, F.S.A. Brian D. Rankin, F.S.A. Bonnie S. Albritton, F.S.A. Jacqueline B. Lee, F.S.A. Xiaoxiao (Lisa) Jiang, F.S.A. Brian C. Stentz, A.S.A. Jennifer M. Allen, A.S.A Josh A. Hammerquist, A.S.A. Johnathan L. O'Dell, A.S.A. Clint Prater, A.S.A. Larry Choi, A.S.A. Kevin Ruggeberg, A.S.A. Traci Hughes, A.S.A.



Kansas City Gary L. Rose, F.S.A. Terry M. Long, F.S.A. Leon L. Langlitz, F.S.A. D. Patrick Glenn, A.S.A., A.C.A.S. Christopher J. Merkel, F.S.A. Christopher H. Davis, F.S.A. Karen E. Elsom, F.S.A. Jill J. Humes, F.S.A. Kimberly S. Shores, F.S.A. Michael A. Brown, F.S.A. Naomi J. Kloeppersmith, F.S.A. Stephanie T. Crownhart, F.S.A. Mark W. Birdsall, F.S.A.

London/Kansas City Timothy A. DeMars, F.S.A., F.I.A. Scott E. Morrow, F.S.A., F.I.A.

Denver Mark P. Stukowski, F.S.A. William J. Gorski, F.S.A.

Indianapolis Kathryn R. Koch, A.C.A.S.

Baltimore David A. Palmer, C.F.E.

April 3, 2017

Jude Daye, Executive Assistant The Vermont Health Plan 445 Industrial Lane Montpelier, VT 05601

Re: The Vermont Health Plan 3Q 2017 LG Rating Program Filing SERFF Tracking #: BCVT-130935776

Dear Jude Daye:

We have been retained by the Green Mountain Care Board ("GMCB") to review the above referenced group products filing submitted on 2/24/2017. The following additional information is required for this filing.

Notice regarding proper responses:

- A minimum-acceptable response to quantitative questions from us must include a spreadsheet calculation with retained formulas such that we can replicate the calculations therein.
- Explanatory responses are merely a supplement to the spreadsheet material and in of themselves will constitute a lack of response.

Questions:

- On exhibit 3G, please confirm that the incremental costs of excluded treatments for specialty drugs that were added into the projection period were calculated using the same number of member months as the claims that were removed from the experience period. If this is not the case, please quantify the impact or explain why the calculation that was used is more appropriate.
- 2. Which contracts were finalized at the time that the unit cost trend assumption was finalized? For any contract negotiations that had begun at that time, please briefly describe the state of the negotiations.





- 3. Please provide support for the proposed trends in the cells D27, J27, N27, D39, J39 and N39 on the Cost Trend tabs.
- 4. We note that the administrative costs in this filing have increased by 25.0%. Please provide a breakdown of the costs drivers. For example:
 - a. Trend: 2.4%
 - b. Increase in membership: -0.4%
 - c. Refreshed Cost Allocation Study: ___%
 - d. Large Cost Plus group moving to ASO: %
 - e. Other, if applicable

Please be aware that we expect to have further questions regarding the filing as the review continues.

To ensure that the review of your filing has been completed before statutory deadlines, we expect you to respond as expeditiously as possible to every objection in our letter, but no later than April 5, 2017. Note that the responses can be submitted separately and do not have to be submitted all at the same time.

We trust that you understand these forms may not be used in Vermont until they are formally approved by the GMCB.

Sincerely,

Jonn Hammerquist

Josh Hammerquist A.S.A., M.A.A.A. Assistant Vice President & Consulting Actuary Lewis & Ellis, Inc. jhammerquist@lewisellis.com (972)850-0850





SERFF Tracking #:	BCVT-130935776	State Tracking #:	Co	ompany Tracking #:
State:	VermontGMCB		Filing Company:	TVHP
TOI/Sub-TOI:	ML02 Multi-Line	- Other/ML02.000 Multi-Line	e - Other	
Product Name:	Q3 2017 TVHP	Large Group Rating Program	n Filing	
Project Name/Numb	per: /			

Objection Letter Status	Pending Response	
Objection Letter Date	03/23/2017	
Submitted Date	03/23/2017	
Respond By Date	03/30/2017	

Dear Jude Daye,

Introduction:

Please see the attached inquiry letter and respond no later than the end of day on March 30th.

Conclusion:

Sincerely, Jacqueline Lee

	BCVT-130935776	State Tracking #:	С	ompany Tracking #:
State:	VermontGMCB		Filing Company:	TVHP
TOI/Sub-TOI:	ML02 Multi-Line	- Other/ML02.000 Multi-Line - 0	Other	
Product Name:	Q3 2017 TVHP L	arge Group Rating Program Fi	ling	
Project Name/Numb	er: /			

Objection Letter Status	Pending Response	
Objection Letter Date	03/07/2017	
Submitted Date	03/07/2017	
Respond By Date	03/14/2017	

Dear Jude Daye,

Introduction:

Please see the attached inquiry letter and respond no later than the end of day on March 14th.

Conclusion:

Sincerely, Jacqueline Lee Dallas Cabe W. Chadick, F.S.A. S. Scott Gibson, F.S.A. Glenn A. Tobleman, F.S.A., F.C.A.S. Michael A. Mayberry, F.S.A. David M. Dillon, F.S.A. Gregory S. Wilson, F.C.A.S. Steven D. Bryson, F.S.A. Brian D. Rankin, F.S.A. Bonnie S. Albritton, F.S.A. Jacqueline B. Lee, F.S.A. Xiaoxiao (Lisa) Jiang, F.S.A. Brian C. Stentz, A.S.A. Jennifer M. Allen, A.S.A Josh A. Hammerquist, A.S.A. Johnathan L. O'Dell, A.S.A. Clint Prater, A.S.A. Larry Choi, A.S.A. Kevin Ruggeberg, A.S.A. Traci Hughes, A.S.A.



Kansas City Gary L. Rose, F.S.A. Terry M. Long, F.S.A. Leon L. Langlitz, F.S.A. D. Patrick Glenn, A.S.A., A.C.A.S. Christopher J. Merkel, F.S.A. Christopher H. Davis, F.S.A. Karen E. Elsom, F.S.A. Jill J. Humes, F.S.A. Kimberly S. Shores, F.S.A. Michael A. Brown, F.S.A. Naomi J. Kloeppersmith, F.S.A. Stephanie T. Crownhart, F.S.A. Mark W. Birdsall, F.S.A. Andrea J. Huckaba, F.S.A., C.E.R.A.

London/Kansas City Timothy A. DeMars, F.S.A., F.I.A. Scott E. Morrow, F.S.A., F.I.A.

Denver Mark P. Stukowski, F.S.A. William J. Gorski, F.S.A.

Indianapolis Kathryn R. Koch, A.C.A.S.

Baltimore David A. Palmer, C.F.E.

March 7, 2017

Jude Daye, Executive Assistant The Vermont Health Plan 445 Industrial Lane Montpelier, VT 05601

Re: The Vermont Health Plan 3Q 2017 LG Rating Program Filing SERFF Tracking #: BCVT-130935776

Dear Jude Daye:

We have been retained by the Green Mountain Care Board ("GMCB") to review the above referenced group products filing submitted on 2/24/2017. The following additional information is required for this filing.

Notice regarding proper responses:

- A minimum-acceptable response to quantitative questions from us must include a spreadsheet calculation with retained formulas such that we can replicate the calculations therein.
- Explanatory responses are merely a supplement to the spreadsheet material and in of themselves will constitute a lack of response.

Questions:

- 1. Please provide an illustrative exhibit of the 25.0% increase in the administrative charges.
- 2. Provide additional details regarding the first footnote on the bottom of page 3 of the Actuarial Memorandum.
- 3. Provide quantitative support for the unit cost trends on page 11 of the Actuarial Memorandum including the Fall 2016 Blue Trend Survey.
- 4. Is the seasonality adjustment described at the bottom of page 4 of the Actuarial Memorandum only used when an experience period of 12 months is not used?
- 5. Please confirm that the revised credibility formula is factored into the projected rate increase.





- 6. Please confirm that the trends at the top of page 14 of the Actuarial Memorandum should be switched.
- 7. Provide the number of new hepatitis C claimants for each quarter year from 2014 to 2016.
- 8. Please compare the projected utilization of PCSK9 inhibitors in 2018 to the utilization in the experience period or calendar year 2016, including a narrative description of the differences.
- 9. Please compare the projected utilization of Orkambi in 2018 to the utilization in the experience period or calendar year 2016, including a narrative description of the differences.
- 10. What level of CTR is required to maintain RBC levels at their current levels due to the impact of trend?
- 11. Please confirm that the 2017 assessment of \$10.30 for the New Hampshire Purchasing Program Payments is per month for each child that is a New Hampshire resident.
- 12. Provide quantitative support for the projected performance payment of \$0.25 PMPM for PCMH.
- 13. Provide quantitative support for the 0.1% estimate of the BCBSVT portion of the total assessment of the Federal Insurer Fee.

Please be aware that we expect to have further questions regarding the filing as the review continues.

To ensure that the review of your filing has been completed before statutory deadlines, we expect you to respond as expeditiously as possible to every objection in our letter, but no later than March 14, 2017. Note that the responses can be submitted separately and do not have to be submitted all at the same time.


We trust that you understand these forms may not be used in Vermont until they are formally approved by the GMCB.

Sincerely,

Josh Hammerquist

Josh Hammerquist A.S.A., M.A.A.A. Assistant Vice President & Consulting Actuary Lewis & Ellis, Inc. jhammerquist@lewisellis.com (972)850-0850







SERFF Tracking #:	BCVT-130935776	State Tracking #:		Company Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line -	Other/ML02.000 Multi-Line - Other			
Product Name:	Q3 2017 TVHP La	arge Group Rating Program Filing			
Project Name/Number:	/				
Response Letter Statu		Submitted to State			
Response Letter Date		04/26/2017			
Submitted Date		04/26/2017			
Dear Noel Hudson,					
Introduction:					

Response 1

Comments:

Please find attached TVHP's responses to L&E's inquiries dated April 19, 2017.

Changed Items:

Supporting Document Schedule Item Changes		
Satisfied - Item:	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 5	
Comments:		
Attachment(s):	Response to 3Q 2017 LG Rating Program Review Inquiry 5 - TVHP.pdf	

No Form Schedule items changed.

No Rate/Rule Schedule items changed.

Conclusion:

Sincerely,

Martine Brisson-Lemieux

SERFF Tracking #:	BCVT-130935776	State Tracking #:		Company Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line -	Other/ML02.000 Multi-Line - Other			
Product Name:	Q3 2017 TVHP La	arge Group Rating Program Filing			
Project Name/Number:	/				

Response Letter

Response Letter Status	Submitted to State
Response Letter Date	04/12/2017
Submitted Date	04/12/2017

Dear Noel Hudson,

Introduction:

Response 1

Comments:

Please find attached TVHP's responses to L&E's inquiries dated April 11, 2017.

Changed Items:

Supporting Document Schedule	e Item Changes
Satisfied - Item:	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 4
Comments:	
Attachment(s):	Response to 3Q 2017 LG Rating Program Review Inquiry 4 - TVHP.pdf Excel Response to 3Q 2017 LG Rating Program Review Inquiry 4 - TVHP.pdf Response to 3Q 2017 LG Rating Program Review Inquiry 4 - TVHP.xlsx

No Form Schedule items changed.

No Rate/Rule Schedule items changed.

Conclusion:

Sincerely, Martine Brisson-Lemieux

SERFF Tracking #:	BCVT-130935776	State Tracking #:		Company Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line -	Other/ML02.000 Multi-Line - Other			
Product Name:	Q3 2017 TVHP La	rge Group Rating Program Filing			
Project Name/Number:	/				
Response Letter Statu		Submitted to State			
Response Letter Date		04/05/2017			
Submitted Date		04/05/2017			
Dear Noel Hudson,					
Introduction:					

Response 1

Comments:

Please find attached TVHP's responses to L&E's inquiries dated April 3, 2017.

Changed Items:

Supporting Document Schedule I	Item Changes
Satisfied - Item:	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 3
Comments:	
Attachment(s):	Response to 3Q 2017 LG Rating Program Review Inquiry 3 - TVHP.pdf

No Form Schedule items changed.

No Rate/Rule Schedule items changed.

Conclusion:

Sincerely,

Martine Brisson-Lemieux

SERFF Tracking #:	BCVT-130935776	State Tracking #:		Company Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line -	Other/ML02.000 Multi-Line - Other			
Product Name:	Q3 2017 TVHP La	arge Group Rating Program Filing			
Project Name/Number:	/				
Response Lett	ter				
Response Letter Stat	us	Submitted to Sta	ate		
Response Letter Date	e	03/31/2017			
Submitted Date		03/31/2017			

Dear Noel Hudson,

Introduction:

Response 1

Comments:

Please find attached TVHP's responses to L&E's inquiries dated March 23, 2017.

Changed Items:

Supporting Document Schedule	Item Changes
Satisfied - Item:	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 2
Comments:	
Attachment(s):	Response to 3Q 2017 LG Rating Program Review Inquiry 2 - TVHP.pdf

No Form Schedule items changed.

No Rate/Rule Schedule items changed.

Conclusion:

Sincerely,

Martine Brisson-Lemieux

SERFF Tracking #:	BCVT-130935776 State Tracking #:	(Company Tracking #:	
State:	VermontGMCB	Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line - Other/ML02.000 Multi-Line -	Other		
Product Name:	Q3 2017 TVHP Large Group Rating Program F	Filing		
Project Name/Number:	/			

Response Letter Status	Submitted to State
Response Letter Date	03/14/2017
Submitted Date	03/14/2017

Dear Noel Hudson,

Introduction:

Response 1

Comments:

Please find attached TVHP's responses to L&E's inquiries dated March 7, 2017.

Changed Items:

Supporting Document Schedule	Item Changes
Satisfied - Item:	Response to TVHP 3Q 2017 LG Rating Program Review Inquiry 1
Comments:	
Attachment(s):	Response to 3Q 2017 LG Rating Program Review Inquiry 1 - TVHP.pdf Response to 3Q 2017 LG Rating Program Review Inquiry 1 - TVHP - Excel.pdf Response to 3Q 2017 LG Rating Program Review Inquiry 1 - TVHP.xlsx

No Form Schedule items changed.

No Rate/Rule Schedule items changed.

Conclusion:

Sincerely, Martine Brisson-Lemieux

SERFF Tracking #:	BCVT-130935776	State Tracking #:		Company Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line - Other/ML02.000 Multi-Line - Other				
Product Name:	Q3 2017 TVHP Large Group Rating Program Filing				
Project Name/Number:	/				

Amendment Letter

Submitted Date: 06/26/2017

Comments:

Please find attached the updated exhibits per the GMCB Order dated June 20, 2017.

Changed Items:

No Form Schedule Items Changed.

No Rate Schedule Items Changed.

Supporting Document Schedule I	tem Changes
Satisfied - Item:	Amended Exhibits per GMCB Order - 06.20.2017
Comments:	
Attachment(s):	TVHP 3Q 2017 LG Rating Program - Ordered Amendment Cover Letter.pdf Q3 2017 TVHP Large Group Rating Program Filing - Revised Exhibits.pdf

SERFF Tracking #:	BCVT-130935776	State Tracking #:	c	Company Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line - Other/ML02.000 Multi-Line - Other				
Product Name:	Q3 2017 TVHP La	Q3 2017 TVHP Large Group Rating Program Filing			
Project Name/Number:	/				

Supporting Document Schedules

Satisfied - Item:	Actuarial Memorandum
Comments:	
Attachment(s):	Q3 2017 TVHP Large Group Rating Program Filing - Actuarial Memorandum.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Civil Union Rating Requirements
Bypass Reason:	Not Required
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Filing Compliance Certification
Comments:	
Attachment(s):	Q3 2017 TVHP Large Group Rating Program Filing - Plain Language Summary.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Third Party Filing Authorization
Bypass Reason:	BCBSVT does not use a Third Party to submit filings.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Plain Language Summary
Comments:	
Attachment(s):	Q3 2017 TVHP Large Group Rating Program Filing - Plain Language Summary.pdf
Item Status:	
Status Date:	
Satisfied - Item:	Exhibits
Comments:	
Attachment(s):	Q3 2017 TVHP Large Group Rating Program Filing - Exhibits.pdf Q3 2017 TVHP Large Group Rating Program Filing - Exhibits.xlsx
Item Status:	

SERFF Tracking #:	BCVT-130935776	State Tracking #:	Company Tracking #:
State:	VermontGMCB		Filing Company: TVHP
Ol/Sub-TOI:	ML02 Multi-Line -	Other/ML02.000 Multi-Line - Other	
Product Name:	Q3 2017 TVHP L	arge Group Rating Program Filing	
Project Name/Number:	/		
Status Date:			
Satisfied - Item:	R	esponse to TVHP 3Q 2017 LC	G Rating Program Review Inquiry 1
Comments:			
Attachment(s):	R	esponse to 3Q 2017 LG Ratin	ng Program Review Inquiry 1 - TVHP.pdf ng Program Review Inquiry 1 - TVHP - Excel.pdf ng Program Review Inquiry 1 - TVHP.xlsx
Item Status:			
Status Date:			
Satisfied - Item:	R	esponse to TVHP 3Q 2017 LC	G Rating Program Review Inquiry 2
Comments:			
Attachment(s):	R	esponse to 3Q 2017 LG Ratin	ng Program Review Inquiry 2 - TVHP.pdf
Item Status:			
Status Date:			
Satisfied - Item:	R	esponse to TVHP 3Q 2017 LC	G Rating Program Review Inquiry 3
Comments:			
Attachment(s):	R	esponse to 3Q 2017 LG Ratin	ng Program Review Inquiry 3 - TVHP.pdf
Item Status:			
Status Date:			
Satisfied - Item:	R	esponse to TVHP 3Q 2017 LC	G Rating Program Review Inquiry 4
Comments:			
Attachment(s):	E	xcel Response to 3Q 2017 LG	ng Program Review Inquiry 4 - TVHP.pdf 6 Rating Program Review Inquiry 4 - TVHP.pdf ng Program Review Inquiry 4 - TVHP.xlsx
Item Status:			
Status Date:			
Satisfied - Item:	R	esponse to TVHP 3Q 2017 LC	G Rating Program Review Inquiry 5
Comments:			
Attachment(s):	R	esponse to 3Q 2017 LG Ratin	ng Program Review Inquiry 5 - TVHP.pdf
Item Status:			
Status Date:			
Satisfied - Item:	Ai	mended Exhibits per GMCB C	Drder - 06.20.2017
Comments:			

SERFF Tracking #:	BCVT-130935776	State Tracking #:	(Company Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line - (ML02 Multi-Line - Other/ML02.000 Multi-Line - Other			
Product Name:	Q3 2017 TVHP La	Q3 2017 TVHP Large Group Rating Program Filing			
Project Name/Number:	/				
Attachment(s):	TV Q3	HP 3Q 2017 LG Rating Progr 2017 TVHP Large Group Ra	am - Ordered Amendment Co ting Program Filing - Revised	ver Letter.pdf Exhibits.pdf	
Item Status:					
Status Date:					

SERFF Tracking #:	BCVT-130935776	State Tracking #:	C	Company Tracking #:	
State:	VermontGMCB		Filing Company:	TVHP	
TOI/Sub-TOI:	ML02 Multi-Line -	Other/ML02.000 Multi-Line - Other			
Product Name:	Q3 2017 TVHP Large Group Rating Program Filing				
Project Name/Number:	/				

Attachment Q3 2017 TVHP Large Group Rating Program Filing - Exhibits.xlsx is not a PDF document and cannot be reproduced here.

Attachment Response to 3Q 2017 LG Rating Program Review Inquiry 1 - TVHP.xlsx is not a PDF document and cannot be reproduced here.

Attachment Response to 3Q 2017 LG Rating Program Review Inquiry 4 - TVHP.xlsx is not a PDF document and cannot be reproduced here.

Table of Contents

1.	PURPOSE	2
2. 2.1 2.2		2
3.	FORMULA DESCRIPTION	3
4. 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 4.1	 Trend Factors Benefit Relativity Factors Manual Rate Administrative Charges Administrative Charges Net Cost of Reinsurance Pharmacy Rebates Contribution to Reserve State Mandates and Assessments 	6 8 . 16 . 20 . 21 . 23 . 24 . 24 . 24
5. 5.1	FACTORS APPLICABLE ONLY TO SPECIFIC PRODUCTS	
6.	HISTORICAL FINANCIAL RESULTS	
7.	ACTUARIAL OPINION	30

1. <u>Purpose</u>

The Vermont Health Plan (TVHP) performs large group rating on a case-by-case basis. Rating is accomplished through a formulaic approach that blends recent group experience with a manual rate according to a credibility formula. Formula results may be adjusted for underwriting judgment and/or management decisions. This filing establishes the formula, manual rate, and accompanying factors that will be used for renewals beginning upon approval of this filing, most notably January 2018 renewals.

Once approved, this filing will be used for large group and grandfathered small group renewals (we will refer to them collectively as Large Groups for the remainder of the filing) prepared for business under the jurisdiction of the Green Mountain Care Board (GMCB) until superseded by a subsequent filing. This filing will apply beginning with rates communicated 10 business days after the date of its approval, and continuing until 10 business days after the date of approval of the next TVHP Large Group Rating Program Filing. The term "communicated," for this purpose, means a written proposal delivered to a large group account.

2. Overview and Rate Impact

2.1. Overview

This filing includes a description of the renewal formula and the development of each of the factors used in it. TVHP projects that about 15,908 members (8,159 subscribers) in 67 groups will be impacted by this filing. These totals include members of both BCBSVT and TVHP.

We will describe in detail the formula used in the renewals. The formula has been modified from the currently approved version (BCVT-130457790). The changes, described in detail below, pertain to the credibility formula and development of Refund-Eligible charges.

We will then detail the factors applicable to all Large Groups. The factors included in the buildup of the projected claims cost include the Large Claims Factors, Trend Factors, Benefit Relativities, and the Manual Rate. In addition to the projected claims cost, we will explain the calculation of administrative charges, the net cost of reinsurance, contribution to reserve, and State and Federal Assessments, all of which are included in the rate development.

Finally, we will discuss factors applicable only to specific products. We offer an Experience Refund Eligible product for which risk charges and settlement administration changes apply.

2.2. Impact of Formula and Factor Changes

To compute the impact of changes to the rating formula and the various factors in this filing on large group premium rates, we produce two renewals for each of the 59 large groups we expect to enroll in 2018 (excluding eight groups without a complete 12 months experience period with two months of runout). The first renewal uses the approved factors currently in force (BCVT-130457790) with an effective date of January 1, 2017. The rates in these renewals are used as a baseline for the comparison with the rates produced by the new factors. The second renewal uses the same experience period as the first but has an effective date of January 1, 2018 and

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Actuarial Memorandum

uses the factors and formulas detailed in this filing. The new trend factors are applied for 12 months to represent an additional year of trend with the new trend assumption.

The result of comparing the renewals across all 59 large groups is an average 8.0 percent rate increase excluding the impact of the Federal Insurer Fee and 10.7 percent when including the impact of the fee. Reasons for the rate increase can be attributed to two main causes: changes in the rating formula and filed factors, and changes mandated due to the Affordable Care Act (ACA).

The largest component of the increase due to changes in the filed factors is the additional year of trend applied to the experience and manual claims. The trend is responsible for a 6.8 percent increase in projected claims, which results in a 6.1 percent increase in premium. Administrative charges are increasing by 25.0 percent, which increases required premium by 1.5 percent. The average rate increase from all changes to the formula and factors is 8.0 percent.

Changes in federal programs under the ACA work to increase the average rate increase by 2.7 percent. The federal insurer fee is assessed to insured groups and goes to pay for some provisions of the ACA. The Consolidated Appropriation Act of 2016 temporarily suspended this fee for 2017. We estimate the fee is 2.6 percent of premium in 2018 and 2.6 percent of premium in 2019.

Component	2017 PMPM	2018 PMPM	PMPM Change	Impact on Premium Increase
Projected Paid claims ¹	\$415.34	\$443.87	\$28.52	6.0%
Administrative charges	\$28.98	\$36.22	\$7.24	1.5%
Contribution to Reserve	\$9.05	\$10.05	\$1.00	0.2%
Federal Programs	\$0.19	\$13.08	\$12.89	2.7%
Additional Items ²	\$18.66	\$19.74	\$1.08	0.2%
Total	\$472.22	\$522.96	\$50.74	10.7%

The overall 10.7 percent rate increase translates to a \$50.74 PMPM increase. The PMPM increase can be broken down as follows:

(1) Projected paid claims include manual claims (5.9 percent increase), experience claims (7.4 percent increase), and projected rebates (5.6 percent increase).

(2) Additional Items includes net cost of reinsurance, Cost Plus stop loss, broker commissions, State mandates and assessments, fees paid to outside vendors, and the Refund-Eligible margin & risk charge.

3. Formula Description

Benefit-Adjusted Projected Single Claims Rate

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Actuarial Memorandum

A sample calculation of this quantity can be found as Exhibit 1A. For each case, we start the rating with a twelve month experience period with two months of runout¹. We determine a pooling point based on the size of the case at the end of the runout period and split the experience period claims (line A) into amounts above (line B) and below (referred to as Capped Claims, line C) the pooling point.

We apply completion factors (line D) developed from the monthly financial reporting process to Capped Claims to produce Completed Capped Claims (line E). We multiply the completed capped claims by the pooling factor (line F, described in section 4.1) to calculate the expected claims above the pooling point (line G). The expected claims above the pooling limit are added to the Completed Capped Claims to produce large-claim-adjusted experience period claims. We then multiply the large-claim-adjusted experience claims by an adjustment factor (line H) to reflect structural changes in the benefit plan from the experience period to the rating period. This is to adjust for such things as mandated benefit changes, contractual provision changes, etc., that, in the judgment of the underwriter, are necessary to make the experience appropriate for the estimation of the expected claims in the rating period. We divide the result (line I) by the number of member months during the experience period (line J) to produce Adjusted Experience Period Claims per member per month (line K).

The Adjusted Experience Period Claims per member per month (PMPM) is then divided by a seasonally-adjusted benefit relativity value to neutralize any effect of seasonality and benefits on the paid claims. To determine this factor, we first determine a benefit relativity factor for each benefit plan (using the factors described in section 4.3) and contract tier type (single, 2-person, family, etc.). Based on the seasonal patterns observed as part of the reserving process for each calendar month, we determine seasonal factors for CDHPs and for non-CDHPs and normalize them so that they total to 12. We combine these factors to calculate seasonal benefit relativity factors for each combination of benefit plan, contract tier type, and month. We apply these factors to the number of contracts for each benefit plan, contract tier type, and month in the experience period. We total the results and divide the resultant sum by the number of member months in the experience period. This produces the Average Experience Period Seasonal Adjusted Benefit Relativity Factor (line L).

Dividing the Adjusted Experience Period Claims PMPM (line K) by the Average Experience Period Seasonal Adjusted Benefit Relativity Factor (line L) produces the Benefit-Adjusted Experience Period Single Claims Rate (line M), which is the expected cost for a single contract in the experience, neutral of benefit and seasonality. We then multiply this by a trend factor (line N, as calculated in section 4.2) to project the claims from the experience period to the rating period. We also multiply by a factor (line O) to account for differences in contracted pharmacy discounts between the experience period and the projection period.

The resulting Projected Single Contract Rate (line P) is then blended (using the credibility formula described below) with the Adjusted Manual Rate (line Q, as described in section 4.4).

The credibility factor (line R) is calculated as follows:

¹ For first year renewals, where twelve months of experience is not available, we generally use claims incurred in nine months with no runout.

$$Credibility = \sqrt{\frac{Member Months}{Upper Bound}}$$

The upper bound is determined based on pooling point as follows:

Pooling Point	Member Months
\$70,000	14,002
\$90,000	16,127
\$110,000	17,923

If member months are greater than the upper bound, the credibility factor will be 1.

The credibility formula has been modified from the currently approved version. We periodically review the credibility formula to ensure that it is expected to produce reasonable results and that it is appropriate for its intended use and purpose². The development of a credibility procedure has two parts: the determination of the threshold for full credibility and the selection and parametrization of a survival function to assign partial credibility. To determine the threshold for full credibility, we used classical (limited fluctuation) credibility theory. According to this theory, full credibility is achieved when, for selected values P and k, the probability that the sample mean differs from its expected value by less than a fraction k of the expected mean is equal to P. Formulaically, for a given distribution X, the number of observations of X required for full credibility is:

$$N_0 * \frac{Var(X)}{(E(X))^2}$$
, where $N_0 = \left(\frac{y_p}{k}\right)^2$ and y_p is the $\frac{(1+P)}{2}$ percentile of the standard normal distribution.

Using the tables created from the combined BCBSVT projected claims file described in section 4.1, the mean and variance of claims by pooling point is calculated. This is then multiplied by N_0 , where P = 90% and k = 0.10. To assign partial credibility, the square root of member months divided by the upper bound is calculated. If a group's pooling point is not in the table, identical data, assumptions and methodology as described above will be used to calculate the upper bound for the required pooling point.

To blend the Projected Single Contract Rate with the Adjusted Manual Rate, we use the following equation:

Benefit-Adjusted Projected Single Claims Rate = Projected Single Contract Rate \times (Credibility) + Adjusted Manual Rate \times (1 - Credibility)

Required premium by Plan, Tier Type

A sample calculation of premium can be found as Exhibit 1B. For each plan and contract tier type anticipated in the rating period, we calculate projected claims (line B1) as the product of

² <u>http://www.actuarialstandardsboard.org/wp-content/uploads/2014/02/asop025_174.pdf</u>

the Benefit-Adjusted Projected Single Claims Rate (S) and the BRV for the plan and contract tier (line A).

The members per contract tier during the last month of the runout period is the basis for the projected members per tier in the rating period. The underwriter will adjust this if, in their opinion, the result is not representative of the expected values in the rating period.³

The calculation for the total required premium by (plan, tier) is as follows:

{ Projected Claims by plan and tier (line B1)	+	
Expected Net Cost of Reinsurance (line B2, as described in section 4.6)	+	
Projected Pharmacy Rebates (line B3, as described in section 4.7)	+	
Administrative Charges (line E, as described in section 4.5)	+	
State Mandates (line C1 to C3, as described in section 4.9)	+	
Federal Mandates } (line D, as described in section 4.10)	1	
{ 1 - Contribution to Reserve (line G, as described in section 4.8) - Broker Commissions (line F) - Federal Insurer Fee (line H, as described in section 4.10)}		
Required premium by plan and tier (line I)		

Underwriting Judgment Adjustments

If, in the underwriter's professional judgment, the specific properties of the case being rated are such that the standard formula would not produce appropriate rates for the rating period, the underwriter will make such modifications as needed to produce appropriate rates. The underwriter will document in the case file the reason(s) for the adjustment(s) and the method of determining the appropriate adjustment(s).

Management Discretionary Adjustments

For marketing or other reasons, management may decide to modify the rates on a specific case or block of cases. The underwriter will document in the case file the adjustment(s) made, along with a description of the nature of the adjustment(s).

4. Factors applicable to all Large Groups

4.1. Large Claims Factors

As described in section 3, experience claims above a certain pooling level are removed from the calculation and replaced by the expected claims above the pooling level. In order to develop the large claims factors used to calculate the expected claims above a pooling level, allowed charges and paid claims through September 30, 2016 were analyzed for the experience years ended December 31, 2013, December 31, 2014, and December 31, 2015. The data includes claims from BCBSVT Cost Plus groups, BCBSVT ASO Groups, BCBSVT Insured Large Groups, and TVHP Insured Large Groups. Combining these homogeneous populations creates greater

³ E.g., the number of contracts in a particular tier may be small (or even 0). In such instances, the underwriter should use appropriate values based on total block of business or other appropriate source.

consistency and credibility within the large claim factor development. Fee-for-Service equivalents were used for capitated services and claims incurred by Medicare Primary members were excluded. Any groups that do not include prescription drugs as a covered expense under their BCBSVT/TVHP benefit plan were also excluded. The source of the data is BCBSVT's data warehouse, except where noted below. To ensure accuracy of claims information, the data used has been reconciled against internal reserving, enrollment, and other financial reports.

For each experience year, allowed charges and paid claim amounts were totaled for each claimant. These were then sorted into categories by the amount of allowed charges. The categories used were:

- \$0 up to \$50
- \$50 up to \$100
- \$100 up to \$200...\$1,900 up to \$2,000
- \$2,000 up to \$2,500...\$9,500 up to \$10,000
- \$10,000 up to \$15,000...\$995,000 up to \$1,000,000
- Further categories in \$5,000 increments as necessary for claims above \$1,000,000

For each category, paid-to-allowed ratios were calculated. The ratios for each year were averaged for each category, while the resulting ratios at allowed amounts greater than \$1,000 were smoothed. The high-to-low-to-high pattern of the ratios observed at allowed amounts less than \$1,000 was maintained; presumably this pattern is due to the increased provision and use of preventive benefits covered at no charge.

Factors were created for use with Insured groups based on data from BCBSVT and TVHP Insured Large Groups. These factors were blended with factors generated by two other distributions of claims to generate the final factors used in the rating program. One set of factors was based on data from the 2014 Milliman Health Cost Guidelines and the other was based on the combined experience of BCBSVT and TVHP Insured Groups, Cost Plus groups, and ASO groups.

We calculated the charge factors assuming experience periods begin on the first day of the quarter. To project the charges for future experience periods, the allowed amounts by claimant for 2013 and 2014 were trended by the observed trends to 2015, and then by 6.9 percent per annum (see section 4.2 for details). The allowed amounts for 2015 were also trended forward at 6.9 percent per annum. For each claimant record, a claim amount was calculated by applying the appropriate factor from the paid/allowed amount factor table. A projected claim file was built by combining the trended 2013 records with two copies of the trended 2014 records and three copies of the 2015 records (thus weighting the 2014 experience twice as heavily and the 2015 experience three times as heavily as the 2013 experience). For a set of limits (in increments of \$5,000), the amounts in excess of the limit for each claim and the amounts under the limit for each claim were totaled and the ratio of these calculated. This produced a factor for each limit value expressing claims above the limit in terms of claims below the limit.

A distribution of claims by amount was generated from the 2014 Milliman Health Cost Guidelines distribution of allowed charges (adjusted for Vermont) by trending the distribution to produce the same expected average annual allowed charge per member as the trended BCBSVT/TVHP distribution and then applying the paid-to-allowed factors calculated above. Factors for claims above the limit as a percentage of those below the limit were calculated from this distribution.

As discussed in Section 3, we develop a credibility procedure using classical credibility. We let X be the paid claims per member-year in our blended experience and select P = 95% and k = 0.10. With these values, the standard for full credibility for the various experience groups is summarized below:

		Claims Threshold
	Member-Years for	for Full
Groups in Base Data	Full Credibility	Credibility
Insured	8,463	\$20,000
Combined	6,392	\$60,000

To determine partial credibility for limits above the threshold, we fit our distribution of claimants above that limit to a Pareto distribution. We selected the Pareto distribution due to

its decreasing, thick-tailed survival function, given by the formula $S(x) = \left(\frac{\theta}{x}\right)^q$ for $x > \theta$, where θ is the threshold for full credibility and q is a parameter estimated from the data.

For each limit, two credibility factors were calculated to blend the three pooling factors. Credibility factor Z is the credibility given to the Insured pooling factor and Credibility Factor Y is the credibility of the remaining (1-Z) given to the combined BCBSVT experience. The blended pooling factor is calculated by the formula Z*(Insured Factor) + (1-Z)*Y*(BCBSVT Combined Factor) + (1-Z)*(1-Y)*(Milliman Factor). This calculation is demonstrated in Exhibit 2A.

Exhibit 2B shows the factors that will be applied to the experience claims under the pooling limit to calculate the expected claims above the limit for Insured groups. These factors are calculated for each experience period starting quarter expected to be covered by this filing.

4.2. Trend Factors

Medical Trend Development

The source of the data is BCBSVT's data warehouse, except where noted below. To ensure accuracy of claims information, the data used has been reconciled against internal reserving, enrollment, and other financial reports. Claims incurred between November 1, 2012 and August 31, 2016, paid through October 31, 2016, were used in the analysis. Completion factors are applied to estimate the ultimate incurred claims for each period shown in the exhibits.

The data includes claims from BCBSVT Cost Plus groups, BCBSVT ASO Groups, BCBSVT Insured Large Groups, and TVHP Insured Large Groups. CDHP and Non-CDHP claims are combined. The data from one large ASO group has been excluded from the medical analysis because they were not active for the entire experience period. Additionally, ASO groups with special pricing arrangements are excluded. Claims from Medicare Primary members are excluded.

BCBSVT and TVHP cover substantially similar populations under similar benefit packages. Combining these homogeneous populations creates greater consistency and credibility within the trend factor development. Using the historical contracted reimbursement schedules, we calculated network factors that represent the different contracts and modify the claims to reflect a single contract. By making these adjustments we can observe the historical cost increases using all large group claims information.

Medical trend is composed of three pieces: cost, utilization, and intensity. In our analysis, we combined utilization and intensity within the utilization metric and analyzed the unit cost separately. Historical experience was normalized for contract changes and then analyzed to derive a utilization trend in the absence of unit cost changes. Future unit cost trends were developed on a discrete basis using the most recent round of contract negotiations as a starting point. The overall trend is the product of these two components.

<u>Utilization</u>

Historical utilization trend patterns were examined by first normalizing claims for unit cost increases. Contract changes for the entirety of the experience period were measured explicitly for each facility within our service area as well as the three largest physician groups.

Increases were measured for fee schedules and other Chargemasters by applying each schedule to a market basket of services. The market basket was defined by using Current Procedural Terminology (CPT) codes & CPT modifier combinations that were present in each of the effective periods the schedules covered. Using the same experience period data used throughout the trend analysis, total allowed costs for the selected CPT & CPT modifier combinations were compared under each schedule to estimate the percentage increase. For contracts under DRG arrangements, we compared the charge for the 1.000 DRG service for each period. Finally, for services under a discount of charge arrangement, we used the contracted chargemaster increase provided by our Provider Contracting department.

This accounted for over 85 percent of allowed claims dollars during the experience period. Costs for other claims are primarily for out-of-area services. Contracting changes for these claims were derived from the Fall 2016 Blue Trend Survey, which is a proprietary and confidential dissemination of the BlueCross BlueShield Association.

Claims were normalized to the October 2016 contract at each unique provider by applying a factor equal to the product of the impact of each contracting change from the experience month through October 2016. The derived trend for other claims was assumed to be continuous. Please see Exhibit 3A for an illustration of this approach.

Exhibit 3B shows the resulting array of allowed PMPM claims costs, before and after normalization for contract changes. We performed a 24-month regression on monthly PMPM costs to match the length of the period used in the calculation of the cost trend (described below). We believe the resulting utilization trend of 1.5 percent to be overstated. The 24-month regression can be unduly influenced by the beginning and end months in the experience period. We observed utilization trends ranging from 0.3 percent to 1.7 percent by shifting the experience period used to calculate the regression. Alternatively, a regression on rolling PMPM costs can be too slow to capture shifts in utilization. We also calculated a year-over-year rolling PMPM utilization trend of 0.9 percent for the year ended August 2016. We have selected a utilization trend of 1.0 percent. This is lower than the trend calculated by our standard methodology, but balances the shifts noted in the monthly regressions and is consistent with the utilization trend of 1.0 percent in the most recently approved Large Group Rating Program filing.

We also investigated the impact of benefit changes throughout the experience period on utilization. Large groups have engaged in a benefit buy-down strategy over the last several years as a means of limiting rate increases. This manifests itself in a lower actuarial value over time and a dampening effect on trend due to decreases in induced utilization, as shown in the table below:

Year Ended	Paid-to-Allowed Ratio	Induced Utilization	Percent Change
October 2013	86.5%	0.981	
August 2014	84.7%	0.965	-1.6%
August 2015	83.6%	0.955	-1.0%
August 2016	84.1%	0.960	0.5%

To account for the impact of the benefit buy-downs in the trend, we normalized claims to the mix of benefits present during the year ended August 2016. We did this by using a factor for each month equal to the ratio of the induced utilization for benefits present in the year ended August 2016 to the induced utilization for benefits present in the year ended that particular month. Exhibit 3C shows that the impact of induced utilization on the utilization trend is 0.3 percent. Applying this adjustment to our selected trend of 1.0 percent results in a final utilization trend of 1.3 percent when accounting for benefit changes. The concept of induced utilization is discussed further in section 4.3.

Unit Cost

Unit cost trends were largely derived from observations of recent contracting and provider budgetary changes.

During the year ended July 2016, roughly 55 percent of total claims dollars were provided by Vermont facilities and providers impacted by the hospital budget review process of the Green Mountain Care Board (GMCB). We started with the assumption that the GMCB would approve hospital budgets for October 1, 2017 and October 1, 2018 that support identical commercial increases as that approved for October 1, 2016. While the GMCB, through increased oversight, has limited the overall increase of hospital budgets in recent years, the cost shift from Medicare and Medicaid has accelerated, driving commercial increases higher. We have little reason to believe that the cost shift will not continue at current levels. Based upon that assumption, Provider Contracting and Actuarial worked together to assess the impact such an increase would have on contract negotiations for BCBSVT Managed Care, BCBSVT Non-Managed Care, and TVHP Managed Care contracts. Provider Contracting provided estimates for specific facilities in 2017 and 2018 that supplanted the assumptions noted above.

Similarly, we assumed for other providers within the BCBSVT service area that overall 2017 and 2018 budget increases would be identical to those implemented during calendar 2016, except when Provider Contracting provided a specific estimate. Again, Provider Contracting and Actuarial worked together to assess the impact these increases would have on contracts for BCBSVT Managed Care, BCBSVT Non-Managed Care, and TVHP Managed Care contracts.

Finally, unit cost increases for providers outside the BCBSVT service area were derived from the Fall 2016 Blue Trend Survey, which is a proprietary and confidential dissemination of the BlueCross BlueShield Association.

For marketing reasons, Provider Contracting has been negotiating different unit cost increases for each of the three contracts. To reflect this, we calculated three different cost trends, one for each contract.

Normalized claims were trended forward using expected increases. Unit cost trend is calculated by dividing claims year-ending December 2018 by claims year-ending June 2017 and converting to an annual factor.

The results of the analysis are summarized in the below chart:

	Annual Unit Cost Trend Assumption		
	BCBSVT Managed Care	BCBSVT Non- Managed Care	TVHP Managed Care
Vermont facilities and providers impacted by GMCB's Hospital Budget Review	4.4%	4.4%	4.4%
Other facilities and providers	4.9%	5.0%	5.0%
Total	4.6%	4.7%	4.7%

Total Medical Trend

The total medical trend factors are the product of the utilization trend and the unit cost trend factors.

	BCBSVT	BCBSVT Non-	TVHP
	Managed	Managed Care	Managed
	Care		Care
Cost Trend	4.6%	4.7%	4.7%
Utilization Trend	1.3%	1.3%	1.3%
Total Medical Trend	6.0%	6.0%	6.0%

To calculate the overall medical total trend to be applied in the renewal formula, we trended the manual rate (see section 4.4) experience medical claims based on the network to calendar year 2018. We then divided the projected claims cost by the experience claims cost to get the overall medical trend.

	BCBSVT Managed Care	BCBSVT Non- Managed Care	TVHP Managed Care	Total
Experience Allowed Claims (Medical Only)	\$7,288,679	\$51,065,123	\$15,209,332	\$73,563,134
Trend Factors for 27 months	1.140276	1.140735	1.140735	
Trended Claims	\$8,311,108	\$58,251,774	\$17,349,818	\$83,912,701
Annual Trend				6.0%

Pharmacy Trend Development

The source of the data is BCBSVT's data warehouse, except where noted below. To ensure accuracy of claims information, the data used has been reconciled against internal reserving, enrollment and other financial reports. The data includes claims from BCBSVT Cost Plus groups, BCBSVT ASO Groups, BCBSVT Insured Large Groups, and TVHP Insured Large Groups. Combining these homogeneous populations creates greater consistency and credibility within the trend factor development. CDHP and Non-CDHP claims are combined. Claims from Medicare Primary members are excluded. The data from ASO groups whose pharmacy benefits are not administered through the BCBSVT contract with ESI are excluded. We used claims incurred from October 1, 2014 to September 30, 2016, paid through October 31, 2016. Completion factors were applied to estimate the ultimate incurred claims for each period shown in the exhibits.

ESI has been the pharmacy benefits manager for BCBSVT and TVHP since July 2009. The initial ESI contract was for a period of 3 years; new contracts became effective July 2012 and July 2015. Similar to the Q3 2016 Large Group Rating Program Filing, we base our cost trend calculation on Average Wholesale Price (AWP) and apply a factor to the rating formula to account for the contracting changes.

With the emergence of new and expensive specialty drugs, as well as the ongoing shift to generics as more brand drugs come off patent, we analyzed the components of trend (cost and utilization) separately for brands, generics, and specialty drugs. We have projected the generic dispensing rate (GDR) based on the brand drugs that are scheduled to lose patent in the projection period. Specialty drugs are very high cost drugs with low utilization. Because of their relative infrequency, it is more appropriate to look at the overall PMPM trends for these drugs rather than separate cost and utilization components. The overall pharmacy trend is calculated by combining the separate projections.

Non-Specialty Drugs

Exhibit 3D provides the monthly and the 12-month rolling data, along with the corresponding year-over-year and exponential regression trends, for non-specialty drugs. These are shown separately for the generic cost, brand cost, and overall non-specialty utilization categories. The number of days supply, rather than the number of scripts, was used to normalize for changes in the days supply per script (e.g. increased use of 90-day fills). Because there are several popular brand drugs that have become generic during the experience period, or will become generic during the projection period, we combined the data for generic and brand

drugs for the purpose of analyzing utilization patterns (the separate GDR projection is applied to the total projected utilization to arrive at brand and generic components). The regressions use 24 data points on the monthly data, in order to best capture an adequate amount of the most recent history of drug costs. We selected annual trends of 5.1 percent for generic cost, 15.6 percent for brand cost, and 0.7 percent for total non-specialty utilization.

Based on our current distribution of days supply and a list of brands expected to move to generic in the period during which these trend rates will be in effect, as provided by ESI, we estimate that GDR will reach 89.0 percent in the projected period. It is important to note that care must be taken in projecting the GDR to avoid the simplistic assumption that generic shift will continue at historical levels. Generic conversion is a very discrete function - while specific dates for generic launches may be impacted by ongoing litigation, the list of brand drugs losing their patent protection is well-recognized in the industry. Furthermore, generic substitution protocols have increased generic substitution rates to well over 99 percent where such switches are clinically viable. For the above reasons, it would be actuarially inappropriate to base a future GDR assumption on a linear projection of past increases, which is why we have chosen to take a far more detailed, and more discrete, approach. Exhibit 3E shows the calculation of the 89.0 percent GDR in the projection period. Utilization for brand drugs losing or expected to lose their patent protection from November 2014 through the projection period is summarized by month. Because Average Wholesale Price (AWP) and effective discounts do not change significantly for most new generic drugs until the six-month exclusivity period has closed (that is, when the generic becomes "multi-source"), monthly utilization for the year ended October 2016 is repeated through six months following each generic launch date (i.e. we assume the same days of supply in November 2016 as we had in November 2015, and so on). After that time, all utilization is expected to shift to generic. We assume drugs with no generic exclusivity period will switch to generic immediately after the patent expires.

Exhibit 3F summarizes the trends for non-specialty drugs and calculates our total non-specialty allowed drug trend as 6.2 percent.

Specialty Drugs

The introduction of new specialty drugs for the treatment of hepatitis C in January 2014 required an adjustment to the trend calculation for specialty drugs. Other high-cost or highutilization drugs have also entered the market recently, such as Orkambi, a treatment for cystic fibrosis with an annual cost of almost \$250,000, and PCSK9 inhibitors like Repatha, used to treat high cholesterol in patients with the genetic disease familial hypercholesterolemia (FH) who have failed one statin and patients who have suffered a heart attack and failed two different statins. To accurately capture the effect of these new drugs on specialty trend, we removed their claims from the experience to calculate a trend rate to apply to these non-excluded claims. We trended those claims forward at the calculated rate for 27 months, then added back in our projections of claims for the new treatments (hepatitis C drugs, Orkambi, and PCSK9 inhibitors). We used the total restated projected claims to calculate a restated specialty trend.

Exhibit 3G, Page 1 shows the calculation of specialty trend both for all specialty drugs and for specialty drugs excluding the new treatments described above. For our regressions, we chose 24 points of 12-month rolling data to capture the most recent history of drug costs. Rolling 12-months regression is more appropriate for specialty drugs because of the low-frequency, high-cost nature of these drugs. The total specialty trend is 17.3 percent. Removing the large cost

increases associated with the new treatments results in a 14.9 percent trend for the remaining specialty drugs.

To project the cost of hepatitis C treatments in the rating period, we began by looking at actual hepatitis C claimants in 2015 and year-to-date 2016. We project 30 hepatitis C claimants in 2018 based on the ratio of claimants to members in 2015. There are several different drugs available for the treatment of hepatitis C (Sovaldi, Viekira Pak, Harvoni, Olysio, and Epclusa are in our experience). Hepatits C drugs are available in 3- and 6-month treatments. We project the distribution amongst the drugs in 2018 will be similar to our experience in 2015. In our experience, roughly 4/5s of claimants receive the 3-month treatment and 1/5 receive the 6-month treatment, so the average claimant receives 3.65 months of the drug. At an average monthly cost of \$30,200, 30 claimants with an average treatment of 3.65 months have a projected 2018 cost of \$3.30 million.

PCSK9 inhibitors such as Repatha are used to treat high cholesterol. BCBSVT's current policy is to approve PCSK9 inhibitors for the treatment of familial hypercholesterolemia (FH), a genetic disease characterized by very high levels of cholesterols in the blood, after failure of one high-does statin for 60 days. Current incidence studies suggest that 200 persons per 100,000 lives are diagnosed with FH. Another indication for these drugs is for patients who have had a heart attack and then failed two different high-dose statins for 60 days. Based on current membership, we project 16 members will use a PCSK9 inhibitor in 2018. With an annual cost of about \$14,000, the projected total is \$225,000.

Orkambi is a drug used in the treatment of cystic fibrosis. In particular, it is used to treat a specific mutation of the disease that is found in roughly 50 percent of cystic fibrosis patients. Orkambi is prescribed to patients age 12 and older. We assumed that 50 percent of our members diagnosed with cystic fibrosis who are at least age 12 will take Orkambi. Orkambi has an annual cost of \$247,000 and we project 8 members will use it. The projected cost for those members is \$1.97 million.

In our previous filing, we made an adjustment for the expected impact of biosimilars. We now do not expect biosimilars to have a cost impact until at least 2020, so the adjustment has been removed.

To calculate the effective specialty trend, we started with the pharmacy claims from the year ended September 30, 2016 experience period and removed the claims for hepatitis C drugs, PCSK9 inhibitors, and Orkambi. We then trended the remaining claims at a 17.3 percent rate for 27 months and added the incremental cost of hepatitis C treatments, PCSK9 inhibitors, and Orkambi for a total restated projected claims. Using this method, the restated effective specialty drug trend is 19.3 percent. See Exhibit 3G, Page 2 for details.

Total Pharmacy Trend

Using the PMPM claims as weights between Non-Specialty and Specialty claims for the 12 months ended September 2016, we calculate the following:

Category	PMPM	Overall Trend
Generic	\$20.14	7.2%
Brand	\$41.25	5.7%
Specialty	\$32.34	19.3%
Total	\$93.73	11.0%

Contract Adjustment Factors

Exhibit 3H contains the contract adjustment factors that will be applied to the drug claims in a group's renewal. For drug claims in the year ended September 30, 2016, we took the AWP of the claims and applied the contracted discounts and dispensing fees for each potential renewal experience period and rating period to calculate adjusted allowed charges. The contract adjustment factor for each experience and rating period combination is the ratio of the adjusted allowed charges. These factors assume that both the experience period and rating period are 12 months. For cases where this is not true, we will calculate an appropriate factor using analogous methodology.

Overall Total Trend

Using the year ended September 2016 for the groups included in the manual rate (see section 4.4), the overall allowed trend is

Catagory	Allowed PMPM	Allowed
Category	Allowed PMPM	Trend
Medical	\$ 424.24	6.0%
Pharmacy	\$ 89.13	11.0%
Total	\$ 513.37	6.9%

While we have included no implicit or explicit margin in our trend selections, we recognize that an environmental change may create a significant shift in either direction. As we have suggested in past years, we would submit an interim trend filing should information become available that meaningfully differs from the underpinnings of the trend analysis in this filing.

Leveraged Trends

The above trends are based on allowed charges and do not account for the leveraging effect of deductibles and copays. We utilized our Benefit Relativity models (see section 4.3 for a description of the methodology) to calculate the impact of leveraging on each benefit. To do so, we calculated the Paid PMPM with and without the trend (as described above). The ratio between the two paid PMPMs is the paid trend for that benefit, and the difference between the paid trend and the allowed trend is the leverage factor. See Exhibits 3I and 3J for example of leverage factors.

Applying the leverage factors for benefits present in the year ended September 2016 for the groups included in the manual rate, we calculate the following paid trends:

Category	Paid PMPM	Paid Trend
Medical	\$ 338.51	7.1%
Pharmacy	\$ 76.36	12.2%
Total	\$ 414.87	8.0%

4.3. Benefit Relativity Factors

<u>Overview</u>

To determine standardized premium rate relationships, also called relativities, we have created models that simulate the impact of member benefits for all types of plans. The models determine the allowed charges for the completed 12 months of claims included in the study and "re-adjudicate" the claims, thereby simulating the impact of member cost sharing for a given benefit plan.

Claims data is from BCBSVT's data warehouse. To ensure accuracy, the claims data used has been reconciled against internal reserving, enrollment and other financial reports. The starting point of the analysis is allowed charges as determined by the BCBSVT claims adjudication system. The claims data includes benefit codes that enable us to identify the services and benefit structures (copays, deductibles, and coinsurance) for each claim.

For each benefit plan of interest, the models produced the simulated PMPM values of the benefits. The PMPM for each plan was then divided by the manual rate, as calculated in section 4.4 but without adjustment for changes in the pharmacy contract, to produce its relativity. Relativities are included for medical only plans, Rx only plans, and integrated CDHP plans.

Incurred allowed charges from July 2015 to June 2016, paid through September 2016, were used in the models. The allowed charges were trended to July 1, 2018, which is the midpoint of the 12-month period that begins January 1, 2018. The majority of the business that will be renewed using these relativity factors has a January 1 renewal date; the rating formula adjusts the trend for non-January renewals (see section 4.4).

The data includes claims from BCBSVT Cost Plus Groups, BCBSVT ASO Groups, BCBSVT Insured Large Groups, and TVHP Insured Large Groups. Combining these homogeneous populations creates greater consistency and credibility within the relativity factor development. CDHP and Non-CDHP claims are combined. We also excluded groups that have special benefits. This predominantly refers to groups that have specific reimbursement with particular providers outside of BCBSVT's contracts and/or claims processing function.

Benefit Relativity Model: Medical

The trends used were the total medical trend, by type of service. Cost trends for each type of service were calculated by the discrete unit cost trend method above, while the same utilization trends were used for all types of service (see section 4.2).

Using the contracted reimbursement schedules, we calculated network factors that represent the different network contracts. Using these factors, we can include all claims in each of the

three networks by adjusting each claim to the basis of a single network. This enables us to combine all the experience for each plan design.

The claims were categorized according to how benefits are paid, and one record was generated for each member, date of service, and type of service. Each record was then assigned a cost share (deductible/coinsurance, copay, covered in full) for each plan available.

The plan designs modeled are:

- BlueCare Lo Options (LO)
- Open Access (OAP)
- BlueCare (HMO)
- Consumer Driven Health Plan (CDHP)

For all products, claims for preventive mandated benefits were assigned a "covered in full" cost share, independently of the product that is being modeled.

The model tested one benefit design at a time. It determined the member portion of the allowed charges, and from this, a total simulated paid PMPM for each benefit design. The impact of copay, deductible, coinsurance, out-of-pocket maximum, and preventive mandated benefits were all considered. If the average allowed cost of a category was less than the copay being examined, it was assumed that the member paid the full cost of the service.

OAP plans have two levels of benefits, In-Network and Out-of-Network. The In-Network benefit levels are applied to providers in the TVHP Managed Care network and the Out-of-Network benefits are applied to BlueCard[®] providers. Services performed at non-participating providers are not covered. In the administration of this benefit, there is no overlap between the In-Network and Out-of-Network deductible and coinsurance.

For CDHP, LO, and HMO plans, benefits are applied only to the TVHP Managed Care network. Services performed at BlueCard[®] providers and other non-participating providers are not covered.

We use BRVs in two places in the rating formula described in section 3. The Average Experience Period Seasonal Adjusted Benefit Relativity Factor (line L in Exhibit 1A) is calculated using BRVs for the benefits in the experience period, while the Projected Claims for the rating period (line B1 in Exhibit 1B) uses BRVs for the benefits in the rating period.

The relativities for the medical products currently in our book of business are displayed on Exhibits 4A and 4B.

Benefit Induced Utilization: Medical

An independent analysis was performed to measure the correlation between the benefit design and the overall health care spending. The correlation used the paid-to-allowed ratio as the independent variable and the total allowed charges (capped at \$30,000 per member per year) as the dependent variable. A 2nd order polynomial was found to best fit the data. The polynomial was then normalized such that the average paid-to-allowed (PA) ratio underlying the base BRV experience returned a utilization adjustment of 1.00. In other words, if a

simulated benefit has a paid-to-allowed ratio less than that of the average, then utilization will be reduced (i.e. factor < 1.00). If a simulated benefit has a paid-to-allowed ratio greater than the average, then the benefit will have induced utilization (i.e. factor > 1.00). The resulting formula is *Medical Utilization* : $0.5670 \times (PA)^2 - 0.0652 \times (PA) + 0.6133$, with a minimum set at 0.74 and a maximum of 1.20.

Benefit Relativity Model: Pharmacy

The trends used were the total trend, by type of drug, as described above (section 4.2) for Brand, Generic, and Specialty drugs.

Within the model, all pharmacy scripts, including specialty, are assigned to one of six categories: Retail Generic, Retail Preferred Brand, Retail non-Preferred Brand, Mail Generic, Mail Preferred Brand, and Mail non-Preferred Brand. We apply flags to identify several categories of drugs that are either required to be covered in full (ACA contraceptives and vaccines) or for which a group may purchase a rider to offer additional coverage (some fertility drugs) or exclusion (lifestyle drugs). We also flag drugs for which a group may offer special cost-sharing arrangements, such a diabetic medications and wellness drugs. We assign these flags by National Drug Codes as reported to us by ESI.

The experience period data was adjusted to reflect the major brands that are expected to become generic during 2017 and 2018. The list was based on a report provided by ESI.

For these brands, in the first 6 months (the exclusivity period), we reduced the Average Wholesale Price (AWP) by 10 percent and kept the brand discount. For the months after the exclusivity period, we reduced the AWP by 10 percent and changed the discount to the generic discount. The 10 percent reduction in AWP is based upon industry standard assumptions, supported by our own analysis of AWP changes for drugs that have moved from brand to generic over the past several years.

One record was created for each member and date of service combination. One record can have more than one script category. The model tested one benefit design at a time. It determined the member portion of the allowed charges and a total simulated paid PMPM for each benefit design. The impact of the deductible, coinsurance, copays and out-of-pocket maximum (OOPM) were considered. Following the ACA, contraceptives and vaccines were excluded from the cost sharing. If the average allowed cost of a category is less than the copay being examined, it is assumed that the member pays only the full cost of the script. With Vermont Act 171, all pharmacy benefits effective January 1, 2017 or later will have an OOPM of \$1,300. It is possible that this limit will increase effective January 1, 2018, following the IRC rules for Health Savings Account and High Deductible Plans. The exhibits include the \$1,300 OOPM benefit on pharmacy for benefits.

The relativities for the pharmacy products currently in our book of business are displayed on Exhibit 4D.

Benefit Induced Utilization: Pharmacy

Independent analysis was performed to measure the correlation between the benefit design and the quantity of pharmacy prescriptions consumed. The pharmacy benefits are adjusted in two

ways. First, the generic utilization varies with the benefit design. Claims and membership data from January 2012 through June 2016 were examined, and a table was created to adjust the base generic utilization up or down depending on the difference in the Generic and Brand copays of the member's drug plan.

Second, a separate analysis was done to adjust for the overall pharmacy benefit. A modeled paid-to-allowed (PA) ratio was assigned to every benefit in the experience period. The correlation used the paid-to-allowed ratio as the independent variable and total allowed charges as the dependent variable. A line was found to best fit the data. The line was then normalized such that the paid-to-allowed ratio underlying the base BRV benefit (manual rate) returned a utilization adjustment of 1.00. The resulting formula is *Pharmacy Utilization* : $1.6201 \times (PA) - 0.4589$, with a minimum set at 0.65 and a maximum of 1.20.

Although we use two steps to calculate the induced utilization, we are not adjusting the data twice. The adjustment for difference in Generic/Brand copays changes the mixture of scripts (i.e. generic dispensing rate) without adjusting the overall frequency of scripts. The richness or leanness of the plan, as measured by the paid to allowed ratio, drives an adjustment to the overall frequency of scripts without changing the mixture of scripts.

Integrated Benefit Relativity Model (CDHP)

The CDHP model combines both the medical and pharmacy models described above. One record was created for each member, date of service and type of service combination. A separate medical and pharmacy paid-to-allowed ratio was calculated, and the appropriate utilization adjustment was made.

The relativities for the CDHP products currently in our book of business are displayed on Exhibit 4C.

Tier Factors

The BRV models calculate the average paid claims of a single member on a particular benefit design. TVHP sells products with rate tiers for multiple members. These rate tiers feature family deductibles and out-of-pocket maximums either in addition to or in place of the individual limits. We refer to products that have family limits in addition to individual limits as Stacked and to products with only family limits as Aggregate. For products renewing after January 1, 2016, members on Aggregate plans are subject to the federal maximum allowed individual out-of-pocket, even if the aggregate out-of-pocket maximum is higher. We refer to these plans as Hybrid.

To price benefits for rate tiers with multiple members, we calculated tier factors to apply to the BRV for the benefit. We used the BRV models to calculate member paid amounts for each member in the model and used every combination of members to create "families" in the following categories:

- One Adult
- Two Adults
- One Adult and One Child, ..., One Adult and Seven Children
- Two Adults and One Child, ..., Two Adults and Seven Children

For each category of family, we calculated the average plan paid amount subject to the family cost sharing. Then we combined the categories of families into rate tiers using the proportion of each category in the experience period membership as a weight. The ratio of plan paid amount for each rate tier to the single rate tier is the tier factor. For Aggregate and Hybrid factors, we grouped products together into three ranges of out-of-pocket maximums and calculated tier factors for each range. We calculated different factors for products with separate medical and drug benefits and for products with integrated benefits (CDHPs). The Hybrid factors are applicable to benefits with a \$7,150 individual out-of-pocket maximum. The tier factors calculated for each range and type of benefit are shown in Exhibit 4E.

These factors assume a family multiplier of two. If a group requests a benefit with a nonstandard multiplier, out-of-pocket maximum, or individual out-of-pocket maximum (for a Hybrid plan) that is not in the exhibit, identical data, assumptions and methodology as described above will be used to calculate appropriate tier factors for the requested benefit.

4.4. Manual Rate

The Manual Rate is the experience paid claims PMPM from the groups impacted by this filing, trended to calendar year 2018 using the trends and pharmacy contracts adjustments described in section 4.2.

Experience Paid Claims, capped at \$750,000 and completed	A	\$ 72,137,723
Overall Paid Trend factor (8.0% for 27 months)	B1	1.190
Pharmacy Contract Adjustment	B ₂	0.995
Projected Total Paid Claims	$C = A \times B_1 \times B_2$	\$ 85,410,917
Total Member Months	D	173,473
Manual Rate	E = C / D	\$ 492.36

Calculation of the Manual Rate

As noted in section 4.3 above, we use a version of the manual rate without the pharmacy contract adjustment as the denominator of the relativity calculation. Per the above calculation, this value is \$494.76. We multiply the benefit relativity by the manual rate to calculate projected manual claims. If both the denominator of the relativity and the manual rate included the pharmacy contract adjustment, they would cancel in the multiplication and the projected claims would not reflect the discounts in the new pharmacy contract.

The Manual Rate is adjusted to reflect a group's particular characteristics, as demonstrated in Exhibit 5A. An adjustment is made for the average age/gender factor (line B) as derived from the 2014 Milliman Health Cost Guidelines, normalized such that the Manual Rate has an age/gender factor of one. The case's industry factor (line C) is developed based on the SIC and a standard table that has been updated based on BCBSVT experience data from October 2014 through September 2015 to reflect relationships between industries. See Exhibit 5B for the schedule of industry factors. These have also been normalized such that the Manual Rate has a factor of one.

For groups with a projection period other than calendar year 2018, the manual rate will be adjusted for trend to reflect the group's projection period (line D) and the additional impact of pharmacy contract changes (line E). Finally, a contract conversion factor (line F) is calculated based on member distribution and tier factors in order to convert from a PMPM to a single rate basis (necessary because the Adjusted Manual Rate is blended with the Projected Single Contract Rate, which is not on a PMPM basis).

4.5. Administrative Charges

The sources of actual expense data in this filing are BCBSVT's data warehouse and accounting records. The Experience Base period for this filing is November 2015 to October 2016. Actual BCBSVT administrative expenses for the Experience Base period are compiled on a GAAP reporting basis. During 2015, BCBSVT completed a comprehensive cost accounting study. The results were refreshed during 2016 to reflect known operational changes. Allocations to specific lines of business on a GAAP reporting basis were updated for the results of this study, beginning in December 2015. In order to normalize experience period data to the same allocation methodology, November 2015 expenses were reallocated according to the results of the cost accounting study. Exhibit 6A provides a reconciliation of the Experience Base period to restated GAAP financial report data.

Experience Base of Actual Expenses

Administrative expenses are allocated under BCBSVT's cost accounting system to lines of business. Overhead expenses are allocated to lines of business on the basis of relative capital requirements, which were measured as each line's relative impact on Risk-Based Capital (RBC). In past filings, we have combined BCBSVT Large Group Insured, BCBSVT Cost Plus and TVHP Large Group Insured actual administrative expenses to calculate the base administrative charges. A Cost Plus group with over 98 percent of the membership of that line of business is moving to an ASO arrangement as of January 1, 2018. We therefore only used Insured Group information for the base administrative charges. This is the main reason for the large increase in administrative charges. The remaining Cost Plus groups will continue to use the same administrative charge factors as the Insured groups.

The cost accounting data by cost center is then allocated into Cost Categories for purposes of determining administrative charges for each specific TVHP group account, given that account's characteristics.⁴ As noted above, BCBSVT updated the allocation methodology to reflect the results from the cost accounting study. With this filing, we are also updating the Group Cost Categories to align with the rules used in the cost allocation model. The Group Cost Categories include:

Account – those expenses that are allocated to specific group accounts on a per group account basis.

Member - those expenses that are allocated on a per member basis.

Contract - those expenses that are allocated on a per contract (subscriber) basis.

Medical Claims - those expenses that are allocated on a per medical claim basis.

Total Projected Claims - those expenses that are allocated on a Capital Requirement basis.

⁴ PUPM costs for Cost Plus members having Medicare Supplement plans are set equal to the corresponding values for conventionally funded Medicare Supplement members. The resulting costs are removed from the Cost Plus cost accounting charges before dividing by the (non-Medicare Supplement) Cost Plus units.

For each of the Group Cost Categories described above, the respective number of unit months during the Experience Base period is tabulated for the Insured Large Group (both BCBSVT and TVHP). These segments are combined in this filing for marketing considerations. The unit months include the number of account months, number of member months, number of contract months and number of medical claims by months. For the expenses allocated on a Capital Requirement basis, the experience administrative charges were divided by total paid claims to calculate a percent of claims factor.

Fees paid to our vendor GHI for the electronic processing of Medicare Supplement claims are not being assigned correctly to all members whose claims go through the GHI system. These members are in the following product categories: Individual Medicare Supplement, Group Medicare Secondary, Cost Plus Medicare Supplement, Cost Plus Medicare Secondary, and TVHP Medigap Blue. They are currently only booked to Individual Medicare Supplement and TVHP Medigap Blue. The GHI fees are reallocated to the appropriate product categories using membership as a weight. This reclassification is reflected in Exhibit 6A.

Other reclassifications reflected in the exhibit include the removal of federal fees (these are added to premium rates separately; see section 4.10) and fees paid to our vendor Health Equity for the administration of Health Savings Accounts and Health Reimbursement Accounts linked to our insurance products (participation in this service is optional and we assign these fees to groups who select the service). For this filing, we have also removed any expenses incurred due to one-time, non-recurring events, as these fees are not expected to continue to occur in the projection period.

Using the adjusted Experience Base administrative expenses and unit months, per unit per month (PUPM) values are calculated. For the group segments included in this filing, there are four such PUPM values and one percent of claims value – one for each of the Cost Categories indicated above.

The Experience Base administrative expenses PUPM are shown in Exhibit 6B, line C.

Projection Factors

Actual administrative costs PUPM from the Experience Base period are projected to each of the rating periods. Projection factors are based on a 2.4 percent annual trend. These projection factors are intended to make reasonable but modest provision for increases in overall operating costs PUPM. Note that there are no known extraordinary or mandate-related costs at this time which require separate provision for the rating periods involved in this filing.

We are assuming that personnel costs (wages and benefits) will increase by 3 percent, the budgeted wage increase for 2017, over the projection period. Other operating costs are assumed to remain flat. Based on year-to-date October 2016 information, we have calculated that 81.4 percent of our administrative costs are for salaries and benefits. We are therefore increasing our projected administrative expenses by the weighted average of 2.4 percent per annum.

		YTD Oct 2016	Percent of Total
Employee costs	А	35,159,939	56.2%
Purchased service	В	19,326,059	30.9%
Other operating costs	C	8,046,148	12.9%
Subtotal administrative expenses	D = A+B+C	62,532,147	100.0%
Total Personnel Cost	E = A / (A +	C)	81.4%
Trend for Personnel Cost	F		3.0%
Total Trend	G = {(1+F) x 1	E + (1.00) x (1-E)} -	2.4%

An examination of historical administrative charges shows a decreasing trend in recent years, driven primarily by membership increases. For 2018, we project total BCBSVT membership will also increase. We calculated PMPM admin charges with experience period enrollment and projected 2018 enrollment and found they decreased by 0.7 percent with the projected increased 2018 enrollment. We assumed that variable costs represent half of the increase, and therefore applied a decrease of 0.4 percent to the base PUPM charges to account for the reduction in membership.

Charges for Group Accounts

The Administrative Charge PUPM figures shown in Exhibit 6B are the values to be applied on an account by account basis, along with each group account's corresponding unit count, to produce account-specific administrative charges. These amounts will then be expressed as equivalent PMPM amounts for each group account.

Amounts for special items or unique services not part of TVHP's standard scope of administrative services (e.g., special booklets, certificates, or reports) are to be determined and applied separately on an account-specific basis. Commissions based on the commission scale applicable to the account are not reflected in the schedule of admin charges in Exhibit 6B; they are to be calculated and applied separately.

4.6. Net Cost of Reinsurance

TVHP has purchased reinsurance for claims in excess of \$750,000 for 2017, and expects to purchase similar reinsurance in future years with limits approximately equal to the 2017 limit increased by trend. We estimate that the target loss ratio for the reinsurance is approximately 75 percent, which implies a cost of reinsurance of approximately 33 percent of claims above the reinsurance limit. For each pricing period starting quarter, we determined an annual cost of reinsurance for the trended reinsurance limit by multiplying the expected annual claims cost above the limit by 33 percent. Dividing this by 12 produces the PMPM cost of reinsurance. The table of these PMPM's, based on pricing period starting quarter, is shown in the table below.

	Pric	ing Period S	Starting Qua	rter	
<u>Q2 2017</u>	<u>Q3 2017</u>	<u>Q4 2017</u>	<u>Q1 2018</u>	<u>Q2 2018</u>	<u>Q3 2018</u>
\$1.55	\$1.59	\$1.61	\$1.65	\$1.67	\$1.69

4.7. Pharmacy Rebates

Pharmacy rebates are calculated by taking the experience period rebates and trending them using the Brand Cost trend (from Exhibit 3D). Pharmacy rebates are paid with an average sixmonth delay from the time of the original claims. For months in the experience for which we do not have detailed rebate information, an estimated rebate amount is included in the calculation.

4.8. Contribution to Reserve

The administrative charges developed are for administrative expenses only, and contain no provision for reserve contribution. Contribution to reserves (CTR) supports the overall financial health of the company for the benefit of all members. CTR is required in order to maintain an adequate level of members' surplus. Surplus is a critical consumer protection that allows members to receive needed care and providers to continue to receive payments in the event of unforeseen adverse events that may otherwise impact TVHP's ability to pay claims. TVHP must remain financially strong in order to continue to provide Vermonters with outstanding member experiences, responsible cost management and access to high value care. TVHP also believes that CTR should be managed to an adequate long-term level, rather than fluctuating significantly from year to year. We believe that maintaining the currently approved CTR of two percent for Insured Groups represents an adequate long-term, yet not excessive, CTR. While this may fall above or below that required to maintain RBC in this or any given future year, consistently maintaining an adequate long-term assumption will allow us to avoid rate shocks in years of high growth in membership or high increases in health care cost trend. Using these long-term assumptions maintains consistency across product lines, which promotes fairness to ratepayers.

Line of Business	Contribution to Reserve
TVHP Insured Groups	2% of premium

4.9. State Mandates and Assessments

Vermont Vaccine Purchasing Program Payments

The Vermont Vaccine Purchasing Program⁵ offers health care providers state-supplied vaccines at no charge by collecting payments from Health plans, insurers, and other payers. The program's assessment is a PMPM for each Vermont resident. The approved assessment for 2017 is \$0.50 for Adults and \$11.95 for Children. We will use these rates until new rates are approved.

⁵ <u>http://www.vtvaccine.org/</u>

New Hampshire Purchasing Program Payments

The New Hampshire Purchasing Program⁶ offers health care providers state-supplied vaccines at no charge by collecting payments from Health plans, insurers, and other payers. The assessment for 2017 is \$10.30 for each child that is a New Hampshire resident. We will use this rate until a new rate is approved.

New York Graduate Medical Education (GME) Program

TVHP pays the New York GME Covered Lives Assessment⁷ for all members who are New York residents. The assessment varies based on the county of residence. We will use the approved 2017 rates until new rates are approved.

Health Care Claims Tax

The Health Care Claims Tax of 0.8 percent applies to all claims or capitations incurred by members with Vermont zip codes. We used the percentage of current members with Vermont zip codes to estimate the percentage of rating period claims expected to be incurred by Vermont members.

Blueprint

TVHP participates in the Vermont Blueprint for Health program. The current assessments for this program, applied to members who are attributed to a Blueprint provider as of the month the renewal is produced, are \$2.77 PMPM for the Community Health Team and \$3.00 PMPM for the Patient Centered Medical Homes (PCMH). PCMH are eligible for up to \$0.50 for performance. We project that our total PMPM for PCMH will be \$3.25. Any updates made to the Blueprint Manual⁸ will be incorporated in renewals.

Other Assessments

Other state mandates and assessments will be included in the calculation as applicable.

4.10. Federal Assessments

Patient-Centered Outcomes Research Institute Fee:

This fee is part of the Affordable Care Act and applies to all plan years ended after September 30, 2012. We estimate the fee to be \$2.44 annually and therefore, we will include a \$0.20 PMPM charge in the rate calculation. This estimate will be updated once additional information is received.

Federal Insurer Fee

The Federal Insurer Fee is intended to help pay for some provisions in the Affordable Care Act. This fee is only applicable to Fully Insured Groups. The Consolidated Appropriation Act of 2016 temporarily suspended this fee for 2017 only. For groups renewing in 2017, we will include the projected 2018 fee, currently estimated at 2.6 percent of premium, prorated for the months in 2018 that the policy will be effective. Please see below for the estimate of the 2018 and 2019 fee, which will be updated once additional information is received.

⁶ <u>http://www.nhvaccine.org/nhvaccine.nsf/pages/home.html</u>

⁷ https://www.health.ny.gov/regulations/hcra/gme/2017_surcharges_and_assessments.htm

⁸ http://blueprintforhealth.vermont.gov/implementation_materials

		2018	2019
Projected Fully Insured Premium subject to the Federal Insurer Fee	a	\$593,391,000	\$630,230,000
Total Industry Assessment for Federal Insurer Fee	b	\$14,300,000,0 00	\$15,600,000,0 00
BCBSVT Portion of Total Assessment (based on 2016 information)	С	0.1%	0.1%
Projected BCBSVT Federal Insurer Fee, grossed up for Federal Income Tax (20%)	d = b x c / 0.8	\$12,130,000	\$13,230,000
Estimated Required Charge as a percent of Total Premium	e = d / a	2.6%	2.6%

Other Assessments

Other federal mandates and assessments will be included in the calculation as applicable.

5. Factors applicable only to specific Products

5.1. Risk and Administrative Charges for Experience Refund Eligible products

Risk Charges for Experience Refund Eligible Plans

The TVHP Experience Refund Eligible products involve pricing margins of 10% or 5% (i.e. expected claims below the pooling limit will be increased by 10% or 5% in the determination of the premium). These factors are applied to total expected claims (before adjustment for pricing margin) and the retention is increased by the risk charge (both in the prospective pricing and in the refund calculation).

Distribution of Individual Claims by Amount

The distribution of individual claims by amount was stochastically modeled using the tables created from the combined BCBSVT projected claims file described in section 4.1 (including BCBSVT Cost Plus Groups, BCBSVT ASO Groups, BCBSVT Insured Groups, and TVHP Insured Groups). For each number of members (N) 25, 50, 100, 150, 200 to 1000 (at 100 increments), 1,500, 2,000 to 5,000 (by 1,000 increments) and 10,000 to 40,000 (by 10,000 increments), 5,000 simulations were run. For each specific stop loss level, the expected claims amount and standard deviation of the distribution of claims less than the specific stop loss level are calculated.

Expected Claims Factors

For each number of members (N) noted above and for each pooling limit, a preliminary expected fraction of aggregate claims in excess of 110%, 115%, 120%, 125% and 130% of expected aggregate claims was calculated. These were then adjusted for uncertainty in the projection of expected claims as described in the table below:

Expected to projected expected	>107.5%	107.5% - 102.5%	102.5% - 97.5%	97.5% - 92.5%	< 92.5%
Fraction of projections	F ₁ *	F ₂ *	F ₃ *	F ₄ *	F ₅ *

* Estimated for distribution

The resulting factors were then multiplied by ratios of claims under the limit to total claims at the various pooling limits. Thus the final factors are applicable to total expected claims.

The tables of factors are contained in Exhibit 7A.

If the expected number of members (N) in the rating period is not one of the values in either table, the value is determined by interpolating linearly between the entries in the table for the numbers of members immediately below and above N.

If a group requests a pooling limit that is not in the exhibit or there are more than 40,000 members, identical data, assumptions and methodology as described above will be used to calculate the appropriate risk charge for the required attachment point.

Settlement Administration Charge

An administration charge equal to a settlement administration charge, offset by an investment income credit, will be added to the group's administrative charges (described in section 4.5).

- 1. Settlement Administration Charge: An additional administrative charge of \$1,740 will be included to offset the costs of administering the retrospective arrangement. This amount is based on the 2017 settlement administration charge of \$1,700 increased by 2.4 percent trend to reflect the assumed increase for the direct staff cost.
- 2. Investment Income Adjustment: A credit of 0.2 percent of the margin at 5% and 0.4 percent of the margin at 10% will be applied to the settlement administrative charge to reflect investment income earned on the margin.

6. Historical Financial Results

Year	Incurred Claims	Earned Premium	Loss Ratio	Number of Groups	Member Months
2012	\$64,804,618	\$75,012,242	86.4%	97	195,686
2013	\$59,893,298	\$65,090,227	92.0%	104	179,709
2014	\$42,277,031	\$46,976,469	90.0%	84	126,349
2015	\$36,936,814	\$42,123,384	87.7%	71	102,396
2016	\$16,719,001	\$19,310,907	86.6%	35	48,249

Below is the combined medical and pharmacy experience for TVHP Large Groups for the prior five calendar years.

The incurred claims and earned premium are from TVHP's GAAP financials. The claims include capitations, fee-for-services claims, certain assessments, and other claims expenses. Note that the 2016 financials have not been finalized at the time of this filing; the 2016 results above are preliminary.

The chart below shows the expected and actual contribution to reserves from the previous five years for Insured Large Groups. The expected contribution to reserves is based on our forecasting model, which incorporates final premiums including amendments ordered by regulators.

Year	Expected	Actual
2012	2.1%	5.0%
2013	3.0%	-1.3%
2014	-3.2%	-3.3%
2015	-4.7%	-2.0%
2016	-4.4%	-4.2%

We used the factors and formula in this filing to project a Medical Loss Ratio (MLR) for 2018. Using the manual rate as a proxy for projected claims, we project a 2018 MLR of 89.7 percent. The TVHP credibility-adjusted MLR for Large Group was 95.4 percent in 2014 and 97.7 percent in 2015.

(A)	Manual Rate	\$490.37	Exhibit 5A
(B)	Rebates	\$9.31	2015 MLR Filing, untrended
(C)	Estimated HCQ	\$4.26	2015 MLR Filing, untrended
(D)	State Mandates and Assessments	\$8.64	Calculation as described on Exhibit 1B, using latest actual PMPM as needed
(E)	MLR Numerator	\$493.96	= (A) - (B) + (C) + (D)
(F)	Projected Claims	\$489.70	= (A) - (B) + (D)
(G)	Net Cost of Reinsurance	\$1.65	Actuarial Memorandum, Section 4.6
(H)	PCORI	\$0.20	Actuarial Memorandum, Section 4.10
(I)	Administrative Charge	\$36.10	Calculation as of January 2018, from Exhibit 6B
(J)	Subtotal	\$527.65	= (F) + (G) + (H) + (I)
(K)	Total Premium	\$565.54	= (J) / (1-0.026-0.021-0.02)
(L)	Federal Insurer Fee	\$14.70	= (K) x 2.6% (from Actuarial Memorandum, Section 4.10)
(M)	Commissions	\$11.88	= (K) x 2.1% (from 2015 MLR filing)
(N)	Contribution to Reserve	\$11.31	= (K) x 2.0% (from Actuarial Memorandum, Section 4.8)
(0)	MLR Denominator	\$550.64	= (K) - (H) - (L)
(P)	MLR	89.7%	= (E) / (O)

The above calculation represents an estimate assuming that all pricing assumptions hold true, and assuming no change from 2015 values for various quantities (e.g. rebates, commissions).

7. Actuarial Opinion

The purpose of this filing is to establish the formula, manual rate and accompanying factors that will be used for renewals of Blue Cross and Blue Shield of Vermont large group plans. This filing is not intended to be used for other purposes.

The data used in this analysis has been reviewed for reasonableness and consistency; however, it has not been audited.

It is my opinion that the rating formula and factors presented in this filing are reasonable, and have been prepared in accordance with applicable Actuarial Standards of Practice. The formula and factors will produce premium rates that are reasonable in relation to the benefits provided, and will not be excessive, deficient or unfairly discriminatory.

I am a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries, and I meet the Academy's Qualification Standards to render this opinion.

and ad

Paul A Schultz, F.S.A., M.A.A.A.

February 23, 2017

The Vermont Health Plan (TVHP) is committed to the health of Vermonters, outstanding member experiences and responsible cost management for all of the people whose lives we touch. By pooling the populations covered by our products, we protect individuals from the unaffordable and potentially ruinous costs associated with significant illnesses or injuries. Our products promote preventive care, health maintenance, and health improvement, and we have in place strong utilization management programs that support members who require medical care and assure that they have access to high value care while avoiding unnecessary costs.

TVHP also works with providers to dampen cost increases through reimbursement strategies that include incentives to both provide and properly manage care. TVHP's vision is a transformed health care system in which every Vermonter has health care coverage, and receives timely, effective, affordable care. None of this work is possible unless TVHP remains financially strong, and that requires that we be allowed to charge rates that cover the medical expenses of the populations it serves.

TVHP performs large group premium rating on a case-by-case basis. Rating is accomplished through a formulaic approach that blends recent group claims experience with a manual rate according to a credibility formula. This filing establishes the rating formula, manual rate and accompanying factors that will be used for large group renewals beginning upon approval of this filing, most notably January 2018 renewals.

The filing describes in detail the formula used in the renewals, along with each of the factors included in that formula. These include large claims pooling factors, medical and pharmacy trends, and benefit relativities, along with the development of the manual rate. In addition, the filing details the calculation of administrative charges, the net cost of reinsurance, contribution to reserve, and state and federal assessments, all of which are included in the rate development. Finally, the filing discusses certain factors applicable only to specific products.

Key results include the following:

- TVHP is proposing paid trends of 7.1 percent for medical claims and 12.2 percent for pharmacy claims, for a total combined trend of 8.0 percent.
- Administrative charges have increased by 25.0 percent from the previous filing on a per member per month basis for the groups impacted by this filing.
- We are proposing a contribution to member reserves of 2 percent for insured groups.
- Our proposed manual rate, the projected average calendar year 2018 paid claims per member per month for groups impacted by this filing, is \$492.36.
- There are an estimated 1,500 contracts (2,700 members) currently enrolled in one of 17 TVHP large group plans that will be affected by this filing.

Our proposed medical trend is higher than what was approved in our most recent large group rating program filing, 6.7 percent. Cost trends have increased from the previous filing due to increases at hospitals not subject to the Green Mountain Care Board's hospital budget review. The pharmacy trend is also higher than the 11.9 percent approved in the previous filing due to higher specialty drug trends.

Administrative charges have increased by 25.0 percent from the previous filing, which increases premium by 1.5 percent. In the previous filing, we grouped together all Insured and Cost Plus administrative charges. We expect significant migration from Cost Plus arrangements to ASO before the effective date of this filing, therefore we used only Insured group data to develop the administrative charges. The exclusion of Cost Plus data removes a source of subsidization for the Insured groups.

A contribution to reserves is required in order to maintain an adequate level of surplus. Surplus is a critical consumer protection that allows subscribers to receive needed care and providers to continue to receive payments in the event of unforeseen adverse events that may otherwise impact TVHP's ability to pay claims. We believe that the levels established in this filing represent an adequate, yet not excessive, contribution to reserves.

We have changed our large group rating formula from the time of previous filing by modifying our credibility formula and changing the development of Refund-Eligible Risk Factors. There were no other material changes. Other factors, including large claim pooling charges and benefit relativities, have been updated but by their nature have neither an inflationary nor deflationary impact on rates across our entire book of business.

The Vermont Health Plan (TVHP) is committed to the health of Vermonters, outstanding member experiences and responsible cost management for all of the people whose lives we touch. By pooling the populations covered by our products, we protect individuals from the unaffordable and potentially ruinous costs associated with significant illnesses or injuries. Our products promote preventive care, health maintenance, and health improvement, and we have in place strong utilization management programs that support members who require medical care and assure that they have access to high value care while avoiding unnecessary costs.

TVHP also works with providers to dampen cost increases through reimbursement strategies that include incentives to both provide and properly manage care. TVHP's vision is a transformed health care system in which every Vermonter has health care coverage, and receives timely, effective, affordable care. None of this work is possible unless TVHP remains financially strong, and that requires that we be allowed to charge rates that cover the medical expenses of the populations it serves.

TVHP performs large group premium rating on a case-by-case basis. Rating is accomplished through a formulaic approach that blends recent group claims experience with a manual rate according to a credibility formula. This filing establishes the rating formula, manual rate and accompanying factors that will be used for large group renewals beginning upon approval of this filing, most notably January 2018 renewals.

The filing describes in detail the formula used in the renewals, along with each of the factors included in that formula. These include large claims pooling factors, medical and pharmacy trends, and benefit relativities, along with the development of the manual rate. In addition, the filing details the calculation of administrative charges, the net cost of reinsurance, contribution to reserve, and state and federal assessments, all of which are included in the rate development. Finally, the filing discusses certain factors applicable only to specific products.

Key results include the following:

- TVHP is proposing paid trends of 7.1 percent for medical claims and 12.2 percent for pharmacy claims, for a total combined trend of 8.0 percent.
- Administrative charges have increased by 25.0 percent from the previous filing on a per member per month basis for the groups impacted by this filing.
- We are proposing a contribution to member reserves of 2 percent for insured groups.
- Our proposed manual rate, the projected average calendar year 2018 paid claims per member per month for groups impacted by this filing, is \$492.36.
- There are an estimated 1,500 contracts (2,700 members) currently enrolled in one of 17 TVHP large group plans that will be affected by this filing.

Our proposed medical trend is higher than what was approved in our most recent large group rating program filing, 6.7 percent. Cost trends have increased from the previous filing due to increases at hospitals not subject to the Green Mountain Care Board's hospital budget review. The pharmacy trend is also higher than the 11.9 percent approved in the previous filing due to higher specialty drug trends.

Administrative charges have increased by 25.0 percent from the previous filing, which increases premium by 1.5 percent. In the previous filing, we grouped together all Insured and Cost Plus administrative charges. We expect significant migration from Cost Plus arrangements to ASO before the effective date of this filing, therefore we used only Insured group data to develop the administrative charges. The exclusion of Cost Plus data removes a source of subsidization for the Insured groups.

A contribution to reserves is required in order to maintain an adequate level of surplus. Surplus is a critical consumer protection that allows subscribers to receive needed care and providers to continue to receive payments in the event of unforeseen adverse events that may otherwise impact TVHP's ability to pay claims. We believe that the levels established in this filing represent an adequate, yet not excessive, contribution to reserves.

We have changed our large group rating formula from the time of previous filing by modifying our credibility formula and changing the development of Refund-Eligible Risk Factors. There were no other material changes. Other factors, including large claim pooling charges and benefit relativities, have been updated but by their nature have neither an inflationary nor deflationary impact on rates across our entire book of business.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing

Example Calculation of Projected Single Claims Rate

Benefit-Adjusted Projected Single Claims Rate:

Experience Period Paid Claims	\$987,000	А
Experience Period Claims Amount above \$70,000 Pooling Limit	\$53,000	В
Capped Claims	\$934,000	C = A - B
Completion Factor	1.011	D
Completed Capped Claims	\$940,000	$E = C \times D$
Pooling Charge Factor	0.206	F
Expected Claims above \$70,000 Pooling Limit	\$190,000	G = E x F
Experience Adjustment Factor	1.000	Н
Adjusted Experience Period Claims	\$1,130,000	$I = (E + G) \times H$
Experience Period Member Months	3,270	J
Adjusted Experience Period Claims PMPM	\$345.57	K = I ÷ J
Average Experience Period Seasonal Adjusted Benefit Relativity Factor	0.761	L
Benefit-Adjusted Experience Period Single Claims Rate	\$453.88	$M = K \div L$
Trend 7.2% per annum for 18 months	1.110	Ν
Pharmacy Contract Adjustment	0.990	0
Projected Single Contract Rate	\$498.73	$P = M \times N \times O$
Adjusted Manual Rate	\$590.97	Q
Credibility factor	48%	R
Benefit-Adjusted Projected Single Claims Rate	\$546.44	$S = (P \times R) + \{ Q \times (1 - R) \}$

Credibility Calculation

Active Member Months	3,264	a
Member Months for Full Credibility at \$70,000 Pooling Limit	14,002	b
Credibility	48%	c = (a / b) ^ 0.5

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing

Example Calculation of Required Premium by Product and Tier Illustrative Only

From Exhibit 1A : Benefit-Adjusted Projected Single Claims Rate (S)

Plan A		Single	2-Person	Family
Members per contract		1.000	2.000	3.940
BRV:	Α	0.929	1.859	2.549
Projected Claims:	$B1 = A \times S$	\$507.80	\$1,015.61	\$1,392.91
Net Cost of Reinsurance:	B2	\$1.50	\$3.00	\$5.91
Projected Rx Rebate:	B3	-\$4.00	-\$8.00	-\$15.76
State Mandates and Assessments		<u> </u>	4- - - -	<u> </u>
Vaccines for Vemonters	C1	\$2.50	\$5.00	\$9.85
Blue Print for Health	C2	\$2.50	\$5.00 \$8.12	\$9.85
Health Care Claims Tax	C3 = 0.8% * B1	\$4.06	\$8.12	\$11.14
Federal Mandates and Assements				
PCORI	D	\$0.20	\$0.40	\$0.79
Administrative Charge	E	\$25.00	\$50.00	\$98.50
Commission (% premium)	F 3.00%			
Contribution to Reserve	G 2.00%			
Federal Insurer Fee	H 2.60%			
Required Premium:	$I = [\Sigma(B_i) + \Sigma(C_i) + D + E] / (1 - F - G - H)$	\$583.95	\$1,167.89	\$1,637.65
Plan B		Single	2-Person	Family
		Single	2-Person 2.000	Family 3.938
Plan B Members per contract BRV:	A	-		-
Members per contract BRV:	A B1 = A x S	1.000 1.023	2.000 2.046	3.938 2.806
Members per contract		1.000	2.000 2.046 \$1,118.01	3.938 2.806 \$1,533.35
Members per contract BRV: Projected Claims:	B1 = A x S	1.000 1.023 \$559.01	2.000 2.046	3.938 2.806
Members per contract BRV: Projected Claims: Net Cost of Reinsurance:	B1 = A x S B2	1.000 1.023 \$559.01 \$1.50	2.000 2.046 \$1,118.01 \$3.00	3.938 2.806 \$1,533.35 \$5.91
Members per contract BRV: Projected Claims: Net Cost of Reinsurance: Projected Rx Rebate:	B1 = A x S B2	1.000 1.023 \$559.01 \$1.50	2.000 2.046 \$1,118.01 \$3.00	3.938 2.806 \$1,533.35 \$5.91
Members per contract BRV: Projected Claims: Net Cost of Reinsurance: Projected Rx Rebate: State Mandates and Assessments	B1 = A x S B2 B3	1.000 1.023 \$559.01 \$1.50 -\$4.00	2.000 2.046 \$1,118.01 \$3.00 -\$8.00	3.938 2.806 \$1,533.35 \$5.91 -\$15.76
Members per contract BRV: Projected Claims: Net Cost of Reinsurance: Projected Rx Rebate: State Mandates and Assessments Vaccines for Vemonters	B1 = A x S B2 B3 C1	1.000 1.023 \$559.01 \$1.50 -\$4.00 \$2.50	2.000 2.046 \$1,118.01 \$3.00 -\$8.00 \$5.00	3.938 2.806 \$1,533.35 \$5.91 -\$15.76 \$9.85
Members per contract BRV: Projected Claims: Net Cost of Reinsurance: Projected Rx Rebate: State Mandates and Assessments Vaccines for Vemonters Blue Print for Health	B1 = A x S B2 B3 C1 C2	1.000 1.023 \$559.01 \$1.50 -\$4.00 \$2.50 \$2.50	2.000 2.046 \$1,118.01 \$3.00 -\$8.00 \$5.00 \$5.00	3.938 2.806 \$1,533.35 \$5.91 -\$15.76 \$9.85 \$9.85
Members per contract BRV: Projected Claims: Net Cost of Reinsurance: Projected Rx Rebate: State Mandates and Assessments Vaccines for Vemonters Blue Print for Health Health Care Claims Tax	B1 = A x S B2 B3 C1 C2	1.000 1.023 \$559.01 \$1.50 -\$4.00 \$2.50 \$2.50	2.000 2.046 \$1,118.01 \$3.00 -\$8.00 \$5.00 \$5.00	3.938 2.806 \$1,533.35 \$5.91 -\$15.76 \$9.85 \$9.85
Members per contract BRV: Projected Claims: Net Cost of Reinsurance: Projected Rx Rebate: State Mandates and Assessments Vaccines for Vemonters Blue Print for Health Health Care Claims Tax	B1 = A x S B2 B3 C1 C2 C3 = 0.8% * B1	1.000 1.023 \$559.01 \$1.50 -\$4.00 \$2.50 \$2.50 \$4.47	2.000 2.046 \$1,118.01 \$3.00 -\$8.00 \$5.00 \$5.00 \$8.94	3.938 2.806 \$1,533.35 \$5.91 -\$15.76 \$9.85 \$9.85 \$12.27
Members per contract BRV: Projected Claims: Net Cost of Reinsurance: Projected Rx Rebate: State Mandates and Assessments Vaccines for Vemonters Blue Print for Health Health Care Claims Tax Federal Mandates and Assements PCORI	B1 = A x S B2 B3 C1 C2 C3 = 0.8% * B1 D1	1.000 1.023 \$559.01 \$1.50 -\$4.00 \$2.50 \$2.50 \$4.47 \$0.20	2.000 2.046 \$1,118.01 \$3.00 -\$8.00 \$5.00 \$5.00 \$8.94 \$0.40	3.938 2.806 \$1,533.35 \$5.91 -\$15.76 \$9.85 \$9.85 \$12.27 \$0.79
Members per contract BRV: Projected Claims: Net Cost of Reinsurance: Projected Rx Rebate: State Mandates and Assessments Vaccines for Vemonters Blue Print for Health Health Care Claims Tax Federal Mandates and Assements PCORI Administrative Charge	B1 = A x S B2 B3 C1 C2 C3 = 0.8% * B1 D1 E	1.000 1.023 \$559.01 \$1.50 -\$4.00 \$2.50 \$2.50 \$4.47 \$0.20	2.000 2.046 \$1,118.01 \$3.00 -\$8.00 \$5.00 \$5.00 \$8.94 \$0.40	3.938 2.806 \$1,533.35 \$5.91 -\$15.76 \$9.85 \$9.85 \$12.27 \$0.79
Members per contract BRV: Projected Claims: Net Cost of Reinsurance: Projected Rx Rebate: State Mandates and Assessments Vaccines for Vemonters Blue Print for Health Health Care Claims Tax Federal Mandates and Assements PCORI Administrative Charge Commission (% premium)	B1 = A x S B2 B3 C1 C2 C3 = 0.8% * B1 D1 E F 3.00%	1.000 1.023 \$559.01 \$1.50 -\$4.00 \$2.50 \$2.50 \$4.47 \$0.20	2.000 2.046 \$1,118.01 \$3.00 -\$8.00 \$5.00 \$5.00 \$8.94 \$0.40	3.938 2.806 \$1,533.35 \$5.91 -\$15.76 \$9.85 \$9.85 \$12.27 \$0.79

\$546.44

a	b	с	d	Z	Y	g = b*Z + c*(1-Z)*Y + d*(1-Z)*(1-Y)
		BCBSVT		Credibility	Credibility (BCBSVT	Insured net
<u>Limits</u>	Insured Groups	Combined	<u>Milliman</u>	(Insured)	Combined)	<u>claim factor</u>
\$30,000	48.5%	45.0%	43.0%	59.5 %	100.0%	47.1%
\$35,000	42.4%	39.3%	37.9%	48.8%	100.0%	40.8%
\$40,000	37.7%	34.8%	33.9%	41.1%	100.0%	36.0%
\$45,000	34.0%	31.1%	30.6%	35.4%	100.0%	32.1%
\$50,000	30.8%	28.2%	27.9%	30.9%	100.0%	29.0%
\$55,000	28.2%	25.7%	25.6%	27.3%	100.0%	26.4%
\$60,000	26.0%	23.5%	23.6%	24.5%	100.0%	24.1%
\$65,000	24.1%	21.7%	21.9%	22.1%	87.6%	22.2%
\$70,000	22.4%	20.1%	20.4%	20.1%	77.4%	20.6%
\$75,000	20.9%	18.7%	19.1%	18.4%	69.1%	19.2%
\$80,000	19.6%	17.4%	17.9%	16.9%	62.1%	17.9%
\$85,000	18.4%	16.3%	16.9%	15.6%	56.1%	16.8%
\$90,000	17.3%	15.3%	16.0%	14.5%	51.0%	15.9%
\$95,000	16.4%	14.4%	15.1%	13.6%	46.7%	15.0%
\$100,000	15.5%	13.6%	14.4%	12.7%	42.9%	14.2%
\$105,000	14.8%	12.8%	13.7%	11.9%	39.5%	13.5%
\$110,000	14.0%	12.2%	13.0%	11.2%	36.6%	12.8%
\$115,000	13.4%	11.5%	12.4%	10.6%	34.0%	12.3%
\$120,000	12.8%	11.0%	11.9%	10.1%	31.7%	11.7%
\$125,000	12.2%	10.5%	11.4%	9.5%	29.6%	11.2%
\$130,000	11.7%	10.0%	10.9%	9.1%	27.7%	10.7%
\$135,000	11.2%	9.5%	10.4%	8.6%	26.0%	10.3%
\$140,000	10.8%	9.1%	10.0%	8.3%	24.5%	9.9%
\$145,000	10.4%	8.7%	9.6%	7.9%	23.1%	9.5%
\$150,000	10.0%	8.3%	9.3%	7.6%	21.9%	9.1%
\$155,000	9.6%	8.0%	8.9%	7.2%	20.7%	8.8%
\$160,000	9.2%	7.6%	8.6%	7.0%	19.7%	8.5%
\$165,000	8.9 %	7.3%	8.3%	6.7%	18.7%	8.2%
\$170,000	8.6%	7.0%	8.0%	6.4%	17.8%	7.9%
\$175,000	8.3%	6.7%	7.8%	6.2%	16.9%	7.6%
\$180,000	8.0%	6.5%	7.5%	6.0%	16.2%	7.4%
\$185,000	7.7%	6.2%	7.2%	5.8%	15.4%	7.1%
\$190,000	7.4%	6.0%	7.0%	5.6%	14.8%	6.9%
\$195,000	7.2%	5.8%	6.8%	5.4%	14.2%	6.7%
\$200,000	7.0%	5.6%	6.6%	5.2%	13.6%	6.5%
\$205,000	6.7%	5.4%	6.4%	5.1%	13.0%	6.3%
\$210,000	6.5%	5.2%	6.2%	4.9%	12.5%	6.1%
\$215,000	6.3%	5.0%	6.0%	4.8%	12.0%	5.9%
\$220,000	6.1%	4.8%	5.8%	4.6%	11.6%	5.7%
\$225,000	5.9%	4.6%	5.7%	4.5%	11.2%	5.6%
\$230,000	5.8%	4.5%	5.5%	4.4%	10.8%	5.4%
\$235,000	5.6%	4.3%	5.4%	4.2%	10.4%	5.3%
\$240,000	5.4%	4.2%	5.2%	4.1%	10.0%	5.1%
\$245,000	5.3%	4.1%	5.1%	4.0%	9.7%	5.0%
\$250,000	5.1%	3.9%	4.9%	3.9%	9.4%	4.9%
\$255,000	5.0%	3.8%	4.8%	3.8%	9.1%	4.7%
\$260,000	4.9%	3.7%	4.7%	3.7%	8.8%	4.6%

a	b	c	d	Z	Y	g = b*Z + c*(1-Z)*Y + d*(1-Z)*(1-Y)
		BCBSVT		Credibility	Credibility (BCBSVT	Insured net
<u>Limits</u>	Insured Groups	Combined	<u>Milliman</u>	(Insured)	Combined)	claim factor
\$265,000	4.7%	3.6%	4.6%	3.6%	8.5%	4.5%
\$270,000	4.6%	3.5%	4.5%	3.6%	8.2%	4.4%
\$275,000	4.5%	3.4%	4.4%	3.5%	8.0%	4.3%
\$280,000	4.4%	3.3%	4.2%	3.4%	7.8%	4.2%
\$285,000	4.3%	3.2%	4.1%	3.3%	7.5%	4.1%
\$290,000	4.2%	3.1%	4.0%	3.2%	7.3%	4.0%
\$295,000	4.1%	3.0%	3.9%	3.2%	7.1%	3.9%
\$300,000	3.9%	2.9%	3.9%	3.1%	6.9%	3.8%
\$305,000	3.8%	2.8%	3.8%	3.0%	6.7%	3.7%
\$310,000	3.7%	2.7%	3.7%	3.0%	6.6%	3.6%
\$315,000	3.6%	2.7%	3.6%	2.9%	6.4%	3.5%
\$320,000	3.5%	2.6%	3.5%	2.9%	6.2%	3.4%
\$325,000	3.5%	2.5%	3.4%	2.8%	6.1%	3.4%
\$330,000	3.4%	2.4%	3.4%	2.7%	5.9%	3.3%
\$335,000	3.3%	2.4%	3.3%	2.7%	5.8%	3.2%
\$340,000	3.2%	2.3%	3.2%	2.6%	5.6%	3.2%
\$345,000	3.1%	2.2%	3.1%	2.6%	5.5%	3.1%
\$350,000	3.0%	2.2%	3.1%	2.6%	5.4%	3.0%
\$355,000	3.0%	2.1%	3.0%	2.5%	5.2%	2.9%
\$360,000	2.9%	2.1%	2.9%	2.5%	5.1%	2.9%
\$365,000	2.8%	2.0%	2.9%	2.4%	5.0%	2.8%
\$370,000	2.8%	2.0%	2.8%	2.4%	4.9%	2.8%
\$375,000	2.7%	1.9%	2.8%	2.3%	4.8%	2.7%
\$380,000	2.6%	1.9%	2.7%	2.3%	4.7%	2.7%
\$385,000	2.6%	1.8%	2.6%	2.3%	4.6%	2.6%
\$390,000	2.5%	1.8%	2.6%	2.2%	4.5%	2.6%
\$395,000	2.5%	1.7%	2.5%	2.2%	4.4%	2.5%
\$400,000	2.4%	1.7%	2.5%	2.1%	4.3%	2.4%
\$405,000	2.4%	1.6%	2.4%	2.1%	4.2%	2.4%
\$410,000	2.3%	1.6%	2.4%	2.1%	4.1%	2.3%
\$415,000	2.3%	1.5%	2.3%	2.0%	4.0%	2.3%
\$420,000	2.3%	1.5%	2.3%	2.0%	4.0%	2.2%
\$425,000	2.2%	1.5%	2.2%	2.0%	3.9%	2.2%
\$430,000	2.2%	1.4%	2.2%	2.0%	3.8%	2.2%
\$435,000	2.1%	1.4%	2.1%	1.9%	3.7%	2.1%
\$440,000	2.1%	1.4%	2.1%	1.9%	3.7%	2.1%
\$445,000	2.0%	1.3%	2.1%	1.9%	3.6%	2.0%
\$450,000	2.0%	1.3%	2.0%	1.8%	3.5%	2.0%
\$455,000	2.0%	1.3%	2.0%	1.8%	3.5%	2.0%
\$460,000	1.9%	1.2%	2.0%	1.8%	3.4%	1.9%
\$465,000	1.9%	1.2%	1.9%	1.8%	3.3%	1.9%
\$470,000	1.8%	1.2%	1.9%	1.7%	3.3%	1.9%
\$475,000	1.8%	1.2%	1.8%	1.7%	3.2%	1.8%
\$480,000	1.8%	1.1%	1.8%	1.7%	3.2%	1.8%
\$485,000	1.7%	1.1%	1.8%	1.7%	3.1%	1.7%
\$490,000	1.7%	1.1%	1.7%	1.7%	3.1%	1.7%
\$495,000	1.7%	1.1%	1.7%	1.6%	3.0%	1.7%

a	b	c	d	Z	Y	g = b*Z + c*(1-Z)*Y + d*(1-Z)*(1-Y)
				Cuedibility		lass used as st
<u>Limits</u>	Insured Groups	BCBSVT Combined	<u>Milliman</u>	Credibility (Insured)	Credibility (BCBSVT Combined)	<u>Insured net</u> <u>claim factor</u>
\$500,000	1.6%	1.0%	1.7%	<u>1.6%</u>	3.0%	1.6%
\$505,000 \$505,000	1.6%	1.0%	1.6%	1.6%	2.9%	1.6%
\$510,000 \$510,000	1.6%	1.0%	1.6%	1.6%	2.9%	1.6%
\$515,000 \$515,000	1.5%	1.0%	1.6%	1.6%	2.8%	1.6%
\$515,000 \$520,000	1.5%	0.9%	1.6%	1.5%	2.8%	1.5%
\$525,000	1.5%	0.9%	1.5%	1.5%	2.7%	1.5%
\$530,000	1.5%	0.9%	1.5%	1.5%	2.7%	1.5%
\$535,000	1.4%	0.9%	1.5%	1.5%	2.7%	1.5%
\$540,000	1.4%	0.9%	1.4%	1.5%	2.6%	1.4%
\$545,000	1.4%	0.8%	1.4%	1.4%	2.6%	1.4%
\$550,000	1.4%	0.8%	1.4%	1.4%	2.5%	1.4%
\$555,000	1.3%	0.8%	1.4%	1.4%	2.5%	1.3%
\$560,000	1.3%	0.8%	1.3%	1.4%	2.5%	1.3%
\$565,000	1.3%	0.8%	1.3%	1.4%	2.4%	1.3%
\$570,000	1.3%	0.8%	1.3%	1.4%	2.4%	1.3%
\$575,000	1.2%	0.7%	1.3%	1.3%	2.4%	1.3%
\$580,000	1.2%	0.7%	1.2%	1.3%	2.3%	1.2%
\$585,000	1.2%	0.7%	1.2%	1.3%	2.3%	1.2%
\$590,000	1.2%	0.7%	1.2%	1.3%	2.3%	1.2%
\$595,000	1.2%	0.7%	1.2%	1.3%	2.2%	1.2%
\$600,000	1.1%	0.7%	1.2%	1.3%	2.2%	1.2%
\$605,000	1.1%	0.7%	1.1%	1.3%	2.2%	1.1%
\$610,000	1.1%	0.6%	1.1%	1.3%	2.1%	1.1%
\$615,000	1.1%	0.6%	1.1%	1.2%	2.1%	1.1%
\$620,000	1.1%	0.6%	1.1%	1.2%	2.1%	1.1%
\$625,000	1.0%	0.6%	1.1%	1.2%	2.1%	1.1%
\$630,000	1.0%	0.6%	1.0%	1.2%	2.0%	1.0%
\$635,000	1.0%	0.6%	1.0%	1.2%	2.0%	1.0%
\$640,000	1.0%	0.6%	1.0%	1.2%	2.0%	1.0%
\$645,000	1.0%	0.6%	1.0%	1.2%	1.9%	1.0%
\$650,000	1.0%	0.5%	1.0%	1.2%	1.9%	1.0%
\$655,000	0.9%	0.5%	1.0%	1.1%	1.9%	1.0%
\$660,000	0.9%	0.5%	0.9%	1.1%	1.9%	0.9%
\$665,000	0.9%	0.5%	0.9%	1.1%	1.8%	0.9%
\$670,000	0.9%	0.5%	0.9%	1.1%	1.8%	0.9%
\$675,000	0.9%	0.5%	0.9%	1.1%	1.8%	0.9%
\$680,000	0.9%	0.5%	0.9%	1.1%	1.8%	0.9%
\$685,000	0.8%	0.5%	0.9%	1.1%	1.8%	0.9%
\$690,000	0.8%	0.5%	0.9%	1.1%	1.7%	0.8%
\$695,000	0.8%	0.5%	0.8%	1.1%	1.7%	0.8%
\$700,000	0.8%	0.4%	0.8%	1.0%	1.7%	0.8%
\$705,000	0.8%	0.4%	0.8%	1.0%	1.7%	0.8%
\$710,000	0.8%	0.4%	0.8%	1.0%	1.7%	0.8%
\$715,000	0.8%	0.4%	0.8%	1.0%	1.6%	0.8%
\$720,000	0.7%	0.4%	0.8%	1.0%	1.6%	0.8%
\$725,000	0.7%	0.4%	0.7%	1.0%	1.6%	0.7%
\$730,000	0.7%	0.4%	0.7%	1.0%	1.6%	0.7%

a	b	с	d	Z	Y	g = b*Z + c*(1-Z)*Y + d*(1-Z)*(1-Y)
				Cue dibility		
<u>Limits</u>	Insured Groups	BCBSVT Combined	Milliman	<u>Credibility</u> (Insured)	Credibility (BCBSVT Combined)	Insured net claim factor
\$735,000	0.7%	0.4%	0.7%	1.0%	1.6%	0.7%
\$740,000	0.7%	0.4%	0.7%	1.0%	1.5%	0.7%
\$740,000 \$745,000	0.7%	0.4%	0.7%	1.0%	1.5%	0.7%
\$745,000 \$750,000	0.7%	0.4%	0.7%	1.0%	1.5%	0.7%
\$755,000 \$755,000	0.7%	0.4%	0.7%	1.0%	1.5%	0.7%
\$760,000	0.7%	0.3%	0.7%	0.9%	1.5%	0.6%
\$765,000 \$765,000	0.6%	0.3%	0.7%	0.9%	1.5%	0.6%
\$770,000 \$770,000	0.6%	0.3%	0.6%	0.9%	1.5%	0.6%
\$775,000 \$775,000	0.6%	0.3%	0.6%	0.9%	1.4%	0.6%
\$775,000 \$780,000	0.6%	0.3%	0.6%	0.9%	1.4%	0.6%
\$785,000 \$785,000	0.6%	0.3%	0.6%	0.9%	1.4%	0.6%
\$790,000	0.6%	0.3%	0.6%	0.9%	1.4%	0.6%
\$795,000 \$795,000	0.6%	0.3%	0.6%	0.9%	1.4%	0.6%
\$795,000 \$800,000	0.6%	0.3%	0.6%	0.9%	1.4%	0.6%
\$800,000 \$805,000	0.6%	0.3%	0.6%	0.9%	1.3%	0.6%
\$805,000 \$810,000	0.6%	0.3%	0.6%	0.9%	1.3%	0.6%
\$815,000 \$815,000	0.5%	0.3%	0.6%	0.9%	1.3%	0.6%
\$815,000 \$820,000	0.5%	0.3%	0.6%	0.9%	1.3%	0.6%
\$820,000 \$825,000	0.5%	0.3%	0.6%	0.9%	1.3%	0.6%
\$823,000 \$830,000	0.5%	0.3%	0.6%	0.8%	1.3%	0.6%
\$830,000 \$835,000	0.5%	0.3%	0.6%	0.8%	1.3%	0.5%
\$833,000 \$840,000	0.5%	0.2%	0.5%	0.8%	1.3%	0.5%
\$845,000 \$845,000	0.5%	0.2%	0.5%	0.8%	1.2%	0.5%
\$850,000 \$850,000	0.5%	0.2%	0.5%	0.8%	1.2%	0.5%
\$855,000 \$855,000	0.5%	0.2%	0.5%	0.8%	1.2%	0.5%
\$860,000	0.5%	0.2%	0.5%	0.8%	1.2%	0.5%
\$865,000 \$865,000	0.5%	0.2%	0.5%	0.8%	1.2%	0.5%
\$870,000	0.5%	0.2%	0.5%	0.8%	1.2%	0.5%
\$875,000	0.4%	0.2%	0.5%	0.8%	1.2%	0.5%
\$880,000	0.4%	0.2%	0.5%	0.8%	1.2%	0.5%
\$885,000	0.4%	0.2%	0.5%	0.8%	1.2%	0.5%
\$890,000	0.4%	0.2%	0.5%	0.8%	1.1%	0.5%
\$895,000	0.4%	0.2%	0.5%	0.8%	1.1%	0.5%
\$900,000	0.4%	0.2%	0.5%	0.8%	1.1%	0.5%
\$905,000	0.4%	0.2%	0.5%	0.8%	1.1%	0.5%
\$910,000	0.4%	0.2%	0.4%	0.7%	1.1%	0.4%
\$915,000	0.4%	0.2%	0.4%	0.7%	1.1%	0.4%
\$920,000	0.4%	0.2%	0.4%	0.7%	1.1%	0.4%
\$925,000	0.4%	0.2%	0.4%	0.7%	1.1%	0.4%
\$930,000	0.4%	0.2%	0.4%	0.7%	1.1%	0.4%
\$935,000	0.4%	0.2%	0.4%	0.7%	1.1%	0.4%
\$940,000	0.4%	0.2%	0.4%	0.7%	1.0%	0.4%
\$940,000 \$945,000	0.4%	0.2%	0.4%	0.7%	1.0%	0.4%
\$950,000	0.4%	0.2%	0.4%	0.7%	1.0%	0.4%
\$955,000	0.3%	0.2%	0.4%	0.7%	1.0%	0.4%
\$960,000	0.3%	0.2%	0.4%	0.7%	1.0%	0.4%
\$965,000	0.3%	0.1%	0.4%	0.7%	1.0%	0.4%
<i>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</i>	0.070	5.170	0.1/0	0.770	1.0/0	0.1/0

a	b	с	d	Z	Y	g = b*Z + c*(1-Z)*Y + d*(1-Z)*(1-Y)
		BCBSVT		Credibility	Credibility (BCBSVT	Insured net
<u>Limits</u>	Insured Groups	Combined	<u>Milliman</u>	(Insured)	Combined)	claim factor
\$970,000	0.3%	0.1%	0.4%	0.7%	1.0%	0.4%
\$975,000	0.3%	0.1%	0.4%	0.7%	1.0%	0.4%
\$980,000	0.3%	0.1%	0.4%	0.7%	1.0%	0.3%
\$985,000	0.3%	0.1%	0.3%	0.7%	1.0%	0.3%
\$990,000	0.3%	0.1%	0.3%	0.7%	1.0%	0.3%
\$995,000	0.3%	0.1%	0.3%	0.7%	0.9%	0.3%
\$1,000,000	0.3%	0.1%	0.3%	0.7%	0.9%	0.3%

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Pooling Charge Factors

Experience Period Starting Quarter

	Q4 2015	Q1 2016	02 2016	<u>Q3 2016</u>		<u>Q1 2017</u>
	claim*	claim*	claim*	claim*	claim*	claim*
<u>Limit</u>	factor	factor	factor	factor	factor	factor
\$30,000	47.05%	47.71%	48.38%	49.06%	49.74%	50.43%
\$35,000	40.81%	41.40%	42.00%	42.61%	43.22%	43.85%
\$40,000	35.99%	36.53%	37.07%	37.62%	38.17%	38.73%
\$45,000	32.14%	32.63%	33.13%	33.63%	34.14%	34.65%
\$50,000	28.99 %	29.44%	29.90%	30.36%	30.83%	31.30%
\$55,000	26.37%	26.79%	27.21%	27.64%	28.07%	28.51%
\$60,000	24.13%	24.52%	24.92%	25.32%	25.73%	26.14%
\$65,000	22.24%	22.61%	22.97 %	23.35%	23.73%	24.11%
\$70,000	20.60%	20.95%	21.30%	21.66%	22.01%	22.37%
\$75,000	1 9.19 %	19.52%	19.84 %	20.18%	20.51%	20.85%
\$80,000	1 7.92 %	18.23%	18.55%	18.88%	19.20%	19.53%
\$85,000	1 6.85 %	17.14%	17.42%	17.71%	18.00%	18.33%
\$90,000	15 .87 %	16.15%	16.43%	16.71%	16.99%	17.28%
\$95,000	14.98%	15.25%	15.52%	15.80%	16.07%	16.35%
\$100,000	14.22%	14.47%	14.71%	14 .96 %	15.21%	15.4 9 %
\$105,000	13.50%	13.75%	13 .99 %	14.24%	14.48%	14.73%
\$110,000	12.84%	13.07%	13.31%	13.56%	13.79%	14.05%
\$115,000	12.27%	12.49%	12.70%	12.91%	13.14%	13.39%
\$120,000	11.71%	11.93%	12.14%	12.36%	12.57%	12. 79 %
\$125,000	11.20%	11.40%	11.61%	11.83%	12.04%	12.26%
\$130,000	10.73%	10.93%	11.13%	11.32%	11.53%	11.75%
\$135,000	10.28%	10.49%	10.68%	10.88%	11.07%	11.27%
\$140,000	9.88%	10.06%	10.25%	10.45%	10.64%	10.84%
\$145,000	9.50%	9.68 %	9.86 %	10.04%	10.22%	10.43%
\$150,000	9.13%	9.31%	9.49 %	9.67%	9.85 %	10.03%
\$155,000	8.80%	8.96 %	9.13%	9.32%	9.49 %	9.68%
\$160,000	8.48%	8.65%	8.81%	8.97 %	9.14%	9.34%
\$165,000	8.17%	8.34%	8.50%	8.67%	8.83%	9.00%
\$170,000	7.89 %	8.05%	8.20%	8.37%	8.53%	8.71%
\$175,000	7.62%	7.78%	7.93%	8.08%	8.24%	8.42%
\$180,000	7.36%	7.52%	7.67%	7.82%	7.97%	8.14%
\$185,000	7.11%	7.26%	7.41%	7.57%	7.72%	7.88%
\$190,000	6.90%	7.03%	7.16%	7.32%	7.47%	7.64%
\$195,000	6.69 %	6.83%	6.96 %	7.09%	7.22%	7.39%
\$200,000	6.48%	6.62%	6.75%	6.89 %	7.02%	7.16%
\$205,000	6.28%	6.42%	6.55%	6.69 %	6.82%	6.96 %

*Percentages to be applied to experience claims below limit, to derive expected claims over limit.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Pooling Charge Factors

	Experience Period Starting Quarter						
	<u>Q4 2015</u>	Q1 2016		Q3 2016		<u>Q1 2017</u>	
	claim*	claim*	claim*	claim*	claim*	claim*	
<u>Limit</u>	factor	factor	factor	<u>factor</u>	<u>factor</u>	factor	
\$210,000	6.07%	6.22%	6.35%	6.49%	6.62%	6.77%	
\$215,000	5. 89 %	6.02%	6.15%	6.30%	6.43%	6.57%	
\$220,000	5.74%	5.85%	5.96%	6.10%	6.24%	6.38%	
\$225,000	5.58%	5.70%	5.81%	5.92 %	6.05%	6.20%	
\$230,000	5.43%	5.55%	5.66%	5.78 %	5.88%	6.01%	
\$235,000	5.28 %	5.40%	5.51%	5.63%	5.74%	5.86%	
\$240,000	5.13%	5.25%	5.37%	5.48%	5.60%	5.72%	
\$245,000	4.98 %	5.10%	5.22%	5.34%	5.45%	5.57%	
\$250,000	4.85%	4.96 %	5.08%	5.20%	5.31%	5.43%	
\$255,000	4.74%	4.84%	4.93%	5.05%	5.17%	5.30%	
\$260,000	4.62%	4.72%	4.82%	4.92%	5.03%	5.16%	
\$265,000	4.51%	4.61%	4.71%	4.80%	4.90%	5.02%	
\$270,000	4.39%	4.50%	4.59%	4.69%	4.79 %	4.89 %	
\$275,000	4.28%	4.38%	4.48%	4.58%	4.68%	4.79%	
\$280,000	4.17%	4.27%	4.37%	4.47%	4.57%	4.68%	
\$285,000	4.07%	4.16%	4.26%	4.37%	4.47%	4.57%	
\$290,000	3.98 %	4.06%	4.15%	4.26%	4.36%	4.47%	
\$295,000	3.88%	3.97%	4.06%	4.15%	4.25%	4.36%	
\$300,000	3.79%	3.88%	3.97%	4.06%	4.15%	4.26%	
\$305,000	3.70%	3.80%	3.88%	3.97%	4.06%	4.15%	
\$310,000	3.61%	3.71%	3.80%	3.89 %	3.97 %	4.06%	
\$315,000	3.52%	3.62%	3.71%	3.80%	3.89 %	3.98%	
\$320,000	3.45%	3.53%	3.62%	3.71%	3.80%	3.90%	
\$325,000	3.38%	3.45%	3.54%	3.63%	3.72%	3.81%	
\$330,000	3.30%	3.38%	3.46%	3.54%	3.63%	3.73%	
\$335,000	3.23%	3.31%	3.39%	3.47%	3.55%	3.65%	
\$340,000	3.16%	3.24%	3.32%	3.40%	3.47%	3.56%	
\$345,000	3.08%	3.17%	3.25%	3.33%	3.40%	3.49%	
\$350,000	3.01%	3.10%	3.18%	3.26%	3.34%	3.42%	
\$355,000	2.94%	3.03%	3.11%	3.19%	3.27%	3.35%	
\$360,000	2.88%	2.96 %	3.04%	3.12%	3.20%	3.29%	
\$365,000	2.82%	2.89 %	2.97 %	3.05%	3.13%	3.22%	
\$370,000	2.77%	2.84%	2.90%	2.98 %	3.07%	3.15%	
\$375,000	2.71%	2.78%	2.85%	2.92 %	3.00%	3.09%	
\$380,000	2.66%	2.73%	2.79 %	2.86%	2.93%	3.02%	
\$385,000	2.61%	2.68%	2.74%	2.81%	2.87%	2.95 %	

*Percentages to be applied to experience claims below limit, to derive expected claims over limit.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Pooling Charge Factors

	Experience Period Starting Quarter							
	<u>Q4 2015</u>	Q1 2016		Q3 2016		<u>Q1 2017</u>		
	claim*	claim*	claim*	claim*	claim*	claim*		
<u>Limit</u>	factor	factor	factor	factor	factor	factor		
\$390,000	2.55%	2.62%	2.69%	2.76%	2.82%	2.89%		
\$395,000	2.50%	2.57%	2.64%	2.70%	2.77%	2.84%		
\$400,000	2.44%	2.52%	2.58%	2.65%	2.72%	2.79%		
\$405,000	2.39%	2.46%	2.53%	2.60%	2.67%	2.74%		
\$410,000	2.34%	2.41%	2.48%	2.55%	2.62%	2.69%		
\$415,000	2.28%	2.36%	2.43%	2.50%	2.57%	2.64%		
\$420,000	2.23%	2.30%	2.38%	2.45%	2.52%	2.59%		
\$425,000	2.19%	2.25%	2.32%	2.40%	2.47%	2.54%		
\$430,000	2.16%	2.21%	2.27%	2.35%	2.42%	2.49%		
\$435,000	2.12%	2.17%	2.23%	2.30%	2.37%	2.44%		
\$440,000	2.08%	2.14%	2.19 %	2.24%	2.32%	2.39%		
\$445,000	2.04%	2.10%	2.15%	2.21%	2.27%	2.34%		
\$450,000	2.00%	2.06%	2.12%	2.17%	2.22%	2.29 %		
\$455,000	1 .96 %	2.02%	2.08%	2.13%	2.19%	2.24%		
\$460,000	1.93%	1 .99 %	2.04%	2.10%	2.15%	2.21%		
\$465,000	1 .89 %	1.95%	2.00%	2.06%	2.12%	2.17%		
\$470,000	1.85%	1.91%	1.97%	2.02%	2.08%	2.13%		
\$475,000	1.81 %	1.87%	1.93%	1.99%	2.04%	2.10%		
\$480,000	1.77%	1.83%	1 .89 %	1.95%	2.01%	2.06%		
\$485,000	1.74%	1.80%	1.86%	1.92%	1.97%	2.03%		
\$490,000	1.70%	1.76%	1.82%	1.88%	1 .94 %	1.99%		
\$495,000	1.67%	1.72%	1.78%	1.84%	1.90%	1.96%		
\$500,000	1.65%	1.69%	1.75%	1.81%	1.87%	1 .92 %		
\$505,000	1.62%	1.66%	1.71%	1.77%	1.83%	1.89%		
\$510,000	1.59%	1.64%	1.68%	1.73%	1.79%	1.85%		
\$515,000	1.56%	1.61%	1.66%	1.70%	1.76%	1.82%		
\$520,000	1.53%	1.58%	1.63%	1.67%	1.72%	1.78%		
\$525,000	1.51%	1.56%	1.60%	1.65%	1.69%	1.75%		
\$530,000	1.48%	1.53%	1.57%	1.62%	1.67%	1.71%		
\$535,000	1.45%	1.50%	1.55%	1.60%	1.64%	1. 69 %		
\$540,000	1.42%	1.47%	1.52%	1.57%	1.61%	1.66%		
\$545,000	1.40%	1.45%	1.49%	1.54%	1.59%	1.64%		
\$550,000	1.37%	1.42%	1.47%	1.52%	1.56%	1.61%		
\$555,000	1.34%	1.39%	1.44%	1.49%	1.54%	1.58%		
\$560,000	1.32%	1.36%	1.41%	1.46%	1.51%	1.56%		
\$565,000	1.30%	1.34%	1.39%	1.44%	1.48%	1.53%		

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Pooling Charge Factors

	Experience Period Starting Quarter							
	<u>Q4 2015</u>	Q1 2016		Q3 2016		<u>Q1 2017</u>		
	claim*	claim*	claim*	claim*	claim*	claim*		
<u>Limit</u>	factor	factor	factor	factor	factor	factor		
\$570,000	1.27%	1.31%	1.36%	1.41%	1.46%	1.51%		
\$575,000	1.25%	1.29%	1.33%	1.38%	1.43%	1.48%		
\$580,000	1.23%	1.27%	1.31%	1.36%	1.41%	1.46%		
\$585,000	1.21%	1.25%	1.29%	1.33%	1.38%	1.43%		
\$590,000	1.1 9 %	1.23%	1.27%	1.31%	1.36%	1.41%		
\$595,000	1.17%	1.21%	1.25%	1.29%	1.33%	1.38%		
\$600,000	1.15%	1.19%	1.23%	1.27%	1.31%	1.35%		
\$605,000	1.13%	1.17%	1.21%	1.25%	1.29%	1.33%		
\$610,000	1.11%	1.15%	1.19%	1.23%	1.27%	1.31%		
\$615,000	1.09%	1.13%	1.17%	1.21%	1.25%	1.29%		
\$620,000	1.07%	1.11%	1.15%	1.19%	1.23%	1.27%		
\$625,000	1.05%	1.09%	1.13%	1.17%	1.21%	1.25%		
\$630,000	1.03%	1.07%	1.11%	1.16%	1.1 9 %	1.23%		
\$635,000	1.02%	1.05%	1.10%	1.14%	1.18%	1.22%		
\$640,000	1.00%	1.04%	1.08%	1.12%	1.16%	1.20%		
\$645,000	0.99 %	1.02%	1.06%	1.10%	1.14%	1.18%		
\$650,000	0.97%	1.01%	1.04%	1.08%	1.12%	1.16%		
\$655,000	0.96%	0.99%	1.02%	1.06%	1.10%	1.14%		
\$660,000	0.94%	0.98%	1.01%	1.04%	1.08%	1.12%		
\$665,000	0.93%	0.96%	0.99%	1.02%	1.06%	1.10%		
\$670,000	0.91%	0.94%	0.98%	1.01%	1.04%	1.08%		
\$675,000	0.90%	0.93%	0.96%	1.00%	1.03%	1.07%		
\$680,000	0.88%	0.91%	0.95%	0.98%	1.01%	1.05%		
\$685,000	0.86%	0.90%	0.93%	0.97%	1.00%	1.03%		
\$690,000	0.85%	0.88%	0.92%	0.95%	0.98%	1.02%		
\$695,000	0.83%	0.87%	0.90%	0.94%	0.97%	1.00%		
\$700,000	0.82%	0.85%	0.89%	0.92%	0.96%	0.99%		
\$705,000	0.80%	0.84%	0.87%	0.91%	0.94%	0.97%		
\$710,000	0.79%	0.82%	0.86%	0.89%	0.93%	0.96%		
\$715,000	0.77%	0.81%	0.84%	0.88%	0.91%	0.95%		
\$720,000	0.76%	0.79%	0.83%	0.86%	0.90%	0.93%		
\$725,000	0.74%	0.78%	0.81%	0.85%	0.88%	0.92%		
\$730,000	0.73%	0.76%	0.80%	0.83%	0.87%	0.90%		
\$735,000	0.71%	0.75%	0.78%	0.82%	0.86%	0.89%		
\$740,000	0.70%	0.73%	0.77%	0.81%	0.84%	0.88%		
\$745,000	0.68%	0.72%	0.76%	0.79%	0.83%	0.86%		

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Pooling Charge Factors

Experience Period Starting Quarter

	<u>Q4 2015</u> <u>Q1 2016</u> <u>Q2</u>		Q2 2016			<u>Q1 2017</u>
	claim*	claim*	claim*	claim*	claim*	claim*
Limit	factor	factor	factor	factor	factor	factor
\$750,000	0.67%	0.70%	0.74%	0.78%	0.81%	0.85%
\$755,000	0.66%	0.69%	0.73%	0.76%	0.80%	0.83%
\$760,000	0.65%	0.67%	0.71%	0.75%	0.78%	0.82%
\$765,000	0.64%	0.66%	0.70%	0.73%	0.77%	0.81%
\$770,000	0.63%	0.65%	0.68%	0.72%	0.76%	0.79%
\$775,000	0.63%	0.65%	0.67%	0.70%	0.74%	0.78%
\$780,000	0.62%	0.64%	0.66%	0.69%	0.73%	0.76%
\$785,000	0.61%	0.63%	0.65%	0.68%	0.71%	0.75%
\$790,000	0.61%	0.63%	0.64%	0.66%	0.70%	0.74%
\$795,000	0.60%	0.62%	0.64%	0.65%	0.68%	0.72%
\$800,000	0.59%	0.61%	0.63%	0.65%	0.67%	0.71%
\$805,000	0.59%	0.61%	0.62%	0.64%	0.66%	0.69%
\$810,000	0.58%	0.60%	0.62%	0.63%	0.65%	0.68%
\$815,000	0.57%	0.59%	0.61%	0.63%	0.64%	0.66%
\$820,000	0.57%	0.59%	0.60%	0.62%	0.64%	0.65%
\$825,000	0.56%	0.58%	0.60%	0.61%	0.63%	0.65%
\$830,000	0.55%	0.57%	0.59%	0.61%	0.62%	0.64%
\$835,000	0.55%	0.56%	0.58%	0.60%	0.62%	0.64%
\$840,000	0.54%	0.56%	0.58%	0.59%	0.61%	0.63%
\$845,000	0.53%	0.55%	0.57%	0.59%	0.61%	0.62%
\$850,000	0.53%	0.54%	0.56%	0.58%	0.60%	0.62%
\$855,000	0.52%	0.54%	0.56%	0.58%	0.59%	0.61%
\$860,000	0.51%	0.53%	0.55%	0.57%	0.59%	0.60%
\$865,000	0.51%	0.52%	0.54%	0.56%	0.58%	0.60%
\$870,000	0.50%	0.52%	0.54%	0.56%	0.57%	0.59%
\$875,000	0.49%	0.51%	0.53%	0.55%	0.57%	0.59%
\$880,000	0.48%	0.50%	0.52%	0.54%	0.56%	0.58%
\$885,000	0.48%	0.50%	0.52%	0.54%	0.55%	0.57%
\$890,000	0.47%	0.49%	0.51%	0.53%	0.55%	0.57%
\$895,000	0.46%	0.48%	0.50%	0.52%	0.54%	0.56%
\$900,000	0.46%	0.48%	0.50%	0.52%	0.54%	0.55%
\$905,000	0.45%	0.47%	0.49%	0.51%	0.53%	0.55%
\$910,000	0.44%	0.46%	0.48%	0.50%	0.52%	0.54%
\$915,000	0.44%	0.46%	0.48%	0.50%	0.52%	0.54%
\$920,000	0.43%	0.45%	0.47%	0.49%	0.51%	0.53%
\$925,000	0.42%	0.44%	0.46%	0.48%	0.50%	0.52%

Exhibit 2B

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Pooling Charge Factors

	Experience Period Starting Quarter									
	<u>Q4 2015</u>	<u>Q1 2016</u>	<u>Q2 2016</u>	<u>Q3 2016</u>	<u>Q4 2016</u>	<u>Q1 2017</u>				
	claim*	claim*	claim*	claim*	claim*	claim*				
<u>Limit</u>	<u>factor</u>	<u>factor</u>	<u>factor</u>	<u>factor</u>	<u>factor</u>	<u>factor</u>				
\$930,000	0.42%	0.44%	0.46%	0.48%	0.50%	0.52%				
\$935,000	0.41%	0.43%	0.45%	0.47%	0.49%	0.51%				
\$940,000	0.40%	0.42%	0.45%	0.47%	0.48%	0.50%				
\$945,000	0.40%	0.42%	0.44%	0.46%	0.48%	0.50%				
\$950,000	0.39%	0.41%	0.43%	0.45%	0.47%	0.49%				
\$955,000	0.38%	0.40%	0.43%	0.45%	0.47%	0.49%				
\$960,000	0.38%	0.40%	0.42%	0.44%	0.46%	0.48%				
\$965,000	0.37%	0.39%	0.41%	0.43%	0.45%	0.47%				
\$970,000	0.36%	0.38%	0.41%	0.43%	0.45%	0.47%				
\$975,000	0.36%	0.38%	0.40%	0.42%	0.44%	0.46%				
\$980,000	0.35%	0.37%	0.39%	0.41%	0.43%	0.45%				
\$985,000	0.34%	0.36%	0.39%	0.41%	0.43%	0.45%				
\$990,000	0.34%	0.36%	0.38%	0.40%	0.42%	0.44%				
\$995,000	0.33%	0.35%	0.37%	0.39%	0.42%	0.44%				
\$1,000,000	0.32%	0.35%	0.37%	0.39%	0.41%	0.43%				

Illustration of Contract Normalization

	Contract	Normalization	Experience	Normalized
Month	Increase	Factor	Claims	Claims
Dec-12		1.1699	\$1,000,000	\$1,169,859
Jan-13		1.1699	\$1,000,000	\$1,169,859
Feb-13		1.1699	\$1,000,000	\$1,169,859
Mar-13		1.1699	\$1,000,000	\$1,169,859
Apr-13		1.1699	\$1,000,000	\$1,169,859
May-13		1.1699	\$1,000,000	\$1,169,859
Jun-13		1.1699	\$1,000,000	\$1,169,859
Jul-13		1.1699	\$1,000,000	\$1,169,859
Aug-13		1.1699	\$1,000,000	\$1,169,859
Sep-13		1.1699	\$1,000,000	\$1,169,859
Oct-13	1.0400	1.1249	\$1,000,000	\$1,124,864
Nov-13		1.1249	\$1,000,000	\$1,124,864
Dec-13		1.1249	\$1,000,000	\$1,124,864
Jan-14		1.1249	\$1,000,000	\$1,124,864
Feb-14		1.1249	\$1,000,000	\$1,124,864
Mar-14		1.1249	\$1,000,000	\$1,124,864
Apr-14		1.1249	\$1,000,000	\$1,124,864
May-14		1.1249	\$1,000,000	\$1,124,864
Jun-14		1.1249	\$1,000,000	\$1,124,864
Jul-14		1.1249	\$1,000,000	\$1,124,864
Aug-14		1.1249	\$1,000,000	\$1,124,864
Sep-14		1.1249	\$1,000,000	\$1,124,864
Oct-14	1.0400	1.0816	\$1,000,000	\$1,081,600
Nov-14		1.0816	\$1,000,000	\$1,081,600
Dec-14		1.0816	\$1,000,000	\$1,081,600
Jan-15		1.0816	\$1,000,000	\$1,081,600
Feb-15		1.0816	\$1,000,000	\$1,081,600
Mar-15		1.0816	\$1,000,000	\$1,081,600
Apr-15		1.0816	\$1,000,000	\$1,081,600
May-15		1.0816	\$1,000,000	\$1,081,600
Jun-15		1.0816	\$1,000,000	\$1,081,600
Jul-15		1.0816	\$1,000,000	\$1,081,600
Aug-15		1.0816	\$1,000,000	\$1,081,600
Sep-15		1.0816	\$1,000,000	\$1,081,600
Oct-15	1.0400	1.0400	\$1,000,000	\$1,040,000
Nov-15		1.0400	\$1,000,000	\$1,040,000
Dec-15		1.0400	\$1,000,000	\$1,040,000
Jan-16		1.0400	\$1,000,000	\$1,040,000
Feb-16		1.0400	\$1,000,000	\$1,040,000
Mar-16		1.0400	\$1,000,000	\$1,040,000
Apr-16		1.0400	\$1,000,000	\$1,040,000
May-16		1.0400	\$1,000,000	\$1,040,000
Jun-16		1.0400	\$1,000,000	\$1,040,000
Jul-16		1.0400	\$1,000,000	\$1,040,000
Aug-16		1.0400	\$1,000,000	\$1,040,000
Sep-16		1.0400	\$1,000,000	\$1,040,000
Oct-16	1.0400	1.0000	\$1,000,000	\$1,000,000
Nov-16		1.0000	\$1,000,000	\$1,000,000

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Medical Trend Development Utilization Trend Calculation

				Adjusted Claims -			
		Original Claims	Original PMPM	Normalized for	Adjusted	Regression on Adjusted	Rolling 12
Month	Membership	-	_	Contract Changes	PMPM	PMPM - 24 Months	PMPM
Nov-12	88,923	\$33,095,262	\$372.18	\$38,965,529	\$438.19	\$414.25	
Dec-12	88,775	\$29,730,346	\$334.90	\$33,285,444	\$374.94	\$414.76	
Jan-13	87,454	\$34,727,441	\$397.09	\$39,000,528	\$445.95	\$415.29	
Feb-13	87,369	\$33,110,638	\$378.97	\$37,426,849	\$428.38	\$415.81	
Mar-13	87,378	\$34,592,332	\$395.89	\$38,778,941	\$443.81	\$416.29	
Apr-13	87,188	\$34,288,529	\$393.27	\$38,313,206	\$439.43	\$416.82	
May-13	87,414	\$34,874,532	\$398.96	\$39,353,818	\$450.20	\$417.33	
Jun-13	87,331	\$32,427,235	\$371.31	\$36,512,475	\$418.09	\$417.86	
Jul-13	87,446	\$33,666,958	\$385.00	\$37,416,998	\$427.89	\$418.37	
Aug-13	87,399	\$34,050,390	\$389.60	\$37,890,167	\$433.53	\$418.90	
Sep-13	87,802	\$30,058,347	\$342.34	\$33,491,069	\$381.44	\$419.43	
Oct-13	87,792	\$35,010,312	\$398.79	\$38,608,348	\$439.77	\$419.95	\$426.74
Nov-13	87,664	\$32,424,576	\$369.87	\$35,866,630	\$409.14	\$420.48	\$424.30
Dec-13	87,613	\$35,281,176	\$402.69	\$39,268,940	\$448.21	\$420.99	\$430.47
Jan-14	86,608	\$36,259,154	\$418.66	\$39,556,165	\$456.73	\$421.53	\$431.35
Feb-14	86,619	\$31,781,025	\$366.91	\$34,688,530	\$400.47	\$422.06	\$429.04
Mar-14	86,439	\$33,999,473	\$393.33	\$37,117,279	\$429.40	\$422.54	\$427.84
Apr-14	86,104	\$36,049,659	\$418.68	\$39,348,385	\$456.99	\$423.08	\$429.27
May-14	86,606	\$33,368,019	\$385.29	\$36,255,868	\$418.63	\$423.60	\$426.64
Jun-14	86,367	\$34,598,001	\$400.59	\$37,503,072	\$434.23	\$424.14	\$427.98
Jul-14	85,471	\$34,197,792	\$400.11	\$37,105,045	\$434.12	\$424.66	\$428.50
Aug-14	85,426	\$32,095,838	\$375.72	\$34,732,067	\$406.57	\$425.20	\$426.27
Sep-14	86,092	\$32,655,694	\$379.31	\$35,163,816	\$408.44	\$425.73	\$428.58
Oct-14	86,136	\$36,676,567	\$425.80	\$39,482,709	\$458.38	\$426.26	\$430.11
Nov-14	86,037	\$32,923,542	\$382.67	\$35,285,374	\$410.12	\$426.80	\$430.23
Dec-14	86,185	\$35,977,416	\$417.44	\$38,528,134	\$447.04	\$427.32	\$430.10
Jan-15	84,280	\$35,478,032	\$420.95	\$37,171,528	\$441.05	\$427.86	\$428.76
Feb-15	84,304	\$33,234,409	\$394.22	\$34,750,964	\$412.21	\$428.41	\$429.79
Mar-15	84,197	\$35,657,416	\$423.50	\$37,219,684	\$442.05	\$428.90	\$430.83
Apr-15	83,735	\$35,977,302	\$429.66	\$37,496,951	\$447.80	\$429.44	\$430.02
May-15	83,665	\$31,951,087	\$381.89	\$33,272,811	\$397.69	\$429.97	\$428.33
Jun-15	83,926	\$36,697,322	\$437.26	\$38,185,603	\$454.99	\$430.51	\$430.03
Jul-15	83,032	\$35,521,369	\$427.80	\$36,898,056	\$444.38	\$431.04	\$430.86
Aug-15	82,740	\$31,851,061	\$384.95	\$33,030,471	\$399.21	\$431.59	\$430.32
Sep-15	82,840	\$33,112,956	\$399.72	\$34,338,973	\$414.52	\$432.13	\$430.89
Oct-15	82,757	\$35,203,678	\$425.39	\$36,324,701	\$438.93	\$432.66	\$429.20
Nov-15	82,866	\$34,449,927	\$415.73	\$35,506,233	\$428.48	\$433.21	\$430.77
Dec-15	82,966	\$34,906,225	\$420.73	\$35,926,918	\$433.03	\$433.74	\$429.56
Jan-16	71,911	\$29,105,306	\$404.74	\$29,357,977	\$408.25	\$434.29	\$427.03
Feb-16	71,491	\$28,899,540	\$404.24	\$29,064,196	\$406.54	\$434.84	\$426.81
Mar-16	71,433	\$33,294,413	\$466.09	\$33,468,500	\$468.53	\$435.36	\$428.57
Apr-16	71,293	\$30,468,308	\$427.37	\$30,587,810	\$429.04	\$435.91	\$426.92
May-16	70,642	\$30,583,144	\$432.93	\$30,751,184	\$435.31	\$436.45	\$430.15
Jun-16	70,409	\$33,417,790	\$474.62	\$33,570,861	\$476.80	\$437.00	\$431.45
Jul-16	69,594	\$28,766,447	\$413.35	\$28,851,451	\$414.57	\$437.54	\$428.98
Aug-16	69,465	\$31,962,821	\$460.13	\$32,013,565	\$460.86	\$438.09	\$434.19

Annual Increase

1.5%

0.9%

Impact of Benefit Changes on Utilization

	1			1			1		
		Adjusted Claims -		Regression on	Average	Normalization	Adjusted Claims - Normalized for		Regression on
		Normalized for	Adjusted	Adjusted PMPM - 24	Induced	Factor for	Contract Changes and	Adjusted	Adjusted PMPM - 24
		Contract Changes	PMPM	Months	Utilization	Induced	Induced Utilization	PMPM	Months
Month	Membership	5			Factor	Utilization	Factor		
Sep-14	86,092	\$35,163,816	\$408.44	\$425.73	0.9644	0.9952	\$34,996,237	\$406.50	\$425.45
Oct-14	86,136	\$39,482,709	\$458.38	\$426.26	0.9634	0.9963	\$39,335,167	\$456.66	\$426.08
Nov-14	86,037	\$35,285,374	\$410.12	\$426.80	0.9621	0.9977	\$35,204,089	\$409.17	\$426.73
Dec-14	86,185	\$38,528,134	\$447.04	\$427.32	0.9608	0.9990	\$38,490,020	\$446.60	\$427.36
Jan-15	84,280	\$37,171,528	\$441.05	\$427.86	0.9606	0.9992	\$37,141,190	\$440.69	\$428.01
Feb-15	84,304	\$34,750,964	\$412.21	\$428.41	0.9604	0.9994	\$34,729,571	\$411.96	\$428.66
Mar-15	84,197	\$37,219,684	\$442.05	\$428.90	0.9590	1.0009	\$37,253,415	\$442.46	\$429.25
Apr-15	83,735	\$37,496,951	\$447.80	\$429.44	0.9577	1.0022	\$37,579,204	\$448.79	\$429.90
May-15	83,665	\$33,272,811	\$397.69	\$429.97	0.9574	1.0026	\$33,357,753	\$398.71	\$430.54
Jun-15	83,926	\$38,185,603	\$454.99	\$430.51	0.9568	1.0031	\$38,305,798	\$456.42	\$431.19
Jul-15	83,032	\$36,898,056	\$444.38	\$431.04	0.9562	1.0038	\$37,039,933	\$446.09	\$431.83
Aug-15	82,740	\$33,030,471	\$399.21	\$431.59	0.9554	1.0047	\$33,184,253	\$401.07	\$432.49
Sep-15	82,840	\$34,338,973	\$414.52	\$432.13	0.9546	1.0055	\$34,526,130	\$416.78	\$433.14
Oct-15	82,757	\$36,324,701	\$438.93	\$432.66	0.9534	1.0068	\$36,570,962	\$441.91	\$433.78
Nov-15	82,866	\$35,506,233	\$428.48	\$433.21	0.9525	1.0077	\$35,780,818	\$431.79	\$434.44
Dec-15	82,966	\$35,926,918	\$433.03	\$433.74	0.9516	1.0086	\$36,237,005	\$436.77	\$435.08
Jan-16	71,911	\$29,357,977	\$408.25	\$434.29	0.9544	1.0057	\$29,524,771	\$410.57	\$435.75
Feb-16	71,491	\$29,064,196	\$406.54	\$434.84	0.9549	1.0051	\$29,213,733	\$408.64	\$436.41
Mar-16	71,433	\$33,468,500	\$468.53	\$435.36	0.9567	1.0033	\$33,579,663	\$470.09	\$437.03
Apr-16	71,293	\$30,587,810	\$429.04	\$435.91	0.9574	1.0026	\$30,665,877	\$430.14	\$437.70
May-16	70,642	\$30,751,184	\$435.31	\$436.45	0.9582	1.0017	\$30,802,782	\$436.04	\$438.34
Jun-16	70,409	\$33,570,861	\$476.80	\$437.00	0.9586	1.0013	\$33,613,591	\$477.40	\$439.01
Jul-16	69,594	\$28,851,451	\$414.57	\$437.54	0.9589	1.0010	\$28,879,207	\$414.97	\$439.66
Aug-16	69,465	\$32,013,565	\$460.86	\$438.09	0.9598	1.0000	\$32,013,565	\$460.86	\$440.33

Annual Increase

1.5%


1.8%

Impact of Benefit Chages	0.3%
Selected Utilization Trend	1.0%
Final Utilization Trend	1.3%

Generic Drugs - Cost Trend

		MONTH	_Y DATA		ROLLING 12				EXPONENTIAL FIT	
		Average				Average				
Incurred		Wholesale		Monthly		Wholesale		Rolling 12	Monthly	Rolling 12
Date	Supply	Price	AWP / Supply	Cost Trend	Supply	Price	AWP / Supply	Cost Trend	Data	Data
Oct-13	2,265,302	\$7,253,442	\$3.20							
Nov-13	2,121,453	\$6,890,535	\$3.25							
Dec-13	2,330,331	\$7,748,884	\$3.33						\$3.37	\$3.22
Jan-14	2,208,744	\$7,255,217	\$3.28						\$3.38	\$3.24
Feb-14	1,981,483	\$6,649,735	\$3.36						\$3.39	\$3.26
Mar-14	2,169,186	\$7,275,654	\$3.35						\$3.41	\$3.27
Apr-14	2,142,425	\$7,197,330	\$3.36						\$3.42	\$3.29
May-14	2,201,938	\$7,439,808	\$3.38						\$3.44	\$3.30
Jun-14	2,177,681	\$7,418,853	\$3.41						\$3.45	\$3.32
Jul-14	2,183,364	\$7,407,211	\$3.39						\$3.46	\$3.34
Aug-14	2,125,774	\$7,322,894	\$3.44						\$3.48	\$3.35
Sep-14	2,143,936	\$7,480,135	\$3.49		26,051,616	\$87,339,698	\$3.35		\$3.49	\$3.37
Oct-14	2,269,593	\$7,892,387	\$3.48	8.6%	26,055,907	\$87,978,642	\$3.38		\$3.51	\$3.39
Nov-14	2,074,398	\$7,272,032	\$3.51	7.9%	26,008,853	\$88,360,139	\$3.40		\$3.52	\$3.40
Dec-14	2,366,560	\$8,426,439	\$3.56	7.1%	26,045,082	\$89,037,694	\$3.42		\$3.54	\$3.42
Jan-15	2,149,349	\$7,563,049	\$3.52	7.1%	25,985,687	\$89,345,527	\$3.44		\$3.55	\$3.44
Feb-15	2,007,242	\$7,092,856	\$3.53	5.3%	26,011,446	\$89,788,648	\$3.45		\$3.57	\$3.46
Mar-15	2,236,538	\$8,036,412	\$3.59	7.1%	26,078,798	\$90,549,407	\$3.47		\$3.58	\$3.47
Apr-15	2,162,941	\$7,733,894	\$3.58	6.4%	26,099,314	\$91,085,971	\$3.49		\$3.59	\$3.49
May-15	2,133,558	\$7,647,472	\$3.58	6.1%	26,030,934	\$91,293,634	\$3.51		\$3.61	\$3.51
Jun-15	2,228,960	\$8,096,823	\$3.63	6.6%	26,082,213	\$91,971,604	\$3.53		\$3.62	\$3.53
Jul-15	2,148,547	\$7,834,374	\$3.65	7.5%	26,047,396	\$92,398,766	\$3.55		\$3.64	\$3.54
Aug-15	2,117,362	\$7,737,849	\$3.65	6.1%	26,038,984	\$92,813,721	\$3.56		\$3.65	\$3.56
Sep-15	2,106,914	\$7,743,606	\$3.68	5.3%	26,001,963	\$93,077,192	\$3.58	6.8%	\$3.67	\$3.58
Oct-15	2,181,592	\$8,093,134	\$3.71	6.7%	25,913,962	\$93,277,940	\$3.60	6.6%	\$3.68	\$3.60
Nov-15	2,088,172	\$7,838,378	\$3.75	7.1%	25,927,736	\$93,844,285	\$3.62	6.5%	\$3.70	\$3.61
Dec-15	2,337,915	\$9,071,729	\$3.88	9.0%	25,899,090	\$94,489,575	\$3.65	6.7%	\$3.71	\$3.63
Jan-16	1,936,583	\$7,198,354	\$3.72	5.6%	25,686,324	\$94,124,880	\$3.66	6.6%	\$3.73	\$3.65
Feb-16	1,887,392	\$7,103,542	\$3.76	6.5%	25,566,473	\$94,135,566	\$3.68	6.7%	\$3.75	\$3.67
Mar-16	2,045,241	\$7,687,932	\$3.76	4.6%	25,375,176	\$93,787,086	\$3.70	6.4%	\$3.76	\$3.69
Apr-16	1,939,781	\$7,270,927	\$3.75	4.8%	25,152,016	\$93,324,119	\$3.71	6.3%	\$3.78	\$3.71
May-16	1,983,834	\$7,505,022	\$3.78	5.5%	25,002,292	\$93,181,669	\$3.73	6.3%	\$3.79	\$3.72
Jun-16	2,004,386	\$7,623,343	\$3.80	4.7%	24,777,719	\$92,708,189	\$3.74	6.1%	\$3.81	\$3.74
Jul-16	1,876,262	\$7,103,515	\$3.79	3.8%	24,505,434	\$91,977,331	\$3.75	5.8%	\$3.82	\$3.76
Aug-16	2,001,917	\$7,602,330	\$3.80	3.9%	24,389,989	\$91,841,812	\$3.77	5.6%	\$3.84	\$3.78
Sep-16	1,894,923	\$7,231,781	\$3.82	3.8%	24,177,997	\$91,329,988	\$3.78	5.5%	\$3.85	\$3.80


Exponential Trend: 5.1% 6.2%



Brand Drugs - Cost Trend

		MONTH	Y DATA			ROLLIN	G 12		EXPONENTIAL FIT	
		Average				Average				
Incurred		Wholesale		Monthly		Wholesale		Rolling 12	Monthly	Rolling 12
Date	Supply	Price	AWP / Supply	Cost Trend	Supply	Price	AWP / Supply	Cost Trend	Data	Data
Oct-13	449,136	\$3,917,276	\$8.72							
Nov-13	419,342	\$3,601,759	\$8.59							
Dec-13	449,080	\$4,056,350	\$9.03						\$9.03	\$8.76
Jan-14	389,997	\$3,563,790	\$9.14						\$9.14	\$8.85
Feb-14	358,317	\$3,388,787	\$9.46						\$9.25	\$8.94
Mar-14	382,954	\$3,609,302	\$9.42						\$9.35	\$9.03
Apr-14	380,892	\$3,563,526	\$9.36						\$9.47	\$9.12
May-14	376,034	\$3,831,644	\$10.19						\$9.58	\$9.22
Jun-14	379,367	\$3,753,958	\$9.90						\$9.70	\$9.31
Jul-14	372,535	\$3,845,503	\$10.32						\$9.82	\$9.41
Aug-14	364,386	\$3,652,956	\$10.02						\$9.94	\$9.51
Sep-14	377,225	\$3,689,243	\$9.78		4,699,265	\$44,474,094	\$9.46		\$10.06	\$9.61
Oct-14	402,087	\$3,961,315	\$9.85	13.0%	4,652,216	\$44,518,133	\$9.57		\$10.18	\$9.71
Nov-14	358,298	\$4,046,277	\$11.29	31.5%	4,591,172	\$44,962,652	\$9.79		\$10.31	\$9.81
Dec-14	433,833	\$4,590,200	\$10.58	17.1%	4,575,924	\$45,496,502	\$9.94		\$10.43	\$9.91
Jan-15	350,411	\$3,765,256	\$10.75	17.6%	4,536,339	\$45,697,968	\$10.07		\$10.56	\$10.02
Feb-15	333,424	\$3,567,558	\$10.70	13.1%	4,511,445	\$45,876,739	\$10.17		\$10.69	\$10.13
Mar-15	361,017	\$3,903,314	\$10.81	14.7%	4,489,508	\$46,170,751	\$10.28		\$10.81	\$10.22
Apr-15	352,702	\$3,771,503	\$10.69	14.3%	4,461,318	\$46,378,728	\$10.40		\$10.94	\$10.33
May-15	345,506	\$3,873,970	\$11.21	10.0%	4,430,790	\$46,421,054	\$10.48		\$11.07	\$10.44
Jun-15	355,405	\$3,929,707	\$11.06	11.7%	4,406,828	\$46,596,803	\$10.57		\$11.21	\$10.55
Jul-15	339,242	\$3,831,948	\$11.30	9.4%	4,373,535	\$46,583,249	\$10.65		\$11.34	\$10.66
Aug-15	345,400	\$4,008,551	\$11.61	15.8%	4,354,550	\$46,938,844	\$10.78		\$11.48	\$10.77
Sep-15	337,809	\$3,888,175	\$11.51	17.7%	4,315,133	\$47,137,776	\$10.92	15.4%	\$11.63	\$10.88
Oct-15	362,989	\$4,132,427	\$11.38	15.6%	4,276,035	\$47,308,888	\$11.06	15.6%	\$11.76	\$11.00
Nov-15	352,014	\$4,045,734	\$11.49	1.8%	4,269,751	\$47,308,345	\$11.08	13.1%	\$11.91	\$11.11
Dec-15	398,340	\$4,575,528	\$11.49	8.6%	4,234,259	\$47,293,673	\$11.17	12.3%	\$12.05	\$11.23
Jan-16	310,221	\$3,722,816	\$12.00	11.7%	4,194,068	\$47,251,232	\$11.27	11.8%	\$12.20	\$11.35
Feb-16	295,201	\$3,493,853	\$11.84	10.6%	4,155,845	\$47,177,527	\$11.35	11.6%	\$12.35	\$11.47
Mar-16	335,856	\$4,159,306	\$12.38	14.5%	4,130,684	\$47,433,520	\$11.48	11.7%	\$12.49	\$11.58
Apr-16	310,301	\$3,820,001	\$12.31	15.1%	4,088,284	\$47,482,018	\$11.61	11.7%	\$12.65	\$11.70
May-16	294,829	\$3,754,412	\$12.73	13.6%	4,037,607	\$47,362,460	\$11.73	12.0%	\$12.80	\$11.82
Jun-16	303,728	\$4,227,512	\$13.92	25.9%	3,985,930	\$47,660,265	\$11.96	13.1%	\$12.96	\$11.95
Jul-16	276,328	\$3,773,739	\$13.66	20.9%	3,923,016	\$47,602,055	\$12.13	13.9%	\$13.11	\$12.07
Aug-16	291,426	\$3,930,361	\$13.49	16.2%	3,869,042	\$47,523,864	\$12.28	14.0%	\$13.27	\$12.20
Sep-16	288,062	\$3,971,983	\$13.79	19.8%	3,819,295	\$47,607,672	\$12.47	14.1%	\$13.44	\$12.33


Exponential Trend: 15.6% 13.3%



Non-Specialty Drugs - Utilization Trend

		MONTH	LY DATA			ROLLIN	G 12		EXPONEN	TAL FIT
				Monthly		-		Rolling 12		
Incurred			Supply per	Utilization			Supply per	Utilization		Rolling 12
Date	Membership	Supply	Member	Trend	Membership	Supply	Member	Trend	Monthly Data	Data
Oct-13	87,012	2,714,438	31.196							
Nov-13	86,891	2,540,795	29.241							
Dec-13	86,846	2,779,411	32.004						30.074	29.407
Jan-14	85,955	2,598,741	30.234						30.093	29.448
Feb-14	85,896	2,339,800	27.240						30.111	29.488
Mar-14	85,753	2,552,141	29.762						30.127	29.525
Apr-14	85,467	2,523,316	29.524						30.145	29.566
May-14	85,847	2,577,972	30.030						30.163	29.605
Jun-14	85,598	2,557,048	29.873						30.181	29.646
Jul-14	84,696	2,555,899	30.177						30.198	29.686
Aug-14	84,609	2,490,160	29.431						30.217	29.727
Sep-14	85,288	2,521,161	29.561		1,029,858	30,750,881	29.859		30.235	29.768
Oct-14	85,329	2,671,680	31.310	0.4%	1,028,175	30,708,123	29.867		30.252	29.808
Nov-14	85,265	2,432,696	28.531	-2.4%	1,026,549	30,600,024	29.809		30.270	29.849
Dec-14	85,377	2,800,393	32.800	2.5%	1,025,080	30,621,006	29.872		30.288	29.889
Jan-15	83,503	2,499,760	29.936	-1.0%	1,022,628	30,522,026	29.847		30.306	29.930
Feb-15	83,568	2,340,666	28.009	2.8%	1,020,300	30,522,892	29.916		30.325	29.971
Mar-15	83,423	2,597,555	31.137	4.6%	1,017,970	30,568,306	30.029		30.341	30.008
Apr-15	82,990	2,515,643	30.313	2.7%	1,015,493	30,560,632	30.094		30.359	30.050
May-15	82,836	2,479,064	29.927	-0.3%	1,012,482	30,461,724	30.086		30.377	30.090
Jun-15	83,112	2,584,365	31.095	4.1%	1,009,996	30,489,042	30.187		30.395	30.131
Jul-15	82,266	2,487,789	30.241	0.2%	1,007,566	30,420,932	30.192		30.413	30.172
Aug-15	81,946	2,462,762	30.053	2.1%	1,004,903	30,393,534	30.245		30.431	30.213
Sep-15	82,038	2,444,723	29.800	0.8%	1,001,653	30,317,096	30.267	1.4%	30.449	30.255
Oct-15	81,970	2,544,581	31.043	-0.9%	998,294	30,189,997	30.242	1.3%	30.467	30.295
Nov-15	82,047	2,440,186	29.741	4.2%	995,076	30,197,486	30.347	1.8%	30.485	30.337
Dec-15	82,123	2,736,255	33.319	1.6%	991,822	30,133,349	30.382	1.7%	30.503	30.378
Jan-16	75,134	2,246,804	29.904	-0.1%	983,453	29,880,392	30.383	1.8%	30.522	30.420
Feb-16	74,713	2,182,593	29.213	4.3%	974,598	29,722,319	30.497	1.9%	30.540	30.462
Mar-16	74,629	2,381,097	31.906	2.5%	965,804	29,505,860	30.551	1.7%	30.557	30.501
Apr-16	74,503	2,250,082	30.201	-0.4%	957,317	29,240,300	30.544	1.5%	30.575	30.543
May-16	73,846	2,278,664	30.857	3.1%	948,327	29,039,899	30.622	1.8%	30.593	30.584
Jun-16	73,597	2,308,114	31.362	0.9%	938,812	28,763,649	30.638	1.5%	30.612	30.626
Jul-16	72,790	2,152,590	29.573	-2.2%	929,336	28,428,450	30.590	1.3%	30.629	30.667
Aug-16	72,698	2,293,343	31.546	5.0%	920,088	28,259,030	30.713	1.5%	30.648	30.709
Sep-16	73,391	2,182,984	29.745	-0.2%	911,441	27,997,292	30.718	1.5%	30.666	30.751

Exponential Trend: 0.7% 1.6%



Generic	Dispensing	Rate	Develo	pment

			1	Generic Dispe	ensing Rate
			Total Non-		
	Generic	Brand	Specialty		
Month	Supply	Supply	Supply	Monthly	Rolling 12
Nov-14	2,074,398	358,298	2,432,696	85.3%	
Dec-14	2,366,560	433,833	2,800,393	84.5%	
Jan-15	2,149,349	350,411	2,499,760	86.0%	
Feb-15	2,007,242	333,424	2,340,666	85.8%	
Mar-15	2,236,538	361,017	2,597,555	86.1%	
Apr-15	2,162,941	352,702	2,515,643	86.0%	
May-15	2,133,558	345,506	2,479,064	86.1%	
Jun-15	2,228,960	355,405	2,584,365	86.2%	
Jul-15	2,148,547	339,242	2,487,789	86.4%	
Aug-15	2,117,362	345,400	2,462,762	86.0%	
Sep-15	2,106,914	337,809	2,444,723	86.2%	
Oct-15	2,181,592	362,989	2,544,581	85.7%	85.8
Nov-15	2,088,172	352,014	2,440,186	85.6%	85.9
Dec-15	2,337,915	398,340	2,736,255	85.4%	85.9
Jan-16	1,936,583	310,221	2,246,804	86.2%	86.0
Feb-16	1,887,392	295,201	2,182,593	86.5%	86.0
Mar-16	2,045,241	335,856	2,381,097	85.9%	86.0
Apr-16	1,939,781	310,301	2,250,082	86.2%	86.0
May-16	1,983,834	294,829	2,278,664	87.1%	86.1
Jun-16	2,004,386	303,728	2,308,114	86.8%	86.1
Jul-16	1,876,262	276,328	2,152,590	87.2%	86.2
Aug-16	2,001,917	291,426	2,293,343	87.3%	86.3
Sep-16	1,894,923	288,062	2,182,984	86.8%	86.4
Oct-16	2,252,562	342,844	2,595,406	86.8%	86.5
Nov-16	2,133,542	320,081	2,453,624	87.0%	86.6
Dec-16	2,390,866	362,116	2,752,982	86.8%	86.7
Jan-17	1,978,372	280,393	2,258,765	87.6%	86.8
Feb-17	1,928,317	266,759	2,195,076	87.8%	86.9
Mar-17	2,089,105	306,814	2,395,919	87.2%	87.0
Apr-17	1,985,263	277,972	2,263,235	87.7%	87.2
May-17	2,018,120	274,535	2,292,655	88.0%	87.2
Jun-17	2,040,174	283,117	2,323,290	87.8%	87.3
Jul-17	1,911,491	254,896	2,166,387	88.2%	87.4
Aug-17	2,037,234	271,679	2,308,913	88.2%	87.5
Sep-17	1,928,497	268,544	2,197,041	87.8%	87.6
Oct-17	2,287,862	319,680	2,607,542	87.7%	87.6
Nov-17	2,153,119	300,505	2,453,624	87.8%	87.7
Dec-17	2,433,105	319,877	2,752,982	88.4%	87.9
Jan-18	2,009,333	249,432	2,258,765	89.0%	88.0
Feb-18	1,958,308	236,767	2,195,076	89.2%	88.1
Mar-18	2,123,874	272,044	2,395,919	88.6%	88.2
Apr-18	2,009,634	253,601	2,263,235	88.8%	88.3
May-18	2,041,750	250,904	2,292,655	89.1%	88.4
Jun-18	2,067,128	256,162	2,323,290	89.0%	88.5
Jul-18	1,935,135	231,252	2,166,387	89.3%	88.6
Aug-18	2,065,835	243,078	2,308,913	89.5%	88.7
Sep-18	1,954,591	242,450	2,197,041	89.0%	88.7
Oct-18	2,321,031	286,511	2,607,542	89.0%	88.9
Nov-18	2,182,474	271,150	2,453,624	88.9%	89.0
Dec-18	2,446,790	306,192	2,752,982	88.9%	89.0

Non-Specialty Drugs


				Non-Specialty
For the 12 months ending September 2016:		Generic	Brand	Total
# Days Supply	a	24,177,997	3,819,295	27,997,292
Allowed Charge per Supply	b	\$0.76	\$9.84	
Total Allowed Charges	c=a*b	\$18,353,253	\$37,599,104	\$55,952,357
Utilization Trends	d			0.7%
Projected # Days Supply (12 months ending December 2018)	e=a*(1+d)^(27/12)			28,447,952
Projected Rolling-12 dispensing rate (Generic and Brand split)	f	89.0%	11.0%	
Non-Specialty Projected # Days Supply: Generic and Brand	g=e*f	25,322,865	3,125,088	
Utilization Trends: Generic and Brand	h=g/a-1	4.7%	-18.2%	
Cost Trends	i	5.1%	15.6%	
Projected Allowed Charge per Supply	$j=b^{*}(1+i)^{(27/12)}$	\$0.85	\$13.64	
Designed Total Allowed Channel	1	624 475 045	¢ 42 (2 (202	£(1 100 100
Projected Total Allowed Charges	k=g*j	\$21,475,915	\$42,624,282	\$64,100,198
Total Trends	l=k/c-1	17.0%	13.4%	14.6%
Annual Trends		7.2%	5.7%	6.2%
PMPM Calculation	-			
Member Months for the 12 months ending September 2016	m			911,441
PMPM by category	n=c/m	\$20.14	\$41.25	\$61.39

Specialty Drug Trend

Hortmet / MORTMET / DAT PARP Image: Constraint of the constrai	F	MONTHLY DATA				PMPM			00	11110 42			1011	EXPONENTIAL FIT	
Instructed Speciality Allowed Speciality Total Speciality Total Speciality Speciality <t< td=""><td>-</td><td></td><td></td><td></td><td></td><td>PMPM</td><td></td><td></td><td></td><td></td><td></td><td>PI</td><td>NPM</td><td>EXPUN</td><td></td></t<>	-					PMPM						PI	NPM	EXPUN	
Interme Allowed Nalwed Total Secialty Secialty Allowed Nalwer															
International Charges															
101/12013 67,012 5 1,746,295 51,746,295 50,007 50,007 111/12013 86,881 5 5 1,724,627 51,723,786 51,232,786 51,232,786 51,232,786 51,232,786 51,232,786 51,232,786 51,232,786 51,232,786 51,232,786 51,232,786 51,232,786 51,244,647 51,744,747 51,724,747 52,722,747 52,722,747 52,722,747 52,722,747 52,722,747 52,722,747 52,722,747 52,722,747 52,722,747 52,722,747 52,722,748 52,722,748 52,724,748 52,724,748 52,724,748 52,724,748 52,724,748 52,724,748 52,724,748 52,724,748 52,724,748 52,724,748 52,724,748 52,744,748 52,744,748 52,744,															
111/12013 86,881 \$ • • 5 1,523,786 \$ 1,523,786 \$ 1,523,786 \$ 1,523,786 \$ 1,523,786 \$ 1,523,786 \$ 1,523,786 \$ 1,784,687 \$ 5,20,55 \$ 1,774,747 \$ 5,20,55 \$ 1,784,687 \$ 5,20,55 \$ 1,784,687 \$ 5,20,55 \$ 1,784,687 \$ 5,20,55 \$ 1,784,687 \$ 5,20,55 \$ 1,784,687 \$ 5,20,57 \$ 1,784,687 \$ 5,20,57 \$ 1,784,687 \$ 5,20,57 \$ 1,787,44 \$ 2,14,77 \$ 1,787,44 \$ 1,787,44 \$ 2,14,77 \$ 1,787,44 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342 \$ 2,198,3423 \$ 2,21,44 \$ 2,21,45 \$ 2,179,444 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342 \$ 2,187,0342								Members	Charges	Charges	Charges	PMPM	PMPM	Specialty	Treatments
121/12013 66.846 S S 1.784.687 S 1.784.687 S 20.55 S 20.58 S 1.819.89 S 20.55 S 20.58 S 1.819.45 S 21.22 S 20.58 S 21.22 S 20.55 S 21.970.42 S 20.856.55 S 20.403 S 20.431 S 20.575 S 20.55 S 21.65 S							-								
11/1/2014 85,956 S - 5 1,845,451 \$1,485,451 \$21,47 \$21,47 \$21,47 21/1/2014 85,783 S 309,503 \$1,189,461 \$2,128,991 \$22,483 \$21,22 \$21,87 \$23,34 41/1/2014 85,767 \$5 909,105 \$1,994,555 \$2,457,659 \$22,87 \$23,34 \$21,57 \$1,859,455 \$2,451,659 \$2,467,659 \$22,87 \$23,20 \$5,767,17 \$1,985,455 \$2,451,659 \$2,22,77 \$22,00 \$5,88 \$21,57,97,185 \$2,187,93,42 \$2,29,99,21,445 \$2,40,33 \$20,2,51 9/1/2014 85,288 \$1,487,003 \$2,197,942 \$2,20,99 \$2,13,77 \$2,20,578 \$2,187,03,42 \$2,29,99,21,44 \$22,40 \$2,137,93 \$2,137,93 \$2,137,93 \$2,137,93 \$2,137,93 \$2,137,93 \$2,137,93 \$2,137,93 \$2,137,93 \$2,137,93 \$2,141,117,143 \$2,17,07,342 \$2,187,03,42 \$2,23,98,203 \$2,23,33 \$2,137,93 \$2,24,43 \$2,07,78 \$2,141,117,143 \$2,113,77 \$2,21,41 \$2,102,505 \$2,197,104 \$2,44,64 \$2,11,41 \$2,113,77															
21/12014 85,866 5 5,88,04 5 1,708,823 5 1,706,767 520,588 521,22		86,846				\$20.55	\$20.55								
31/12014 85,73 5 90,500 5 1,819,461 5 2,28,97 523,34 41/12014 85,467 5 050,910 5 1,944,555 5 2,434,65 S28,85 522,65 523,34 5		85,955				\$21.47	\$21.47								
4/1/2014 85,467 \$ 473,065 \$ 1,944,545 \$ 247,659 \$22,87 \$23,34 5/1/2014 85,986 \$ 157,71 \$ 1,944,555 \$ 2,431,465 \$ \$22,827 \$23,20 7/1/2014 84,696 \$ 225,897 \$ 1,863,302 \$ 2,099,199 \$24,79 \$22,004 9/1/2014 85,288 \$ 148,700 \$ 1,786,982 \$ 1,787,982 \$ 2,197,982 \$ 2,190,414 \$ 2,21,993,420 \$ 2,33,95 \$21,145 \$ 2,21,994,344 \$ 2,41,993,923 \$23,159 \$21,145 \$ 2,21,994,344 \$ 2,41,994,394 \$24,194,444 \$ 2,41,954,939 \$23,155 \$21,403 \$21,31 \$21,30 \$21,345 \$21,345 \$21,944,345 \$24,956,533 \$21,345	2/1/2014	85,896		\$ 1,708,823	\$ 1,767,627	\$20.58	\$19.89								
5/1/2014 85,897 \$ 0.994,555 \$ 2.433,465 \$ \$22,65 \$23,20 6/1/2014 84,696 \$ 2.053,877 \$ 1.983,302 \$ 2.099,199 \$22,72 \$20,08 1.029,858 \$ 2.113,278 \$ 2.187,0342 \$ 2.32,93 \$	3/1/2014	85,753				\$24.83	\$21.22								
6/1/2014 85,598 5 175,741 5 1,985,454 5 2,111,195 525,25 523,20 7/1/2014 84,669 5 255,897 5 1,864,351 524,79 522,004 1	4/1/2014	85,467	\$ 473,065	\$ 1,994,594	\$ 2,467,659	\$28.87	\$23.34								
7/1/2014 84,696 5 235,897 5 1,863,302 5 2,079,582 522,00 8/1/2014 84,696 5 202,613 5 1,863,302 5 2,079,582 522,00 5 2,113,278 5 2,1870,342 5 2,3983,620 523,29 521,24 524,31 520,78 521,72 520,983 1,029,858 5 2,113,278 5 2,107,442 5 2,3983,620 523,29 521,24 524,31 520,78 521,061 521,061 521,33 521,351 521,051 521,061 521,061 521,051 521,061 521,061 521,051 521,061 521,061 521,051 521,061<	5/1/2014	85,847	\$ 508,910	\$ 1,944,555	\$ 2,453,465	\$28.58	\$22.65								
8/1/2014 84,609 \$ 202,631 \$ 1,84,951 \$ 2,04,7582 \$ 2,14,4 \$ \$ 2,113,278 \$ 2,1870,342 \$ 2,3,983,620 \$ \$ 2,113,278 \$ 2,1870,342 \$ 2,3,983,620 \$ \$ 2,113,278 \$ 2,1870,342 \$ 2,3,983,620 \$ \$ 2,113,278 \$ 2,1994,434 \$ 2,21,93 2,21,33 S,21,39 S,21,39 S,21,39 S,21,39 S,21,33 S,21,39 S,21,33 S,21,39 S,21,34 S,21,39 S,21,34 S,22,345 S,21,346,22 S,21,34 S,22,340 S,21,34 S,22,345 S,21,345 <ths< td=""><td>6/1/2014</td><td>85,598</td><td>\$ 175,741</td><td>\$ 1,985,454</td><td>\$ 2,161,195</td><td>\$25.25</td><td>\$23.20</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></ths<>	6/1/2014	85,598	\$ 175,741	\$ 1,985,454	\$ 2,161,195	\$25.25	\$23.20								
9/1/2014 85,288 \$ 148,700 \$ 1,788,982 \$ 19,37,682 \$22,72 \$20,98 1,029,858 \$ 2,18,779,342 \$ 2,398,620 \$22,29 \$21,24 \$24,03 \$20,78 10/1/2014 85,265 \$ 1,780,737 \$ 1,780,737 \$ 1,780,737 \$ 2,740,238 \$21,992,414 \$2 2,436,525 \$2,436,525 \$2,54,60 \$22,440 \$21,061 12/1/2014 85,367 \$ 3,550,35 \$ 1,780,794 \$ 1,780,778 \$ 2,517,6104 \$22,456 \$23,55 \$21,461 \$24,460 \$21,66 12/1/2015 83,568 \$ 5,779,474 \$2,277,078 \$2,775,75 \$20,641 1,022,608 \$2,407,947 \$2,546 \$21,98 \$24,43 \$2,57,57 \$21,99 \$24,43 \$2,52,646 \$21,98 \$24,13 \$2,11,017 \$3,552,242 \$2,49,81,33 \$26,591,612 \$26,12 \$22,22,275 \$22,49 \$21,417 \$2,47,98 \$2,47,98 \$2,47,98 \$2,49,81,39 \$26,41 \$22,22,85 \$2,54,65 \$21,99,80 \$2,591,612 <td< td=""><td>7/1/2014</td><td>84,696</td><td>\$ 235,897</td><td>\$ 1,863,302</td><td>\$ 2,099,199</td><td>\$24.79</td><td>\$22.00</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	7/1/2014	84,696	\$ 235,897	\$ 1,863,302	\$ 2,099,199	\$24.79	\$22.00								
10/1/2014 85,329 S 89,227 S 1,870,387 S 1,999,614 S22,97 S21,92 1,026,549 S 2,1994,434 S 2,4196,939 S23,53 S21,39 S24,31 S20,78 11/1/2014 85,367 S 1,85,47 S 1,755,053 S 1,913,400 S22,44 S20,58 S S22,450 S S24,515 S21,450 S24,40 S21,65 12/1/2015 83,503 S 347,594 S 1,788,031 S S27,71 1,025,080 S S24,407,596 S S2,460,523 S21,465 S21,46 S21,47 S21,47 S21,46,313 S21,46,313 S21,47 S21,46 S21,46,414 S22,47 S21,57<	8/1/2014	84,609	\$ 202,631	\$ 1,864,951	\$ 2,067,582	\$24.44	\$22.04								
11/1/2014 85,265 \$ 158,347 \$ 1,755,053 \$ 1,913,400 \$22.44 \$20.58 1,026,549 \$ 2,360,852 \$ 2,2,257,00 \$ 2,4,586,553 \$21.95 \$21.65 \$24.60 \$21.06 12/1/2014 83,503 \$ 3,075,842 \$ 1,726,748 \$ 2,2,456,553 \$23.95 \$21.65 \$24.60 \$21.92 \$24.88 \$21.34 1/1/2015 83,503 \$ 5,777,714 \$ 2,777,778 \$27.75 \$20.64 1,002,028 \$3,558,242 \$ 25,975,729 \$25.46 \$21.99 \$25.47 \$21.93 3/1/2015 83,568 \$ 2,079,407 \$ 2,744,874 \$32.90 \$24.93 1,017,970 \$3,908,180 \$2,24,923,487 \$2,66,19 \$2,612 \$22.28 \$25.75 \$22.149 1/1/2015 83,112 \$480,145 \$ 2,048,635 \$2,24,921 1,007,966 \$4,495,593 \$2,311,912 \$2,66,85 \$22.71 \$26.63 \$22.40 \$21.91 \$23.40 \$27.72,852,852 \$22.40 \$26.47 \$27.72 \$26.63 </td <td>9/1/2014</td> <td>85,288</td> <td>\$ 148,700</td> <td>\$ 1,788,982</td> <td>\$ 1,937,682</td> <td>\$22.72</td> <td>\$20.98</td> <td>1,029,858</td> <td>\$ 2,113,27</td> <td>8 \$ 21,870,342</td> <td>\$ 23,983,620</td> <td>\$23.29</td> <td>\$21.24</td> <td>\$24.03</td> <td>\$20.51</td>	9/1/2014	85,288	\$ 148,700	\$ 1,788,982	\$ 1,937,682	\$22.72	\$20.98	1,029,858	\$ 2,113,27	8 \$ 21,870,342	\$ 23,983,620	\$23.29	\$21.24	\$24.03	\$20.51
11/1/2014 85,265 \$ 158,347 \$ 1,755,053 \$ 1,913,400 \$22.44 \$20.58 1,026,549 \$ 2,242,25,700 \$ 2,4,586,553 \$23.95 \$21.65 \$24.60 \$21.06 12/1/2014 83,503 \$ 2,024,003 \$ 2,27.81 \$22.17 1,022,628 \$ 2,24,07.65 \$ 2,4,586 \$21.92 \$24.88 \$21.43 2/1/2015 83,503 \$ 5,57,244 \$ 2,77,078 \$27.75 \$20.64 1,002,020 \$ 3,558,224 \$ 2,69,75,729 \$25.46 \$21.98 \$25.47 \$21.92 3/1/2015 83,568 \$ 5 1,007,407 \$ 3,708,108 \$2,24,73,84 \$2 2,69,161 \$26.12 \$22.28 \$25.75 \$22.14 3/1/2015 83,112 \$ 46,535 \$2,24,98 1,017,970 \$3,908,108 \$2,24,98,104 \$2,21,98 \$26.418 \$22.42 \$26.457 \$2,11,92 \$26.457 \$2,149,24 \$26.457 \$2,149,24 \$26.457 \$2,149,243 \$2,67,57 \$2,24.94 \$24.94 \$2,	10/1/2014	85.329	\$ 89,227	\$ 1,870,387	\$ 1,959,614	\$22.97	\$21.92	1.028.175	\$ 2,202,50	5 \$ 21,994,434	\$ 24,196,939	\$23.53	\$21.39	\$24.31	\$20,78
12/1/2014 85,377 \$ 350,235 \$ 2,024,003 \$ 2,374,238 \$ \$2,374 1,025,080 \$ 2,711,087 \$ 22,465,017 \$ 25,175,104 \$24,56 \$21,92 \$24,88 \$21,34 1/1/2015 83,563 \$ 3/7,544 \$ 1,784,714 \$2,277,078 \$22,588 \$21,41 1,002,030 \$3,552,422 \$2,475,757 \$2,54,66,278 \$24,90 \$21,918 \$25,47 \$21,92 \$25,47 \$21,92 \$25,48 \$21,92 \$25,47 \$21,92 \$25,48 \$21,92 \$25,47 \$21,92 \$25,47 \$21,92 \$24,88 \$21,95 \$21,92 </td <td>11/1/2014</td> <td></td> <td>\$ 158,347</td> <td>\$ 1,755,053</td> <td>\$ 1,913,400</td> <td></td> <td>\$20.58</td> <td></td> <td>\$ 2,360,85</td> <td>2 \$ 22,225,700</td> <td>\$ 24,586,553</td> <td>\$23.95</td> <td>\$21.65</td> <td></td> <td>\$21.06</td>	11/1/2014		\$ 158,347	\$ 1,755,053	\$ 1,913,400		\$20.58		\$ 2,360,85	2 \$ 22,225,700	\$ 24,586,553	\$23.95	\$21.65		\$21.06
1/1/2015 83,503 \$ 347,594 \$ 1,788,031 \$ 2,125,625 \$ \$ 5,25,58 \$ 3,058,682 \$ \$	12/1/2014														
2/1/2015 83,568 \$ 552,364 \$ 1,724,714 \$ 2,277,078 \$22,725 \$20,64 1,020,300 \$ 3,552,242 \$ 25,975,729 \$25,46 \$21,98 \$25,47 \$21,92 3/1/2015 82,990 \$ 522,99 1,017,970 \$ 3,908,180 \$ 25,975,729 \$25,46 \$21,98 \$25,47 \$21,92 4/1/2015 82,990 \$ 1,007,907 \$ 3,908,180 \$ 22,683,432 \$2,61,91,893 \$26,412 \$22,28 \$25,07 \$22,49 5/1/2015 82,940 \$ 4,405,535 \$2,23,001,70 \$22,42 1,007,966 \$4,405,535 \$2,712,58 \$22,66,55 \$22,30 \$26,619 \$27,72,58 \$26,67 \$2,199,144 \$26,67 \$2,199,149 \$2,66,67 \$2,199,149 \$2,66,67 \$2,199,149 \$2,66,67 \$2,199,949 \$2,407,148 \$2,24,24 \$2,007,129 \$2,106,133 \$2,72,72 \$23,03 \$2,047,149 \$2,24,249 \$2,010,163 \$2,407,149 \$2,24,24 \$2,010,103 \$4,607,379 \$2,311,045 \$2,311,045 \$2,316,046 \$2,77,0							-	,,							
3/1/2015 83,423 S 665,468 S 2,079,407 S 2,744,874 S32,90 S24,93 1,017,970 S 3,908,180 S 2,2683,432 S 26,591,612 S22,12 S22,125 S22,15 S22,175 S22,19 4/1/2015 82,836 S 746,870 S 1,007,186 S 2,469,139 S 2,641,939 S2,641 S22,215 S22,075 S22,79 6/1/2015 83,112 S 480,145 S 2,408,895 S 2,248,830 S30,07 S24,29 1,007,966 S 4,405,593 S 2,719,194 S2,625 S22,79 S23,70 6/1/2015 83,102 S 1,007,966 S 4,405,593 S 2,717,19,528 S27,72 S23,72 <															
4/1/2015 82,990 \$ 788,700 \$ 1,907,186 \$ 2,695,886 \$32,48 \$22,98 1,015,493 \$ 4,223,815 \$ 2,6,819,839 \$26,41 \$22,25 \$26,05 \$22,49 5/1/2015 82,836 \$ 476,728 \$ 2,464,535 \$ 2,242,820 \$34,08 \$22,31 \$ 2,409,109 \$ 2,2199,104 \$2,2,585 \$22,21 \$26,65 \$22,11 \$26,65 \$22,11 \$26,65 \$22,11 \$26,65 \$22,31,10 \$2,668 \$27,52,885 \$27,72,858 \$27,72,858 \$27,72,958 \$27,72,958 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,70 \$23,05 \$27,40 \$24,404 \$24,404 \$24															
5/1/2015 82,836 \$ 476,284 \$ 2,346,535 \$ 2,822,2820 \$34.08 \$28.33 1,012,482 \$ 4,191,190 \$ 22,998,004 \$ 27,189,194 \$26.85 \$22.71 \$26.35 \$22.72 6/1/2015 83,112 \$ 40,145 \$ 2,046,675 \$ 2,488,89 \$30.07 \$24.242 1,009,966 \$ 4,469,593 \$ 2,725,683 \$27.75 \$22.80 \$26.66 \$23.10 8/1/2015 81,946 \$ 266,075 \$ 1,909,976 \$ 4,660,535 \$ 2,718,168 \$27.75 \$22.80 \$26.35 \$23.40 8/1/2015 81,946 \$ 266,075 \$ 1,909,596 \$ 4,667,979 \$ 23,163,626 \$ 2,783,1606 \$27.70 \$23.03 \$24.36 10/1/2015 81,970 \$ 86,567 \$ 2,179,569 \$2,66.77 \$2,115,83 \$2,04,972 \$24.94 \$24.29 995,076 \$4,407,932 \$2,8,461,848 \$28.95 \$24.07 \$28.26 \$24.36 11/1/2015		, .						· · · · ·							
6/1/2015 83,112 \$ 480,145 \$ 2,498,839 \$ \$ 1,009,996 \$ 4,495,593 \$ 2,725,6838 \$ \$ \$ \$ \$ 2,725,6838 \$ \$ \$ \$ \$ 2,725,6838 \$ \$ \$ \$ \$ \$ \$ \$ 2,725,6838 \$ \$ \$ \$ \$ \$ \$ 2,727,1858 \$ \$ \$ \$ \$ 2,719,1605 \$ 4,667,979 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ 2,717,155 \$ 2,717,155 \$ 2,717,155 \$ \$ \$ 2,717,155 \$ 2,717,155 \$ 2,717,155 \$ 2,717,155 \$ 2,717,155 \$ 2,717,155 \$ 2,717,155 \$ 2,717,155 \$ 2,717,15															
7/1/2015 82,266 S 344,89 S 1,951,380 S 2,296,219 S27,91 S22,72 1,007,566 S 4,667,397 S 2,119,323 S 2,722,858 S27,52 S22,95 S26,97 S23,40 8/1/2015 81,944 S 2,660,75 S 1,907,566 S 4,667,975 S 2,119,323 S 2,723,858 S27,72 S22,95 S26,97 S23,47 9/1/2015 82,038 S 2,660,75 S 1,175,300 S 2,655 S25,51 1,001,633 S 2,34,67,649 S 2,80,74,92 S28,31,600 S 2,34,749 S 2,34,76,49 S 2,80,74,92 S28,36 S23,47 S24,40 10/1/2015 82,047 S 3,19,508 S 2,471,619 S 2,446,972 S24,469 995,076 S 4,407,932 S 2,814,308 S28,36 S23,47 S24,86 12/1/2016 82,123 S 1,71,659 S 2,471,015 S 2,642,720 S22,559 S25,50 S25,30 93,481 S 4,409,932 S 2,814,808 S28,98 S24,92 S28,56 S24,00 S28,58 S24,50	6/1/2015					\$30.07	\$24.29					\$27.25		\$26.66	
9/1/2015 82,038 \$ 86,564 \$ 2,093,005 \$ 2,179,569 \$ 26,57 \$ 255.51 1,001,653 \$ 4,605,843 \$ 23,467,649 \$ 28,073,492 \$ 28,03 \$ 23,43 \$ 27,61 \$ 24.04 10/1/2015 81,970 \$ 86,567 \$ 2,115,863 \$ 2,202,430 \$ 26,687 \$ 252.51 998,294 \$ 4,603,183 \$ 2,3,71,125 \$ 28,116,308 \$ 228,36 \$ 223,55 \$ 27,93 \$ 24,36 11/1/2015 82,047 \$ 53,096 \$ 2,1992,476 \$ 2,404,2142 \$ 24,497,932 \$ 23,950,949 \$ 2,8448,881 \$ 28,59 \$ 24,60 \$ 28,28,6 \$ 223,40 \$ 228,68 \$ 224,69 \$ 23,950,949 \$ 2,8448,81 \$ 28,59 \$ 24,60 \$ 28,28,6 \$ 224,69 \$ 228,60 \$ 228,56 \$ 254,69 \$ 228,61 \$ 228,56 \$ 224,69 \$ 228,56 \$ 21,902,87 \$ 2,914 \$ 24,29 \$ 28,014,881 \$ 28,59 \$ 24,60 \$ 28,28,8 \$ 224,60 \$ 28,28,8 \$ 224,60 \$ 28,28,8 \$ 224,60 \$ 228,56 \$ 25,20 \$ 1/1/2016 \$ 75,134 \$ 21,720 \$ 1,900,826 \$ 1,922,546 \$ 25,559 \$ 25,50 \$ 93,50 \$ 93,433 \$ 3,993,481 \$ 24,510,802 \$ 2,80,428 \$ 228,98 \$ 224,92 \$ 228,56 \$ 25,50 \$ 25,50 \$ 95,50 \$ 95,50 \$ 93,433 \$ 3,993,481 \$ 24,510,802 \$ 2,80,428 \$ 229,82 \$ 224,92 \$ 228,92 \$ 225,56 \$ 25,50 \$ 95,50 \$ 24,768 \$ 24,914 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 529,41 \$ 526,40 \$ 529,51 \$ 51/12016 \$ 73,846 \$ 241,535 \$ 2,245,50 \$ 537,38 \$ 532,81 \$ 93,31 \$ 938,812 \$ 2,463,179 \$ 25,508,53 \$ 28,80,114 \$ 529,90 \$ 52,285 \$ 30,28 \$ 526,73 \$ 51/12016 \$ 73,846 \$ 241,535 \$ 2,245,494 \$ 53,404 \$ 53,307 \$ 929,306 \$ 2,326,473 \$ 52,509 \$ 52,673 \$ 50,28 \$ 52,271 \$ 50,28 \$ 52,271 \$ 50,28 \$ 52,271 \$ 50,28 \$ 52,291 \$ 52,41 \$ 52,94 \$ 52,673 \$ 50,28 \$ 52,271 \$ 50,28 \$ 52,271 \$ 50,28 \$ 52,271 \$ 50,28 \$ 52,291 \$ 52,40 \$ 52,99 \$ 52,633 \$ 51/12016 \$ 73,846 \$ 241,535 \$ \$ 2,447,449 \$ 53,88 \$ 53,41 \$ 9		82,266				\$27.91	\$23.72					\$27.52	\$22.95	\$26.97	\$23.40
$\begin{array}{c c c c c c c c c c c c c c c c c c c $														\$27.29	
11/1/2015 82,047 \$ 53,096 \$ 1,992,876 \$ 22,045,972 \$24,94 \$24,29 995,076 \$ 4,497,932 \$ 23,950,949 \$ 28,448,881 \$28,59 \$24,07 \$28,26 \$24,69 12/1/2015 82,123 \$ 17,1679 \$ 2,404,700 \$22,18 \$30,09 991,822 \$ 4,197,935 \$24,914,960 \$28,947,850 \$24,906 \$28,950 \$24,400 \$28,858 \$24,90 \$28,92 \$28,940 \$28,950 \$24,90 \$28,92 \$28,92 \$28,940 \$28,92 \$28,920	9/1/2015	82,038	\$ 86,564	\$ 2,093,005	\$ 2,179,569	\$26.57	\$25.51	1,001,653	\$ 4,605,84	3 \$ 23,467,649	\$ 28,073,492	\$28.03	\$23.43	\$27.61	\$24.04
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	10/1/2015	81,970	\$ 86,567	\$ 2,115,863	\$ 2,202,430	\$26.87	\$25.81	998,294	\$ 4,603,18	3 \$ 23,713,125	\$ 28,316,308	\$28.36	\$23.75	\$27.93	\$24.36
1/1/2016 75,134 \$ 21,720 \$ 1,900,826 \$ 1,922,546 \$25.59 \$25.30 983,453 \$ 3,993,481 \$ 24,510,802 \$ 28,504,283 \$28,98 \$24.92 \$28.92 \$25.36 2/1/2016 74,629 \$ 264,213 \$ 2,985,434 \$ 24,02,655 \$29.21 \$25.41 \$29.26 \$25.70 3/1/2016 74,629 \$ 2,643,853 \$ 2,761,838 \$ 3,301,47 \$ 24,70,655 \$29.21 \$25.44 \$29.26 \$25.70 3/1/2016 74,629 \$ 2,643,853 \$ 2,761,141 \$32.83 \$27.37 \$2,878,378 \$2,52,761,144 \$29,41 \$29.94 \$29.99 \$26.38 5/1/2016 73,846 \$ 241,535 \$ 2,487,473 \$33.68 \$30.41 948,327 \$2,643,629 \$2,5175,587 \$2,781,916 \$29.94 \$26.95 \$30.28 \$26.73 5/1/2016 73,846 \$2,41,161 \$2,780,856 \$37.738 \$33.738 \$33.73 938,812 \$2,463,179 \$2,5175,587	11/1/2015	82,047	\$ 53,096	\$ 1,992,876	\$ 2,045,972	\$24.94	\$24.29	995,076	\$ 4,497,93	2 \$ 23,950,949	\$ 28,448,881	\$28.59	\$24.07	\$28.26	\$24.69
2/1/2016 74,713 \$ 261,291 \$ 1,982,160 \$ 2,243,450 \$30.03 \$26.53 974,598 \$ 3,702,407 \$ 24,768,247 \$ 28,470,655 \$29.21 \$25.41 \$29.26 \$25.70 3/1/2016 74,629 \$ 264,538 \$ 2,743,538 \$35.89 \$32.35 965,804 \$ 3,01,478 \$ 28,470,655 \$29.41 \$25.99 \$26.39 \$29.46 \$28,470,455 \$28,471,48 \$29.44 \$25.99 \$26.38 \$29.44 \$21.99 \$29.44 \$25.99 \$26.38 \$29.44 \$21.99 \$29.45 \$28.46,314 \$29.44 \$29.45 \$28.46,314 \$29.44 \$25.99 \$26.38 \$29.44 \$25.976 \$27.81,873 \$21.95,175,87 \$27.81,814 \$21.99,045 \$21.45,35 \$2.487,473 \$33.68 \$30.41 948,327 \$2.643,429 \$2.76,184,27 \$2.76,184,27 \$2.76,184,27 \$2.78,184,374 \$2.9,94 \$2.52,771,184 \$2.9,94 \$2.65,55 \$30.28 \$2.62,73 \$30.28	12/1/2015	82,123	\$ 171,659	\$ 2,471,061	\$ 2,642,720	\$32.18	\$30.09	991,822	\$ 4,319,35	6 \$ 24,398,006	\$ 28,717,362	\$28.95	\$24.60	\$28.58	\$25.01
3/1/2016 74,629 \$ 264,538 \$ 2,413,995 \$ 2,678,533 \$35.89 \$32.35 965,804 \$ 3,10,178 \$ 25,102,836 \$ 28,404,314 \$29.41 \$25.99 \$26,338 4/1/2016 73,846 \$ 2,416,134 \$22,83 \$27,93 957,317 \$ 2,878,78 \$ 22,715,184 \$ 28,154,562 \$29,941 \$25,90 \$26,33 5/1/2016 73,846 \$ 2,414,312 \$ 2,437,373 \$ 25,175,787 \$ 27,819,166 \$29,941 \$26,90 \$29,94 \$26,33 5/1/2016 73,846 \$ 2,415,357 \$ 27,819,161 \$29,94 \$26,55 \$30,28 \$26,73 6/1/2016 73,846 \$ 2,425,948 \$2,437,479 \$33,68 \$30,31 938,812 \$ 2,443,479 \$2,580,033 \$28,90 \$27,28 \$30,94 \$27,45 7/1/2016 72,690 \$ 3,29,817 \$2,438,279 \$2,580,693 <td>1/1/2016</td> <td>75,134</td> <td>\$ 21,720</td> <td>\$ 1,900,826</td> <td>\$ 1,922,546</td> <td>\$25.59</td> <td>\$25.30</td> <td>983,453</td> <td>\$ 3,993,48</td> <td>1 \$ 24,510,802</td> <td>\$ 28,504,283</td> <td>\$28.98</td> <td>\$24.92</td> <td>\$28.92</td> <td>\$25.36</td>	1/1/2016	75,134	\$ 21,720	\$ 1,900,826	\$ 1,922,546	\$25.59	\$25.30	983,453	\$ 3,993,48	1 \$ 24,510,802	\$ 28,504,283	\$28.98	\$24.92	\$28.92	\$25.36
4/1/2016 74,503 \$ 365,601 \$ 2,080,534 \$ 2,446,134 \$32.83 \$27.93 957,317 \$ 2,878,378 \$ 25,276,184 \$ 28,154,562 \$29.41 \$26.40 \$29.94 \$26.38 5/1/2016 73,846 \$ 24,1535 \$ 2,245,938 \$2,326,11 948,327 \$ 2,463,429 \$ 27,117,587 \$ 27,819,116 \$29.94 \$26.55 \$30.28 \$26.73 6/1/2016 73,846 \$ 24,1535 \$ 2,245,938 \$2,37.38 \$33.31 938,812 \$ 2,463,179 \$25,080,503 \$ 28,071,233 \$29.90 \$27.48 \$30.64 \$27.93 7/1/2016 72,590 \$ 2,247,149 \$33.68 \$30.31 938,812 \$ 2,463,179 \$ 25,806,293 \$ 28,071,233 \$29.90 \$27.48 \$30.64 \$27.99 7/1/2016 72,698 \$ 2,399,174 \$ 2,386,214 \$ 2,899,09 \$27.45 \$30.93 \$27.45 \$30.93 \$27.45 \$30.93 \$27.45 \$	2/1/2016	74,713	\$ 261,291	\$ 1,982,160	\$ 2,243,450	\$30.03	\$26.53	974,598	\$ 3,702,40	7 \$ 24,768,247	\$ 28,470,655	\$29.21	\$25.41	\$29.26	\$25.70
5/1/2016 73,846 \$ 241,535 \$ 2,245,938 \$ 2,487,473 \$33.68 \$30.41 948,327 \$ 2,643,629 \$ 2,51,75,587 \$ 2,78,19,216 \$29.34 \$26.55 \$30.28 \$26.73 6/1/2016 73,597 \$ 299,695 \$ 2,441,161 \$ 2,750,856 \$37.38 \$33.1 938,812 \$ 2,463,179 \$ 25,608,053 \$ 28,071,233 529.90 \$27.28 \$30.64 \$27.49 7/1/2016 72,790 \$ 2,239,017 \$ 2,249,017 \$21,477,479 \$33.62 \$30.77 \$29,336 \$2,389,219 \$2,22,513 \$30.37 \$27.49 8/1/2016 72,698 \$ 3,39,418 \$2,490,408 \$2,947,473 \$2,489,419 \$2,362,114 \$2,589,619 \$2,82,21,513 \$20,37 \$2,247,453 8/1/2016 72,698 \$3,39,138 \$2,447,479 \$33,62 \$35,78 \$2,990,277 \$2,65,552,28 \$2,899,4905 \$31,15 \$2,82,439 \$	3/1/2016	74,629	\$ 264,538	\$ 2,413,995	\$ 2,678,533	\$35.89	\$32.35	965,804	\$ 3,301,47	8 \$ 25,102,836	\$ 28,404,314	\$29.41	\$25.99	\$29.59	\$26.03
6/1/2016 73,597 \$ 299,695 \$ 2,451,161 \$ 2,750,856 \$33,31 938,812 \$ 2,43,179 \$ 25,680,033 \$ 28,071,233 \$29,90 \$27,28 \$30,64 \$27,09 7/1/2016 72,790 \$ 2,239,625 \$ 2,447,499 \$33,62 \$30,77 \$29,336 \$2,326,214 \$2,589,693 \$2,822,513 \$30,37 \$27,45 8/1/2016 72,696 \$ 339,138 \$2,447,499 \$33,62 \$30,77 \$2,326,214 \$2,589,693 \$2,822,513 \$30,37 \$27,45 8/1/2016 72,696 \$ 339,138 \$2,407,133 \$29,90 \$27,28 \$30,93 \$2,27,45 8/1/2016 72,696 \$ 339,138 \$2,407,133 \$29,90 \$27,27 \$2,608,93 \$2,82,94,305 \$31,15 \$2,844 \$2,947,323 \$29,90 \$27,27 \$2,608,94,95 \$31,15 \$2,849,37 \$2,899,455 \$31,15 \$2,847,82 \$2,899,455 \$31,15 \$2,847,82 \$2,899,455	4/1/2016	74,503	\$ 365,601	\$ 2,080,534	\$ 2,446,134	\$32.83	\$27.93	957,317	\$ 2,878,37	8 \$ 25,276,184	\$ 28,154,562	\$29.41	\$26.40	\$29.94	\$26.38
7/1/2016 72,790 \$ 207,874 \$ 2,239,625 \$ 2,447,499 \$33.62 \$30.77 929,336 \$ 2,326,214 \$ 25,896,299 \$ 28,222,513 \$30.37 \$27.87 \$30.99 \$27.45 8/1/2016 72,698 \$ 339,138 \$ 2,048,184 \$2,947,322 \$40.54 \$35.88 920,088 \$2,399,277 \$26,595,228 \$28,994,505 \$31.51 \$28.91 \$31.36 \$27.82		.,	. ,												
8/1/2016 72,698 \$ 339,138 \$ 2,608,184 \$ 2,947,322 \$40.54 \$35.88 920,088 \$ 2,399,277 \$ 2,6595,228 \$ 28,994,505 \$31.51 \$28.91 \$31.36 \$27.82															
9/1/2016 73,391 \$ 399,975 \$ 2,258,931 \$ 2,658,906 \$ 36.23 \$ 30.78 911,441 \$ 2,712,688 \$ 26,761,154 \$ 29,473,842 \$ 32.34 \$ 29.36 \$ 31.73 \$ 28.20		,	,												
	9/1/2016	73,391	\$ 399,975	\$ 2,258,931	\$ 2,658,906	\$36.23	\$30.78	911,441	\$ 2,712,68	8 \$ 26,761,154	\$ 29,473,842	\$32.34	\$29.36	\$31.73	\$28.20

1. New treatments are hepatitis C drugs, PCSK9 inhibitors, and Orkambi

Exponential Trend: 14.9% 17.3%



Restated Specialty Drug Trend

Pharmacy Specialty Claims in the Experience	Α	\$ 29,473,842
Claims Removed from the Experience		
Hepatitis C	B1	\$2,393,099
PCSK9 Inhibitors ¹	B2	\$51,939
Orkambi	B3	\$267,651
Total	B = B1+B2+B3	\$2,712,688
Pharmacy Specialty Claims without Excluded Drugs	C = A - B	\$ 26,761,154
Projected Specialty Claims using a 14.1% trend for 27 months	D = C x (1.141)^(27/12)	\$38,313,061
Adding Incremental Cost of Excluded Treatments for the Projection Period		
Hepatitis C	E1	\$3,297,770
PCSK9 Inhibitors	E2	\$225,344
Orkambi	E3	\$1,973,878
Total	E = E1+E2+E3	\$5,496,992
Restated Projected Specialty Claims	F = D + E	\$43,810,053
Restated Specialty Trend	G = (F/A)^(12/27) -1	19.3%

1. PCSK9 inhibitors in the formulary include Praluent, which was approved by the FDA on July 24, 2015, and Repatha, which was approved by the FDA on August 27, 2015.

Contract Adjustment Factors

	Projection Beginning													
		7/1/2017	8/1/2017	9/1/2017	10/1/2017	11/1/2017	12/1/2017	1/1/2018	2/1/2018	3/1/2018	4/1/2018	5/1/2018	6/1/2018	7/1/2018
	10/1/2015	0.9782	0.9775	0.9767	0.9759	0.9752	0.9744	0.9736	0.9729	0.9721	0.9713	0.9706	0.9698	0.9690
E	11/1/2015	0.9796	0.9788	0.9781	0.9773	0.9765	0.9758	0.9750	0.9742	0.9735	0.9727	0.9719	0.9712	0.9704
x	12/1/2015	0.9810	0.9802	0.9794	0.9787	0.9779	0.9771	0.9764	0.9756	0.9748	0.9741	0.9733	0.9725	0.9718
р	1/1/2016	0.9823	0.9816	0.9808	0.9800	0.9793	0.9785	0.9777	0.9770	0.9762	0.9754	0.9747	0.9739	0.9731
e	2/1/2016	0.9837	0.9830	0.9822	0.9814	0.9807	0.9799	0.9791	0.9783	0.9776	0.9768	0.9760	0.9753	0.9745
r i	3/1/2016	0.9851	0.9843	0.9836	0.9828	0.9820	0.9813	0.9805	0.9797	0.9790	0.9782	0.9774	0.9766	0.9759
é	4/1/2016	0.9865	0.9857	0.9850	0.9842	0.9834	0.9827	0.9819	0.9811	0.9803	0.9796	0.9788	0.9780	0.9773
n	5/1/2016	0.9879	0.9871	0.9864	0.9856	0.9848	0.9840	0.9833	0.9825	0.9817	0.9810	0.9802	0.9794	0.9786
с	6/1/2016	0.9893	0.9885	0.9878	0.9870	0.9862	0.9854	0.9847	0.9839	0.9831	0.9823	0.9816	0.9808	0.9800
e	7/1/2016		0.9899	0.9892	0.9884	0.9876	0.9868	0.9861	0.9853	0.9845	0.9837	0.9830	0.9822	0.9814
	8/1/2016			0.9899	0.9891	0.9884	0.9876	0.9868	0.9860	0.9853	0.9845	0.9837	0.9829	0.9822
В	9/1/2016				0.9899	0.9891	0.9884	0.9876	0.9868	0.9860	0.9853	0.9845	0.9837	0.9829
e	10/1/2016					0.9899	0.9891	0.9884	0.9876	0.9868	0.9860	0.9852	0.9845	0.9837
g	11/1/2016						0.9899	0.9891	0.9883	0.9876	0.9868	0.9860	0.9852	0.9845
1	12/1/2016							0.9899	0.9891	0.9883	0.9876	0.9868	0.9860	0.9852
n n	1/1/2017								0.9899	0.9891	0.9883	0.9875	0.9868	0.9860
i	2/1/2017									0.9899	0.9891	0.9883	0.9875	0.9868
'n	3/1/2017										0.9899	0.9891	0.9883	0.9875
g	4/1/2017											0.9899	0.9891	0.9883
-	5/1/2017												0.9899	0.9891
	6/1/2017													0.9898

Benefit Leverage Factors

BlueCare LO Options (LO) and Open Access (OAP) Medical Plans

				In-Net	work Benefi		Out-o	of-Network Ben	efits			
index	Product	Deductible	Coinsurance	Out-of- Pocket	Office Copay	Specialist Copay	ER ¹ Copay	AMB Copay	Deductible	Coinsurance	Out-of- Pocket	Leverage Factor
1	LO	\$2,500	0%	\$2,500								1.1%
2	LO	\$3,000	0%	\$3,000								1.2%
3	OAP	\$750	20%	\$2,250	\$35	\$50	\$150	\$150	\$1,500	30%	\$4,500	0.8%
4	OAP	\$3,000	0%	\$4,100	\$30	\$30	\$100		\$6,000	30%	\$8,200	1.0%
5	OAP	\$3,000	20%	\$5,300	\$30	\$30			\$5,000	40%	\$10,600	1.1%

1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at 100%.

2. For the LO product, Office and Specialist Copay can be under the deductible.

3. LO does not have Out-of-Network benefits.

BlueCare (HMO) Medical Plans

					In-Network	Benefits				
index	Product	Inpatient Care Deductible ²	Outpatient Surgery Copay	Combined Inpatient / Outpatient Deductible ²	Office Copay	Specialist Copay	ER ³ Copay	AMB Copay	Out-of- Pocket	Leverage Factor
1	HMO	\$0	\$0		\$25	\$35	\$250	\$0	\$6,850	0.3%
2	HMO	\$250	\$100		\$10	\$20	\$50	\$0	\$6,850	0.1%
3	HMO	\$250	\$100		\$25	\$40	\$100	\$50	\$6,850	0.3%
4	HMO	\$500	\$200		\$20	\$30	\$100	\$100	\$6,850	0.2%
5	HMO	\$500	\$200		\$25	\$40	\$150	\$50	\$6,850	0.3%
6	HMO			\$750	\$20	\$30	\$50	\$50	\$6,850	0.3%
7	HMO	\$2,000	\$1,000		\$20	\$30	\$50	\$50	\$6,850	0.3%
8	HMO			\$3,000	\$20	\$30	\$100	\$50	\$6,850	0.5%

1. All HMO Plans have a DME rider benefit of: \$0 deductible, 20% coinsurance, built into the relativity.

2. Maximum of 2/yr per family

3. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are the covered at 100%.

4. HMO Plans do not have Out-of-Network benefits.

Consumer Driven Health Plans (CDHP's)

					Leverage Factor					
index	Product	Deductible	Coinsurance	Out-of- Pocket	RX OOPM Limit ³	Wellness Rx ¹	Drugs After Deductible ²	Diabetic Supplies	Medical	Rx
1	CDHP	\$1,500	0%	\$1,500	\$1,300	0%	N/A	SAAO	0.8%	0.9%
2	CDHP	\$2,500	0%	\$2,500	\$1,300	0%	N/A	SAAO	1.1%	1.1%
3	CDHP	\$3,000	0%	\$3,000	\$1,300	0%	N/A	SAAO	1.2%	1.1%
4	CDHP	\$4,000	0%	\$4,000	\$1,300	0%	N/A	SAAO	1.4%	1.2%
5	CDHP	\$5,000	0%	\$5,000	\$1,300	0%	N/A	SAAO	1.6%	1.2%
6	CDHP	\$6,600	0%	\$6,600	\$1,300	N/A	N/A	SAAO	1.8%	2.0%

1. Wellness Rx: if applicable, cost sharing rules apply before the deductible is satisfied.

The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.

2. All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

3. The Rx OOPM Limit is as described in Vermont Act 171.

Benefit Leverage Factors

Index	Туре	Deductible	Retail Generic	Retail Preferred Brand	Retail Non- Preferred Brand	Mail Order Generic	Mail Order Preferred Brand	Mail Order Non- Preferred Brand	ООРМ	Diabetic Supplies	Leverage Factor
1	CM1	\$100	\$5	40%	60%	\$10	40%	60%	\$1,300	SAAO	1.3%
2	COI	\$0	50%	50%	50%	50%	50%	50%	\$1,300	SAAO	1.2%
3	COP	\$0	\$10	\$20	\$40	\$20	\$40	\$80	\$1,300	SAAO	0.8%
4	COP	\$0	\$10	\$25	\$25	\$20	\$50	\$50	\$1,300	SAAO	0.8%
5	COP	\$0	\$10	\$25	\$40	\$20	\$50	\$80	\$1,300	100%	0.8%
6	COP	\$0	\$10	\$25	\$50	\$20	\$50	\$100	\$1,300	SAAO	0.9%
7	COP	\$0	\$10	\$25	\$60	\$20	\$50	\$120	\$1,300	SAAO	0.9%
8	COP	\$0	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	0.9%
9	COP	\$0	\$10	\$35	\$60	\$20	\$70	\$120	\$1,300	SAAO	1.0%
10	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,300	100%	0.8%
11	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,300	SAAO	0.9%
12	COP	\$0	\$15	\$30	\$45	\$30	\$60	\$90	\$1,300	SAAO	1.0%
13	COP	\$0	\$20	\$40	\$60	\$40	\$80	\$120	\$1,300	SAAO	1.2%
14	COP	\$0	\$5	\$20	\$35	\$10	\$40	\$70	\$1,300	SAAO	0.7%
15	COP	\$0	\$5	\$20	\$45	\$10	\$40	\$90	\$1,300	100%	0.6%
16	COP	\$0	\$5	\$30	\$50	\$10	\$60	\$100	\$1,300	SAAO	0.8%
17	COP	\$0	\$5	\$45	\$90	\$10	\$90	\$180	\$1,300	SAAO	1.0%
18	COP	\$100	\$10	\$15	\$30	\$20	\$30	\$60	\$1,300	SAAO	1.0%
19	COP	\$100	\$10	\$25	\$45	\$20	\$50	\$90	\$1,300	SAAO	1.1%
20	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	100%	1.0%
21	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	1.2%
22	COP	\$100	\$15	\$30	\$45	\$30	\$60	\$90	\$1,300	SAAO	1.2%
23	COP	\$100	\$15	\$40	\$60	\$30	\$80	\$120	\$1,300	SAAO	1.4%
24	COP	\$100	\$5	\$20	\$40	\$10	\$40	\$80	\$1,300	SAAO	1.0%
25	COP	\$100	\$5	\$25	\$50	\$10	\$50	\$100	\$1,300	SAAO	1.0%
26	COP	\$50	\$10	\$20	\$35	\$20	\$40	\$70	\$1,300	SAAO	0.9%
27	COP	\$50	\$10	\$25	\$35	\$20	\$50	\$70	\$1,300	SAAO	1.0%
28	COP	\$50	\$10	\$25	\$40	\$20	\$50	\$80	\$1,300	SAAO	1.0%
29	COP	\$50	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	1.0%
30	COP	\$50	\$5	\$10	\$25	\$10	\$20	\$50	\$1,300	SAAO	0.7%

* Type: COI = coinsurance; COP = copay; CM1 = combined
* Diabetic: If "100%" then Diabetic medications and supplies are covered at 100% of allowed charges;

If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.

BlueCare LO Options (LO) and Open Access (OAP) Medical Plans

				In-Networ	k Benefits				Out	of-Network Ben	efits	Relativity Factor
index	Product	Deductible	Coinsurance	Out-of- Pocket	Office Copay	Specialist Copay	ER ¹ Copay	AMB Copay	Deductible	Coinsurance	Out-of- Pocket	Active
1	LO	\$2,500	0%	\$2,500								0.6934
2	LO	\$3,000	0%	\$3,000								0.6562
3	OAP	\$750	20%	\$2,250	\$35	\$50	\$150	\$150	\$1,500	30%	\$4,500	0.8160
4	OAP	\$3,000	0%	\$4,100	\$30	\$30	\$100		\$6,000	30%	\$8,200	0.7296
5	OAP	\$3,000	20%	\$5,300	\$30	\$30	\$100		\$5,000	40%	\$10,600	0.6791

1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at 100%.

2. For the LO product, Office and Specialist Copay can be under the deductible.

3. LO does not have Out-of-Network benefits.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Benefit Plan Relative Value Factors BlueCare (HMO) Medical Plans

					In-Netwo	ork Benefit	S		
index	Product	IP	OP	HOSP	РСР	SCP	ER	AMB	OOPM
1	HMO	\$0	\$0		\$25	\$35	\$250	\$0	\$0
2	HMO	\$250	\$100		\$10	\$20	\$50	\$0	\$0
3	HMO	\$250	\$100		\$25	\$40	\$100	\$50	\$0
4	HMO	\$500	\$200		\$20	\$30	\$100	\$100	\$0
5	HMO	\$500	\$200		\$25	\$40	\$150	\$50	\$0
6	HMO			\$750	\$20	\$30	\$50	\$50	\$0
7	HMO	\$2,000	\$1,000		\$20	\$30	\$50	\$50	\$0
8	HMO			\$3,000	\$20	\$30	\$100	\$50	\$0

РСР	Primary Care Physician Copay
SCP IP	Specialist Physician Copay
IP	Inpatient Care Deductible (max of 2/yr per family)
OP	Outpatient Surgery Copay
HOSP	Combined Inpatient Care & Outpatient Surgery Deductible (max of 2/yr per family)
ER	Emergency Room Copay
AMB	Ambulance Copay
OOPM	Per ACA, all copays accumulate toward the Out of Pocket Maximum

1. All HMO Plans have a DME rider benefit of: \$0 deductible, 20% coinsurance, built into the relativity.

Consumer Driven Health Plans (CDHP's)

					In-Network				Relativity Factor
index	Product	Deductible	Coinsurance	Out-of-Pocket	RX OOPM Limit ³	Wellness Rx ¹	Drugs After Deductible ²	Diabetic Supplies	Active
1	CDHP	\$1,500	0%	\$1,500	\$1,300	0%	N/A	SAAO	0.9865
2	CDHP	\$1,500	0%	\$1,500	\$1,300	N/A	N/A	SAAO	0.9750
3	CDHP	\$1,500	20%	\$2,500	\$1,300	0%	N/A	SAAO	0.9089
4	CDHP	\$1,500	20%	\$2,500	\$1,300	N/A	N/A	SAAO	0.8942
5	CDHP	\$2,000	0%	\$2,000	\$1,300	0%	N/A	SAAO	0.9241
6	CDHP	\$2,000	0%	\$2,000	\$1,300	N/A	N/A	SAAO	0.9100
7	CDHP	\$2,000	20%	\$3,000	\$1,300	0%	N/A	SAAO	0.8583
8	CDHP	\$2,250	0%	\$2,250	\$1,300	0%	N/A	SAAO	0.8977
9	CDHP	\$2,250	0%	\$2,250	\$1,300	N/A	N/A	SAAO	0.8825
10	CDHP	\$2,500	0%	\$2,500	\$1,300	0%	N/A	SAAO	0.8735
11	CDHP	\$2,500	0%	\$2,500	\$1,300	N/A	N/A	SAAO	0.8576
12	CDHP	\$2,500	20%	\$5,000	\$1,300	0%	N/A	SAAO	0.7779
13	CDHP	\$2,600	20%	\$5,000	\$1,300	0%	N/A	SAAO	0.7730
14	CDHP	\$3,000	0%	\$3,000	\$1,300	N/A	\$10/\$35/\$50	SAAO	0.8140
15	CDHP	\$3,000	0%	\$3,000	\$1,300	0%	N/A	SAAO	0.8313
16	CDHP	\$3,000	0%	\$3,000	\$1,300	\$10/\$30/\$50	N/A	SAAO	0.8247
17	CDHP	\$3,000	0%	\$3,000	\$1,300	N/A	N/A	SAAO	0.8140
18	CDHP	\$3,000	20%	\$5,000	\$1,300	0%	N/A	SAAO	0.7551
19	CDHP	\$3,000	20%	\$5,500	\$1,300	0%	10%/25%/25%	SAAO	0.7467
20	CDHP	\$4,000	0%	\$4,000	\$1,300	0%	N/A	SAAO	0.7642
21	CDHP	\$4,000	20%	\$6,450	\$1,300	0%	N/A	SAAO	0.6945
22	CDHP	\$5,000	0%	\$5,000	\$1,300	0%	N/A	SAAO	0.7126
23	CDHP	\$5,000	0%	\$5,000	\$1,300	N/A	N/A	SAAO	0.6924
24	CDHP	\$6,000	0%	\$6,000	\$1,300	0%	N/A	SAAO	0.6711
25	CDHP	\$6,450	0%	\$6,450	\$1,300	0%	N/A	SAAO	0.6549
26	CDHP	\$6,450	0%	\$6,450	\$1,300	N/A	N/A	SAAO	0.6337
27	CDHP	\$6,550	0%	\$6,550	\$1,300	0%	N/A	SAAO	0.6516
28	CDHP	\$6,550	0%	\$6,550	\$1,300	N/A	N/A	SAAO	0.6302
29	CDHP	\$6,600	0%	\$6,600	\$1,300	N/A	N/A	SAAO	0.6285
30	CDHP	\$6,850	0%	\$6,850	\$1,300	0%	N/A	SAAO	0.6416

1. Wellness Rx: if applicable, cost sharing rules apply *before* the deductible is satisfied.

The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.

2. All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

3. The **Rx OOPM** Limit is as described in Vermont Act 171.

Prescription Drug Cards

					Copay (\$) /	Coinsurance	(%)				Relativity
Index	Туре	Deductible	Retail Generic	Retail Preferred Brand	Retail Non- Preferred Brand	Mail Order Generic	Mail Order Preferred Brand	Mail Order Non- Preferred Brand	ООРМ	Diabetic Supplies	Active
1	CM1	\$100	\$5	40%	60%	\$10	40%	60%	\$1,300	SAAO	0.1566
2	COI	\$0	50%	50%	50%	50%	50%	50%	\$1,300	SAAO	0.1394
3	COP	\$0	\$10	\$20	\$40	\$20	\$40	\$80	\$1,300	SAAO	0.2208
4	COP	\$0	\$10	\$25	\$25	\$20	\$50	\$50	\$1,300	SAAO	0.2157
5	COP	\$0	\$10	\$25	\$40	\$20	\$50	\$80	\$1,300	100%	0.2183
6	COP	\$0	\$10	\$25	\$50	\$20	\$50	\$100	\$1,300	SAAO	0.2118
7	COP	\$0	\$10	\$25	\$60	\$20	\$50	\$120	\$1,300	SAAO	0.2105
8	COP	\$0	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	0.2100
9	COP	\$0	\$10	\$35	\$60	\$20	\$70	\$120	\$1,300	SAAO	0.1892
10	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,300	100%	0.2157
11	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,300	SAAO	0.2106
12	COP	\$0	\$15	\$30	\$45	\$30	\$60	\$90	\$1,300	SAAO	0.2026
13	COP	\$0	\$20	\$40	\$60	\$40	\$80	\$120	\$1,300	SAAO	0.1923
14	COP	\$0	\$5	\$20	\$35	\$10	\$40	\$70	\$1,300	SAAO	0.2282
15	COP	\$0	\$5	\$20	\$45	\$10	\$40	\$90	\$1,300	100%	0.2312
16	COP	\$0	\$5	\$30	\$50	\$10	\$60	\$100	\$1,300	SAAO	0.2039
17	COP	\$0	\$5	\$45	\$90	\$10	\$90	\$180	\$1,300	SAAO	0.1964
18	COP	\$100	\$10	\$15	\$30	\$20	\$30	\$60	\$1,300	SAAO	0.2095
19	COP	\$100	\$10	\$25	\$45	\$20	\$50	\$90	\$1,300	SAAO	0.1983
20	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	100%	0.2017
21	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	0.1960
22	COP	\$100	\$15	\$30	\$45	\$30	\$60	\$90	\$1,300	SAAO	0.1908
23	COP	\$100	\$15	\$40	\$60	\$30	\$80	\$120	\$1,300	SAAO	0.1687
24	COP	\$100	\$5	\$20	\$40	\$10	\$40	\$80	\$1,300	SAAO	0.2095
25	COP	\$100	\$5	\$25	\$50	\$10	\$50	\$100	\$1,300	SAAO	0.2063
26	COP	\$50	\$10	\$20	\$35	\$20	\$40	\$70	\$1,300	SAAO	0.2139
27	COP	\$50	\$10	\$25	\$35	\$20	\$50	\$70	\$1,300	SAAO	0.2064
28	COP	\$50	\$10	\$25	\$40	\$20	\$50	\$80	\$1,300	SAAO	0.2057
29	COP	\$50	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	0.2026
30	COP	\$50	\$5	\$10	\$25	\$10	\$20	\$50	\$1,300	SAAO	0.2301

* Type: COI = coinsurance; COP = copay; CM1 = combined (COP/COP/COI)
 * Diabetic: If "100%" then Diabetic medications and supplies are covered at 100% of allowed charges;

If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.

Tier Factors for Benefits with Separate Medical and Pharmacy Deductibles

		2-Ti	er		3-Tier			4-	Tier	
Out-of-Pocket							Subscriber Subscriber			
Range	Туре	Single	Family	Single	2-Person	Family	Single	& Spouse	& Children	Family
NA/Stacked	Stacked	1.000	2.379	1.000	2.000	2.743	1.000	2.000	1.653	2.810
\$0 - \$3,499	Aggregate	1.000	2.319	1.000	1.839	2.690	1.000	1.928	1.598	2.757
\$3,500 - \$4,999	Aggregate	1.000	2.249	1.000	1.791	2.605	1.000	1.877	1.552	2.669
\$5,000 - \$7,150	Aggregate	1.000	2.210	1.000	1.749	2.568	1.000	1.836	1.504	2.633
\$0 - \$3,499	Hybrid	1.000	2.322	1.000	1.840	2.696	1.000	1.928	1.603	2.762
\$3,500 - \$4,999	Hybrid	1.000	2.252	1.000	1.794	2.607	1.000	1.881	1.555	2.671
\$5,000 - \$7,150	Hybrid	1.000	2.260	1.000	1.812	2.608	1.000	1.902	1.547	2.674

Tier Factors for Benefits with Integrated Medical and Pharmacy Deductibles

		2-Ti	er		3-Tier			4-	Tier	
Out-of-Pocket							Subscriber Subscriber			
Range	Туре	Single	Family	Single	2-Person	Family	Single	& Spouse	& Children	Family
NA/Stacked	Stacked	1.000	2.379	1.000	2.000	2.743	1.000	2.000	1.653	2.810
\$0 - \$3,499	Aggregate	1.000	2.282	1.000	1.783	2.669	1.000	1.877	1.517	2.740
\$3,500 - \$4,999	Aggregate	1.000	2.195	1.000	1.718	2.565	1.000	1.811	1.442	2.636
\$5,000 - \$7,150	Aggregate	1.000	2.116	1.000	1.662	2.468	1.000	1.753	1.383	2.538
\$0 - \$3,499	Hybrid	1.000	2.282	1.000	1.783	2.669	1.000	1.877	1.517	2.740
\$3,500 - \$4,999	Hybrid	1.000	2.208	1.000	1.735	2.574	1.000	1.828	1.455	2.645
\$5,000 - \$7,150	Hybrid	1.000	2.235	1.000	1.799	2.572	1.000	1.895	1.493	2.642

Example of Manual Rate Adjustment

Contract Conversion	Contract Distribution	Members	Tier Factor	"Contract Tiers"
Projection Period	7/1/2018			
Industry Factor	0.965			
Age/Gender Factor	0.940			
Group Information				
Trend Factor	8.40%			
Projection Period	7/1/2018			
Average Industry Factor	1.000			
Average Age/Gender Factor	1.000			
Manual Rate	\$490.37			

Contract Conversion	Contract Distribution	meniber 3		Contract hers
Single	25	25	1	25
Two-Person	25	50	2	50
Family	50	197	2.743	137.15
	100	272		212.2

Manual Rate	A	\$490.37
Adjustment for Age/Gender	B = 0.94 / 1	0.9400
Adjustment for Industry	C = 0.965 / 1	0.9650
Adjustment for Trend	D = 8.4% for 2 months	1.0412
Pharmacy Contract Adjustment	E =	0.9953
Contract Conversion Factor	F = 212.15 / 272	1.2821
Adjusted Manual Rate	G = A x B x C x D x E x F	\$590.97

Industry Factors

2-Digit SIC Code Industry Description	Normalized Factor
01 Agricultural Production - Crops	0.9
02 Agricultural Production - Livestock And Animal Specialties	0.9
07 Agricultural Services	0.9
08 Forestry	0.9
09 Fishing, Hunting And Trapping	1.0
10 Metal Mining	1.1
12 Coal Mining	1.1
13 Oil And Gas Extraction	1.0
14 Mining And Quarrying Of Nonmetallic Minerals, Except Fuels	1.0
15 Building Cnstrctn - General Contractors & Operative Builders	0.9
16 Heavy Cnstrctn, Except Building Construction - Contractors	0.9
17 Construction - Special Trade Contractors	0.9
20 Food And Kindred Products	0.9
21 Tobacco Products	1.0
22 Textile Mill Products	0.9
23 Apparel, Finished Prdcts From Fabrics & Similar Materials	0.9
24 Lumber And Wood Products, Except Furniture	1.0
25 Furniture And Fixtures	0.9
26 Paper And Allied Products	0.9
27 Printing, Publishing And Allied Industries	0.9
28 Chemicals And Allied Products	0.9
29 Petroleum Refining And Related Industries	0.9
30 Rubber And Miscellaneous Plastic Products	0.9
31 Leather And Leather Products	0.9
32 Stone, Clay, Glass, And Concrete Products	0.9
33 Primary Metal Industries	0.9
34 Fabricated Metal Prdcts, Except Machinery & Transport Eqpmnt	0.9
35 Industrial And Commercial Machinery And Computer Equipment	0.9
36 Electronic, Elctrcl Egpmnt & Cmpnts, Excpt Computer Egpmnt	0.9
37 Transportation Equipment	0.9
38 Mesr/Anlyz/Cntrl Instrmnts; Photo/Med/Opt Gds; Watchs/Clocks	0.9
39 Miscellaneous Manufacturing Industries	0.9
40 Railroad Transportation	0.9
41 Local, Suburban Transit & Interurbn Hgwy Passenger Transport	1.0
42 Motor Freight Transportation	1.0
43 United States Postal Service	0.9
44 Water Transportation	1.0
45 Transportation By Air	0.9
46 Pipelines, Except Natural Gas	0.9
47 Transportation Services	0.9
48 Communications	0.9
49 Electric, Gas And Sanitary Services	0.9
50 Wholesale Trade - Durable Goods	0.9
51 Wholesale Trade - Nondurable Goods	0.9
52 Building Matrials, Hrdwr, Garden Supply & Mobile Home Dealrs	0.9
53 General Merchandise Stores	0.9
54 Food Stores	0.9
55 Automotive Dealers And Gasoline Service Stations	1.0
56 Apparel And Accessory Stores	0.9
57 Home Furniture, Furnishings And Equipment Stores	0.9
58 Eating And Drinking Places	1.0
59 Miscellaneous Retail	0.9
60 Depository Institutions	0.9
61 Nondepository Credit Institutions	0.9
62 Security & Commodity Brokers, Dealers, Exchanges & Services	0.9
63 Insurance Carriers	0.9
64 Insurance Agents, Brokers And Service	0.9
65 Real Estate	0.9
	0.9
67 Holding And Other Investment Offices 70 Hotels, Rooming Houses, Camps, And Other Lodging Places	1.0
70 Hetele Describent Herene Conner And Others Ledeten Disses	1

Industry Factors

2-Digit	Normalized
SIC Code Industry Description	Factor
72 Personal Services	1.011
73 Business Services	0.954
75 Automotive Repair, Services And Parking	1.003
76 Miscellaneous Repair Services	0.967
78 Motion Pictures	0.980
79 Amusement And Recreation Services	1.053
80 Health Services	1.109
81 Legal Services	1.001
82 Educational Services	0.958
83 Social Services	1.109
84 Museums, Art Galleries And Botanical And Zoological Gardens	0.965
86 Membership Organizations	1.014
87 Engineering, Accounting, Research, Management & Related Svcs	0.916
88 Private Households	0.965
89 Services, Not Elsewhere Classified	0.969
91 Executive, Legislative & General Government, Except Finance	1.109
92 Justice, Public Order And Safety	1.109
93 Public Finance, Taxation And Monetary Policy	1.02
94 Administration Of Human Resource Programs	1.02
95 Administration Of Environmental Quality And Housing Programs	1.02
96 Administration Of Economic Programs	1.02
97 National Security And International Affairs	1.05
99 Nonclassifiable Establishments	0.96

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Administrative Charges Development

Reconciliation of Experience Base Administrative Expense to Restated GAAP Expenses

(Dollars in 000's)

	11/15 - 10/16	Rec	onciliation to GAAF) ⁽¹⁾
	Experience		Reclassification	Reported
Business Segment	Base	Commissions	ltems ⁽²⁾	Expenses
Large Group				
BCBSVT Insured	\$6,054	\$1,347	(\$2,165)	\$9,566
BCBSVT Cost Plus and ASO	\$23,401	\$267	(\$830)	\$24,497
TVHP Insured	\$2,512	\$474	(\$623)	\$3,609
Large Group Subtotal	\$31,967	\$2,088	(\$3,617)	\$37,672
Individual/Other				
BCBSVT Small Group (QHP and Non-QHP)	\$15,151	\$34	(\$5,463)	\$20,647
BCBSVT Individual (QHP and Non-QHP)	\$13,188	\$0	(\$3,497)	\$16,685
TVHP Small Group	\$1	\$0	\$1	\$0
Medicare Supplement	\$1,216	\$0	(\$106)	\$1,322
Cost Plus Medicare Supplement ⁽³⁾	\$342	\$0	\$342	
TVHP Medigap Blue	\$1,988	\$0	(\$125)	\$2,113
Other Member Categories				
FEP	\$3,956	\$0	(\$1,735)	\$5,691
Blue MedicareRx	\$878	\$0	(\$83)	\$961
Other Categories				
СВА	\$9,411	(\$29)	(\$159)	\$9,541
Host	\$1,624	\$0	(\$222)	\$1,847
Total	\$79,722	\$2,093	(\$14,664)	\$96,478

Notes:

(1) Sources: Commissions and Reclassification Items are from Internal BCBSVT reports. Reported Expenses are from Underwriting Results GAAP Basis, restated for the new allocation, for the Experience Base period.

(2) Reclassification Items include the allocation of GHI expenses across relevant member categories and the removal of federal fees.

(3) Allocation of expenses for Cost Plus members with Med Supp coverage based on cost PMPM for insured Med Supp members. In GAAP financials, expenses are included in Large Group Cost Plus.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Administrative Charges Development

Administrative Charges PUPM

				c			Large Group	
Unit		Account	Member	Contract	Medical Claim	Projected Claims	Subtotal	CP Medsup
Administrative Expenses		\$1,143,714	\$3,667,679	\$220,754	\$665,378	\$2,868,147	\$8,565,672	
Unit Months		1,339	239,980	122,259	567,115	\$96,639,491		
Expense PUPM		\$854.16	\$15.28	\$1.81	\$1.17	3.0%		\$27.85
Increase for Membership		-0.4%	-0.4%	-0.4%	-0.4%			-0.4%
Updated Expense PUPM	E = (1+D) x C	\$850.97	\$15.23	\$1.80	\$1.17			\$27.75
Annual Trend	F	2.4%	2.4%	2.4%	2.4%			2.4%
Monthly Trend Factor	$G = (1+F)^{(1/12)}$	1.0020	1.0020	1.0020	1.0020			1.0020
Months of Trend to First Effective Period	Н	20	20	20	20			20
Projection Periods								
Effective Date		Account	Member	Contract	Medical Claim	Projected Claims		
Jul-17	I = E x G ^ (H/12)	\$853.82	\$15.28	\$1.81	\$1.17	3.0%		\$27.84
Aug-17	J = I x G	\$855.54	\$15.31	\$1.81	\$1.17	3.0%		\$27.90
Sep-17	$K = J \times G$	\$857.26	\$15.34	\$1.81	\$1.18	3.0%		\$27.95
Oct-17		\$858.99	\$15.37	\$1.82	\$1.18	3.0%		\$28.01
Nov-17		\$860.72	\$15.40	\$1.82	\$1.18	3.0%		\$28.06
Dec-17		\$862.45	\$15.43	\$1.82	\$1.18	3.0%		\$28.12
Jan-18		\$864.18	\$15.46	\$1.83	\$1.19	3.0%		\$28.18
Feb-18		\$865.92	\$15.49	\$1.83	\$1.19	3.0%		\$28.23
Mar-18		\$867.66	\$15.52	\$1.83	\$1.19	3.0%		\$28.29
Apr-18		\$869.41	\$15.56	\$1.84	\$1.19	3.0%		\$28.35
May-18		\$871.16	\$15.59	\$1.84	\$1.20	3.0%		\$28.40
Jun-18		\$872.91	\$15.62	\$1.85	\$1.20	3.0%		\$28.46
Jul-18		\$874.67	\$15.65	\$1.85	\$1.20	3.0%		\$28.52
Aug-18		\$876.43	\$15.68	\$1.85	\$1.20	3.0%		\$28.58
Sep-18		\$878.19	\$15.71	\$1.86	\$1.21	3.0%		\$28.63
Oct-18		\$879.96	\$15.74	\$1.86	\$1.21	3.0%		\$28.69

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	10% Maigin
\$30,000	25	7.403%	6.144%
\$30,000	50	4.960%	3.797%
\$30,000	100	3.318%	2.251%
\$30,000	150	2.697%	1.715%
\$30,000	200	2.204%	1.289%
\$30,000	300	1.785%	0.933%
\$30,000	400	1.385%	0.632%
\$30,000	500	1.248%	0.523%
\$30,000	600	1.072%	0.409%
\$30,000	700	0.928%	0.323%
\$30,000	800	0.829%	0.264%
\$30,000	900	0.741%	0.217%
\$30,000	1,000	0.696%	0.192%
\$30,000	1,500	0.445%	0.085%
\$30,000	2,000	0.330%	0.045%
\$30,000	3,000	0.170%	0.011%
\$30,000	4,000	0.114%	0.004%
\$30,000	5,000	0.084%	0.003%
\$30,000	10,000	0.022%	0.001%
\$30,000	20,000	0.003%	0.001%
\$30,000	30,000	0.002%	0.001%
\$30,000	40,000	0.002%	0.001%
\$35,000	25	8.196%	6.881%
\$35,000	50	5.480%	4.255%
\$35,000	100	3.671%	2.539%
\$35,000	150	2.989%	1.944%
\$35,000	200	2.450%	1.471%
\$35,000	300	1.983%	1.069%
\$35,000	400	1.544%	0.734%
\$35,000	500	1.404%	0.617%
\$35,000	600	1.215%	0.490%
\$35,000	700	1.056%	0.390%
\$35,000	800	0.947%	0.322%
\$35,000	900	0.851%	0.267%
\$35,000	1,000	0.797%	0.236%
\$35,000	1,500	0.519%	0.110%
\$35,000	2,000	0.392%	0.061%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$35,000	3,000	0.204%	0.016%
\$35,000	4,000	0.138%	0.006%
\$35,000	5,000	0.102%	0.003%
\$35,000	10,000	0.028%	0.001%
\$35,000	20,000	0.004%	0.001%
\$35,000	30,000	0.002%	0.001%
\$35,000	40,000	0.002%	0.001%
\$40,000	25	8.882%	7.520%
\$40,000	50	5.928%	4.656%
\$40,000	100	3.975%	2.794%
\$40,000	150	3.240%	2.146%
\$40,000	200	2.662%	1.633%
\$40,000	300	2.151%	1.188%
\$40,000	400	1.683%	0.827%
\$40,000	500	1.538%	0.701%
\$40,000	600	1.336%	0.562%
\$40,000	700	1.166%	0.451%
\$40,000	800	1.052%	0.377%
\$40,000	900	0.950%	0.316%
\$40,000	1,000	0.887%	0.278%
\$40,000	1,500	0.584%	0.133%
\$40,000	2,000	0.448%	0.077%
\$40,000	3,000	0.236%	0.021%
\$40,000	4,000	0.161%	0.008%
\$40,000	5,000	0.119%	0.004%
\$40,000	10,000	0.034%	0.001%
\$40,000	20,000	0.004%	0.001%
\$40,000	30,000	0.002%	0.001%
\$40,000	40,000	0.002%	0.001%
\$45,000	25	9.508%	8.108%
\$45,000	50	6.341%	5.029%
\$45,000	100	4.258%	3.034%
\$45,000	150	3.471%	2.334%
\$45,000	200	2.857%	1.785%
\$45,000	300	2.308%	1.302%
\$45,000	400	1.813%	0.917%
\$45,000	500	1.663%	0.782%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$45,000	600	1.446%	0.629%
\$45,000	700	1.268%	0.510%
\$45,000	800	1.150%	0.432%
\$45,000	900	1.041%	0.363%
\$45,000	1,000	0.969%	0.319%
\$45,000	1,500	0.645%	0.156%
\$45,000	2,000	0.501%	0.094%
\$45,000	3,000	0.266%	0.026%
\$45,000	4,000	0.183%	0.010%
\$45,000	5,000	0.135%	0.006%
\$45,000	10,000	0.039%	0.001%
\$45,000	20,000	0.005%	0.001%
\$45,000	30,000	0.002%	0.001%
\$45,000	40,000	0.002%	0.001%
\$50,000	25	10.079%	8.645%
\$50,000	50	6.719%	5.372%
\$50,000	100	4.520%	3.259%
\$50,000	150	3.684%	2.508%
\$50,000	200	3.040%	1.930%
\$50,000	300	2.452%	1.407%
\$50,000	400	1.933%	1.001%
\$50,000	500	1.780%	0.860%
\$50,000	600	1.547%	0.692%
\$50,000	700	1.364%	0.567%
\$50,000	800	1.240%	0.483%
\$50,000	900	1.126%	0.409%
\$50,000	1,000	1.046%	0.359%
\$50,000	1,500	0.704%	0.180%
\$50,000	2,000	0.551%	0.111%
\$50,000	3,000	0.296%	0.032%
\$50,000	4,000	0.204%	0.013%
\$50,000	5,000	0.152%	0.007%
\$50,000	10,000	0.045%	0.001%
\$50,000	20,000	0.006%	0.001%
\$50,000	30,000	0.002%	0.001%
\$50,000	40,000	0.002%	0.001%
\$55,000	25	10.603%	9.141%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$55,000	50	7.073%	5.694%
\$55,000	100	4.765%	3.470%
\$55,000	150	3.880%	2.670%
\$55,000	200	3.212%	2.067%
\$55,000	300	2.585%	1.506%
\$55,000	400	2.044%	1.080%
\$55,000	500	1.889%	0.934%
\$55,000	600	1.641%	0.752%
\$55,000	700	1.452%	0.621%
\$55,000	800	1.324%	0.533%
\$55,000	900	1.207%	0.454%
\$55,000	1,000	1.118%	0.397%
\$55,000	1,500	0.759%	0.204%
\$55,000	2,000	0.599%	0.128%
\$55,000	3,000	0.325%	0.038%
\$55,000	4,000	0.224%	0.016%
\$55,000	5,000	0.168%	0.009%
\$55,000	10,000	0.051%	0.001%
\$55,000	20,000	0.007%	0.001%
\$55,000	30,000	0.002%	0.001%
\$55,000	40,000	0.002%	0.001%
\$60,000	25	11.080%	9.595%
\$60,000	50	7.401%	5.992 %
\$60,000	100	4.988%	3.662%
\$60,000	150	4.062%	2.822%
\$60,000	200	3.372%	2.196%
\$60,000	300	2.707%	1.598%
\$60,000	400	2.144%	1.153%
\$60,000	500	1.988%	1.002%
\$60,000	600	1.729%	0.810%
\$60,000	700	1.534%	0.673%
\$60,000	800	1.402%	0.579%
\$60,000	900	1.282%	0.497%
\$60,000	1,000	1.186%	0.434%
\$60,000	1,500	0.812%	0.227%
\$60,000	2,000	0.644%	0.144%
\$60,000	3,000	0.353%	0.045%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$60,000	4,000	0.244%	0.019%
\$60,000	5,000	0.182%	0.010%
\$60,000	10,000	0.057%	0.001%
\$60,000	20,000	0.008%	0.001%
\$60,000	30,000	0.002%	0.001%
\$60,000	40,000	0.002%	0.001%
\$65,000	25	11.518%	10.013%
\$65,000	50	7.707%	6.271%
\$65,000	100	5.195%	3.844%
\$65,000	150	4.231%	2.965%
\$65,000	200	3.525%	2.320%
\$65,000	300	2.821%	1.685%
\$65,000	400	2.238%	1.222%
\$65,000	500	2.082%	1.067%
\$65,000	600	1.811%	0.864%
\$65,000	700	1.610%	0.721%
\$65,000	800	1.474%	0.624%
\$65,000	900	1.352%	0.538%
\$65,000	1,000	1.250%	0.469%
\$65,000	1,500	0.863%	0.250%
\$65,000	2,000	0.687%	0.161%
\$65,000	3,000	0.380%	0.051%
\$65,000	4,000	0.264%	0.022%
\$65,000	5,000	0.197%	0.012%
\$65,000	10,000	0.062%	0.001%
\$65,000	20,000	0.009%	0.001%
\$65,000	30,000	0.003%	0.001%
\$65,000	40,000	0.002%	0.001%
\$70,000	25	11.929%	10.406%
\$70,000	50	7.993%	6.534%
\$70,000	100	5.390%	4.014%
\$70,000	150	4.390%	3.099%
\$70,000	200	3.668%	2.436%
\$70,000	300	2.931%	1.770%
\$70,000	400	2.327%	1.288%
\$70,000	500	2.170%	1.129%
\$70,000	600	1.887%	0.915%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$70,000	700	1.684%	0.769%
\$70,000	800	1.542%	0.665%
\$70,000	900	1.417%	0.577%
\$70,000	1,000	1.310%	0.503%
\$70,000	1,500	0.911%	0.273%
\$70,000	2,000	0.727%	0.177%
\$70,000	3,000	0.407%	0.059%
\$70,000	4,000	0.284%	0.025%
\$70,000	5,000	0.211%	0.014%
\$70,000	10,000	0.067%	0.001%
\$70,000	20,000	0.010%	0.001%
\$70,000	30,000	0.003%	0.001%
\$70,000	40,000	0.002%	0.001%
\$75,000	25	12.314%	10.775%
\$75,000	50	8.265%	6.788%
\$75,000	100	5.575%	4.179%
\$75,000	150	4.540%	3.229%
\$75,000	200	3.800%	2.544%
\$75,000	300	3.035%	1.852%
\$75,000	400	2.410%	1.351%
\$75,000	500	2.252%	1.187%
\$75,000	600	1.958%	0.963%
\$75,000	700	1.752%	0.814%
\$75,000	800	1.605%	0.705%
\$75,000	900	1.477%	0.613%
\$75,000	1,000	1.367%	0.536%
\$75,000	1,500	0.956%	0.294%
\$75,000	2,000	0.764%	0.193%
\$75,000	3,000	0.433%	0.066%
\$75,000	4,000	0.303%	0.029%
\$75,000	5,000	0.225%	0.016%
\$75,000	10,000	0.072%	0.001%
\$75,000	20,000	0.011%	0.001%
\$75,000	30,000	0.003%	0.001%
\$75,000	40,000	0.002%	0.001%
\$80,000	25	12.678%	11.127%
\$80,000	50	8.524%	7.029%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$80,000	100	5.751%	4.337%
\$80,000	150	4.684%	3.351%
\$80,000	200	3.924%	2.648%
\$80,000	300	3.133%	1.930%
\$80,000	400	2.488%	1.410%
\$80,000	500	2.331%	1.244%
\$80,000	600	2.027%	1.010%
\$80,000	700	1.818%	0.858%
\$80,000	800	1.664%	0.742%
\$80,000	900	1.534%	0.648%
\$80,000	1,000	1.421%	0.568%
\$80,000	1,500	0.998%	0.315%
\$80,000	2,000	0.801%	0.208%
\$80,000	3,000	0.457%	0.073%
\$80,000	4,000	0.321%	0.032%
\$80,000	5,000	0.239%	0.018%
\$80,000	10,000	0.077%	0.002%
\$80,000	20,000	0.013%	0.001%
\$80,000	30,000	0.003%	0.001%
\$80,000	40,000	0.002%	0.001%
\$85,000	25	13.018%	11.456%
\$85,000	50	8.763%	7.254%
\$85,000	100	5.914%	4.487%
\$85,000	150	4.815%	3.464%
\$85,000	200	4.038%	2.744%
\$85,000	300	3.224%	2.002%
\$85,000	400	2.560%	1.465%
\$85,000	500	2.404%	1.298%
\$85,000	600	2.090%	1.054%
\$85,000	700	1.877%	0.898%
\$85,000	800	1.716%	0.776%
\$85,000	900	1.587%	0.681%
\$85,000	1,000	1.471%	0.598%
\$85,000	1,500	1.037%	0.335%
\$85,000	2,000	0.834%	0.223%
\$85,000	3,000	0.480%	0.080%
\$85,000	4,000	0.338%	0.036%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	Inelliber 3	570 Margin	10% Maigin
\$85,000	5,000	0.253%	0.020%
\$85,000	10,000	0.082%	0.002%
\$85,000	20,000	0.014%	0.001%
\$85,000	30,000	0.003%	0.001%
\$85,000	40,000	0.002%	0.001%
\$90,000	25	13.345%	11.774%
\$90,000	50	8.987%	7.464%
\$90,000	100	6.073%	4.633%
\$90,000	150	4.943%	3.574%
\$90,000	200	4.148%	2.835%
\$90,000	300	3.311%	2.071%
\$90,000	400	2.629%	1.518%
\$90,000	500	2.475%	1.350%
\$90,000	600	2.152%	1.097%
\$90,000	700	1.934%	0.936%
\$90,000	800	1.766%	0.808%
\$90,000	900	1.637%	0.713%
\$90,000	1,000	1.519%	0.627%
\$90,000	1,500	1.075%	0.354%
\$90,000	2,000	0.866%	0.237%
\$90,000	3,000	0.502%	0.086%
\$90,000	4,000	0.355%	0.040%
\$90,000	5,000	0.265%	0.022%
\$90,000	10,000	0.087%	0.002%
\$90,000	20,000	0.015%	0.001%
\$90,000	30,000	0.003%	0.001%
\$90,000	40,000	0.002%	0.001%
\$95,000	25	13.652%	12.076%
\$95,000	50	9.197%	7.662%
\$95,000	100	6.222%	4.770%
\$95,000	150	5.064%	3.679%
\$95,000	200	4.251%	2.922%
\$95,000	300	3.392%	2.136%
\$95,000	400	2.695%	1.568%
\$95,000	500	2.542%	1.399%
\$95,000	600	2.210%	1.138%
\$95,000	700	1.989%	0.973%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$95,000	800	1.813%	0.838%
\$95,000	900	1.685%	0.743%
\$95,000	1,000	1.564%	0.655%
\$95,000	1,500	1.111%	0.373%
\$95,000	2,000	0.897%	0.251%
\$95,000	3,000	0.523%	0.093%
\$95,000	4,000	0.372%	0.043%
\$95,000	5,000	0.278%	0.024%
\$95,000	10,000	0.091%	0.002%
\$95,000	20,000	0.016%	0.001%
\$95,000	30,000	0.004%	0.001%
\$95,000	40,000	0.002%	0.001%
\$100,000	25	13.939%	12.359%
\$100,000	50	9.398%	7.851%
\$100,000	100	6.362%	4.898%
\$100,000	150	5.175%	3.776%
\$100,000	200	4.348%	3.005%
\$100,000	300	3.469%	2.198%
\$100,000	400	2.755%	1.615%
\$100,000	500	2.605%	1.446%
\$100,000	600	2.264%	1.177%
\$100,000	700	2.038%	1.008%
\$100,000	800	1.856%	0.867%
\$100,000	900	1.730%	0.772%
\$100,000	1,000	1.606%	0.681%
\$100,000	1,500	1.145%	0.391%
\$100,000	2,000	0.925%	0.265%
\$100,000	3,000	0.543%	0.099%
\$100,000	4,000	0.388%	0.047%
\$100,000	5,000	0.290%	0.026%
\$100,000	10,000	0.096%	0.002%
\$100,000	20,000	0.017%	0.001%
\$100,000	30,000	0.004%	0.001%
\$100,000	40,000	0.002%	0.001%
\$105,000	25	14.220%	12.638%
\$105,000	50	9.597%	8.039%
\$105,000	100	6.502%	5.026%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$105,000	150	5.283%	3.870%
\$105,000	200	4.445%	3.087%
\$105,000	300	3.545%	2.260%
\$105,000	400	2.814%	1.662%
\$105,000	500	2.667%	1.493%
\$105,000	600	2.317%	1.215%
\$105,000	700	2.088%	1.042%
\$105,000	800	1.899%	0.896%
\$105,000	900	1.775%	0.801%
\$105,000	1,000	1.648%	0.708%
\$105,000	1,500	1.179%	0.409%
\$105,000	2,000	0.953%	0.278%
\$105,000	3,000	0.563%	0.106%
\$105,000	4,000	0.403%	0.051%
\$105,000	5,000	0.302%	0.028%
\$105,000	10,000	0.100%	0.002%
\$105,000	20,000	0.018%	0.001%
\$105,000	30,000	0.004%	0.001%
\$105,000	40,000	0.002%	0.001%
\$110,000	25	14.490%	12.908%
\$110,000	50	9.786%	8.218%
\$110,000	100	6.635%	5.148%
\$110,000	150	5.389%	3.962%
\$110,000	200	4.538%	3.166%
\$110,000	300	3.620%	2.320%
\$110,000	400	2.871%	1.707%
\$110,000	500	2.726%	1.537%
\$110,000	600	2.368%	1.252%
\$110,000	700	2.135%	1.075%
\$110,000	800	1 .9 41%	0.925%
\$110,000	900	1.817%	0.829%
\$110,000	1,000	1.689%	0.734%
\$110,000	1,500	1.211%	0.427%
\$110,000	2,000	0.980%	0.290%
\$110,000	3,000	0.582%	0.112%
\$110,000	4,000	0.418%	0.055%
\$110,000	5,000	0.314%	0.030%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	To Margin
\$110,000	10,000	0.105%	0.002%
\$110,000	20,000	0.019%	0.001%
\$110,000	30,000	0.004%	0.001%
\$110,000	40,000	0.002%	0.001%
\$115,000	25	14.739%	13.157%
\$115,000	50	9.962%	8.387%
\$115,000	100	6.756%	5.261%
\$115,000	150	5.487%	4.048%
\$115,000	200	4.625%	3.242%
\$115,000	300	3.689%	2.377%
\$115,000	400	2.924%	1.749%
\$115,000	500	2.779%	1.578%
\$115,000	600	2.415%	1.287%
\$115,000	700	2.178%	1.106%
\$115,000	800	1.980%	0.951%
\$115,000	900	1.857%	0.855%
\$115,000	1,000	1.727%	0.759%
\$115,000	1,500	1.240%	0.444%
\$115,000	2,000	1.006%	0.303%
\$115,000	3,000	0.600%	0.118%
\$115,000	4,000	0.432%	0.058%
\$115,000	5,000	0.326%	0.033%
\$115,000	10,000	0.109%	0.003%
\$115,000	20,000	0.020%	0.001%
\$115,000	30,000	0.004%	0.001%
\$115,000	40,000	0.002%	0.001%
\$120,000	25	14.980%	13.398%
\$120,000	50	10.138%	8.555%
\$120,000	100	6.877%	5.373%
\$120,000	150	5.582%	4.133%
\$120,000	200	4.711%	3.316%
\$120,000	300	3.756%	2.432%
\$120,000	400	2.977%	1.792%
\$120,000	500	2.831%	1.618%
\$120,000	600	2.461%	1.322%
\$120,000	700	2.221%	1.136%
\$120,000	800	2.017%	0.977%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$120,000	900	1.897%	0.882%
\$120,000	1,000	1.763%	0.783%
\$120,000	1,500	1.269%	0.460%
\$120,000	2,000	1.030%	0.315%
\$120,000	3,000	0.618%	0.125%
\$120,000	4,000	0.445%	0.062%
\$120,000	5,000	0.337%	0.035%
\$120,000	10,000	0.113%	0.003%
\$120,000	20,000	0.022%	0.001%
\$120,000	30,000	0.005%	0.001%
\$120,000	40,000	0.002%	0.001%
\$125,000	25	15.215%	13.633%
\$125,000	50	10.311%	8.721%
\$125,000	100	6.995%	5.482%
\$125,000	150	5.675%	4.215%
\$125,000	200	4.796%	3.390%
\$125,000	300	3.822%	2.487%
\$125,000	400	3.030%	1.833%
\$125,000	500	2.882%	1.657%
\$125,000	600	2.507%	1.355%
\$125,000	700	2.261%	1.165%
\$125,000	800	2.054%	1.002%
\$125,000	900	1.935%	0.908%
\$125,000	1,000	1.799%	0.807%
\$125,000	1,500	1.297%	0.476%
\$125,000	2,000	1.055%	0.327%
\$125,000	3,000	0.635%	0.131%
\$125,000	4,000	0.458%	0.066%
\$125,000	5,000	0.348%	0.037%
\$125,000	10,000	0.117%	0.003%
\$125,000	20,000	0.023%	0.001%
\$125,000	30,000	0.005%	0.001%
\$125,000	40,000	0.002%	0.001%
\$130,000	25	15.433%	13.853%
\$130,000	50	10.474%	8.879%
\$130,000	100	7.104%	5.583%
\$130,000	150	5.762%	4.292%

Experience Refund Risk Charge Factors*

Pooling	members	E% Margin	10% Margin
Limit	members	5% Margin	10% Margin
\$130,000	200	4.878%	3.461%
\$130,000	300	3.885%	2.539%
\$130,000	400	3.079%	1.873%
\$130,000	500	2.931%	1.695%
\$130,000	600	2.550%	1.388%
\$130,000	700	2.300%	1.193%
\$130,000	800	2.089%	1.026%
\$130,000	900	1.971%	0.933%
\$130,000	1,000	1.834%	0.829%
\$130,000	1,500	1.324%	0.492%
\$130,000	2,000	1.078%	0.339%
\$130,000	3,000	0.652%	0.137%
\$130,000	4,000	0.471%	0.069%
\$130,000	5,000	0.359%	0.040%
\$130,000	10,000	0.121%	0.003%
\$130,000	20,000	0.024%	0.001%
\$130,000	30,000	0.005%	0.001%
\$130,000	40,000	0.002%	0.001%
\$135,000	25	15.640%	14.063%
\$135,000	50	10.630%	9.031%
\$135,000	100	7.210%	5.680%
\$135,000	150	5.843%	4.365%
\$135,000	200	4.958%	3.531%
\$135,000	300	3.944%	2.589%
\$135,000	400	3.126%	1.9 11%
\$135,000	500	2.977%	1.732%
\$135,000	600	2.590%	1.418%
\$135,000	700	2.336%	1.219%
\$135,000	800	2.122%	1.050%
\$135,000	900	2.005%	0.956%
\$135,000	1,000	1.866%	0.851%
\$135,000	1,500	1.349%	0.507%
\$135,000	2,000	1.100%	0.350%
\$135,000	3,000	0.668%	0.143%
\$135,000	4,000	0.484%	0.073%
\$135,000	5,000	0.369%	0.042%
\$135,000	10,000	0.125%	0.004%

Experience Refund Risk Charge Factors*

Pooling			
Limit	members	5% Margin	10% Margin
\$135,000	20,000	0.025%	0.001%
\$135,000	30,000	0.005%	0.001%
\$135,000	40,000	0.002%	0.001%
\$140,000	25	15.845%	14.271%
\$140,000	50	10.784%	9.180%
\$140,000	100	7.314%	5.777%
\$140,000	150	5.923%	4.436%
\$140,000	200	5.037%	3.600%
\$140,000	300	4.003%	2.638%
\$140,000	400	3.172%	1.948%
\$140,000	500	3.023%	1.768%
\$140,000	600	2.631%	1.448%
\$140,000	700	2.372%	1.245%
\$140,000	800	2.155%	1.073%
\$140,000	900	2.039%	0.980%
\$140,000	1,000	1.898%	0.872%
\$140,000	1,500	1.375%	0.521%
\$140,000	2,000	1.122%	0.362%
\$140,000	3,000	0.684%	0.149%
\$140,000	4,000	0.496%	0.076%
\$140,000	5,000	0.380%	0.044%
\$140,000	10,000	0.129%	0.004%
\$140,000	20,000	0.026%	0.001%
\$140,000	30,000	0.006%	0.001%
\$140,000	40,000	0.002%	0.001%
\$145,000	25	16.039%	14.467%
\$145,000	50	10.931%	9.324%
\$145,000	100	7.414%	5.870%
\$145,000	150	5.999%	4.505%
\$145,000	200	5.113%	3.666%
\$145,000	300	4.060%	2.686%
\$145,000	400	3.216%	1.983%
\$145,000	500	3.067%	1.803%
\$145,000	600	2.669%	1.477%
\$145,000	700	2.406%	1.270%
\$145,000	800	2.187%	1.096%
\$145,000	900	2.072%	1.003%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	5% Margin	10% Margin
\$145,000	1,000	1.928%	0.893%
\$145,000	1,500	1.399%	0.536%
\$145,000	2,000	1.143%	0.373%
\$145,000	3,000	0.699%	0.155%
\$145,000	4,000	0.508%	0.080%
\$145,000	5,000	0.389%	0.047%
\$145,000	10,000	0.133%	0.004%
\$145,000	20,000	0.027%	0.001%
\$145,000	30,000	0.006%	0.001%
\$145,000	40,000	0.002%	0.001%
\$150,000	25	16.216%	14.648%
\$150,000	50	11.071%	9.461%
\$150,000	100	7.509%	5.958%
\$150,000	150	6.072%	4.570%
\$150,000	200	5.183%	3.729%
\$150,000	300	4.113%	2.731%
\$150,000	400	3.258%	2.018%
\$150,000	500	3.109%	1.836%
\$150,000	600	2.705%	1.504%
\$150,000	700	2.439%	1.294%
\$150,000	800	2.218%	1.118%
\$150,000	900	2.103%	1.025%
\$150,000	1,000	1.957%	0.913%
\$150,000	1,500	1.422%	0.550%
\$150,000	2,000	1.163%	0.384%
\$150,000	3,000	0.714%	0.161%
\$150,000	4,000	0.519%	0.083%
\$150,000	5,000	0.399%	0.049%
\$150,000	10,000	0.137%	0.004%
\$150,000	20,000	0.028%	0.001%
\$150,000	30,000	0.006%	0.001%
\$150,000	40,000	0.002%	0.001%
\$155,000	25	16.385%	14.819%
\$155,000	50	11.204%	9.594%
\$155,000	100	7.601%	6.044%
\$155,000	150	6.143%	4.634%
\$155,000	200	5.251%	3.789%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$155,000	300	4.164%	2.775%
\$155,000	400	3.299%	2.051%
\$155,000	500	3.150%	1.869%
\$155,000	600	2.740%	1.531%
\$155,000	700	2.470%	1.317%
\$155,000	800	2.248%	1.139%
\$155,000	900	2.133%	1.047%
\$155,000	1,000	1.985%	0.933%
\$155,000	1,500	1.444%	0.563%
\$155,000	2,000	1.183%	0.395%
\$155,000	3,000	0.728%	0.166%
\$155,000	4,000	0.530%	0.087%
\$155,000	5,000	0.408%	0.051%
\$155,000	10,000	0.140%	0.004%
\$155,000	20,000	0.029%	0.001%
\$155,000	30,000	0.006%	0.001%
\$155,000	40,000	0.002%	0.001%
\$160,000	25	16.546%	14.982%
\$160,000	50	11.334%	9.724%
\$160,000	100	7.690%	6.126%
\$160,000	150	6.213%	4.697%
\$160,000	200	5.315%	3.847%
\$160,000	300	4.214%	2.818%
\$160,000	400	3.339%	2.084%
\$160,000	500	3.190%	1 .90 1%
\$160,000	600	2.774%	1.557%
\$160,000	700	2.499%	1.339%
\$160,000	800	2.277%	1.160%
\$160,000	900	2.163%	1.068%
\$160,000	1,000	2.012%	0.951%
\$160,000	1,500	1.466%	0.576%
\$160,000	2,000	1.202%	0.405%
\$160,000	3,000	0.742%	0.171%
\$160,000	4,000	0.541%	0.090%
\$160,000	5,000	0.418%	0.053%
\$160,000	10,000	0.144%	0.005%
\$160,000	20,000	0.030%	0.001%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	J / Margin	10% Maigin
\$160,000	30,000	0.007%	0.001%
\$160,000	40,000	0.002%	0.001%
\$165,000	25	16.696%	15.134%
\$165,000	50	11.457%	9.846%
\$165,000	100	7.774%	6.205%
\$165,000	150	6.280%	4.758%
\$165,000	200	5.376%	3.901%
\$165,000	300	4.261%	2.858%
\$165,000	400	3.377%	2.115%
\$165,000	500	3.229%	1.932%
\$165,000	600	2.806%	1.582%
\$165,000	700	2.527%	1.360%
\$165,000	800	2.305%	1.180%
\$165,000	900	2.191%	1.088%
\$165,000	1,000	2.038%	0.969%
\$165,000	1,500	1.487%	0.589%
\$165,000	2,000	1.220%	0.415%
\$165,000	3,000	0.755%	0.177%
\$165,000	4,000	0.552%	0.094%
\$165,000	5,000	0.427%	0.055%
\$165,000	10,000	0.148%	0.005%
\$165,000	20,000	0.032%	0.001%
\$165,000	30,000	0.007%	0.001%
\$165,000	40,000	0.002%	0.001%
\$170,000	25	16.837%	15.278%
\$170,000	50	11.576%	9.965%
\$170,000	100	7.855%	6.282%
\$170,000	150	6.345%	4.817%
\$170,000	200	5.435%	3.954%
\$170,000	300	4.307%	2.898%
\$170,000	400	3.414%	2.146%
\$170,000	500	3.266%	1.962%
\$170,000	600	2.838%	1.606%
\$170,000	700	2.555%	1.380%
\$170,000	800	2.333%	1.200%
\$170,000	900	2.218%	1.107%
\$170,000	1,000	2.062%	0.986%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$170,000	1,500	1.508%	0.602%
\$170,000	2,000	1.238%	0.425%
\$170,000	3,000	0.768%	0.182%
\$170,000	4,000	0.562%	0.097%
\$170,000	5,000	0.435%	0.058%
\$170,000	10,000	0.151%	0.005%
\$170,000	20,000	0.033%	0.001%
\$170,000	30,000	0.007%	0.001%
\$170,000	40,000	0.002%	0.001%
\$175,000	25	16.976%	15.418%
\$175,000	50	11.694%	10.081%
\$175,000	100	7.936%	6.357%
\$175,000	150	6.411%	4.877%
\$175,000	200	5.492%	4.005%
\$175,000	300	4.353%	2.937%
\$175,000	400	3.450%	2.176%
\$175,000	500	3.302%	1.991%
\$175,000	600	2.869%	1.630%
\$175,000	700	2.583%	1.401%
\$175,000	800	2.360%	1.220%
\$175,000	900	2.244%	1.126%
\$175,000	1,000	2.086%	1.002%
\$175,000	1,500	1.528%	0.615%
\$175,000	2,000	1.255%	0.434%
\$175,000	3,000	0.780%	0.187%
\$175,000	4,000	0.572%	0.100%
\$175,000	5,000	0.444%	0.060%
\$175,000	10,000	0.154%	0.005%
\$175,000	20,000	0.034%	0.001%
\$175,000	30,000	0.007%	0.001%
\$175,000	40,000	0.002%	0.001%
\$180,000	25	17.105%	15.549%
\$180,000	50	11.805%	10.193%
\$180,000	100	8.009%	6.426%
\$180,000	150	6.474%	4.935%
\$180,000	200	5.546%	4.053%
\$180,000	300	4.396%	2.974%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$180,000	400	3.485%	2.205%
\$180,000	500	3.337%	2.019%
\$180,000	600	2.898%	1.653%
\$180,000	700	2.609%	1.421%
\$180,000	800	2.386%	1.239%
\$180,000	900	2.269%	1.145%
\$180,000	1,000	2.109%	1.018%
\$180,000	1,500	1.548%	0.627%
\$180,000	2,000	1.271%	0.444%
\$180,000	3,000	0.793%	0.192%
\$180,000	4,000	0.581%	0.103%
\$180,000	5,000	0.452%	0.062%
\$180,000	10,000	0.158%	0.006%
\$180,000	20,000	0.034%	0.001%
\$180,000	30,000	0.008%	0.001%
\$180,000	40,000	0.002%	0.001%
\$185,000	25	17.232%	15.678%
\$185,000	50	11.915%	10.303%
\$185,000	100	8.081%	6.494%
\$185,000	150	6.536%	4.992 %
\$185,000	200	5.598%	4.100%
\$185,000	300	4.438%	3.011%
\$185,000	400	3.520%	2.235%
\$185,000	500	3.371%	2.046%
\$185,000	600	2.927 %	1.675%
\$185,000	700	2.635%	1.440%
\$185,000	800	2.411%	1.258%
\$185,000	900	2.294%	1.163%
\$185,000	1,000	2.131%	1.034%
\$185,000	1,500	1.567%	0.639%
\$185,000	2,000	1.288%	0.453%
\$185,000	3,000	0.804%	0.197%
\$185,000	4,000	0.591%	0.107%
\$185,000	5,000	0.461%	0.064%
\$185,000	10,000	0.161%	0.006%
\$185,000	20,000	0.035%	0.001%
\$185,000	30,000	0.008%	0.001%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	10% Margin
\$185,000	40,000	0.002%	0.001%
\$190,000	25	17.357%	15.804%
\$190,000	50	12.021%	10.410%
\$190,000	100	8.151%	6.561%
\$190,000	150	6.596%	5.048%
\$190,000	200	5.650%	4.146%
\$190,000	300	4.480%	3.046%
\$190,000	400	3.554%	2.263%
\$190,000	500	3.405%	2.074%
\$190,000	600	2.956%	1.698%
\$190,000	700	2.660%	1.460%
\$190,000	800	2.436%	1.277%
\$190,000	900	2.319%	1.181%
\$190,000	1,000	2.153%	1.050%
\$190,000	1,500	1.586%	0.651%
\$190,000	2,000	1.304%	0.462%
\$190,000	3,000	0.816%	0.202%
\$190,000	4,000	0.600%	0.110%
\$190,000	5,000	0.469%	0.066%
\$190,000	10,000	0.164%	0.006%
\$190,000	20,000	0.036%	0.001%
\$190,000	30,000	0.008%	0.001%
\$190,000	40,000	0.002%	0.001%
\$195,000	25	17.475%	15.924%
\$195,000	50	12.122%	10.511%
\$195,000	100	8.219%	6.626%
\$195,000	150	6.655%	5.102%
\$195,000	200	5.699%	4.190%
\$195,000	300	4.519%	3.081%
\$195,000	400	3.587%	2.291%
\$195,000	500	3.438%	2.101%
\$195,000	600	2.983%	1.719%
\$195,000	700	2.685%	1.479%
\$195,000	800	2.460%	1.295%
\$195,000	900	2.343%	1.198%
\$195,000	1,000	2.175%	1.065%
\$195,000	1,500	1.605%	0.663%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	J% Margin	10% Maigin
\$195,000	2,000	1.319%	0.471%
\$195,000	3,000	0.827%	0.207%
\$195,000	4,000	0.609%	0.113%
\$195,000	5,000	0.477%	0.068%
\$195,000	10,000	0.167%	0.006%
\$195,000	20,000	0.037%	0.001%
\$195,000	30,000	0.008%	0.001%
\$195,000	40,000	0.002%	0.001%
\$200,000	25	17.586%	16.037%
\$200,000	50	12.220%	10.610%
\$200,000	100	8.286%	6.690%
\$200,000	150	6.711%	5.154%
\$200,000	200	5.747%	4.233%
\$200,000	300	4.557%	3.114%
\$200,000	400	3.619%	2.318%
\$200,000	500	3.470%	2.127%
\$200,000	600	3.010%	1.741%
\$200,000	700	2.709%	1.498%
\$200,000	800	2.484%	1.313%
\$200,000	900	2.366%	1.215%
\$200,000	1,000	2.196%	1.080%
\$200,000	1,500	1.623%	0.674%
\$200,000	2,000	1.334%	0.479%
\$200,000	3,000	0.839%	0.212%
\$200,000	4,000	0.618%	0.116%
\$200,000	5,000	0.485%	0.071%
\$200,000	10,000	0.170%	0.007%
\$200,000	20,000	0.038%	0.001%
\$200,000	30,000	0.008%	0.001%
\$200,000	40,000	0.002%	0.001%
\$205,000	25	17.694%	16.147%
\$205,000	50	12.315%	10.706%
\$205,000	100	8.352%	6.754%
\$205,000	150	6.767%	5.207%
\$205,000	200	5.795%	4.277%
\$205,000	300	4.595%	3.147%
\$205,000	400	3.651%	2.345%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$205,000	500	3.503%	2.154%
\$205,000	600	3.037%	1.762%
\$205,000	700	2.734%	1.517%
\$205,000	800	2.508%	1.331%
\$205,000	900	2.388%	1.232%
\$205,000	1,000	2.217%	1.095%
\$205,000	1,500	1.641%	0.686%
\$205,000	2,000	1.349%	0.488%
\$205,000	3,000	0.850%	0.217%
\$205,000	4,000	0.627%	0.119%
\$205,000	5,000	0.493%	0.073%
\$205,000	10,000	0.173%	0.007%
\$205,000	20,000	0.039%	0.001%
\$205,000	30,000	0.009%	0.001%
\$205,000	40,000	0.002%	0.001%
\$210,000	25	17.799%	16.253%
\$210,000	50	12.409%	10.801%
\$210,000	100	8.417%	6.816%
\$210,000	150	6.822%	5.258%
\$210,000	200	5.842%	4.319%
\$210,000	300	4.632%	3.179%
\$210,000	400	3.683%	2.372%
\$210,000	500	3.534%	2.180%
\$210,000	600	3.064%	1.784%
\$210,000	700	2.758%	1.537%
\$210,000	800	2.531%	1.348%
\$210,000	900	2.410%	1.248%
\$210,000	1,000	2.237%	1.109%
\$210,000	1,500	1.658%	0.697%
\$210,000	2,000	1.364%	0.497%
\$210,000	3,000	0.860%	0.221%
\$210,000	4,000	0.636%	0.122%
\$210,000	5,000	0.501%	0.075%
\$210,000	10,000	0.177%	0.007%
\$210,000	20,000	0.040%	0.001%
\$210,000	30,000	0.009%	0.001%
\$210,000	40,000	0.003%	0.001%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	10% Margin
\$215,000	25	17.899%	16.354%
\$215,000	50	12.498%	10.891%
\$215,000	100	8.479%	6.875%
\$215,000	150	6.875%	5.308%
\$215,000	200	5.887 %	4.359%
\$215,000	300	4.667%	3.210%
\$215,000	400	3.714%	2.398%
\$215,000	500	3.565%	2.205%
\$215,000	600	3.089%	1.804%
\$215,000	700	2.782%	1.555%
\$215,000	800	2.553%	1.365%
\$215,000	900	2.432%	1.264%
\$215,000	1,000	2.256%	1.123%
\$215,000	1,500	1.675%	0.708%
\$215,000	2,000	1.378%	0.505%
\$215,000	3,000	0.871%	0.226%
\$215,000	4,000	0.645%	0.125%
\$215,000	5,000	0.509%	0.077%
\$215,000	10,000	0.180%	0.007%
\$215,000	20,000	0.041%	0.001%
\$215,000	30,000	0.009%	0.001%
\$215,000	40,000	0.003%	0.001%
\$220,000	25	17.994%	16.451%
\$220,000	50	12.582%	10.977%
\$220,000	100	8.536%	6.931%
\$220,000	150	6.926%	5.356%
\$220,000	200	5.929 %	4.397%
\$220,000	300	4.701%	3.240%
\$220,000	400	3.743%	2.422%
\$220,000	500	3.593%	2.229%
\$220,000	600	3.114%	1.823%
\$220,000	700	2.804%	1.572%
\$220,000	800	2.574%	1.382%
\$220,000	900	2.452%	1.279%
\$220,000	1,000	2.275%	1.137%
\$220,000	1,500	1.691%	0.718%
\$220,000	2,000	1.391%	0.513%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$220,000	3,000	0.881%	0.230%
\$220,000	4,000	0.653%	0.128%
\$220,000	5,000	0.517%	0.080%
\$220,000	10,000	0.183%	0.008%
\$220,000	20,000	0.042%	0.001%
\$220,000	30,000	0.009%	0.001%
\$220,000	40,000	0.003%	0.001%
\$225,000	25	18.087%	16.545%
\$225,000	50	12.664%	11.061%
\$225,000	100	8.591%	6.984%
\$225,000	150	6.974%	5.401%
\$225,000	200	5.969%	4.434%
\$225,000	300	4.733%	3.269%
\$225,000	400	3.771%	2.446%
\$225,000	500	3.621%	2.253%
\$225,000	600	3.137%	1.842%
\$225,000	700	2.825%	1.590%
\$225,000	800	2.595%	1.397%
\$225,000	900	2.472%	1.294%
\$225,000	1,000	2.293%	1.150%
\$225,000	1,500	1.707%	0.728%
\$225,000	2,000	1.404%	0.520%
\$225,000	3,000	0.891%	0.235%
\$225,000	4,000	0.661%	0.131%
\$225,000	5,000	0.524%	0.082%
\$225,000	10,000	0.185%	0.008%
\$225,000	20,000	0.043%	0.001%
\$225,000	30,000	0.010%	0.001%
\$225,000	40,000	0.003%	0.001%
\$230,000	25	18.177%	16.636%
\$230,000	50	12.743%	11.142%
\$230,000	100	8.646%	7.038%
\$230,000	150	7.021%	5.445%
\$230,000	200	6.008%	4.469%
\$230,000	300	4.765%	3.297%
\$230,000	400	3.798%	2.469%
\$230,000	500	3.648%	2.275%

Experience Refund Risk Charge Factors*

Pooling			100/ Маняін
Limit	members	5% Margin	10% Margin
\$230,000	600	3.159%	1.860%
\$230,000	700	2.846%	1.606%
\$230,000	800	2.615%	1.413%
\$230,000	900	2.491%	1.308%
\$230,000	1,000	2.310%	1.162%
\$230,000	1,500	1.722%	0.738%
\$230,000	2,000	1.416%	0.528%
\$230,000	3,000	0.901%	0.239%
\$230,000	4,000	0.669%	0.134%
\$230,000	5,000	0.531%	0.084%
\$230,000	10,000	0.188%	0.008%
\$230,000	20,000	0.044%	0.001%
\$230,000	30,000	0.010%	0.001%
\$230,000	40,000	0.003%	0.001%
\$235,000	25	18.263%	16.723%
\$235,000	50	12.819%	11.220%
\$235,000	100	8.701%	7.090%
\$235,000	150	7.067%	5.489%
\$235,000	200	6.047%	4.505%
\$235,000	300	4.796%	3.325%
\$235,000	400	3.824%	2.491%
\$235,000	500	3.674%	2.297%
\$235,000	600	3.182%	1.878%
\$235,000	700	2.867%	1.623%
\$235,000	800	2.634%	1.428%
\$235,000	900	2.509%	1.322%
\$235,000	1,000	2.327%	1.175%
\$235,000	1,500	1.737%	0.748%
\$235,000	2,000	1.428%	0.535%
\$235,000	3,000	0.910%	0.243%
\$235,000	4,000	0.676%	0.137%
\$235,000	5,000	0.538%	0.086%
\$235,000	10,000	0.191%	0.009%
\$235,000	20,000	0.045%	0.001%
\$235,000	30,000	0.010%	0.001%
\$235,000	40,000	0.003%	0.001%
\$240,000	25	18.347%	16.808%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	10% Margin
\$240,000	50	12.894%	11.296%
\$240,000	100	8.754%	7.142%
\$240,000	150	7.112%	5.532%
\$240,000	200	6.086%	4.540%
\$240,000	300	4.827%	3.353%
\$240,000	400	3.850%	2.513%
\$240,000	500	3.700%	2.319%
\$240,000	600	3.204%	1.896%
\$240,000	700	2.887%	1.638%
\$240,000	800	2.653%	1.443%
\$240,000	900	2.527%	1.335%
\$240,000	1,000	2.344%	1.187%
\$240,000	1,500	1.752%	0.758%
\$240,000	2,000	1.440%	0.542%
\$240,000	3,000	0.919%	0.247%
\$240,000	4,000	0.684%	0.139%
\$240,000	5,000	0.545%	0.088%
\$240,000	10,000	0.193%	0.009%
\$240,000	20,000	0.046%	0.001%
\$240,000	30,000	0.010%	0.001%
\$240,000	40,000	0.003%	0.001%
\$245,000	25	18.427%	16.888%
\$245,000	50	12.966%	11.369%
\$245,000	100	8.806%	7.193%
\$245,000	150	7.158%	5.575%
\$245,000	200	6.124%	4.574%
\$245,000	300	4.858%	3.380%
\$245,000	400	3.876%	2.535%
\$245,000	500	3.724%	2.339%
\$245,000	600	3.225%	1.913%
\$245,000	700	2.905%	1.653%
\$245,000	800	2.671%	1.457%
\$245,000	900	2.545%	1.349%
\$245,000	1,000	2.360%	1.199%
\$245,000	1,500	1.766%	0.767%
\$245,000	2,000	1.451%	0.549%
\$245,000	3,000	0.927%	0.251%

Experience Refund Risk Charge Factors*

Pooling			
Limit	members	5% Margin	10% Margin
\$245,000	4,000	0.691%	0.142%
\$245,000	5,000	0.552%	0.090%
\$245,000	10,000	0.196%	0.009%
\$245,000	20,000	0.047%	0.001%
\$245,000	30,000	0.011%	0.001%
\$245,000	40,000	0.003%	0.001%
\$250,000	25	18.500%	16.962%
\$250,000	50	13.030%	11.435%
\$250,000	100	8.856%	7.241%
\$250,000	150	7.200%	5.615%
\$250,000	200	6.160%	4.607%
\$250,000	300	4.887%	3.407%
\$250,000	400	3.900%	2.555%
\$250,000	500	3.748%	2.359%
\$250,000	600	3.245%	1.929%
\$250,000	700	2.923%	1.668%
\$250,000	800	2.689%	1.471%
\$250,000	900	2.562%	1.361%
\$250,000	1,000	2.376%	1.210%
\$250,000	1,500	1.780%	0.776%
\$250,000	2,000	1.462%	0.555%
\$250,000	3,000	0.935%	0.255%
\$250,000	4,000	0.698%	0.145%
\$250,000	5,000	0.558%	0.092%
\$250,000	10,000	0.198%	0.009%
\$250,000	20,000	0.047%	0.001%
\$250,000	30,000	0.011%	0.001%
\$250,000	40,000	0.003%	0.001%
\$255,000	25	18.569%	17.032%
\$255,000	50	13.091%	11.498%
\$255,000	100	8.903%	7.288%
\$255,000	150	7.241%	5.653%
\$255,000	200	6.194%	4.638%
\$255,000	300	4.915%	3.432%
\$255,000	400	3.923%	2.575%
\$255,000	500	3.770%	2.378%
\$255,000	600	3.264%	1.945%

Experience Refund Risk Charge Factors*

Pooling	1		100/ 11
Limit	members	5% Margin	10% Margin
\$255,000	700	2.940%	1.681%
\$255,000	800	2.706%	1.484%
\$255,000	900	2.578%	1.373%
\$255,000	1,000	2.391%	1.221%
\$255,000	1,500	1.793%	0.785%
\$255,000	2,000	1.472%	0.561%
\$255,000	3,000	0.943%	0.258%
\$255,000	4,000	0.705%	0.147%
\$255,000	5,000	0.564%	0.094%
\$255,000	10,000	0.201%	0.010%
\$255,000	20,000	0.048%	0.001%
\$255,000	30,000	0.011%	0.001%
\$255,000	40,000	0.003%	0.001%
\$260,000	25	18.637%	17.101%
\$260,000	50	13.151%	11.559%
\$260,000	100	8.951%	7.335%
\$260,000	150	7.282%	5.692%
\$260,000	200	6.229%	4.670%
\$260,000	300	4.943%	3.457%
\$260,000	400	3.947%	2.595%
\$260,000	500	3.793%	2.397%
\$260,000	600	3.283%	1.960%
\$260,000	700	2.957%	1.695%
\$260,000	800	2.723%	1.497%
\$260,000	900	2.593%	1.385%
\$260,000	1,000	2.406%	1.232%
\$260,000	1,500	1.806%	0.793%
\$260,000	2,000	1.482%	0.568%
\$260,000	3,000	0.950%	0.262%
\$260,000	4,000	0.712%	0.150%
\$260,000	5,000	0.570%	0.096%
\$260,000	10,000	0.203%	0.010%
\$260,000	20,000	0.049%	0.001%
\$260,000	30,000	0.011%	0.001%
\$260,000	40,000	0.003%	0.001%
\$265,000	25	18.705%	17.169%
\$265,000	50	13.210%	11.620%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$265,000	100	8.998%	7.381%
\$265,000	150	7.322%	5.730%
\$265,000	200	6.263%	4.702%
\$265,000	300	4.971%	3.483%
\$265,000	400	3.970%	2.615%
\$265,000	500	3.815%	2.416%
\$265,000	600	3.302%	1.975%
\$265,000	700	2.973%	1.709%
\$265,000	800	2.740%	1.511%
\$265,000	900	2.609%	1.397%
\$265,000	1,000	2.421%	1.243%
\$265,000	1,500	1.819%	0.802%
\$265,000	2,000	1.492%	0.574%
\$265,000	3,000	0.958%	0.265%
\$265,000	4,000	0.718%	0.152%
\$265,000	5,000	0.576%	0.098%
\$265,000	10,000	0.206%	0.010%
\$265,000	20,000	0.050%	0.001%
\$265,000	30,000	0.012%	0.001%
\$265,000	40,000	0.003%	0.001%
\$270,000	25	18.772%	17.238%
\$270,000	50	13.268%	11.680%
\$270,000	100	9.045%	7.428%
\$270,000	150	7.363%	5.768%
\$270,000	200	6.298%	4.734%
\$270,000	300	4.999%	3.508%
\$270,000	400	3.993%	2.635%
\$270,000	500	3.837%	2.435%
\$270,000	600	3.321%	1 .99 1%
\$270,000	700	2.990%	1.722%
\$270,000	800	2.757%	1.524%
\$270,000	900	2.624%	1.409%
\$270,000	1,000	2.436%	1.255%
\$270,000	1,500	1.832%	0.811%
\$270,000	2,000	1.502%	0.580%
\$270,000	3,000	0.966%	0.269%
\$270,000	4,000	0.725%	0.155%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$270,000	5,000	0.583%	0.100%
\$270,000	10,000	0.208%	0.010%
\$270,000	20,000	0.051%	0.001%
\$270,000	30,000	0.012%	0.001%
\$270,000	40,000	0.003%	0.001%
\$275,000	25	18.838%	17.304%
\$275,000	50	13.326%	11.739%
\$275,000	100	9.091%	7.473%
\$275,000	150	7.403%	5.806%
\$275,000	200	6.332%	4.766%
\$275,000	300	5.026%	3.533%
\$275,000	400	4.017%	2.655%
\$275,000	500	3.859%	2.454%
\$275,000	600	3.339%	2.006%
\$275,000	700	3.007%	1.736%
\$275,000	800	2.774%	1.538%
\$275,000	900	2.640%	1.421%
\$275,000	1,000	2.451%	1.266%
\$275,000	1,500	1.845%	0.820%
\$275,000	2,000	1.512%	0.586%
\$275,000	3,000	0.974%	0.273%
\$275,000	4,000	0.732%	0.158%
\$275,000	5,000	0.589%	0.102%
\$275,000	10,000	0.210%	0.011%
\$275,000	20,000	0.051%	0.001%
\$275,000	30,000	0.012%	0.001%
\$275,000	40,000	0.003%	0.001%
\$280,000	25	18.901%	17.367%
\$280,000	50	13.383%	11.797%
\$280,000	100	9.136%	7.517%
\$280,000	150	7.442%	5.843%
\$280,000	200	6.366%	4.797%
\$280,000	300	5.053%	3.558%
\$280,000	400	4.040%	2.674%
\$280,000	500	3.881%	2.472%
\$280,000	600	3.358%	2.021%
\$280,000	700	3.023%	1.749%

Experience Refund Risk Charge Factors*

Pooling	mambana	EQ/ Margin	100/ Маняія
Limit	members	5% Margin	10% Margin
\$280,000	800	2.791%	1.551%
\$280,000	900	2.655%	1.432%
\$280,000	1,000	2.466%	1.277%
\$280,000	1,500	1.858%	0.829%
\$280,000	2,000	1.522%	0.593%
\$280,000	3,000	0.981%	0.276%
\$280,000	4,000	0.739%	0.160%
\$280,000	5,000	0.594%	0.104%
\$280,000	10,000	0.213%	0.011%
\$280,000	20,000	0.052%	0.001%
\$280,000	30,000	0.012%	0.001%
\$280,000	40,000	0.003%	0.001%
\$285,000	25	18.963%	17.430%
\$285,000	50	13.439%	11.855%
\$285,000	100	9.181%	7.560%
\$285,000	150	7.481%	5.880%
\$285,000	200	6.399%	4.828%
\$285,000	300	5.080%	3.582%
\$285,000	400	4.063%	2.694%
\$285,000	500	3.903%	2.491%
\$285,000	600	3.376%	2.036%
\$285,000	700	3.039%	1.762%
\$285,000	800	2.807%	1.564%
\$285,000	900	2.670%	1.444%
\$285,000	1,000	2.481%	1.288%
\$285,000	1,500	1.871%	0.837%
\$285,000	2,000	1.532%	0.599%
\$285,000	3,000	0.989%	0.280%
\$285,000	4,000	0.746%	0.163%
\$285,000	5,000	0.600%	0.106%
\$285,000	10,000	0.215%	0.011%
\$285,000	20,000	0.053%	0.001%
\$285,000	30,000	0.012%	0.001%
\$285,000	40,000	0.003%	0.001%
\$290,000	25	19.021%	17.489%
\$290,000	50	13.492%	11.909%
\$290,000	100	9.223%	7.603%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	10% Margin
\$290,000	150	7.518%	5.916%
\$290,000	200	6.430%	4.858%
\$290,000	300	5.105%	3.605%
\$290,000	400	4.085%	2.713%
\$290,000	500	3.924%	2.509%
\$290,000	600	3.393%	2.050%
\$290,000	700	3.054%	1.774%
\$290,000	800	2.823%	1.577%
\$290,000	900	2.684%	1.455%
\$290,000	1,000	2.495%	1.299%
\$290,000	1,500	1.883%	0.845%
\$290,000	2,000	1.541%	0.605%
\$290,000	3,000	0.996%	0.283%
\$290,000	4,000	0.752%	0.166%
\$290,000	5,000	0.606%	0.108%
\$290,000	10,000	0.217%	0.011%
\$290,000	20,000	0.054%	0.001%
\$290,000	30,000	0.013%	0.001%
\$290,000	40,000	0.003%	0.001%
\$295,000	25	19.076%	17.544%
\$295,000	50	13.541%	11.959%
\$295,000	100	9.264%	7.643%
\$295,000	150	7.553%	5.950%
\$295,000	200	6.461%	4.886%
\$295,000	300	5.129%	3.627%
\$295,000	400	4.107%	2.732%
\$295,000	500	3.944%	2.526%
\$295,000	600	3.410%	2.064%
\$295,000	700	3.069%	1.787%
\$295,000	800	2.838%	1.589%
\$295,000	900	2.698%	1.466%
\$295,000	1,000	2.508%	1.309%
\$295,000	1,500	1.894%	0.853%
\$295,000	2,000	1.550%	0.610%
\$295,000	3,000	1.003%	0.287%
\$295,000	4,000	0.759%	0.168%
\$295,000	5,000	0.611%	0.110%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$295,000	10,000	0.220%	0.012%
\$295,000	20,000	0.054%	0.001%
\$295,000	30,000	0.013%	0.001%
\$295,000	40,000	0.003%	0.001%
\$300,000	25	19.128%	17.597%
\$300,000	50	13.589%	12.008%
\$300,000	100	9.305%	7.684%
\$300,000	150	7.587%	5.983%
\$300,000	200	6.491%	4.915%
\$300,000	300	5.153%	3.649%
\$300,000	400	4.129%	2.750%
\$300,000	500	3.963%	2.544%
\$300,000	600	3.426%	2.077%
\$300,000	700	3.083%	1.799%
\$300,000	800	2.853%	1.601%
\$300,000	900	2.712%	1.477%
\$300,000	1,000	2.521%	1.319%
\$300,000	1,500	1.905%	0.861%
\$300,000	2,000	1.559%	0.616%
\$300,000	3,000	1.010%	0.290%
\$300,000	4,000	0.765%	0.171%
\$300,000	5,000	0.616%	0.112%
\$300,000	10,000	0.222%	0.012%
\$300,000	20,000	0.055%	0.001%
\$300,000	30,000	0.013%	0.001%
\$300,000	40,000	0.003%	0.001%
\$305,000	25	19.178%	17.648%
\$305,000	50	13.636%	12.057%
\$305,000	100	9.345%	7.724%
\$305,000	150	7.620%	6.016%
\$305,000	200	6.520%	4.943%
\$305,000	300	5.176%	3.670%
\$305,000	400	4.150%	2.769%
\$305,000	500	3.983%	2.560%
\$305,000	600	3.442%	2.091%
\$305,000	700	3.097%	1.810%
\$305,000	800	2.868%	1.612%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	5% Margin	10% Maigin
\$305,000	900	2.726%	1.487%
\$305,000	1,000	2.534%	1.329%
\$305,000	1,500	1.916%	0.868%
\$305,000	2,000	1.568%	0.621%
\$305,000	3,000	1.017%	0.294%
\$305,000	4,000	0.771%	0.173%
\$305,000	5,000	0.621%	0.114%
\$305,000	10,000	0.224%	0.012%
\$305,000	20,000	0.056%	0.001%
\$305,000	30,000	0.013%	0.001%
\$305,000	40,000	0.003%	0.001%
\$310,000	25	19.226%	17.696%
\$310,000	50	13.682%	12.104%
\$310,000	100	9.384%	7.763%
\$310,000	150	7.653%	6.048%
\$310,000	200	6.550%	4.970%
\$310,000	300	5.199%	3.690%
\$310,000	400	4.171%	2.786%
\$310,000	500	4.002%	2.577%
\$310,000	600	3.458%	2.104%
\$310,000	700	3.111%	1.822%
\$310,000	800	2.882%	1.624%
\$310,000	900	2.739%	1.498%
\$310,000	1,000	2.547%	1.338%
\$310,000	1,500	1.927%	0.876%
\$310,000	2,000	1.576%	0.627%
\$310,000	3,000	1.024%	0.297%
\$310,000	4,000	0.777%	0.175%
\$310,000	5,000	0.626%	0.115%
\$310,000	10,000	0.226%	0.012%
\$310,000	20,000	0.057%	0.001%
\$310,000	30,000	0.014%	0.001%
\$310,000	40,000	0.003%	0.001%
\$315,000	25	19.273%	17.743%
\$315,000	50	13.728%	12.151%
\$315,000	100	9.422%	7.801%
\$315,000	150	7.685%	6.080%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	10% Margin
\$315,000	200	6.578%	4.998%
\$315,000	300	5.221%	3.711%
\$315,000	400	4.192%	2.804%
\$315,000	500	4.020%	2.593%
\$315,000	600	3.473%	2.117%
\$315,000	700	3.125%	1.833%
\$315,000	800	2.895%	1.634%
\$315,000	900	2.752%	1.508%
\$315,000	1,000	2.559%	1.348%
\$315,000	1,500	1.937%	0.883%
\$315,000	2,000	1.584%	0.632%
\$315,000	3,000	1.030%	0.300%
\$315,000	4,000	0.783%	0.178%
\$315,000	5,000	0.631%	0.117%
\$315,000	10,000	0.228%	0.013%
\$315,000	20,000	0.057%	0.001%
\$315,000	30,000	0.014%	0.001%
\$315,000	40,000	0.003%	0.001%
\$320,000	25	19.319%	17.790%
\$320,000	50	13.771%	12.195%
\$320,000	100	9.459%	7.839%
\$320,000	150	7.717%	6.111%
\$320,000	200	6.607%	5.025%
\$320,000	300	5.243%	3.731%
\$320,000	400	4.212%	2.821%
\$320,000	500	4.039%	2.609%
\$320,000	600	3.489%	2.129%
\$320,000	700	3.139%	1.844%
\$320,000	800	2.909%	1.645%
\$320,000	900	2.764%	1.518%
\$320,000	1,000	2.571%	1.357%
\$320,000	1,500	1.948%	0.890%
\$320,000	2,000	1.592%	0.637%
\$320,000	3,000	1.037%	0.303%
\$320,000	4,000	0.789%	0.180%
\$320,000	5,000	0.636%	0.119%
\$320,000	10,000	0.230%	0.013%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	10% Margin
\$320,000	20,000	0.058%	0.001%
\$320,000	30,000	0.014%	0.001%
\$320,000	40,000	0.003%	0.001%
\$325,000	25	19.364%	17.835%
\$325,000	50	13.812%	12.237%
\$325,000	100	9.496%	7.876%
\$325,000	150	7.749%	6.143%
\$325,000	200	6.635%	5.051%
\$325,000	300	5.266%	3.752%
\$325,000	400	4.232%	2.839%
\$325,000	500	4.057%	2.625%
\$325,000	600	3.504%	2.142%
\$325,000	700	3.152%	1.855%
\$325,000	800	2.922%	1.656%
\$325,000	900	2.777%	1.527%
\$325,000	1,000	2.583%	1.366%
\$325,000	1,500	1.958%	0.897%
\$325,000	2,000	1.600%	0.642%
\$325,000	3,000	1.044%	0.307%
\$325,000	4,000	0.795%	0.183%
\$325,000	5,000	0.641%	0.120%
\$325,000	10,000	0.232%	0.013%
\$325,000	20,000	0.059%	0.001%
\$325,000	30,000	0.014%	0.001%
\$325,000	40,000	0.003%	0.001%
\$330,000	25	19.404%	17.876%
\$330,000	50	13.850%	12.276%
\$330,000	100	9.530%	7.911%
\$330,000	150	7.778%	6.172%
\$330,000	200	6.662%	5.077%
\$330,000	300	5.286%	3.770%
\$330,000	400	4.250%	2.854%
\$330,000	500	4.074%	2.639%
\$330,000	600	3.517%	2.153%
\$330,000	700	3.164%	1.865%
\$330,000	800	2.934%	1.665%
\$330,000	900	2.788%	1.536%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	1.000		4.2750
\$330,000	1,000	2.594%	1.375%
\$330,000	1,500	1.967%	0.904%
\$330,000	2,000	1.607%	0.647%
\$330,000	3,000	1.049%	0.310%
\$330,000	4,000	0.801%	0.185%
\$330,000	5,000	0.645%	0.122%
\$330,000	10,000	0.234%	0.014%
\$330,000	20,000	0.059%	0.001%
\$330,000	30,000	0.014%	0.001%
\$330,000	40,000	0.003%	0.001%
\$335,000	25	19.441%	17.913%
\$335,000	50	13.885%	12.311%
\$335,000	100	9.563%	7.944%
\$335,000	150	7.806%	6.199 %
\$335,000	200	6.687%	5.101%
\$335,000	300	5.304%	3.788%
\$335,000	400	4.268%	2.870%
\$335,000	500	4.089%	2.653%
\$335,000	600	3.529%	2.163%
\$335,000	700	3.176%	1.875%
\$335,000	800	2.946%	1.674%
\$335,000	900	2.799%	1.545%
\$335,000	1,000	2.605%	1.383%
\$335,000	1,500	1.977%	0.910%
\$335,000	2,000	1.614%	0.651%
\$335,000	3,000	1.055%	0.312%
\$335,000	4,000	0.806%	0.187%
\$335,000	5,000	0.649%	0.123%
\$335,000	10,000	0.236%	0.014%
\$335,000	20,000	0.060%	0.001%
\$335,000	30,000	0.015%	0.001%
\$335,000	40,000	0.003%	0.001%
\$340,000	25	19.477%	17.949%
\$340,000	50	13.918%	12.345%
\$340,000	100	9.596%	7.978%
\$340,000	150	7.833%	6.226%
\$340,000	200	6.711%	5.124%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$340,000	300	5.322%	3.804%
\$340,000	400	4.284%	2.884%
\$340,000	500	4.105%	2.667%
\$340,000	600	3.542%	2.174%
\$340,000	700	3.187%	1.884%
\$340,000	800	2.957%	1.683%
\$340,000	900	2.809%	1.553%
\$340,000	1,000	2.615%	1.390%
\$340,000	1,500	1.985%	0.916%
\$340,000	2,000	1.621%	0.656%
\$340,000	3,000	1.061%	0.315%
\$340,000	4,000	0.811%	0.189%
\$340,000	5,000	0.653%	0.125%
\$340,000	10,000	0.238%	0.014%
\$340,000	20,000	0.061%	0.001%
\$340,000	30,000	0.015%	0.001%
\$340,000	40,000	0.003%	0.001%
\$345,000	25	19.510%	17.982%
\$345,000	50	13.949%	12.376%
\$345,000	100	9.627%	8.010%
\$345,000	150	7.859%	6.251%
\$345,000	200	6.735%	5.146%
\$345,000	300	5.340%	3.820%
\$345,000	400	4.301%	2.898%
\$345,000	500	4.120%	2.680%
\$345,000	600	3.554%	2.184%
\$345,000	700	3.197%	1.893%
\$345,000	800	2.968%	1.692%
\$345,000	900	2.819%	1.561%
\$345,000	1,000	2.624%	1.398%
\$345,000	1,500	1.993%	0.922%
\$345,000	2,000	1.627%	0.660%
\$345,000	3,000	1.066%	0.318%
\$345,000	4,000	0.816%	0.191%
\$345,000	5,000	0.657%	0.126%
\$345,000	10,000	0.239%	0.014%
\$345,000	20,000	0.061%	0.001%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	10% Margin
\$345,000	30,000	0.015%	0.001%
\$345,000	40,000	0.003%	0.001%
\$350,000	25	19.543%	18.015%
\$350,000	50	13.979%	12.407%
\$350,000	100	9.658%	8.041%
\$350,000	150	7.886%	6.277%
\$350,000	200	6.758%	5.168%
\$350,000	300	5.357%	3.836%
\$350,000	400	4.317%	2.912%
\$350,000	500	4.134%	2.693%
\$350,000	600	3.566%	2.194%
\$350,000	700	3.208%	1.902%
\$350,000	800	2.979%	1.701%
\$350,000	900	2.829%	1.568%
\$350,000	1,000	2.634%	1.405%
\$350,000	1,500	2.001%	0.928%
\$350,000	2,000	1.633%	0.664%
\$350,000	3,000	1.071%	0.320%
\$350,000	4,000	0.821%	0.193%
\$350,000	5,000	0.661%	0.128%
\$350,000	10,000	0.241%	0.014%
\$350,000	20,000	0.062%	0.001%
\$350,000	30,000	0.015%	0.001%
\$350,000	40,000	0.003%	0.001%
\$355,000	25	19.576%	18.048%
\$355,000	50	14.009%	12.438%
\$355,000	100	9.688%	8.071%
\$355,000	150	7.912%	6.302%
\$355,000	200	6.781%	5.191%
\$355,000	300	5.374%	3.852%
\$355,000	400	4.333%	2.926%
\$355,000	500	4.149%	2.706%
\$355,000	600	3.578%	2.204%
\$355,000	700	3.219%	1.911%
\$355,000	800	2.990%	1.709%
\$355,000	900	2.838%	1.576%
\$355,000	1,000	2.644%	1.413%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	J% Margin	10% Maigin
\$355,000	1,500	2.009%	0.933%
\$355,000	2,000	1.640%	0.668%
\$355,000	3,000	1.076%	0.323%
\$355,000	4,000	0.826%	0.195%
\$355,000	5,000	0.665%	0.129%
\$355,000	10,000	0.243%	0.015%
\$355,000	20,000	0.062%	0.001%
\$355,000	30,000	0.015%	0.001%
\$355,000	40,000	0.003%	0.001%
\$360,000	25	19.609%	18.081%
\$360,000	50	14.039%	12.468%
\$360,000	100	9.719%	8.102%
\$360,000	150	7.938%	6.328%
\$360,000	200	6.804%	5.213%
\$360,000	300	5.391%	3.868%
\$360,000	400	4.349%	2.941%
\$360,000	500	4.165%	2.720%
\$360,000	600	3.590%	2.214%
\$360,000	700	3.229%	1.919%
\$360,000	800	3.001%	1.718%
\$360,000	900	2.848%	1.584%
\$360,000	1,000	2.653%	1.420%
\$360,000	1,500	2.017%	0.939%
\$360,000	2,000	1.646%	0.672%
\$360,000	3,000	1.082%	0.326%
\$360,000	4,000	0.831%	0.197%
\$360,000	5,000	0.669%	0.131%
\$360,000	10,000	0.244%	0.015%
\$360,000	20,000	0.063%	0.001%
\$360,000	30,000	0.015%	0.001%
\$360,000	40,000	0.003%	0.001%
\$365,000	25	19.643%	18.115%
\$365,000	50	14.068%	12.498%
\$365,000	100	9.749%	8.133%
\$365,000	150	7.964%	6.353%
\$365,000	200	6.828%	5.235%
\$365,000	300	5.409%	3.884%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit		-	-
\$365,000	400	4.365%	2.955%
\$365,000	500	4.180%	2.733%
\$365,000	600	3.602%	2.224%
\$365,000	700	3.240%	1.928%
\$365,000	800	3.011%	1.726%
\$365,000	900	2.858%	1.592%
\$365,000	1,000	2.663%	1.428%
\$365,000	1,500	2.025%	0.945%
\$365,000	2,000	1.653%	0.676%
\$365,000	3,000	1.087%	0.328%
\$365,000	4,000	0.836%	0.199%
\$365,000	5,000	0.673%	0.132%
\$365,000	10,000	0.246%	0.015%
\$365,000	20,000	0.064%	0.001%
\$365,000	30,000	0.016%	0.001%
\$365,000	40,000	0.003%	0.001%
\$370,000	25	19.674%	18.147%
\$370,000	50	14.096%	12.526%
\$370,000	100	9.778%	8.163%
\$370,000	150	7.990%	6.378%
\$370,000	200	6.850%	5.257%
\$370,000	300	5.426%	3.900%
\$370,000	400	4.381%	2.969%
\$370,000	500	4.194%	2.746%
\$370,000	600	3.614%	2.234%
\$370,000	700	3.250%	1.937%
\$370,000	800	3.022%	1.735%
\$370,000	900	2.868%	1.600%
\$370,000	1,000	2.673%	1.435%
\$370,000	1,500	2.033%	0.950%
\$370,000	2,000	1.659%	0.680%
\$370,000	3,000	1.092%	0.331%
\$370,000	4,000	0.840%	0.201%
\$370,000	5,000	0.677%	0.134%
\$370,000	10,000	0.248%	0.015%
\$370,000	20,000	0.064%	0.001%
\$370,000	30,000	0.016%	0.001%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Maigin	10% Maigin
\$370,000	40,000	0.004%	0.001%
\$375,000	25	19.702%	18.175%
\$375,000	50	14.121%	12.552%
\$375,000	100	9.805%	8.190%
\$375,000	150	8.013%	6.402%
\$375,000	200	6.870%	5.276%
\$375,000	300	5.442%	3.915%
\$375,000	400	4.396%	2.982%
\$375,000	500	4.208%	2.758%
\$375,000	600	3.625%	2.244%
\$375,000	700	3.259%	1.945%
\$375,000	800	3.032%	1.743%
\$375,000	900	2.877%	1.607%
\$375,000	1,000	2.681%	1.442%
\$375,000	1,500	2.040%	0.955%
\$375,000	2,000	1.664%	0.684%
\$375,000	3,000	1.097%	0.333%
\$375,000	4,000	0.845%	0.203%
\$375,000	5,000	0.681%	0.135%
\$375,000	10,000	0.249%	0.016%
\$375,000	20,000	0.065%	0.001%
\$375,000	30,000	0.016%	0.001%
\$375,000	40,000	0.004%	0.001%
\$380,000	25	19.730%	18.202%
\$380,000	50	14.147%	12.578%
\$380,000	100	9.831%	8.217%
\$380,000	150	8.037%	6.425%
\$380,000	200	6.891%	5.296%
\$380,000	300	5.458%	3.930%
\$380,000	400	4.410%	2.995%
\$380,000	500	4.221%	2.770%
\$380,000	600	3.637%	2.253%
\$380,000	700	3.269%	1.953%
\$380,000	800	3.042%	1.750%
\$380,000	900	2.885%	1.614%
\$380,000	1,000	2.690%	1.449%
\$380,000	1,500	2.047%	0.960%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	To Margin
\$380,000	2,000	1.670%	0.688%
\$380,000	3,000	1.102%	0.336%
\$380,000	4,000	0.849%	0.205%
\$380,000	5,000	0.685%	0.136%
\$380,000	10,000	0.251%	0.016%
\$380,000	20,000	0.065%	0.001%
\$380,000	30,000	0.016%	0.001%
\$380,000	40,000	0.004%	0.001%
\$385,000	25	19.757%	18.229%
\$385,000	50	14.173%	12.605%
\$385,000	100	9.857%	8.244%
\$385,000	150	8.059%	6.447%
\$385,000	200	6.911%	5.315%
\$385,000	300	5.474%	3.945%
\$385,000	400	4.425%	3.008%
\$385,000	500	4.234%	2.781%
\$385,000	600	3.648%	2.263%
\$385,000	700	3.278%	1.960%
\$385,000	800	3.051%	1.758%
\$385,000	900	2.894%	1.621%
\$385,000	1,000	2.698%	1.455%
\$385,000	1,500	2.054%	0.965%
\$385,000	2,000	1.675%	0.691%
\$385,000	3,000	1.106%	0.338%
\$385,000	4,000	0.854%	0.207%
\$385,000	5,000	0.688%	0.138%
\$385,000	10,000	0.252%	0.016%
\$385,000	20,000	0.066%	0.001%
\$385,000	30,000	0.016%	0.001%
\$385,000	40,000	0.004%	0.001%
\$390,000	25	19.783%	18.256%
\$390,000	50	14.198%	12.631%
\$390,000	100	9.881%	8.269%
\$390,000	150	8.081%	6.470%
\$390,000	200	6.930%	5.334%
\$390,000	300	5.489%	3.959%
\$390,000	400	4.439%	3.021%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit		-	-
\$390,000	500	4.247%	2.793%
\$390,000	600	3.659%	2.272%
\$390,000	700	3.286%	1.967%
\$390,000	800	3.060%	1.765%
\$390,000	900	2.902%	1.628%
\$390,000	1,000	2.706%	1.462%
\$390,000	1,500	2.061%	0.970%
\$390,000	2,000	1.681%	0.695%
\$390,000	3,000	1.111%	0.340%
\$390,000	4,000	0.858%	0.209%
\$390,000	5,000	0.692%	0.139%
\$390,000	10,000	0.254%	0.016%
\$390,000	20,000	0.066%	0.001%
\$390,000	30,000	0.016%	0.001%
\$390,000	40,000	0.004%	0.001%
\$395,000	25	19.808%	18.280%
\$395,000	50	14.224%	12.657%
\$395,000	100	9.905%	8.293%
\$395,000	150	8.103%	6.491%
\$395,000	200	6.949%	5.352%
\$395,000	300	5.504%	3.973%
\$395,000	400	4.452%	3.033%
\$395,000	500	4.259%	2.804%
\$395,000	600	3.669%	2.281%
\$395,000	700	3.294%	1.974%
\$395,000	800	3.069%	1.772%
\$395,000	900	2.911%	1.634%
\$395,000	1,000	2.714%	1.468%
\$395,000	1,500	2.068%	0.975%
\$395,000	2,000	1.686%	0.698%
\$395,000	3,000	1.115%	0.343%
\$395,000	4,000	0.862%	0.211%
\$395,000	5,000	0.695%	0.140%
\$395,000	10,000	0.255%	0.016%
\$395,000	20,000	0.067%	0.001%
\$395,000	30,000	0.017%	0.001%
\$395,000	40,000	0.004%	0.001%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$400,000	25	19.832%	18.305%
\$400,000	50	14.249%	12.682%
\$400,000	100	9.927%	8.316%
\$400,000	150	8.124%	6.512%
\$400,000	200	6.967%	5.370%
\$400,000	300	5.519%	3.987%
\$400,000	400	4.465%	3.045%
\$400,000	500	4.271%	2.814%
\$400,000	600	3.679%	2.289%
\$400,000	700	3.302%	1.981%
\$400,000	800	3.078%	1.779%
\$400,000	900	2.918%	1.641%
\$400,000	1,000	2.721%	1.473%
\$400,000	1,500	2.074%	0.980%
\$400,000	2,000	1.691%	0.701%
\$400,000	3,000	1.119%	0.345%
\$400,000	4,000	0.866%	0.213%
\$400,000	5,000	0.698%	0.142%
\$400,000	10,000	0.257%	0.017%
\$400,000	20,000	0.067%	0.001%
\$400,000	30,000	0.017%	0.001%
\$400,000	40,000	0.004%	0.001%
\$405,000	25	19.857%	18.329%
\$405,000	50	14.272%	12.706%
\$405,000	100	9.949%	8.337%
\$405,000	150	8.144%	6.532%
\$405,000	200	6.985 %	5.387%
\$405,000	300	5.533%	4.000%
\$405,000	400	4.478%	3.056%
\$405,000	500	4.282%	2.824%
\$405,000	600	3.689%	2.297%
\$405,000	700	3.310%	1.988%
\$405,000	800	3.086%	1.786%
\$405,000	900	2.926%	1.647%
\$405,000	1,000	2.729%	1.479%
\$405,000	1,500	2.080%	0.984%
\$405,000	2,000	1.696%	0.705%

Experience Refund Risk Charge Factors*

Pooling	mombors	5% Margin	10% Margin
Limit	members	5% Margin	10% Margin
\$405,000	3,000	1.123%	0.347%
\$405,000	4,000	0.870%	0.214%
\$405,000	5,000	0.701%	0.143%
\$405,000	10,000	0.258%	0.017%
\$405,000	20,000	0.068%	0.001%
\$405,000	30,000	0.017%	0.001%
\$405,000	40,000	0.004%	0.001%
\$410,000	25	19.882%	18.354%
\$410,000	50	14.296%	12.729%
\$410,000	100	9.969%	8.358%
\$410,000	150	8.165%	6.553%
\$410,000	200	7.003%	5.404%
\$410,000	300	5.548%	4.014%
\$410,000	400	4.490%	3.068%
\$410,000	500	4.294%	2.835%
\$410,000	600	3.698%	2.305%
\$410,000	700	3.318%	1.994%
\$410,000	800	3.094%	1.793%
\$410,000	900	2.934%	1.653%
\$410,000	1,000	2.736%	1.485%
\$410,000	1,500	2.087%	0.989%
\$410,000	2,000	1.700%	0.708%
\$410,000	3,000	1.127%	0.349%
\$410,000	4,000	0.874%	0.216%
\$410,000	5,000	0.705%	0.144%
\$410,000	10,000	0.260%	0.017%
\$410,000	20,000	0.068%	0.001%
\$410,000	30,000	0.017%	0.001%
\$410,000	40,000	0.004%	0.001%
\$415,000	25	19.908%	18.380%
\$415,000	50	14.319%	12.752%
\$415,000	100	9.989 %	8.379%
\$415,000	150	8.185%	6.574%
\$415,000	200	7.020%	5.420%
\$415,000	300	5.562%	4.027%
\$415,000	400	4.503%	3.079%
\$415,000	500	4.306%	2.845%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$415,000	600	3.708%	2.313%
\$415,000	700	3.325%	2.001%
\$415,000	800	3.102%	1.799%
\$415,000	900	2.941%	1.660%
\$415,000	1,000	2.743%	1.490%
\$415,000	1,500	2.093%	0.993%
\$415,000	2,000	1.705%	0.711%
\$415,000	3,000	1.131%	0.351%
\$415,000	4,000	0.877%	0.217%
\$415,000	5,000	0.708%	0.145%
\$415,000	10,000	0.261%	0.017%
\$415,000	20,000	0.069%	0.001%
\$415,000	30,000	0.017%	0.001%
\$415,000	40,000	0.004%	0.001%
\$420,000	25	19.931%	18.402%
\$420,000	50	14.340%	12.774%
\$420,000	100	10.008%	8.398%
\$420,000	150	8.205%	6.593%
\$420,000	200	7.036%	5.436%
\$420,000	300	5.575%	4.040%
\$420,000	400	4.515%	3.090%
\$420,000	500	4.317%	2.855%
\$420,000	600	3.717%	2.321%
\$420,000	700	3.333%	2.007%
\$420,000	800	3.110%	1.805%
\$420,000	900	2.949%	1.665%
\$420,000	1,000	2.750%	1.496%
\$420,000	1,500	2.099%	0.997%
\$420,000	2,000	1.710%	0.714%
\$420,000	3,000	1.135%	0.353%
\$420,000	4,000	0.881%	0.219%
\$420,000	5,000	0.711%	0.146%
\$420,000	10,000	0.262%	0.017%
\$420,000	20,000	0.069%	0.001%
\$420,000	30,000	0.017%	0.001%
\$420,000	40,000	0.004%	0.001%
\$425,000	25	19.952%	18.424%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$425,000	50	14.359%	12.794%
\$425,000	100	10.026%	8.416%
\$425,000	150	8.224%	6.613%
\$425,000	200	7.052%	5.452%
\$425,000	300	5.589%	4.052%
\$425,000	400	4.527%	3.101%
\$425,000	500	4.328%	2.865%
\$425,000	600	3.725%	2.329%
\$425,000	700	3.340%	2.013%
\$425,000	800	3.117%	1.812%
\$425,000	900	2.956%	1.671%
\$425,000	1,000	2.757%	1.501%
\$425,000	1,500	2.105%	1.001%
\$425,000	2,000	1.714%	0.717%
\$425,000	3,000	1.139%	0.355%
\$425,000	4,000	0.885%	0.221%
\$425,000	5,000	0.714%	0.148%
\$425,000	10,000	0.264%	0.018%
\$425,000	20,000	0.069%	0.001%
\$425,000	30,000	0.017%	0.001%
\$425,000	40,000	0.004%	0.001%
\$430,000	25	19.973%	18.444%
\$430,000	50	14.379%	12.813%
\$430,000	100	10.043%	8.434%
\$430,000	150	8.242%	6.631%
\$430,000	200	7.067%	5.467%
\$430,000	300	5.601%	4.064%
\$430,000	400	4.538%	3.112%
\$430,000	500	4.338%	2.874%
\$430,000	600	3.734%	2.336%
\$430,000	700	3.346%	2.019%
\$430,000	800	3.125%	1.817%
\$430,000	900	2.962%	1.677%
\$430,000	1,000	2.763%	1.506%
\$430,000	1,500	2.110%	1.005%
\$430,000	2,000	1.718%	0.719%
\$430,000	3,000	1.143%	0.357%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	5% Margin	10% Maigin
\$430,000	4,000	0.888%	0.222%
\$430,000	5,000	0.716%	0.149%
\$430,000	10,000	0.265%	0.018%
\$430,000	20,000	0.070%	0.001%
\$430,000	30,000	0.018%	0.001%
\$430,000	40,000	0.004%	0.001%
\$435,000	25	19.992%	18.464%
\$435,000	50	14.397%	12.832%
\$435,000	100	10.058%	8.450%
\$435,000	150	8.259%	6.648%
\$435,000	200	7.081%	5.481%
\$435,000	300	5.613%	4.075%
\$435,000	400	4.548%	3.121%
\$435,000	500	4.347%	2.882%
\$435,000	600	3.742%	2.343%
\$435,000	700	3.353%	2.024%
\$435,000	800	3.131%	1.823%
\$435,000	900	2.969%	1.683%
\$435,000	1,000	2.769%	1.510%
\$435,000	1,500	2.115%	1.009%
\$435,000	2,000	1.722%	0.722%
\$435,000	3,000	1.146%	0.359%
\$435,000	4,000	0.891%	0.224%
\$435,000	5,000	0.719%	0.150%
\$435,000	10,000	0.266%	0.018%
\$435,000	20,000	0.070%	0.001%
\$435,000	30,000	0.018%	0.001%
\$435,000	40,000	0.004%	0.001%
\$440,000	25	20.012%	18.483%
\$440,000	50	14.415%	12.850%
\$440,000	100	10.074%	8.466%
\$440,000	150	8.276%	6.666%
\$440,000	200	7.096%	5.495%
\$440,000	300	5.624%	4.086%
\$440,000	400	4.559%	3.131%
\$440,000	500	4.357%	2.891%
\$440,000	600	3.750%	2.350%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$440,000	700	3.359%	2.030%
\$440,000	800	3.138%	1.829%
\$440,000	900	2.976%	1.688%
\$440,000	1,000	2.775%	1.515%
\$440,000	1,500	2.121%	1.013%
\$440,000	2,000	1.726%	0.724%
\$440,000	3,000	1.150%	0.360%
\$440,000	4,000	0.894%	0.225%
\$440,000	5,000	0.721%	0.151%
\$440,000	10,000	0.267%	0.018%
\$440,000	20,000	0.070%	0.001%
\$440,000	30,000	0.018%	0.001%
\$440,000	40,000	0.004%	0.001%
\$445,000	25	20.031%	18.503%
\$445,000	50	14.434%	12.869%
\$445,000	100	10.089%	8.482%
\$445,000	150	8.293%	6.683%
\$445,000	200	7.111%	5.510%
\$445,000	300	5.636%	4.097%
\$445,000	400	4.570%	3.141%
\$445,000	500	4.366%	2.900%
\$445,000	600	3.758%	2.357%
\$445,000	700	3.365%	2.035%
\$445,000	800	3.145%	1.834%
\$445,000	900	2.982%	1.693%
\$445,000	1,000	2.780%	1.519%
\$445,000	1,500	2.126%	1.017%
\$445,000	2,000	1.730%	0.727%
\$445,000	3,000	1.153%	0.362%
\$445,000	4,000	0.898%	0.227%
\$445,000	5,000	0.724%	0.152%
\$445,000	10,000	0.268%	0.018%
\$445,000	20,000	0.071%	0.001%
\$445,000	30,000	0.018%	0.001%
\$445,000	40,000	0.004%	0.001%
\$450,000	25	20.050%	18.521%
\$450,000	50	14.452%	12.888%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$450,000	100	10.104%	8.497%
\$450,000	150	8.309%	6.700%
\$450,000	200	7.125%	5.524%
\$450,000	300	5.648%	4.108%
\$450,000	400	4.580%	3.150%
\$450,000	500	4.376%	2.908%
\$450,000	600	3.766%	2.364%
\$450,000	700	3.371%	2.040%
\$450,000	800	3.152%	1.840%
\$450,000	900	2.989%	1.699%
\$450,000	1,000	2.786%	1.524%
\$450,000	1,500	2.131%	1.020%
\$450,000	2,000	1.734%	0.730%
\$450,000	3,000	1.156%	0.364%
\$450,000	4,000	0.901%	0.228%
\$450,000	5,000	0.726%	0.153%
\$450,000	10,000	0.269%	0.019%
\$450,000	20,000	0.071%	0.001%
\$450,000	30,000	0.018%	0.001%
\$450,000	40,000	0.004%	0.001%
\$455,000	25	20.068%	18.539%
\$455,000	50	14.470%	12.906%
\$455,000	100	10.119%	8.513%
\$455,000	150	8.325%	6.716%
\$455,000	200	7.139%	5.538%
\$455,000	300	5.659%	4.118%
\$455,000	400	4.590%	3.160%
\$455,000	500	4.385%	2.916%
\$455,000	600	3.774%	2.371%
\$455,000	700	3.377%	2.046%
\$455,000	800	3.159%	1.845%
\$455,000	900	2.995 %	1.704%
\$455,000	1,000	2.791%	1.528%
\$455,000	1,500	2.136%	1.024%
\$455,000	2,000	1.737%	0.732%
\$455,000	3,000	1.160%	0.366%
\$455,000	4,000	0.904%	0.229%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$455,000	5,000	0.729%	0.154%
\$455,000	10,000	0.270%	0.019%
\$455,000	20,000	0.072%	0.001%
\$455,000	30,000	0.018%	0.001%
\$455,000	40,000	0.004%	0.001%
\$460,000	25	20.087%	18.558%
\$460,000	50	14.488%	12.924%
\$460,000	100	10.134%	8.527%
\$460,000	150	8.340%	6.731%
\$460,000	200	7.153%	5.551%
\$460,000	300	5.670%	4.128%
\$460,000	400	4.600%	3.169%
\$460,000	500	4.394%	2.924%
\$460,000	600	3.782%	2.377%
\$460,000	700	3.383%	2.051%
\$460,000	800	3.165%	1.850%
\$460,000	900	3.001%	1.709%
\$460,000	1,000	2.797%	1.532%
\$460,000	1,500	2.141%	1.027%
\$460,000	2,000	1.741%	0.735%
\$460,000	3,000	1.163%	0.367%
\$460,000	4,000	0.907%	0.231%
\$460,000	5,000	0.731%	0.155%
\$460,000	10,000	0.271%	0.019%
\$460,000	20,000	0.072%	0.001%
\$460,000	30,000	0.018%	0.001%
\$460,000	40,000	0.004%	0.001%
\$465,000	25	20.105%	18.576%
\$465,000	50	14.506%	12.942%
\$465,000	100	10.148%	8.542%
\$465,000	150	8.356%	6.747%
\$465,000	200	7.166%	5.565%
\$465,000	300	5.681%	4.139%
\$465,000	400	4.610%	3.178%
\$465,000	500	4.403%	2.932%
\$465,000	600	3.790%	2.384%
\$465,000	700	3.390%	2.056%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$465,000	800	3.172%	1.856%
\$465,000	900	3.008%	1.714%
\$465,000	1,000	2.802%	1.536%
\$465,000	1,500	2.146%	1.031%
\$465,000	2,000	1.745%	0.737%
\$465,000	3,000	1.166%	0.369%
\$465,000	4,000	0.910%	0.232%
\$465,000	5,000	0.734%	0.156%
\$465,000	10,000	0.273%	0.019%
\$465,000	20,000	0.072%	0.001%
\$465,000	30,000	0.018%	0.001%
\$465,000	40,000	0.004%	0.001%
\$470,000	25	20.123%	18.594%
\$470,000	50	14.524%	12.959%
\$470,000	100	10.162%	8.556%
\$470,000	150	8.371%	6.762%
\$470,000	200	7.179%	5.578%
\$470,000	300	5.691%	4.149%
\$470,000	400	4.620%	3.187%
\$470,000	500	4.411%	2.940%
\$470,000	600	3.798%	2.391%
\$470,000	700	3.396%	2.061%
\$470,000	800	3.178%	1.861%
\$470,000	900	3.014%	1.720%
\$470,000	1,000	2.808%	1.541%
\$470,000	1,500	2.150%	1.034%
\$470,000	2,000	1.748%	0.739%
\$470,000	3,000	1.169%	0.371%
\$470,000	4,000	0.913%	0.234%
\$470,000	5,000	0.736%	0.156%
\$470,000	10,000	0.274%	0.019%
\$470,000	20,000	0.073%	0.001%
\$470,000	30,000	0.018%	0.001%
\$470,000	40,000	0.004%	0.001%
\$475,000	25	20.140%	18.610%
\$475,000	50	14.540%	12.976%
\$475,000	100	10.175%	8.569%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	570 Margin	10% Margin
\$475,000	150	8.385%	6.777%
\$475,000	200	7.192 %	5.590%
\$475,000	300	5.702%	4.159%
\$475,000	400	4.630%	3.196%
\$475,000	500	4.420%	2.948%
\$475,000	600	3.806%	2.398%
\$475,000	700	3.402%	2.066%
\$475,000	800	3.185%	1.866%
\$475,000	900	3.020%	1.725%
\$475,000	1,000	2.813%	1.545%
\$475,000	1,500	2.155%	1.038%
\$475,000	2,000	1.752%	0.742%
\$475,000	3,000	1.172%	0.372%
\$475,000	4,000	0.916%	0.235%
\$475,000	5,000	0.738%	0.157%
\$475,000	10,000	0.275%	0.019%
\$475,000	20,000	0.073%	0.001%
\$475,000	30,000	0.019%	0.001%
\$475,000	40,000	0.004%	0.001%
\$480,000	25	20.156%	18.627%
\$480,000	50	14.557%	12 .992 %
\$480,000	100	10.188%	8.583%
\$480,000	150	8.400%	6.792%
\$480,000	200	7.204%	5.602%
\$480,000	300	5.713%	4.169%
\$480,000	400	4.639%	3.205%
\$480,000	500	4.429%	2.955%
\$480,000	600	3.814%	2.404%
\$480,000	700	3.408%	2.072%
\$480,000	800	3.191%	1.872%
\$480,000	900	3.026%	1.730%
\$480,000	1,000	2.818%	1.549%
\$480,000	1,500	2.160%	1.041%
\$480,000	2,000	1.756%	0.744%
\$480,000	3,000	1.176%	0.374%
\$480,000	4,000	0.919%	0.236%
\$480,000	5,000	0.741%	0.158%

Experience Refund Risk Charge Factors*

Pooling	m o m b o zo	EQ/ Margin	10% Маняія
Limit	members	5% Margin	10% Margin
\$480,000	10,000	0.276%	0.020%
\$480,000	20,000	0.073%	0.001%
\$480,000	30,000	0.019%	0.001%
\$480,000	40,000	0.004%	0.001%
\$485,000	25	20.174%	18.644%
\$485,000	50	14.572%	13.008%
\$485,000	100	10.201%	8.596%
\$485,000	150	8.413%	6.806%
\$485,000	200	7.216%	5.614%
\$485,000	300	5.723%	4.178%
\$485,000	400	4.649%	3.213%
\$485,000	500	4.437%	2.963%
\$485,000	600	3.822%	2.411%
\$485,000	700	3.413%	2.076%
\$485,000	800	3.197%	1.877%
\$485,000	900	3.032%	1.735%
\$485,000	1,000	2.823%	1.553%
\$485,000	1,500	2.164%	1.044%
\$485,000	2,000	1.759%	0.747%
\$485,000	3,000	1.179%	0.376%
\$485,000	4,000	0.922%	0.238%
\$485,000	5,000	0.743%	0.159%
\$485,000	10,000	0.277%	0.020%
\$485,000	20,000	0.074%	0.001%
\$485,000	30,000	0.019%	0.001%
\$485,000	40,000	0.004%	0.001%
\$490,000	25	20.189%	18.659%
\$490,000	50	14.586%	13.022%
\$490,000	100	10.212%	8.607%
\$490,000	150	8.426%	6.819%
\$490,000	200	7.227%	5.625%
\$490,000	300	5.732%	4.187%
\$490,000	400	4.657%	3.221%
\$490,000	500	4.444%	2.970%
\$490,000	600	3.829%	2.417%
\$490,000	700	3.418%	2.081%
\$490,000	800	3.203%	1.881%

Experience Refund Risk Charge Factors*

Pooling	members	5% Margin	10% Margin
Limit	members	5% Margin	10% Margin
\$490,000	900	3.038%	1.739%
\$490,000	1,000	2.828%	1.557%
\$490,000	1,500	2.168%	1.047%
\$490,000	2,000	1.762%	0.749%
\$490,000	3,000	1.181%	0.377%
\$490,000	4,000	0.925%	0.239%
\$490,000	5,000	0.745%	0.160%
\$490,000	10,000	0.278%	0.020%
\$490,000	20,000	0.074%	0.001%
\$490,000	30,000	0.019%	0.001%
\$490,000	40,000	0.004%	0.001%
\$495,000	25	20.203%	18.673%
\$495,000	50	14.599%	13.035%
\$495,000	100	10.223%	8.618%
\$495,000	150	8.438%	6.831%
\$495,000	200	7.238%	5.636%
\$495,000	300	5.741%	4.195%
\$495,000	400	4.665%	3.229%
\$495,000	500	4.451%	2.976%
\$495,000	600	3.835%	2.423%
\$495,000	700	3.423%	2.085%
\$495,000	800	3.208%	1.886%
\$495,000	900	3.043%	1.744%
\$495,000	1,000	2.833%	1.561%
\$495,000	1,500	2.172%	1.050%
\$495,000	2,000	1.766%	0.751%
\$495,000	3,000	1.184%	0.379%
\$495,000	4,000	0.927%	0.240%
\$495,000	5,000	0.747%	0.161%
\$495,000	10,000	0.279%	0.020%
\$495,000	20,000	0.074%	0.001%
\$495,000	30,000	0.019%	0.001%
\$495,000	40,000	0.004%	0.001%
\$500,000	25	20.218%	18.688%
\$500,000	50	14.612%	13.048%
\$500,000	100	10.234%	8.630%
\$500,000	150	8.450%	6.844%

Experience Refund Risk Charge Factors*

Pooling Limit	members	5% Margin	10% Margin
\$500,000	200	7.249%	5.646%
\$500,000	300	5.750%	4.204%
\$500,000	400	4.673%	3.237%
\$500,000	500	4.459%	2.983%
\$500,000	600	3.842%	2.428%
\$500,000	700	3.428%	2.089%
\$500,000	800	3.213%	1.890%
\$500,000	900	3.048%	1.748%
\$500,000	1,000	2.838%	1.564%
\$500,000	1,500	2.176%	1.053%
\$500,000	2,000	1.769%	0.753%
\$500,000	3,000	1.187%	0.380%
\$500,000	4,000	0.930%	0.241%
\$500,000	5,000	0.749%	0.162%
\$500,000	10,000	0.279%	0.020%
\$500,000	20,000	0.074%	0.001%
\$500,000	30,000	0.019%	0.001%
\$500,000	40,000	0.004%	0.001%



March 14, 2017

Mr. Josh Hammerquist, A.S.A., M.A.A.A. Assistant Vice President & Consulting Actuary Lewis & Ellis, Inc.

Subject: Your 03/07/2017 Questions re: The Vermont Health Plan 3Q 2017 TVHP Large Group Rating Program Filing (SERFF Tracking #: BCVT-130935776)

Dear Mr. Hammerquist:

In response to your request dated March 7, 2017, here are your questions and our answers:

1. Please provide an illustrative exhibit of the 25.0% increase in the administrative charges.

Below are the calculations of the total administrative charges for the 2017 and 2018 mock renewals for the 59 groups with 12 months of experience we expect to renew 2018.

For the 2017 mock renewals, the charges were based on four cost categories: Account, Billing Group, Member, and Cost Plus Medicare Supplement Member.

	Account	Billing Group	Member	Cost Plus Medicare Supplement Member
Charge	\$405.49	\$520.04	\$24.83	\$28.95
Monthly Units	59	69	14,406	53
Total Admin PMPM				\$29.09

For the 2018 mock renewals, the charges were based on six cost categories: Account, Member, Contract, Medical Claim Count, Projected Claims, and Cost Plus Medicare Supplement Member. These cost categories best align with our current cost allocation model.

	Account	Member	Contract	Medical Claim Count	Total Projected Claims	Cost Plus Medicare Supplement Member
Charge	\$864.18	\$15.46	\$1.83	\$1.19	3.0%	\$29.29
Monthly Units	59	14,406	7,317	32,567	\$6,548,864	53
Total Admin PM	NPM					\$36.36

The increase in administrative costs is 36.36/29.09 - 1 = 25.0 percent. As indicated in the Memorandum, the bulk of the increase is due to the change from combining Large

Group Insured and Cost Plus to only using Large Group Insured for experience period expenses.

2. Provide additional details regarding the first footnote on the bottom of page 3 of the Actuarial Memorandum.

Below is the first line of the table in the Memorandum comparing the mock renewals from 2017 to 2018, along with the first footnote:

Component	2017 PMPM	2018 PMPM	PMPM Change	Impact on Premium Increase
Projected Paid claims ¹	\$415.34	\$443.87	\$28.52	6.9 %

(1) Projected paid claims include manual claims (5.9 percent increase), experience claims (7.4 percent increase), and projected rebates (5.6 percent increase).

Projected paid claims increased by \$28.52 PMPM. The components in the projected paid claims are manual claims, experience claims, and projected rebates. For each group, manual and experience claims are blended by credibility. Projected rebates are applied to the blended claims to get the total projected paid claims. Below are the increases for each component in aggregate for the 59 renewing large groups with 12 months of experience:

Component	2017 PMPM	2018 PMPM	PMPM Change	Percent Change
Manual Claims	\$401.54	\$425.29	\$23.75	5.9 %
Experience Claims	\$442.94	\$475.78	\$32.84	7.4%
Blended Claims	\$423.94	\$452.95	\$29.01	6.8%
Projected Rebates	-\$8.60	-\$9.09	-\$0.48	5.6%
Projected Paid Claims	\$415.34	\$443.87	\$28.52	6.9%

- 3. This question involves confidential and proprietary information and has been provided under separate cover.
- 4. Is the seasonality adjustment described at the bottom of page 4 of the Actuarial Memorandum only used when an experience period of 12 months is not used?

No. As described in Section 3, we calculate a seasonally-adjusted benefit relativity value. Based on the seasonal patterns observed as part of the reserving process for each calendar month, we determine seasonal factors for CDHPs and for non-CDHPs and normalize them so that they total to 12. Then, a benefit relativity value (BRV) for each benefit in the experience period is calculated. The benefit relativity values are multiplied by the seasonal factors to calculate a seasonally-adjusted factor.

For each benefit by tier, the seasonally-adjusted benefit relativity value is multiplied by the benefit's enrollment and tier factor (as described in Section 4.3). The products are then summed by month and for the entire experience period. To calculate the impact of seasonality, the process is repeated using the non-seasonally adjusted benefit relativity value. The sum of the seasonally-adjusted factors is divided by the sum of the non-seasonally-adjusted factors in order to calculate the impact of seasonality on the

experience. If there were no changes in benefits or enrollment, the normalization of the seasonality factors would cause the seasonal adjustment to be 1.000. An example is provided below with illustrative seasonal factors, benefit relativity values, and enrollment.

	Seasonal	ity Factors	Benefit Relativity Values		Seasonality Adjusted Benef Relativity Values			
Month	Medical	Pharmacy	Medical	Pharmacy	Total	Medical	Pharmacy	Total
201601	1.013	0.987	0.800	0.200	1.000	0.810	0.197	1.008
201602	0.954	0.978	0.800	0.200	1.000	0.763	0.196	0.959
201603	1.004	0.991	0.800	0.200	1.000	0.803	0.198	1.002
201604	1.009	1.013	0.800	0.200	1.000	0.807	0.203	1.009
201605	1.025	0.982	0.800	0.200	1.000	0.820	0.196	1.017
201606	0.968	0.982	0.800	0.200	1.000	0.775	0.196	0.971
201607	0.991	0.996	0.800	0.200	1.000	0.793	0.199	0.992
201608	0.996	0.991	0.800	0.200	1.000	0.797	0.198	0.995
201609	1.017	0.978	0.800	0.200	1.000	0.814	0.196	1.009
201610	0.964	1.004	0.800	0.200	1.000	0.771	0.201	0.972
201611	0.954	1.029	0.800	0.200	1.000	0.763	0.206	0.969
201612	1.004	1.004	0.800	0.200	1.000	0.803	0.201	1.004

		Enrollment			Tier Factors	5	∑ (BRV *	Σ (Seasonal BRV *
Month	Single	2-Person	Family	Single	2-Person	Family	Enrollment * Tier Factor)	Enrollment * Tier Factor)
201601	34	31	34	1	2	2.743	189.3	190.7
201602	35	33	32	1	2	2.743	188.8	181.0
201603	35	32	35	1	2	2.743	195.0	195.3
201604	32	30	35	1	2	2.743	188.0	189.8
201605	34	32	35	1	2	2.743	194.0	197.2
201606	34	35	35	1	2	2.743	200.0	194.3
201607	32	35	32	1	2	2.743	189.8	188.3
201608	30	32	31	1	2	2.743	179.0	178.1
201609	33	34	30	1	2	2.743	183.3	185.0
201610	31	34	34	1	2	2.743	192.3	186.9
201611	35	35	30	1	2	2.743	187.3	181.5
201612	32	30	32	1	2	2.743	179.8	180.6
	•			•		Sum	2,266.5	2,248.6

Seasonal Adjustment

= 2,248.6 / 2,266.5 =

0.9921

5. Please confirm that the revised credibility formula is factored into the projected rate increase.

We confirm that the revised credibility formula is factored into the projected rate increase.

6. Please confirm that the trends at the top of page 14 of the Actuarial Memorandum should be switched.

We confirm that the trends at the top of page 14 of the Actuarial Memorandum should be switched. The total specialty trend is 14.9 percent and the trend for non-excluded specialty drugs is 17.3 percent.

7. Provide the number of new hepatitis C claimants for each quarter year from 2014 to 2016.

Below is the number of new hepatitis C claimants by quarter from 2014 to 2016:

	-	
Year	Quarter	Claimants
2014	1	12
2014	2	5
2014	3	4
2014	4	7
2015	1	16
2015	2	13
2015	3	1
2015	4	4
2016	1	7
2016	2	5
2016	3	11

8. Please compare the projected utilization of PCSK9 inhibitors in 2018 to the utilization in the experience period or calendar year 2016, including a narrative description of the differences.

In calendar year 2016, there were 12 members who filled a total of 72 scripts for a PCSK9 inhibitor. Of the 12 members, three stopped taking a PCSK9 inhibitor during the year, one had monthly scripts with the exception of a three-month gap, and the remaining 8 had monthly scripts without interruption following the first script. The table below shows the number of scripts filled each month:

Month	Scripts
January	1
February	1
March	2
April	8
May	4

June	7
July	7
August	6
September	9
October	7
November	9
December	11

For our 2018 projection, we assumed there would be 16 members taking a PCSK9 inhibitor and that each member would fill 12 scripts. This assumes a slight uptake in the number of members between 2016 and 2018 as the PCSK9 inhibitors gain market acceptance.

9. Please compare the projected utilization of Orkambi in 2018 to the utilization in the experience period or calendar year 2016, including a narrative description of the differences.

In calendar year 2016, there was one member taking Orkambi who stopped in November. This member had been filling one script per month since Orkambi was approved in August 2015. In 2017, two new members began taking Orkambi. We project there will be 8 members taking Orkambi in 2018 and anticipate each member will fill 12 scripts. This projection was developed using incidence estimates provided by our Chief Medical Officer. Given that this is a new drug, we believe it is more appropriate to use the clinical estimates rather than extrapolating emerging experience.

10. What level of CTR is required to maintain RBC levels at their current levels due to the impact of trend?

A CTR of 1.8 percent would be required to maintain RBC at 700 percent, the top end of our target range, due to the impact of Large Group premium increases. Please see the attached file *Response to 3Q 2017 LG Rating Program Review Inquiry 1 - TVHP.xlsx* for the detailed calculation. You will note that we've made a relatively minor enhancement to our methodology in order to allocate investment income on the basis of capital requirements rather than premium and premium equivalents. Capital requirements are derived from the contribution each line of business makes toward the Authorized Control Level, the denominator in the RBC calculation.

Note that we are precluded by Vermont law from publicly discussing our current RBC percentage. We have accordingly interpreted your question to mean "within our target RBC range" rather than "at [the] current [RBC] levels."

11. Please confirm that the 2017 assessment of \$10.30 for the New Hampshire Purchasing Program Payments is per month for each child that is a New Hampshire resident.

We confirm that this is the correct assessment. The New Hampshire Vaccine Association (NHVA) Notice dated October 28, 2016¹ states the NVHA board set the 2017 assessment at \$10.30 per assessable life per month. An assessable life is defined as a child under 19

28NHVAWebsiteNoticeReAssessmentRate.html/\$File/2016-10-

¹ http://www.nhvaccine.org/nhvaccine.nsf/documents/2016-10-

^{28% 20}NHVA% 20Website% 20Notice% 20Re% 20Assessment% 20Rate.pdf

years of age who resides in New Hampshire. This amount is applied to all members who meet the definition of assessable lives. We will use this rate until a new rate is approved.

12. Provide quantitative support for the projected performance payment of \$0.25 PMPM for PCMH.

PCMH performance payments were introduced on January 1, 2016. Since prior data was not available at that time, \$0.25 PMPM was selected as it is the midpoint of the range of possible payments. 2016 PCMH performance payments averaged \$0.20 PMPM for large groups.

13. Provide quantitative support for the 0.1% estimate of the BCBSVT portion of the total assessment of the Federal Insurer Fee.

The IRS Annual Fee on Health Insurance Providers for 2016 Invoice, dated August 24, 2016, calculated the BCBSVT portion of the total assessment as:

 $\frac{\text{Net premiums taken into account for BCBSVT}}{\text{Net premiums taken into account for all covered entities}} = \frac{\$536,434,161.00}{\$632,428,972,565.09} = 0.085\%$

Although the estimate of the BCBSVT portion is displayed rounded to 0.1% in Section 4.10, the unrounded number was used to calculate the projected BCBSVT Federal Insurer Fee.

Please let us know if you have any further questions, or if we can provide additional clarity on any of the items above.

Sincerely,

alat

Paul Schultz, F.S.A., M.A.A.A.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Actuarial Memorandum

Minimum Required CTR Calculation		2017 Forecast			Restated to Reflect LG Premium Increases to 2018	
BCBSVT Enterprise Totals		Premium	Share of Capital Requirement	Projected Premium Increase	Premium	Share of Capital Requirement
QHP	Α	\$417,566,717	53.49%		\$417,566,717	52.86%
BCBSVT and TVHP Large Group Insured	В	\$74,631,421	14.73%	1.080	\$80,616,861	15.73%
All Other	C		31.78%			31.41%
Investment Income	D	\$3,82	24,611		\$3,82	24,611
Tax Rate	E	2	.0%		2	0%
Investment Income Net of Taxes	F = D x (1-E)	\$3,059,689			\$3,059,689	
Large Group Insured Share of Investment Income	G = F x B%	\$450),801		\$481	,269
Estimated YE 2017 Authorized Control Level (ACL)	н		\$23,495,304			
Estimated ACL Reflecting LG Premium Increases to 2018	J		\$23,713,572			
Increase in Capital Required to Maintain Target RBC Level	K = 700% x (J-H)		\$1,527,876			
Additional Required Grossed Up for FIT	L = K/(1-E)		\$1,909,845			
CTR Required from LG in 2018	M = L-G		\$1,428,576			
Required LG Insured CTR Factor to Maintain Target RBC	CTR = M/\$B		1.8%			



March 31, 2017

Mr. Josh Hammerquist, A.S.A., M.A.A.A. Assistant Vice President & Consulting Actuary Lewis & Ellis, Inc.

Subject: Your 03/23/2017 Questions re: The Vermont Health Plan 3Q 2017 TVHP Large Group Rating Program Filing (SERFF Tracking #: BCVT-130935776)

Dear Mr. Hammerquist:

In response to your request dated March 23, 2017, here are *your questions* and our answers:

- 1. This question involves confidential and proprietary information and has been provided under separate cover.
- 2. Please provide the percentage change in administrative costs for all lines of business combined.

The administrative costs for all lines of business combined were \$29.62 per member per month (PMPM) in the previous filing and are \$30.99 in the current filing, for an increase of 4.6 percent. For lines of business other than Large Group, the administrative costs were \$31.56 in the previous filing and are \$30.52 in the current filing, for a decrease of 3.3 percent. Note that these values are from the experience period in each filing and have not been adjusted for trend or projected changes in membership across all lines of business.

While reviewing the development of the administrative charges, we discovered an error in the calculation of the Large Group per unit per month (PUPM) charges. In Exhibit 6B of the filing, we calculated the PUPM for each cost category effective July 2017 by multiplying the updated experience period PUPM by the monthly trend raised to the (months of trend/12) power. As the trend is already monthly instead of annual, there is no need to divide the months of trend by 12. The trend factors used for trending to July 2017 were $(1.002)^{(20/12)} = 1.0034$ instead of the correct factor of $(1.002)^{20} = 1.0410$. Charges for subsequent periods were calculated by multiplying the July 2017 charges by the monthly trend. Therefore, all of the PUPMs in Exhibit 6B are understated.

The impact of this error is \$0.84 PMPM for the 59 renewing large groups with 12 months of experience. This represents an additional 2.9 percent increase over the previous filing's administrative charges, for a total increase of 27.9 percent. We are electing to not correct the filing for this error.

3. What is the impact of the billback expenses on the administrative trend in this filing?

Billback expenses were treated as any other expense in this filing. Experience billbacks of \$1.59 PMPM were trended to a projected January 2018 value of \$1.61 PMPM.

Recent developments regarding the GMCB billback suggest that this portion of our administrative charges will be underfunded. The projected portion of the proposed FY 2018 GMCB billback that will be allocated to BCBSVT Large Group Insured lines of business is \$3.13 PMPM.

4. Please reconcile the difference in the percent change in the manual claims and experience claims in the response to question #2 in the letter dated March 7, 2017.

The manual claims for each of the 59 renewing groups with 12 months of experience are the product of the Manual Rate, adjustments for industry and demographics, a contract conversion factor, and the BRV for the group's renewing benefits. The product of the Manual Rate and the BRV equals the paid claims PMPM for the renewing benefit as determined by the BRV model. The BRV model uses claims from all Cost Plus groups, ASO groups, and Insured groups with both medical and Rx coverage in the BRV experience period (July 2015 to June 2016, paid through September 2016).

The experience claims for each group begin with completed experience period claims (October 2015 to September 2016, paid through November 2016), from which actual claims above the pooling level are removed and replaced with expected claims above the pooling level. These claims are trended to the rating period and adjusted for changes in benefit.

There are several differences in the calculations of the experience and manual claims that lead to different increases in each. The experience base for each is different: the total experience claims for the 59 renewing groups are only a part of the BRV experience, which also includes ASO groups and large groups who were enrolled during the experience but are no longer enrolled. The experience periods are also different between the BRV model and the experience renewal.

5. How does the utilization of Orkambi for all lines of business compare to the utilization for large groups and the projected utilization in 2018?

The actual and projected utilization of Orkambi by line of business is below. The pharmacy trend was developed using claims from BCBSVT Cost Plus groups, BCBSVT ASO Groups, BCBSVT Insured Large Groups, and TVHP Insured Large Groups. Combining these homogeneous populations creates greater consistency and credibility within the trend factor development. To maintain consistency with the claims base used to develop trend, the projected members utilizing Orkambi is inclusive of all the aforementioned subgroups. As demonstrated below, the proportion of projected utilization of Orkambi attributable to groups impacted by the filing is significantly less than 8, due to the difference in the membership used to develop trend and the projected membership.

Line of Business	Year	Members
Large Group	2016 Actual	1
QHP	2016 Actual	7

(a)	Member Months in Trend Base	911,441	Exhibit 3F
(b)	Average Monthly Members	75,953	(a)/12
(c)	Projected Orkambi Members in Trend Base	8	
(d)	Incidence	1 in 9,495	(c)/(b)
(e)	Projected Members Impacted by the Filing	15,908	Pg. 2 Actuarial Memorandum
(f)	Projected Large Group Members utilizing Orkambi	1.68	(e)*(d)

6. If the taxes and fees associated with the Affordable Care Act are repealed, please describe how this will impact the groups in this filing and whether these changes would be expected to be filed.

The two Affordable Care Act taxes and fees currently charged to large groups, the Federal Insurer Fee and Patient-Centered Outcomes Research Institute Fee, are included in the rating formula. If either is repealed or modified, we will modify the rating formula to reflect the appropriate amount, if any, that should be charged. We do not expect a need to file any changes. In the memorandum, we state the current and expected charges for all state and federal mandates and note that any updates will be incorporated into the rating formula as appropriate.

Please let us know if you have any further questions, or if we can provide additional clarity on any of the items above.

Sincerely,

lat

Paul Schultz, F.S.A., M.A.A.A.



April 5, 2017

Mr. Josh Hammerquist, A.S.A., M.A.A.A. Assistant Vice President & Consulting Actuary Lewis & Ellis, Inc.

Subject: Your 04/03/2017 Questions re: The Vermont Health Plan 3Q 2017 TVHP Large Group Rating Program Filing (SERFF Tracking #: BCVT-130935776)

Dear Mr. Hammerquist:

In response to your request dated April 3, 2017, here are your questions and our answers:

1. On exhibit 3G, please confirm that the incremental costs of excluded treatments for specialty drugs that were added into the projection period were calculated using the same number of member months as the claims that were removed from the experience period. If this is not the case, please quantify the impact or explain why the calculation that was used is more appropriate.

The projected incremental costs of excluded treatments for PCSK9 and Orkambi erroneously included members who were not in the experience period. Additionally, certain ICD-10 codes that should have been used in identifying the populations that may utilize the drugs were not included. With these adjustments, we confirm that the experience and projection member months base are consistent. A restated specialty trend development is below, which includes the revised number of members expected to utilize Orkambi and PCSK9.

Pharmacy Specialty Claims in the Experience	Α	\$29,473,842
Claims Removed from the Experience		
Hepatitis C	B1	\$2,393,099
PCSK9 Inhibitors	B2	\$51,939
Orkambi	B3	\$267,651
Total	B = B1 + B2 + B3	\$2,712,688
Pharmacy Specialty Claims without Excluded Drugs	C = A - B	\$26,761,154
Projected Specialty Claims using a 14.1% trend for 27 months	D = C x (1.141) ^(27/12)	\$38,313,061
Adding Incremental Cost of Excluded Treatmen	nts for the Projection Pe	riod
Hepatitis C	E1	\$3,297,770
PCSK9 Inhibitors (20 members)	E2	\$281,680
Orkambi (5 members)	E3	\$1,233,674
Total	E = E1+E2+E3	\$4,813,124
Restated Projected Specialty Claims	F = D + E	\$43,126,185
Restated Specialty Trend	G = (F/A)^(12/27) -1	18.4%
Restated Specially frend	$0 = (1/A) (12/27)^{-1}$	10.4/0
Restated Allowed Pharmacy Trend	$G = (I/R) (IZ/ZI)^{-1}$	10.6%

The restated total allowed trend is 0.06% lower than the filed trend. We estimate the impact on the average increase is roughly equivalent to the differences in total allowed trends.

We will amend our filing to reflect the updated trend factors once the review process is complete and all amendments have been identified. Until that point, all responses to inquiries will reflect the filed pharmacy trend.

2. Which contracts were finalized at the time that the unit cost trend assumption was finalized? For any contract negotiations that had begun at that time, please briefly describe the state of the negotiations.

As of the date of filing, no future contracts were finalized nor had negotiations begun for any contract with effective dates after the filing date. The unit cost trend assumption is inclusive of the finalized contracting information from all contracts effective prior to the date of the filing.

3. Please provide support for the proposed trends in the cells D27, J27, N27, D39, J39 and N39 on the Cost Trend tabs.

For specific facilities, Provider Contracting provided estimated trends that supplanted our general assumption that future unit cost increases would mirror past increases. The proposed trends in the specific cells referenced reflect the best estimate of Provider Contracting at the time of filing.

4. This question involves confidential and proprietary information and has been provided under separate cover.

Please let us know if you have any further questions, or if we can provide additional clarity on any of the items above.

Sincerely,

21 a A

Paul Schultz, F.S.A., M.A.A.A.



April 12, 2017

Mr. Josh Hammerquist, A.S.A., M.A.A.A. Assistant Vice President & Consulting Actuary Lewis & Ellis, Inc.

Subject: Your 04/11/2017 Questions re: The Vermont Health Plan 3Q 2017 TVHP Large Group Rating Program Filing (SERFF Tracking #: BCVT-130935776)

Dear Mr. Hammerquist:

In response to your request dated April 11, 2017, here are your questions and our answers:

1. Please provide a revised Exhibit 3C with 46 months of historical data ending August 2016.

Please see the attached *Response to 3Q 2017 LG Rating Program Review Inquiry 4 - TVHP.xlsx* with 46 months of historical data ending August 2016.

Please let us know if you have any further questions, or if we can provide additional clarity on any of the items above.

Sincerely,

Q C

Paul Schultz, F.S.A., M.A.A.A.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Medical Trend Development

Impact of Benefit Changes on Utilization

							Adjusted Claims -		
		Adjusted Claims -		Regression on	Average	Normalization	Normalized for		Regression on
		Normalized for	Adjusted	Adjusted PMPM - 24	Induced	Factor for	Contract Changes and	Adjusted	Adjusted PMPM - 24
		Contract Changes	PMPM	Months	Utilization	Induced	Induced Utilization	PMPM	Months
Month	Membership	eontrace enanges		morrens	Factor	Utilization	Factor		montrib
Nov-12	88,923	\$38,965,529	\$438.19	\$414.25	0.9958	0.9639	\$37,559,775	\$422.39	\$411.71
Dec-12	88,775	\$33,285,444	\$374.94	\$414.76	0.9946	0.9651	\$32,123,334	\$361.85	\$412.31
Jan-13	87,454	\$39,000,528	\$445.95	\$415.29	0.9933	0.9663	\$37,687,970	\$430.95	\$412.94
Feb-13	87,369	\$37,426,849	\$428.38	\$415.81	0.9922	0.9674	\$36,206,440	\$414.41	\$413.57
Mar-13	87,378	\$38,778,941	\$443.81	\$416.29	0.9905	0.9690	\$37,577,811	\$430.06	\$414.14
Apr-13	87,188	\$38,313,206	\$439.43	\$416.82	0.9891	0.9705	\$37,181,539	\$426.45	\$414.77
May-13	87,414	\$39,353,818	\$450.20	\$417.33	0.9882	0.9713	\$38,225,724	\$437.30	\$415.38
Jun-13	87,331	\$36,512,475	\$418.09	\$417.86	0.9877	0.9718	\$35,482,302	\$406.30	\$416.01
Jul-13	87,446	\$37,416,998	\$427.89	\$418.37	0.9859	0.9736	\$36,428,386	\$416.58	\$416.63
Aug-13	87,399	\$37,890,167	\$433.53	\$418.90	0.9844	0.9750	\$36,943,601	\$422.70	\$417.26
Sep-13	87,802	\$33,491,069	\$381.44	\$419.43	0.9802	0.9792	\$32,793,997	\$373.50	\$417.90
Oct-13	87,792	\$38,608,348	\$439.77	\$419.95	0.9811	0.9784	\$37,772,756	\$430.25	\$418.51
Nov-13	87,664	\$35,866,630	\$409.14	\$420.48	0.9772	0.9822	\$35,228,109	\$401.85	\$419.15
Dec-13	87,613	\$39,268,940	\$448.21	\$420.99	0.9746	0.9849	\$38,676,076	\$441.44	\$419.77
Jan-14	86,608	\$39,556,165	\$456.73	\$420.99	0.9740	0.9860	\$39,001,302	\$450.32	\$419.77
Feb-14	86,619	\$34,688,530	\$400.47	\$421.55	0.9735	0.9869	\$34,232,722	\$395.21	\$421.05
Mar-14	86,439	\$37,117,279	\$429.40	\$422.54	0.9714	0.9881	\$36,677,264	\$424.31	\$421.63
Apr-14	86,104	\$39,348,385	\$456.99	\$423.08	0.9702	0.9893	\$38,928,791	\$452.11	\$422.27
May-14	86,606	\$36,255,868	\$418.63	\$423.60	0.9685	0.9911	\$35,931,535	\$414.89	\$422.89
Jun-14	86,367	\$37,503,072	\$434.23	\$424.14	0.9669	0.9927	\$37,228,882	\$431.05	\$423.54
Jul-14	85,471	\$37,105,045	\$434.12	\$424.66	0.9664	0.9932	\$36,853,960	\$431.05 \$431.19	\$424.16
Aug-14	85,426	\$34,732,067	\$406.57	\$425.20	0.9652	0.9945	\$34,540,990	\$404.34	\$424.81
Sep-14	86,092	\$35,163,816	\$400.37 \$408.44	\$425.73	0.9644	0.9952	\$34,996,237	\$406.50	\$425.45
Oct-14	86,136	\$39,482,709	\$458.38	\$426.26	0.9634	0.9963	\$39,335,167	\$456.66	\$426.08
Nov-14	86,037	\$35,285,374	\$410.12	\$426.80	0.9621	0.9977	\$35,204,089	\$409.17	\$426.73
Dec-14	86,185	\$38,528,134	\$447.04	\$427.32	0.9608	0.9990	\$38,490,020	\$446.60	\$427.36
Jan-15	84,280	\$37,171,528	\$441.05	\$427.86	0.9606	0.9992	\$37,141,190	\$440.69	\$428.01
Feb-15	84,304	\$34,750,964	\$412.21	\$428.41	0.9604	0.9994	\$34,729,571	\$411.96	\$428.66
Mar-15	84,197	\$37,219,684	\$442.05	\$428.90	0.9590	1.0009	\$37,253,415	\$442.46	\$429.25
Apr-15	83,735	\$37,496,951	\$447.80	\$429.44	0.9577	1.0022	\$37,579,204	\$448.79	\$429.90
May-15	83,665	\$33,272,811	\$397.69	\$429.97	0.9574	1.0026	\$33,357,753	\$398.71	\$430.54
Jun-15	83,926	\$38,185,603	\$454.99	\$430.51	0.9568	1.0031	\$38,305,798	\$456.42	\$431.19
Jul-15	83,032	\$36,898,056	\$444.38	\$431.04	0.9562	1.0038	\$37,039,933	\$446.09	\$431.83
Aug-15	82,740	\$33,030,471	\$399.21	\$431.59	0.9554	1.0047	\$33,184,253	\$401.07	\$432.49
Sep-15	82,840	\$34,338,973	\$414.52	\$432.13	0.9546	1.0055	\$34,526,130	\$416.78	\$433.14
Oct-15	82,757	\$36,324,701	\$438.93	\$432.66	0.9534	1.0068	\$36,570,962	\$441.91	\$433.78
Nov-15	82,866	\$35,506,233	\$428.48	\$433.21	0.9525	1.0077	\$35,780,818	\$431.79	\$434.44
Dec-15	82,966	\$35,926,918	\$433.03	\$433.74	0.9516	1.0086	\$36,237,005	\$436.77	\$435.08
Jan-16	71,911	\$29,357,977	\$433.03 \$408.25	\$434.29	0.9544	1.0057	\$29,524,771	\$430.77 \$410.57	\$435.08
Feb-16	71,491	\$29,064,196	\$406.25 \$406.54	\$434.84	0.9549	1.0051	\$29,213,733	\$408.64	\$436.41
Mar-16	71,431	\$33,468,500	\$468.53	\$435.36	0.9567	1.0033	\$33,579,663	\$408.04 \$470.09	\$437.03
Apr-16	71,293	\$30,587,810	\$408.53 \$429.04	\$435.91	0.9574	1.0026	\$30,665,877	\$470.09 \$430.14	\$437.03
May-16	70,642	\$30,751,184	\$435.31	\$436.45	0.9582	1.0017	\$30,802,782	\$430.14 \$436.04	\$438.34
Jun-16	70,409	\$33,570,861	\$435.31 \$476.80	\$437.00	0.9586	1.0013	\$33,613,591	\$430.04 \$477.40	\$439.01
Jul-16	69,594	\$28,851,451	\$470.80 \$414.57	\$437.54	0.9589	1.0010	\$28,879,207	\$477.40 \$414.97	\$439.66
Aug-16	69,465	\$32,013,565	\$460.86	\$437.54	0.9598	1.0000	\$32,013,565	\$460.86	\$439.00
	07,100	<i>\$52,013,303</i>	¥ 100.00	\$150.07	017070		<i>452,013,303</i>	÷ 100.00	\$110.55

Annual Increase

1.5%

1.8%

Impact of Benefit Chages0.3%Selected Utilization Trend1.0%Final Utilization Trend1.3%



April 26, 2017

Mr. Josh Hammerquist, A.S.A., M.A.A.A. Assistant Vice President & Consulting Actuary Lewis & Ellis, Inc.

Subject: Your 04/19/2017 Questions re: The Vermont Health Plan 3Q 2017 TVHP Large Group Rating Program Filing (SERFF Tracking #: BCVT-130935776)

Dear Mr. Hammerquist:

In response to your request dated April 19, 2017, here are your questions and our answers:

General Methodology Questions

1. Page 3*: Do your 2 months run out factors remove explicit conservatism and reflect any claims retractions that may take place in future time periods?

Completion factors are our best estimates and do not include margin. Our reserving models account for projected future claims adjustments when calculating completion factors.

2. Page 3: Your administrative increases for this filing seem unreasonable. Can you demonstrate a drop in administrative expense to other lines of business? If yes, please specify what lines of businesses and how much of a decrease you are planning to apply to each.

The administrative costs underlying the previous Large Group filing were \$29.62 per member per month (PMPM) for all lines of business combined versus \$30.99 in the current filing, an increase of 4.6 percent. The administrative costs underlying the previous Large Group filing were \$31.56 for lines of business other than Large Group, as compared to \$30.52 in the current filing, a decrease of 3.3 percent. Note that these values are from the experience period in each filing and have not been adjusted for trend or projected changes in membership across all lines of business.

Planned administrative charges for other lines of business are outside of the scope of this filing and have not yet been finalized.

3. We did not see references to the impact of the change in definition of the Large Group size. What changes if any have you made to the filing to reflect this change in Large Group size?

We did not make any changes to reflect the change in the definition of Large Group in this filing. The manual rate (section 4.4 of the Actuarial Memorandum) only includes experience claims from groups that are impacted by this filing. Factors that are

calculated using more than just Insured Large Group data use sufficiently credible data and do not need to be adjusted for this change.

4. Page 6: Underwriting judgement: what is your process of reviewing the Underwriter's rationale to ensure it is in line with factor filings and other regulation?

Every renewal is reviewed by a Senior Underwriter and the Manager of Underwriting and/or the Chief Actuary to ensure any underwriting judgment applied is reasonable, appropriate, and in line with the factor filing and other regulations.

Trend

5. On page 2 you identify changes to the rating formula (pertaining to the credibility formula, calculation of ISL factors, and development of ASL and Refund-Eligible charges) and on page 3 you outline how you checked the average change in all accounts from the changes in factors. Please supply the distribution of changes to individual accounts by each of the formula changes and all of them in total. Please show a count of accounts impacted grouped by 2% intervals (that is 7+% increase, 5 to 7% increase, 3 to 5% increase, 1 to 3% increase,+-1% change, 1 to 3% decrease...,more than 7% decrease.)

A distribution of the impact of the four changes individually and in aggregate is below. The change is measured as the difference from the total premium or premiumequivalent developed from the filed rating formula.

Formula Changes	Credibility	ISL	ASL	Refund - Eligible	Total
¥	credibitity	15		Ligible	
More than 7% increase	3	0	0	0	3
5 to 7% increase	0	0	0	0	0
3 to 5% increase	8	0	0	0	9
1 to 3% increase	7	1	0	0	8
+/- 1% change	29	2	3	0	27
1 to 3% decrease	9	0	0	0	9
3 to 5% decrease	2	0	0	0	2
5 to 7% decrease	1	0	0	0	1
More than 7% decrease	0	0	0	0	0
Not Applicable	0	56	56	59	0

While the changes to ISL and ASL factor development affect three groups each and the changes to Refund-Eligible risk charge development affects no current groups, every Large Group is affected by the change to the credibility formula. We changed the formula in part to give more credibility to a group's experience in the rating formula, which will decrease the need for underwriting judgment.

- 6. Page 10: Where in the utilization trend development do you reflect your attempts to mitigate unnecessary utilization?
 - a. Are you planning to drive utilization to more optimal (high quality / low cost) levels?

BCBSVT has a long track record of developing and implementing effective utilization management programs that enable the delivery of the right care in the right setting at the right time. Examples of our current programs include:

- Pharmacy step therapy, quantity limits and prior authorizations
- RationalMed pharmacy safety program. Integrates medical and pharmacy claim data to provide drug-drug and drug-condition interaction warning to pharmacists prior to a drug being dispensed.
- Whole person integrated medical and mental health substance abuse high utilization case management program.
- Integrated Utilization Management including medical prior authorizations.
- Radiology utilization management program.
- Prevalent Chronic condition management program case management for common diseases such as diabetes and asthma.
- Rare condition case management working with Accordant Health Care a national case management vendor with subject matter expertise in rare disease.
- Better Beginnings perinatal support and care management program.
- Hospital readmission avoidance program integrated care and utilization management.
- End of Life program care management for patients receiving palliative or hospice care.

The prescription drug programs alone saved over \$20 million across our book of business in 2016. The medical programs contributed over an additional \$20 million of savings through appropriate utilization. The impact of these programs are implicitly included in both the base claims data and the calculation of utilization trend.

Much of the utilization increase is in preventive visits and appropriate care. Our assessment of the drivers of potentially unnecessary utilization increase have led us to examine treatment patterns in outpatient facility (i.e. ER and outpatient surgical procedures), specialty pharmacy and more specifically in the areas of cardiovascular disease, GI endoscopy as well as mental health and substance abuse.

It takes several budget cycles to build and implement new utilization management programs, and for these programs to have an impact on care delivery. Programs are currently in development to mitigate ER use (utilization in Vermont is well above regional benchmarks) and outpatient surgical/facility procedures. We have also recently expanded programs in select areas:

- Specialty pharmacy
 - i. We work with our pharmacy benefit manager, Express Scripts (ESI), to realize the best price points available in the market and reduce the impact of price inflation of specialty drugs
 - ii. We have instituted innovative indication based pricing for certain classes of specialty drugs with ESI to leverage pricing by clinical utility with the pharmaceutical companies
 - iii. We have a full time pharmacist who travels the state and "details" our network providers on new programs, adverse prescribing trends and alternatives to higher cost pharmaceuticals which are clinically appropriate. This detailing initiative has been well received by our network providers.
- Cardiovascular Disease
 - i. We are working with our members to improve engagement with our disease management programs and our cardiac rehab program which have proven value to modulate adverse utilization
- Mental Health and Substance Abuse
 - i. Through our partnership with Brattleboro Retreat, Vermont Collaborative Care, we have integrated a whole person approach to our case and utilization management programs through integrated resources which include focused clinical expertise in the areas of mental health and substance abuse. Through this and components of the program we have significantly driven down inpatient and ER utilization and increased outpatient ongoing care with a mental health and substance abuse provider. In addition we support the state Hub and Spoke program through innovative care management and payment programs as well as eliminating benefit based barriers to care for our members. We will continue to expand this work.

b. Please describe any activities intended to place providers at risk for unnecessary utilization or to review patterns of unnecessary utilization.

BCBSVT's Quality Improvement and Integrated Health Programs review patterns of utilization identifying potential outliers within our network. BCBSVT's Quality and Audit teams engage with providers identified as outliers, creating action plans to address concerns and at times including financial penalties.

In addition, BCBSVT and UVMMC are currently conducting a knee and hip replacement episode of care pilot wherein UVMMC is at 100% risk for costs exceeding the average episode price. BCBSVT is currently evaluating the impact of the pilot and potential for expansion.

On a broader level, BCBSVT continues to be involved in conversations with Vermont ACOs to evaluate the potential for a 2018 risk pilot. The pilot would be limited to a small population in the initial years and expanded if successful.

c. Are either action plans included as offsets to the utilization trend increase?

BCBSVT has had robust utilization programs in place for a number of years, therefore the impact of utilization programs is already in the base used to develop medical and pharmacy trend. It is critical that BCBSVT continue to develop and expand our suite of utilization management programs in order to help maintain the relatively low levels of utilization trend observed in recent years. We believe our future programs will continue to achieve similar levels of success as our current and past programs. Because the impact of continually expanding programming has already had an effect on observed utilization trends, making any further explicit adjustment to utilization trend is unnecessary.

7. Page 12: Please demonstrate how you adjust for scripts transitioning from brand to generic and itemize the resulting drop in trend.

The brand to generic transition is calculated discretely on a month-by-month basis, using anticipated end dates for brand patent protection and generic exclusivity. In general, when a brand drug loses its patent, the manufacturer has an exclusivity period during which it makes the only generic version of the drug. Following this period, which is typically six months, other manufacturers may bring their own generic versions to market. During the exclusivity period, the cost of a single-source generic most closely approximates its brand equivalent. Therefore, for the purpose of the GDR calculation, we assume that the brand drug will be utilized during the generic exclusivity period. In this way, we do not overestimate the cost impact of shifts to single-source generics. Significant cost savings occur once the exclusivity period is over and multiple generic versions are available. Therefore, the GDR is calculated as a ratio of multi-source generics to the total of all drugs. The GDR calculation assumes that once the exclusivity period expires all brand (or single-source generic) utilization will cease and become low-cost multi-source generic utilization. An illustrative example of the GDR calculation is provided below. The rolling 12-month dispensing rate that is calculated is used on Exhibit 3F. Please note that in this context, specialty drugs are not included in the GDR calculation.

							Scripts b	y Month					
		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec
	Feb	500			-								
ng	Mar	500	500										
nding	Apr	500	500	500									
ш	May	500	500	500	500								
Exclusivity	Jun	500	500	500	500	500							
Visr	Jul	500	500	500	500	500	500						
clt	Aug	500	500	500	500	500	500	500					
	Sep	500	500	500	500	500	500	500	500				
Lic.	Oct	500	500	500	500	500	500	500	500	500			
Generic	Nov	500	500	500	500	500	500	500	500	500	500		
Ğ	Dec	500	500	500	500	500	500	500	500	500	500	500	
	Jan	500	500	500	500	500	500	500	500	500	500	500	500
All (Other Brand	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000
	Generic	894,000	894,500	895,000	895,500	896,000	896,500	897,000	897,500	898,000	898,500	899,000	899,500
	Total	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000
N	Nonthly GDR	89.40%	89.45%	89.50%	89.55%	89.60%	89.65%	89.70%	89.75%	89.80%	89.8 5%	89.90 %	89.9 5%
											Roll	ing 12 GDR	89.68%

Example of script transition from brand to generic:

The GDR for the year ended September 2016 was 86.4% and the projected GDR is 89.0%. This change decreased the pharmacy trend by 3.9%

Benefit Relativities

8. Page 18: In your Induced Utilization approach, please explain how you controlled for the presence of multiple benefit offerings and its potential of adverse selection.

BCBSVT Large Group underwriting rules restrict multiple benefit offerings that would create an undue amount of adverse selection. These rules mitigate any adverse selection in the experience used to develop relativities.

9. Page 18: Please describe any new or innovative benefit designs or aspects which you introduced and which could lead to a cost reduction in the rating period and specify the amount of the cost reduction.

Large groups are afforded flexibility in their benefit design. This allows groups to tailor benefits in a way which best serves the needs of their employees. As this is a factor filing rather than a rate filing, any new benefit selections will be priced at the time of renewal. As noted in Section 4.3 of the Actuarial Memorandum, an actuarial cost model is used to simulate the cost and utilization impact of plan design changes.

Administrative Cost

10. Please provide your total administrative costs for all groups for each year over the past five years, the total population number served each year, and the per member per month administrative charge for Individual, Small group, and Large group for each year.

The table below includes administrative cost for total business (BCBSVT and TVHP) and for Large Group specifically. Note that the administrative cost excludes taxes and fees included in administrative cost per accounting rules, as well as broker commissions.

	Total Busine	ss (BCBSVT an	d TVHP)	Large Group Only
Calendar Year	Administrative Charges	Member Months	PMPM	РМРМ
2012	76,197,077	2,469,206	30.86	30.07
2013	80,063,051	2,646,390	30.25	27.62
2014	79,149,610	2,930,539	27.01	26.83
2015	82,533,713	2,972,182	27.77	28.78
2016	83,309,713	2,947,287	28.27	29.60

- 11. Pages 23- 25: Besides economies of scale could you describe any administrative cost savings programs? Such programs would include but are not limited to:
 - a. Activities to remove waste or address inefficiency
 - b. Insourcing or outsourcing functions at lower costs
 - c. Reduction in broker compensation or other reductions to distribution channel costs
 - d. Re-evaluation of and/or limits on senior management or board compensation packages
- 12. Pages 23-25: If any administrative cost reduction programs are described in your answer to question 14, how are the cost savings built into rate projections?
- 13. Pages 23-25: You mentioned an account's moving to ASO. Why wouldn't this account still pay its fair share of overhead cost as ASO? Did it receive a reduction in services offered?
- 14. Pages 23-25: We did not see information about the cost impact of Wellness programs. Please provide a demonstration of the administrative cost of Wellness programs and any support showing that the programs reduce medical costs.
- 15. Pages 23-25: Will Small Group or Individual lines receive an administrative cost reduction or is this an overall corporate increase?

Our answer below is intended to respond to questions 11 through 15.

In the last 5 years we have reduced administrative costs per member per month by 8.4 percent. Only 6 cents of each dollar paid by our members goes to administrative costs, while over 90 cents are used to pay claims. The balance, 3 cents, is for assessments including the Federal Insurer Fee, VITL, HCCA and PCOR. A combination of knowledgeable and committed staff, robust processes and use of technology delivers world-class member experiences that place us consistently in the top quartile of Member Touchpoint Measures among BlueCross BlueShield plans and among national leaders in first call resolution.

We continuously look for ways to improve efficiency. Functions and contracts are regularly reviewed to ensure they are provided in the most efficient and cost effective manner possible. Executive compensation is benchmarked annually with an external advisor and reviewed at the BCBSVT Board level to verify that senior management is compensated appropriately. At a more granular level, employees are engaged through initiatives such as Blue IDEAs (Initiatives Deserving Exploratory Analysis), which was launched in 2014 to support the Plan's strategic objective of organizational efficiency and our mission of responsible cost management on behalf of our members. The focus of the program is to create long term competitive advantage through administrative cost reductions, and to establish a culture that recognizes the importance of continuous improvement and encourages and supports employees in this effort. Over the last three years, this program has created more than \$4.3 million in administrative expense savings for the benefit of our members. These savings are passed through to members through the use of updated base experience in ongoing factor filings.

All lines of business pay their fair share of overhead expenses on the basis of capital requirements. Since Cost Plus business requires significantly less capital than more traditionally insured business, movement away from the Cost Plus line of business will have a significant impact on the per member costs included in this filing. As explained in the Actuarial Memorandum, the membership movement is only between Cost Plus and ASO and is not expected to have impacts on other lines of business.

Compared to industry benchmarks including much larger health plans, we perform near the median in terms of overall per member per month administrative costs. By market segment, our per member per month rates - including those for Large Group that were included in this filing - are aligned with the benchmark experience in the most recent benchmarking study. Prior to the increases in this and the previous filing, our Large Group admin rates were significantly below industry benchmarks.

BCBSVT believes wellness programming is an important part of our administrative services. We offer programs that help groups develop and implement worksite health and wellness programs. These programs help improve employee health, productivity, morale, retention and help to reduce health care costs. The experience cost of wellness services included in the administrative charges was \$0.39 PMPM.

BCBSVT has had wellness programs in place for a number of years, therefore the impact of the programs is the group's claims experience. Because of the relatively small size of our health plan, it is difficult to measure the claims impact of our wellness programming. Reductions in medical costs and utilization trend are reflected in the rating through the use of base experience and our observations of utilization trend.

Please note that broker compensation is not included in administrative charges.

Large Group Financial Performance

- 16. Page 31: Large Group performance has been historically poor. Is this a corporate wide issue or historically have other lines been subsidizing Large Group?
- 17. Page 31: Is there any implicit subsidization of Large Group by other lines of business built into future period projections?

Our answer below is intended to respond to questions 16 and 17.

We rate each line of business independently and no subsidization across lines of business is included in any of our rating. The medical loss ratios demonstrated on Page 31 may be higher than those typically associated in the industry with solid financial results. However, because of BCBSVT's competitive administrative costs, the Large Group line has been performing to expectations in recent years. Consider the financial reporting loss and expense ratios in the chart below:

Year	Incurred Claims	Earned Premium	Administrative Charges*	Loss & Expense Ratio
2012	\$394,390,754	\$425,696,914	\$28,060,304	99.2 %
2013	\$399,543,340	\$428,024,970	\$30,149,551	100.4%
2014	\$398,416,821	\$428,215,842	\$26,201,323	99.2 %
2015	\$410,671,695	\$438,023,593	\$25,903,341	99.7 %
2016	\$335,400,839	\$356,244,218	\$20,674,875	100.0%

*Please note that in financial reporting, administrative charges include broker commission, federal fees and some taxes per GAAP accounting rules.

Other

18. Exhibit 5B: SIC (Industry) factors: When was the last time you reviewed and to what extent are the industry factors supported by data? How do you ensure these do not implicitly or unintentionally adversely lead to discrimination in rates?

We updated the Industry Factors as part of the Q3 2016 Large Group Rating Program Filing (BCVT-130453174). Our membership base is not large enough to develop credible industry factors so we use a blend of data from industry sources.

Please let us know if you have any further questions, or if we can provide additional clarity on any of the items above.

Sincerely,

and GA

Paul Schultz, F.S.A., M.A.A.A.



June 26, 2017

Noel Hudson Director of Health Policy Green Mountain Care Board 89 Main Street, Third Floor, City Center Montpelier, Vermont 05620

Subject: The Vermont Health Plan - NAIC # 95696 Q3 2017 Large Group Rating Program Filing

Dear Mr. Hudson:

Pursuant to the Green Mountain Care Board's Decision and Order dated May 24, 2017, we are writing to confirm that The Vermont Health Plan will incorporate the ordered modifications to the large group rating program filing. The Vermont Health Plan has filed amended exhibits which incorporate the ordered allowed medical and pharmacy trends. A supplemental exhibit is provided which calculates the impact of the ordered trends on the manual rate.

Should you have any questions, please do not hesitate to contact us.

Sincerely,

las

Paul Schultz, F.S.A., M.A.A.A.

Manual Rate Calculation

Calculation of the Manual Rate

Experience Paid Claims, capped at \$750,000 and completed	A	\$72,137,723
Overall Paid Trend factor (6.5% for 27 months)	B ₁	1.15
Pharmacy Contract Adjustment	B ₂	0.995
Projected Total Paid Claims	$C = A \times B_1 \times B_2$	\$82,655,103
Total Member Months	D	173,473
Manual Rate	E = C / D	\$476.47

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Medical Trend Development

Benefit Leverage Factors

BlueCare LO Options (LO) and Open Access (OAP) Medical Plans

				In-Net	work Benefi	ts			Out-c			
index	Product	Deductible	Coinsurance	Out-of- Pocket	Office Copay	Specialist Copay	ER ¹ Copay	AMB Copay	Deductible	Coinsurance	Out-of- Pocket	Leverage Factor
1	LO	\$2,500	0%	\$2,500								1.1%
2	LO	\$3,000	0%	\$3,000								1.2%
3	OAP	\$750	20%	\$2,250	\$35	\$50	\$150	\$150	\$1,500	30%	\$4,500	0.8%
4	OAP	\$3,000	0%	\$4,100	\$30	\$30	\$100		\$6,000	30%	\$8,200	1.0%
5	OAP	\$3,000	20%	\$5,300	\$30	\$30			\$5,000	40%	\$10,600	1.1%

1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at 100%.

2. For the LO product, Office and Specialist Copay can be under the deductible.

3. LO does not have Out-of-Network benefits.

BlueCare (HMO) Medical Plans

					In-Network	Benefits				
index	Product	Inpatient Care Deductible ²	Outpatient Surgery Copay	Combined Inpatient / Outpatient Deductible ²	Office Copay	Specialist Copay	ER ³ Copay	AMB Copay	Out-of- Pocket	Leverage Factor
1	HMO	\$0	\$0		\$25	\$35	\$250	\$0	\$6,850	0.3%
2	HMO	\$250	\$100		\$10	\$20	\$50	\$0	\$6,850	0.1%
3	HMO	\$250	\$100		\$25	\$40	\$100	\$50	\$6,850	0.3%
4	HMO	\$500	\$200		\$20	\$30	\$100	\$100	\$6,850	0.2%
5	HMO	\$500	\$200		\$25	\$40	\$150	\$50	\$6,850	0.3%
6	HMO			\$750	\$20	\$30	\$50	\$50	\$6,850	0.3%
7	HMO	\$2,000	\$1,000		\$20	\$30	\$50	\$50	\$6,850	0.3%
8	HMO			\$3,000	\$20	\$30	\$100	\$50	\$6,850	0.5%

1. All HMO Plans have a DME rider benefit of: \$0 deductible, 20% coinsurance, built into the relativity.

2. Maximum of 2/yr per family

3. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are the covered at 100%.

4. HMO Plans do not have Out-of-Network benefits.

Consumer Driven Health Plans (CDHP's)

				In	-Network				Leverage Factor		
index	Product	Deductible	Coinsurance	Out-of- Pocket	RX OOPM Limit ³	Wellness Rx ¹	Drugs After Deductible ²	Diabetic Supplies	Medical	Rx	
1	CDHP	\$1,500	0%	\$1,500	\$1,300	0%	N/A	SAAO	0.7%	0.7%	
2	CDHP	\$2,500	0%	\$2,500	\$1,300	0%	N/A	SAAO	0.9%	0.9%	
3	CDHP	\$3,000	0%	\$3,000	\$1,300	0%	N/A	SAAO	1.0%	0.9%	
4	CDHP	\$4,000	0%	\$4,000	\$1,300	0%	N/A	SAAO	1.2%	0.9%	
5	CDHP	\$5,000	0%	\$5,000	\$1,300	0%	N/A	SAAO	1.3%	1.0%	
6	CDHP	\$6,600	0%	\$6,600	\$1,300	N/A	N/A	SAAO	1.4%	1.6%	

1. Wellness Rx: if applicable, cost sharing rules apply before the deductible is satisfied.

The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.

2. All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

3. The Rx OOPM Limit is as described in Vermont Act 171.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Pharmacy Trend Development

Benefit Leverage Factors

					Copay (\$) /	Coinsurance	(%)				
Index	Туре	Deductible	Retail Generic	Retail Preferred Brand	Retail Non- Preferred Brand	Mail Order Generic	Mail Order Preferred Brand	Mail Order Non- Preferred Brand	ООРМ	Diabetic Supplies	Leverage Factor
1	CM1	\$100	\$5	40%	60%	\$10	40%	60%	\$1,300	SAAO	1.1%
2	COI	\$0	50%	50%	50%	50%	50%	50%	\$1,300	SAAO	0.9%
3	COP	\$0	\$10	\$20	\$40	\$20	\$40	\$80	\$1,300	SAAO	0.7%
4	COP	\$0	\$10	\$25	\$25	\$20	\$50	\$50	\$1,300	SAAO	0.7%
5	COP	\$0	\$10	\$25	\$40	\$20	\$50	\$80	\$1,300	100%	0.6%
6	COP	\$0	\$10	\$25	\$50	\$20	\$50	\$100	\$1,300	SAAO	0.7%
7	COP	\$0	\$10	\$25	\$60	\$20	\$50	\$120	\$1,300	SAAO	0.8%
8	COP	\$0	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	0.8%
9	COP	\$0	\$10	\$35	\$60	\$20	\$70	\$120	\$1,300	SAAO	0.8%
10	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,300	100%	0.7%
11	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,300	SAAO	0.8%
12	COP	\$0	\$15	\$30	\$45	\$30	\$60	\$90	\$1,300	SAAO	0.8%
13	COP	\$0	\$20	\$40	\$60	\$40	\$80	\$120	\$1,300	SAAO	0.9%
14	COP	\$0	\$5	\$20	\$35	\$10	\$40	\$70	\$1,300	SAAO	0.6%
15	COP	\$0	\$5	\$20	\$45	\$10	\$40	\$90	\$1,300	100%	0.5%
16	COP	\$0	\$5	\$30	\$50	\$10	\$60	\$100	\$1,300	SAAO	0.7%
17	COP	\$0	\$5	\$45	\$90	\$10	\$90	\$180	\$1,300	SAAO	0.8%
18	COP	\$100	\$10	\$15	\$30	\$20	\$30	\$60	\$1,300	SAAO	0.8%
19	COP	\$100	\$10	\$25	\$45	\$20	\$50	\$90	\$1,300	SAAO	0.9%
20	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	100%	0.8%
21	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	1.0%
22	COP	\$100	\$15	\$30	\$45	\$30	\$60	\$90	\$1,300	SAAO	1.0%
23	COP	\$100	\$15	\$40	\$60	\$30	\$80	\$120	\$1,300	SAAO	1.1%
24	COP	\$100	\$5	\$20	\$40	\$10	\$40	\$80	\$1,300	SAAO	0.8%
25	COP	\$100	\$5	\$25	\$50	\$10	\$50	\$100	\$1,300	SAAO	0.8%
26	COP	\$50	\$10	\$20	\$35	\$20	\$40	\$70	\$1,300	SAAO	0.7%
27	COP	\$50	\$10	\$25	\$35	\$20	\$50	\$70	\$1,300	SAAO	0.8%
28	COP	\$50	\$10	\$25	\$40	\$20	\$50	\$80	\$1,300	SAAO	0.8%
29	COP	\$50	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	0.9%
30	COP	\$50	\$5	\$10	\$25	\$10	\$20	\$50	\$1,300	SAAO	0.6%

* Type: COI = coinsurance; COP = copay; CM1 = combined
* Diabetic: If "100%" then Diabetic medications and supplies are covered at 100% of allowed charges;

If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Benefit Plan Relative Value Factors

BlueCare LO Options (LO) and Open Access (OAP) Medical Plans

				In-Networ	k Benefits				Out-	efits	Relativity Factor	
index	Product	Deductible	Coinsurance	Out-of- Pocket	Office Copay	Specialist Copay	ER ¹ Copay	AMB Copay	Deductible	Coinsurance	Out-of- Pocket	Active
1	LO	\$2,500	0%	\$2,500								0.6900
2	LO	\$3,000	0%	\$3,000								0.6522
3	OAP	\$750	20%	\$2,250	\$35	\$50	\$150	\$150	\$1,500	30%	\$4,500	0.8153
4	OAP	\$3,000	0%	\$4,100	\$30	\$30	\$100		\$6,000	30%	\$8,200	0.7277
5	OAP	\$3,000	20%	\$5,300	\$30	\$30	\$100		\$5,000	40%	\$10,600	0.6769

1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at 100%.

2. For the LO product, Office and Specialist Copay can be under the deductible.

3. LO does not have Out-of-Network benefits.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Benefit Plan Relative Value Factors BlueCare (HMO) Medical Plans

_		In-Network Benefits								
index	Product	IP	OP	HOSP	РСР	SCP	ER	AMB	OOPM	
1	HMO	\$0	\$0		\$25	\$35	\$250	\$0	\$0	
2	HMO	\$250	\$100		\$10	\$20	\$50	\$0	\$0	
3	HMO	\$250	\$100		\$25	\$40	\$100	\$50	\$0	
4	HMO	\$500	\$200		\$20	\$30	\$100	\$100	\$0	
5	HMO	\$500	\$200		\$25	\$40	\$150	\$50	\$0	
6	HMO			\$750	\$20	\$30	\$50	\$50	\$0	
7	HMO	\$2,000	\$1,000		\$20	\$30	\$50	\$50	\$0	
8	HMO			\$3,000	\$20	\$30	\$100	\$50	\$0	

РСР	Primary Care Physician Copay
SCP	Specialist Physician Copay
IP	Inpatient Care Deductible (max of 2/yr per family)
OP	Outpatient Surgery Copay
HOSP	Combined Inpatient Care & Outpatient Surgery Deductible (max of 2/yr per family)
ER	Emergency Room Copay
AMB	Ambulance Copay
OOPM	Per ACA, all copays accumulate toward the Out of Pocket Maximum

1. All HMO Plans have a DME rider benefit of: \$0 deductible, 20% coinsurance, built into the relativity.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Benefit Plan Relative Value Factors

Consumer Driven Health Plans (CDHP's)

		In-Network								
index	Product	Deductible	Coinsurance	Out-of-Pocket	RX OOPM Limit ³	Wellness Rx ¹	Drugs After Deductible ²	Diabetic Supplies	Active	
1	CDHP	\$1,500	0%	\$1,500	\$1,300	0%	N/A	SAAO	0.9802	
2	CDHP	\$1,500	0%	\$1,500	\$1,300	N/A	N/A	SAAO	0.9685	
3	CDHP	\$1,500	20%	\$2,500	\$1,300	0%	N/A	SAAO	0.9014	
4	CDHP	\$1,500	20%	\$2,500	\$1,300	N/A	N/A	SAAO	0.8866	
5	CDHP	\$2,000	0%	\$2,000	\$1,300	0%	N/A	SAAO	0.9167	
6	CDHP	\$2,000	0%	\$2,000	\$1,300	N/A	N/A	SAAO	0.9023	
7	CDHP	\$2,000	20%	\$3,000	\$1,300	0%	N/A	SAAO	0.8503	
8	CDHP	\$2,250	0%	\$2,250	\$1,300	0%	N/A	SAAO	0.8899	
9	CDHP	\$2,250	0%	\$2,250	\$1,300	N/A	N/A	SAAO	0.8744	
10	CDHP	\$2,500	0%	\$2,500	\$1,300	0%	N/A	SAAO	0.8654	
11	CDHP	\$2,500	0%	\$2,500	\$1,300	N/A	N/A	SAAO	0.8492	
12	CDHP	\$2,500	20%	\$5,000	\$1,300	0%	N/A	SAAO	0.7693	
13	CDHP	\$2,600	20%	\$5,000	\$1,300	0%	N/A	SAAO	0.7642	
14	CDHP	\$3,000	0%	\$3,000	\$1,300	N/A	\$10/\$35/\$50	SAAO	0.8052	
15	CDHP	\$3,000	0%	\$3,000	\$1,300	0%	N/A	SAAO	0.8226	
16	CDHP	\$3,000	0%	\$3,000	\$1,300	\$10/\$30/\$50	N/A	SAAO	0.8158	
17	CDHP	\$3,000	0%	\$3,000	\$1,300	N/A	N/A	SAAO	0.8052	
18	CDHP	\$3,000	20%	\$5,000	\$1,300	0%	N/A	SAAO	0.7460	
19	CDHP	\$3,000	20%	\$5,500	\$1,300	0%	10%/25%/25%	SAAO	0.7376	
20	CDHP	\$4,000	0%	\$4,000	\$1,300	0%	N/A	SAAO	0.7547	
21	CDHP	\$4,000	20%	\$6,450	\$1,300	0%	N/A	SAAO	0.6851	
22	CDHP	\$5,000	0%	\$5,000	\$1,300	0%	N/A	SAAO	0.7029	
23	CDHP	\$5,000	0%	\$5,000	\$1,300	N/A	N/A	SAAO	0.6824	
24	CDHP	\$6,000	0%	\$6,000	\$1,300	0%	N/A	SAAO	0.6611	
25	CDHP	\$6,450	0%	\$6,450	\$1,300	0%	N/A	SAAO	0.6449	
26	CDHP	\$6,450	0%	\$6,450	\$1,300	N/A	N/A	SAAO	0.6234	
27	CDHP	\$6,550	0%	\$6,550	\$1,300	0%	N/A	SAAO	0.6415	
28	CDHP	\$6,550	0%	\$6,550	\$1,300	N/A	N/A	SAAO	0.6200	
29	CDHP	\$6,600	0%	\$6,600	\$1,300	N/A	N/A	SAAO	0.6183	
30	CDHP	\$6,850	0%	\$6,850	\$1,300	0%	N/A	SAAO	0.6317	

1. Wellness Rx: if applicable, cost sharing rules apply *before* the deductible is satisfied.

The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.

2. All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

3. The **Rx OOPM** Limit is as described in Vermont Act 171.

The Vermont Health Plan Q3 2017 Large Group Rating Program Filing Benefit Plan Relative Value Factors

Prescription Drug Cards

			Copay (\$) / Coinsurance (%)								Relativity
Index	Туре	Deductible	Retail Generic	Retail Preferred Brand	Retail Non- Preferred Brand	Mail Order Generic	Mail Order Preferred Brand	Mail Order Non- Preferred Brand	ООРМ	Diabetic Supplies	Active
1	CM1	\$100	\$5	40%	60%	\$10	40%	60%	\$1,300	SAAO	0.1518
2	COI	\$0	50%	50%	50%	50%	50%	50%	\$1,300	SAAO	0.1351
3	COP	\$0	\$10	\$20	\$40	\$20	\$40	\$80	\$1,300	SAAO	0.2150
4	COP	\$0	\$10	\$25	\$25	\$20	\$50	\$50	\$1,300	SAAO	0.2100
5	COP	\$0	\$10	\$25	\$40	\$20	\$50	\$80	\$1,300	100%	0.2128
6	COP	\$0	\$10	\$25	\$50	\$20	\$50	\$100	\$1,300	SAAO	0.2061
7	COP	\$0	\$10	\$25	\$60	\$20	\$50	\$120	\$1,300	SAAO	0.2048
8	COP	\$0	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	0.2043
9	COP	\$0	\$10	\$35	\$60	\$20	\$70	\$120	\$1,300	SAAO	0.1839
10	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,300	100%	0.2101
11	COP	\$0	\$15	\$25	\$40	\$30	\$50	\$80	\$1,300	SAAO	0.2048
12	COP	\$0	\$15	\$30	\$45	\$30	\$60	\$90	\$1,300	SAAO	0.1969
13	COP	\$0	\$20	\$40	\$60	\$40	\$80	\$120	\$1,300	SAAO	0.1865
14	COP	\$0	\$5	\$20	\$35	\$10	\$40	\$70	\$1,300	SAAO	0.2226
15	COP	\$0	\$5	\$20	\$45	\$10	\$40	\$90	\$1,300	100%	0.2258
16	COP	\$0	\$5	\$30	\$50	\$10	\$60	\$100	\$1,300	SAAO	0.1987
17	COP	\$0	\$5	\$45	\$90	\$10	\$90	\$180	\$1,300	SAAO	0.1910
18	COP	\$100	\$10	\$15	\$30	\$20	\$30	\$60	\$1,300	SAAO	0.2036
19	COP	\$100	\$10	\$25	\$45	\$20	\$50	\$90	\$1,300	SAAO	0.1925
20	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	100%	0.1960
21	COP	\$100	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	0.1901
22	COP	\$100	\$15	\$30	\$45	\$30	\$60	\$90	\$1,300	SAAO	0.1849
23	COP	\$100	\$15	\$40	\$60	\$30	\$80	\$120	\$1,300	SAAO	0.1634
24	COP	\$100	\$5	\$20	\$40	\$10	\$40	\$80	\$1,300	SAAO	0.2037
25	COP	\$100	\$5	\$25	\$50	\$10	\$50	\$100	\$1,300	SAAO	0.2004
26	COP	\$50	\$10	\$20	\$35	\$20	\$40	\$70	\$1,300	SAAO	0.2081
27	COP	\$50	\$10	\$25	\$35	\$20	\$50	\$70	\$1,300	SAAO	0.2007
28	COP	\$50	\$10	\$25	\$40	\$20	\$50	\$80	\$1,300	SAAO	0.1999
29	COP	\$50	\$10	\$30	\$50	\$20	\$60	\$100	\$1,300	SAAO	0.1969
30	COP	\$50	\$5	\$10	\$25	\$10	\$20	\$50	\$1,300	SAAO	0.2244

* Type: COI = coinsurance; COP = copay; CM1 = combined (COP/COP/COI)
 * Diabetic: If "100%" then Diabetic medications and supplies are covered at 100% of allowed charges;

If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.